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1.1 MONOCYTES/MACROPHAGES 
With emphasis on their role in pulmonary diseases 
1.1.1 Historical background 
In 1882 /lya I'litch Metchnikoff, a Russian zoologist and anatomist, described for the 
first time that a special kind of cell in loose connective tissue could phagocytose foreign 
material (1,2). Different names were given to this cell, but most people know it nowadays 
as macrophage (which means "big eater") to underline the morphological difference with 
the "little eaters" (microphages, which was the early name given to another phagocytosing 
cell type now known as polymorphonuclear granulocytel. For a long time macrophages 
were classified together with other cell types (vascular endothelial cells, fibroblasts, 
reticular cells and histiocytesl as the reticuloendothelial system because of their common 
ability to concentrate supravital stains injected intravenously (3). However, this concept 
of the reticuloendothelial system did not recognize differences in function and origin. 
Therefore, based upon similarities between both morphology, function, kinetics and 
hemopoietic origin the mononuclear phagocyte system was postulated in 1972 (4,5). 
Nowadays, the different tissue macrophages, the peripheral blood monocytes (PBM) and 
their bone marrow precursors are considered to belong to the mononuclear phagocyte 
system (6,7). Nevertheless, some aspects remain unclear and raise intriguing questionsi 
originally, dendritic cells were excluded from the mononuclear phagocyte system, whereas 
this status was uncertain for Langerhans cells, veiled cells and lymph node macrophages 
(4,5). Recently, it was shown that human monocytes could be stimulated in vitro to 
express functional and phenotypic characteristics of dendritic cells (8-11). In these studies, 
serum (9) and thyroid hormones (11) were used to induce dendritic qualities. Antibodies 
to GM-CSF, TNF-Cl and IL·6 inhibited this induction (11). Another study showed that 
dendritic cells proliferate in cultures of cells from human bone marrow (12). Therefore, 
evidence is growing that also dendritic cells may be regarded as belonging to the 
mononuclear phagocyte system (7). However, the origin of follicular dendritic cells present 
in the germinal centers within the lymph nodes and spleen remains a fascinating field of 
research where data from different experiments come to different conclusions. A monocytic 
origin for follicular dendritic cells cannot be excluded, but most results support the view 
that these cells derive from local cells with a fibroblastic or mesenchymal origin (13). 
Mononuclear phagocytes (i.e. cells belonging to the mononuclear phagocyte system) 
can be found in the bone marrow, circulation and several tissues (6,7,14,15). Blood 
mononuclear phagocytes are generally called monocytes. Monocytes are able to leave the 
bloodstream and to enter the tissues or serous body cavities (16,17). These migrated 
monocytes, tissue mononuclear phagocytes, are generally called macrophages. This 
process of migration of mononuclear phagocytes from the bone marrow to the bloodstream 
and eventually to the different tissues represents an important way of maintaining the 
population of tissue macrophages. However, there are also reports which show that tissue 
macrophages themselves are able to proliferate, thereby maintaining the population 
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independently of the bone marrow (16,18-21). Different names were given to the tissue 
macrophages, which are now all considered to belong to the mononuclear phagocyte 
system (6). Figure 1 summarizes the different types of tissue mononuclear phagocytes. 
Other types of macrophages may be found in tissues under inflammatory conditions. Under 
these conditions monocytes are recruited from the bloodstream generally to a greater 
extent, and develop into inflammatory macrophage types, usually called exudate 
macrophages. In chronic inflammatory reactions, which may lead to the formation of 
granulomas, multinucleated giant cells, which are formed by fusion of cells, and epithelioid 
cells may be found 122,231. Also these cells arise from monocytesimacrophages and 
belong to the mononuclear phagocyte system. 
Bone marrow Blood 
pluripolent 
stem cell CFU·GEMI.l CFU·GM CFU·I.I monocyle 
0-0-0-0-0-
polymorphonuclear 
granulocyte 
eosinophilic granulocyte 
basophilic granulocyte 
mast cell 
erythrocyte 
platelet 
B cells 
T cells 
Tissue 
connective tissue 
spleen 
thymus 
lymph node 
lymph fluid 
lung 
liver 
central nervous system 
bone 
skin 
synovia 
abdominal cavity 
kidney 
Inflammation 
Macrophage 
histiocyte 
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dendritic celt 
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Figure 1. Hypothetical scheme of the developmental stages of human mononuclear phagocytes, leading 
eventually to the different tissue macrophages. In this scheme, mononuclear phagocyte development Is 
depicted as a linear continuum. Final differentiation into the different tissue macrophages is induced in the 
specific micro-environment of the different tissues. Other models that may explain mononuclear phagocyte 
heterogeneity are discussed in the text. Abbreviations used in this figure: 
CFU-GEMM granulocyte erythrocyte macrophage megakaryocyte colony forming unit 
CFU-GM granulocyte macrophage colony forming unit 
CFU-M macrophage colony forming unit 
1.1.2 Heterogeneity of rnonocytes/rnacrophages 
Initially, differences in morphology and anatomical location interfered with the 
recognition of a distinct cell system, and tissue macrophages were given uncorrelated 
14 
Introduction 
names (see Figure 1). Once the concept of a unified mononuclear phagocyte system was 
established, the obvious question arose how to explain the phenotypic and functional 
diversity of the cells belonging to this system. On the one hand, mononuclear phagocytes 
from a particular tissue or anatomical site may differ greatly from mononuclear phagocytes 
from other sites. The differences in morphology (e.g. cell size, shape of nucleus, ratio of 
cytoplasm: nucleus, ability to stretch in in vitro culture), in expression of cell membrane 
proteins (e.g. CD14 and RFD9 Ag), and in function (e.g. phagocytosis, cytotoxicity, 
regulation of inflammatory and immune responses) are best known. On the other hand, the 
population of mononuclear phagocytes itself from a particular tissue or anatomical site may 
be heterogeneous, again with regard to the morphology, function and expression of 
proteins. To facilitate a clear discussion about this subject one has to realize that four 
different, but interacting, cellular processes (Le. proliferation, differentiation, maturation, 
activation) (see Figure 2) determine the development, and the ultimate cellular heterogene-
ity among mononuclear phagocytes. 
3 u--(~) O-l){:: 6-6-~ 
o o<fc,)- 4~ 
2 6 -j(~ 
1. proliferation ~
2. differentiation 
3. maturation 
4. activation 
Figure 2, Proliferation, maturation, differentiation and activation in the generation of cellular heterogeneity, 
In this figure, heterogeneity is represented by differences in the expression of cell membrane antigens (II, 
0, A, g. ~ and *). 
Proliferation is defined as the replication of cells giving rise to daughter cells which are 
identical to their parent cell. Proliferation is probably always accompanied by differentiation 
or maturation, which explains why daughter cells are often different from their parent cell. 
The only exceptions to this rule concern germ cells and tumor cells, 
Differentiation is defined as the development of cellular diversity/heterogeneity by 
passing through a stage at which a cell is receptive to several stimuli and has the ability 
to acquire one out of several specific phenotypes with accompanying functions. Under the 
influence of specific environmental factors only one specific phenotype will be acquired, 
This new phenotype is different from the parental cell phenotype and the process of 
differentiation is in principal irreversible, After passing such a pOint of differentiation and 
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having acquired a certain differentiated phenotype, a cell will develop to a more mature 
stage Hnked with more mature cellular properties. 
Maturation concerns the process during which each stage with a certain cellular 
phenotype will be followed inevitably by the next stage with another, more mature cellular 
phenotype. Also the process of maturation is considered to be irreversible. 
Activation is a reversible process by which cells exhibit a temporary altered phenotype 
to perform temporarily an enhanced or new function. 
Proliferation, differentiation, maturation and activation of mononuclear phagocytes are 
regulated by environmental factors (24,25), including cell-to-cell interactions (25,26), cell-
to-extracellular matrix interactions (27), several soluble regulatory glycoprotein molecules, 
generally called cytokines (e.g. IL-3, IL-4, M-CSF, GM-CSF) (25,28-321. and other soluble 
mediators (e.g. 1 ,25-dihydroxyvitamin D3 , glucocorticoids, substance P, neurotensinl (33-
35). It is important to realize that one specific environmental factor may affect a cell type 
at various stages of development. The outcome of such an effect may, however, depend 
on the stage of development (30,36,37). For instance, in immature cells TNF-a enhanced 
IFN-y-induced MHC class" expression, whereas in more mature cells this additive effect 
of TNF-a. was eliminated (36). Furthermore, it is known now that, in general, a combination 
of environmental factors is needed to modulate particular aspects of cellular phenotype or 
function (38,39). 
Essentially, all mononuclear phagocytes present in the different tissues derive from 
precursor cells in the bone marrow. Proliferation and maturation result in more mature cells 
and are accompanied by changes in morphology and function. At some points in this 
generation of heterogeneity, differentiation takes place. When and where differentiation 
leading to distinct and separate cell lineages occurs, is still a matter of argument and 
heated discussions (7). One view suggests that terminal differentiation of mononunuclear 
phagocytes is driven by the local microenvironment of the different tissues. The seeding 
of PBM to different tissues is supposed to be random, and heterogeneity among PBM 
should be explained as differences in maturation stage (7,42,43). 
Another view proposes that already in the bone marrow multiple separate differentiati-
on lineages exist. These different lineages should give rise to separate lineages of PBM. 
Tissue destination of these lineages of PBM is supposed to be "pre-programmed", and each 
of the lineages is believed to mature to one particular type of tissue macrophages. A study 
in the human fetus showed the presence of two accessory cell populations distinguishable 
by the expression of eel! membrane antigens (40). Furthermore, this study demonstrated 
that this heterogeneity is maintained during fetal development, although both populations 
seemed to undergo additional phenotypic changes. These results are in concordance with 
the view that already at an early stage mononuclear phagocytes are committed to one 
particular phenotype. Recently, data were presented at the eighth "Annual Conference of 
the European Macrophage Study Group" showing the existence of phenotypically distinct 
monocyte subsets in humans (41). CD64+ and CD64- monocytes appeared to be 
committed to mainly phagocytic and highly efficient antigen-presenting functions, 
respectively. Further studies are needed to unravel the precise origin of mono-
cyte/macrophage heterogeneity. 
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1.1.3 Monocytes/macrophages in pulmonary diseases 
An important function of macrophages, as the name itself already reveals, is to 
phagocytose material. These cells are able to phagocytose waste originated in the body 
itself or from outside the body. For example, worn-out erythrocytes are removed in the 
spleen, liver and bone marrow by macrophages (44), whereas inhaled carbon particles in 
cigarette smoke are phagocytosed in the lung by alveolar macrophages (AM) (45,46). 
Furthermore, they are able to phagocytose and destroy microorganisms (46,47). 
Phagocytosis is mediated by cell membrane receptors present on monocytes/macrophages, 
which include Fc receptors (48), complement receptors [CR-1 (CD35) and CR-3 
(CD11 b/CD18)J (49), and carbohydrate receptors such as the macrophage mannose 
receptor (50). These properties turn macrophages, as part of innate immunity, into crucial 
cells in host defense (51). On the other hand, some obligatory or facultative intracellular 
pathogens use phagocytosis to their advantage, using macrophages to avoid detection and 
to reach suitable niches within the host (52). Mycobacterium tuberculosis represents a 
notorious example (53). Once inside the macrophage, it prevents phagosome-lysosome 
fusion and thrives within resident AM eventually causing the death of the host cell. Another 
microorganism that is able to resist the antibacterial activities of professional phagocytes 
concerns Yersinia pestis. It may cause bubonic or pneumonic plague, and its ability to resist 
phagocytosis results from the Yop E cytotoxin, a plasmid-encoded protein (54). An example 
of a viral microorganism which uses macrophages to reach otherwise inaccessible host 
regions, e.g. the brain, concerns the human immunodeficiency virus (HIV), although its 
mechanism to "survive" in macrophages differs fundamentally from M. tuberculosis or Y. 
pestis (55,56). Some macrophage-tropic HIV strains may integrate in the genomic material 
of mononuclear phagocytes, turning itself "invisible" for the host defense system. In this 
way, mononuclear phagocytes may act as major reservoirs of virus infection and the 
integrated virus may be transported to various organs. 
Besides the above-mentioned role as scavenger cells, mononuclear phagocytes are 
nowadays also known to have important functions in inflammatory and immunological 
processes (46,57,58). They have been recognized now to initiate and perpetuate or to 
suppress these processes, acting either as antigen-presenting cells or regulatory cells, 
respectively (Figure 3). Mononuclear phagocytes, at least some of them in various tissues, 
are able to take up and process antigens. After endocytosis and processing (59) of a 
particular antigenic peptide, presentation to CD4 + T cells requires the expression of MHC 
class 1I molecules (for a recent review: 60). MHC class II is expressed as an alp heterodi-
mer on the cell surface of some cell types. A third protein, the invariant chain, is 
characteristic of newly synthesized MHC class II and may help in optimal processing and 
presentation of antigens. Most mononuclear phagocytes express MHC class II molecules. 
It is now known that processed antigenic peptides may already associate with MHC class 
II molecules intracellularly within Iysosomes before surface expression. Processed antigen 
expressed ("presented") on the cell surface in association with MHC class 1/ may interact 
with specific T cell receptors (which are associated with the CD3 Ag) leading to T cell 
activation (61). Antigen presenting capacity can be influenced by environmental factors. 
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Exposure to T cell derived cytokines such as [FN~y and IL~4 induces an enhanced expression 
of MHC class" molecules resulting in increased antigen presenting capacity of macropha-
ges (62), However, although generally regarded as important antigen presenting cells for 
antigen-primed or allogeneic T cells, most macrophages seem to be unable to stimulate the 
proliferation of naive syngeneic T cells (63,64), On the other hand, dendritic cells seem to 
be specialized in stimulation of these T cells (63,64). The latter findings leave us with an 
apparent paradox of a cell type with, on the one hand, high efficiency of presentation of 
antigens which require processing, and, on the other hand, poor phagocytic and processing 
activity. 
Tabla 1. Major secretory products of mononuclear phagocytes. * 
Main group of products 
cytokines 
growth factors 
Individual products 
IL-la 
IL-1 P 
IL-1RA 
IL-6 
G·CSF 
M-CSF 
GM·CSF 
TGF·p 
IL-8 
IL·10 
IL-12 
IL·15 
FGF 
IGF-1 
MIP 1 +2 
PDGF 
arachidonic acid metabolites 5-lipoxygenase products 
cyclooxygenase products 
PAF 
enzymes and enzyme inhibitors proteases 
lipases 
DNases 
ANases 
clotting factors and complement components factor VII, IX, X 
C3a, C3b, C5a 
plasma binding proteins 
reactive oxygen and nitrogen products 
C1, C2, C3, C4, C5 
transferrin 
lactoferrin 
transcobalamin 
apolipoprotein E 
superoxide 
hydrogen peroxide 
nitric oxide 
* Adapted from references 14, 15,46,58,75 and 183. 
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phosphatases 
glycosidases 
sulphatases 
arglnases 
IFN-a 
TNF-a 
TNF-P 
a1-anti-proteinase 
a2-macroglobulin 
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Interestingly, in some viral infections macrophages appeared better antigen presenting cells 
than dendritic cells (65). Whether dendritic cells differentiate in vivo from monocytes and 
acquire this specific antigen presenting capacity within a particular micro-environment or 
arise from a distinct precursor within the bone marrow is stHI disputable (60). Evidence 
from recent in vitro studies shows that dendritic cells may be generated from blood 
monocytes (8-11). 
The affinity of MHC class II-bound antigen for T cell receptors is low, and additional 
protein interactions are required for optimal T cell activation. It is now recognized that, 
besides MHC class /I molecules, also other accessory molecules are of great importance in 
optimal antigen presentation. The way in which antigen presenting cells and T cells interact 
is greatly facilitated by adhesion molecules and other accessory molecules. Interactions of 
MHC class II, LFA-1(CD11a/CD18), LFA-3(CD58) and B7(CD80) with CD4 Ag, ICAM-1 
(CD54), CD2 and CD28 Ag, respectively, are best known (66-69; for recent reviews: 
70,71). Both the surface expression of these adhesion molecules and the actual results of 
protein-ligand interaction have been shown to be regulated by cytokines (62,72-74). 
In addition to their ability as antigen presenting cells to initiate immunological and 
inflammatory reactions, mononuclear phagocytes are also potent regulatory cells. This 
function is created by their ability to secrete over a hundred biologically active molecules 
and their ability to respond to stimuli through specific receptors for these stimuli (58,75-
77). Table 1 shows a summary of substances which can be secreted by mononuclear 
phagocytes, whether or not after activation or after reaching a certain stage of maturation 
or differentiation. This potency of mononuclear phagocytes to secrete such a diverse 
arsenal of biologically active molecules turns these cells into modulators of many 
physiological processes, such as inflammation, atherosclerosis (78), wound healing (79) 
and defense against malignancy (80,81) or infection. Such an important role as "process-
modulator" can only be performed properly if mononuclear phagocytes are also able to 
perceive environmental signals. These signals may include direct cellular and matrix 
interactions or secreted molecules, and are picked up by cell membrane receptors or 
intracellular receptors (76). Direct cellular and matrix interactions are, from the mononuclear 
phagocytes' side, mediated by cell membrane receptors. Many of these belong to the 
integrin superfamily and interact with specific ligand-proteins from the side of the 
interacting cell or matrix. Soluble molecules secreted by other cells may influence 
mononuclear phagocytes through specific cell membrane receptors (e.g. receptors for 
several cytokines) or intracellular receptors (e.g. receptors for various steroids). Table 2 
shows a summary of soluble mediators to which mononuclear phagocytes have been 
shown to be receptive. Beholding the extensiveness of possibilities to influence other cells 
or to be influenced by other cells in vitro, makes us realize that the in vivo interactions 
involving mononuclear phagocytes may be at least as complex and that safe therapeutical 
intervention still needs further understanding. 
Because of their above-mentioned immunological, inflammatory and regulatory 
properties, and because of their ubiquity in the lung (interstitial monocytes/macrophages, 
AM, dendritic cells), mononuclear phagocytes are supposed to be pivotal cells in 
immunological and inflammatory processes underlying many pulmonary diseases. 
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Table 2. Soluble mediators whIch have been shown to affect mononuclear phagocytes' function or 
phenotype. * 
Mediator 
IL-l 
IL-1RA 
IL-2 
IL-3 
IL-4 
IL-7 
IL-l0 
IL-13 
TNF-a 
IFN-a 
IFN-P 
IFN-y 
TGF-p 
PDGF 
M-CSF 
GM-CSF 
MCP-l 
RANTES 
glucocorticoids 
vitamine 0 
LPS 
eicosanoids 
PAF 
C5a 
Action on mononuclear phagocytes 
chemotaxis; release of IL-l, TNF and CSF 
antagoniz8tion of Il-l effects 
production of TNF-u 
maturation/differentiation 
enhanced MHC class II, CD23 and CD13 Ag expression; maturation/differentiation; 
decreased production of Il-l and TNF-a 
pro-inflammatory actions (Increased production of IL-l, IL-6 and TNF-a; increased 
tumoricidal activity) 
anti-inflammatory actions (decreased production of fl-1, IL-6, IL-a, TNF-a, GM-CSF 
and PGE2 ; decreased tumoricidal activity) 
comparable to Il-4 effects 
chemotaxis; release of PAF, Il-l and PGE2 
modulation of activation 
modulation of activation 
enhanced MHC class II expression; enhanced bactericidal and tumoricidal activity; 
enhanced antigen presenting capacity; increased production of Il-l and TNF-a 
chemotaxis; modulation of activation 
chemotaxis 
maturation/differentiation; secretion of IFN-a, TNF-a and G-CSF 
maturation/differentiation 
chemotaxis 
chemotaxis 
maturation/differentiation; modulation of activation 
maturation/differentiation 
induction of immediate early genes (proto-oncogenes, e.g. c-fos, c-myc or c-fms) 
and cytokine expression (e.g. Il-1 and TNF-aJ 
chemotaxis 
chemotaxis 
chemotaxis 
• Adapted from references 46, 76, 77 and the relevant references in Table 3, 
Their role in antigen-mediated or allergic lung diseases, such as asthma and extrinsic 
allergic alveolitis, is generally accepted because of their antigen-presenting capacity, The 
initial event in allergic asthma is thought to be presentation of antigen by dendritic 
cells/monocytes/macrophages to T lymphocytes as described above. It is still uncertain 
whether this presentation takes place right in the alveolar compartment where antigens are 
deposited, Another possible site where antigen presenting cells, after migrating from the 
alveoli, could interact with lymphocytes may be the draining lymph nodes. Eventually, this 
cellular interaction results in the production of inflammatory mediators by both antigen 
presenting cells and T lymphocytes (Figure 3). Furthermore, T lymphocytes will develop 
into Th2 lymphocytes. This subset of T cells is able to produce certain cytokines IIL-4, IL-5, 
IL-10 and IL-13) which playa pivotal regulatory role in the pathogenesis of allergic asthma. 
The development of Th2 cells is influenced by the balance between different cytokines (and 
probably hormones) in the cellular microenvironment. IL-4, and probably specific factors 
20 
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produced by antigen-presenting cells, play an important role in the development of these 
Th2 cells. The initial cellular source of IL-4 is still uncertain, but at present research is 
focussed on mast cells and a subpopulation of T lymphocytes (Figure 4) (82). 
Known' un~no' ... m antigen 
j 
Figure 3. Hypothetical and simplified cellular interactions in the pathogenesis of allergic inflammatory rung 
diseases. The different cell types are boxed. 
Cell type 
antigen-presenting 
Tcell 
subset 
Cytoklne 
production 
Cytoklne effects 
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Figure 4. Hypothetical role of cytokines In the development of CD4 + T celf subsets. The effects of cytokines 
produced by Th2 celfs which may playa role in allergic asthma are boxed. 
The interaction of T cells with antigen-presenting cells results in the production of a 
range of cytokines. This will lead to the recruitment and activation of other cell types (e.g. 
eosinophils and neutrophils, other mononuclear phagocytes and lymphocytes) at the initial 
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site of antigen deposition in the lung. In allergic asthma, the first contact of T lymphocytes 
with an antigen presented by mononuclear phagocytes will eventually result in help to B 
cells to produce specific antibodies. In this way, a person becomes sensitized to the 
antigen. Every following contact with the antigen will lead to activation of multiple cell 
types with release of inflammatory mediators, resulting in clinical symptoms. Acute 
asthmatic symptoms are thought to result from humoral, IgE dependent reactions. B 
lymphocytes producing these antibodies are at the end of the cellular cascade, but 
mononuclear phagocytes play the primary and initial role in the generation of these 
symptoms (Figure 3) (83,84). The late asthmatic symptoms and complaints of bronchial 
hyperresponsiveness are believed to be caused by (chronic) inflammation of the bronchial 
wall (85), This inflammation is characterized by infiltrates of T cells and mononuclear 
phagocytes, stressing again the irnportance of the latter cell type not only in the initiation, 
but also in the effector phase of the inflammatory response. The question why not 
everybody exposed to a particular antigen develops allergic symptoms, is still the base of 
many research projects. 
In addition to their powerful pro-inflammatory functions, a subset of mononuclear 
phagocytes have also been postulated as important suppressors of T cell-mediated 
inflammation (86,87). In the healthy lung, pro-inflammatory and immunosuppressive 
mononuclear phagocytes are balanced in proportion and activity, but in bronchial biopsies 
of asthmatic patients a reduced proportion of immunosuppressive macrophages was found 
(86). 
Presentation of a hypothesized, but still unidentified antigen by mononuclear 
phagocytes may underlie the cellular etiology in some lung diseases (SS). In sarcoidosis, 
the limited diversity of the T cell receptor in junctional regions suggests a response from 
a specific antigenic stimulus (89,90). Furthermore, aberrant cytokine release from AM has 
been demonstrated in sarcoidosis, suggesting dysregulation of the immune response 
(91,92). 
In granulomatous lung diseases, mononuclear phagocytes are known to be required to 
generate granulomas. Within a certain microenvironment, these cells mature into epithelioid 
cells, which, upon fusion, develop into multinucleated giant cells, also called Langhans cells 
(22,23). A better understanding of the pathogenesis of granulomatous inflammations will 
come from further insight in the mechanisms underlying maturation, differentiation and 
functioning of the mononuclear phagocytes involved. 
Also in fibrotic lung diseases, either primary or secondary, mononuclear phagocytes 
are an essential cell type because of the production of factors that caI.Jse accumulation, 
activation and proliferation of structural cells (93). Mononuclear phagocytes are able to 
release a great variety of such factors. Platelet-derived growth factor (PDGF) is chemotactic 
and mitogenic for both fibroblasts, neutrophils and monocytes (for a review: 94). The 
proto-oncogene c-sis encodes for the PDGF-B chain, and its expression is increased in AM 
from patients with idiopathic pulmonary fibrosis (IPFII9fi). PDGF secreted by AM may bind 
to structural cells, e.g. fibroblasts, or smooth muscle cells. Next, these cells become 
activated to produce an excess of extracellular matrix molecules resulting in fibrotic 
scarring. Alveolar macrophage-derived growth factor (AMDGF) is constitutively produced 
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by AM from patients with IPF (96). Together with PDGF and fibronectin, it stimulates 
proliferation of fibroblasts. This growth factor has been shown to be identical to a high 
molecular weight form of insulin-like growth factor-I (IGF-I, somatomedin-C) (97). 
Transforming growth factors (TGF) produced by activated AM are chemotactic for both 
monocytes and fibroblasts (98-100). They also stimulate monocytes and fibroblasts to 
produce growth factors and extracellular components, respectively (99,101, for a recent 
review: 102). The production of tumor necrosis factor (TN F)-a by AM may stimulate 
migration of neutrophils across the vascular endothelium and growth of fibroblasts 
(103,104). Therefore, also TNF-a released by AM may be an actual mediator in the 
pathogenesis of fibrotic lung diseases. Recently, the production of TNF-a by PBM-derived 
macrophages in cystic fibrosis was shown to be substantially higher than in normal 
macrophages (105). This appeared to be due to an increased rate of TNF-a gene 
transcription by cystic fibrosis macrophages, and may underlie the cachexia commonly seen 
in these patients. 
In conclusion, mononuclear phagocytes should be considered as important cells in 
many diseases, including pulmonary diseases. On the one hand, they protect us, thanks to 
their phagocytosing and microbicidal capacities, against invading microorganisms. In this 
way, they may prevent infectious diseases. On the other hand, mononuclear phagocytes 
are also recognized as central cells in the pathogenesis of lung diseases with either 
immunological or inflammatory components, because of their ability to present antigens, 
to secrete a multitude of mediators, and to respond to environmental stimuli. In this way, 
they are able to control the function of many other cell types. Better insight in the 
functioning of mononuclear phagocytes will hopefully lead to new possibilities to intervene 
in the course of pulmonary diseases. 
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1.2 CYTOKINES 
With emphasis on their production by and Influence on monocytes/macrophages 
1.2.1. Historical background 
Communication between cells, which in concerted action perform immunological or 
inflammatory tasks, seems obvious at present, and it is known now that cells interact 
through direct cell-to-cell contacts and through soluble or cell-membrane-bound signalling 
proteins, called cytokines (1 06). However, it was only in 1966 that for the first time it was 
realized that a soluble factor released in cultures of antigen-sensitized lymphocytes could 
influence the function of phagocytes (reviewed in 39(107). This specific factor was named 
migration inhibitory factor or MIF. In the following years various biological activities were 
demonstrated in the culture broth from antigen·stimulated lymphocytes. In 1969, the 
generic term Iymphokines was suggested to be used to describe such biological activities 
(1071. In 1979 the fist attempt was made to devise a nomenclature for Iymphokines that 
clustered certain biological activities and was independent of particular bioassays 
(108,109). The name interleukin (IL) was chosen describing the communication between 
white blood cells. At the same time lymphocyte activating factor (LAF)' 8 cell activating 
factor, 8 cell differentiation factor and mitogenic protein were classified as IL-1, whereas 
T cell growth factor, thymocyte mitogenic factor and killer cell helper factor were classified 
as IL-2. At the sixth "International Congress of Immunology" in 1986 it was agreed that 
a new interleukin would first be named according to its biologic property or properties, but 
once the amino acid sequence of the human form was established, it would be assigned 
an interleukin number (1111. Since thattime, fifteen interleukins have been described (111· 
132). Furthermore, the interleukins are nowadays considered as part of a larger group of 
protein molecules, referred to as cytokines, including the interleukins, interferons, tumor 
necrosis factors and growth factors (133). This heterogeneous group of cytokines has a 
number of characteristics: 
1. cytokines are low molecular weight « 30 kDa in monomeric form) proteins which are often glycosylated; 
2. cytokines regulate a wide spectrum of biologic events relevant to inflammation, immunity, metabolism, 
cell growth, cell maturation and differentiation, flbrogenesis, and homeostasis; 
3. cytokines are usually produced transiently and locally, acting in a paracrine or autocrine, rather than 
endocrine, manner; 
4. cytokines are extremely potent, often being active at nanomolar or picomolar concentrations; 
5. interaction of cytokines with high affinity cell surface receptors eventually leads to modulation of RNA 
and protein synthesis, which results in an altered cell function; 
6. individual cytokines have multiple (pleiotropic) activities whilst different cytokines may mediate similar 
effects (redundancy); 
7. cytokines interact in a network by inducing each other, influencing cytokine cell surface receptor 
expression, and by synergistic, additive or antagonistic effects on cell function; 
8. the genes for several cytokines are clustered on chromosomes (IL-l«/p, IL-1RA and IL-1R on 
chromosome 2; GM-CSF, M-CSF, M-CSFR, IL-3, IL-4, IL-5 and IL-13 on chromosome 5). which may 
explain why these factors are expressed in a coordinated fashion following cell activation (134,135). 
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Table 3. Cellular sources and a selection of effects of human cytokines. ." 
;;i 
Cytokine Other name Cellular source Biological action Reference 
'" 
IL-1a/13 BAF, ETAF, LAF mononuclear phagocytes. endothelial cells, maturation and proliferation of Band T cells; 111 
NK celis, B cells, fibroblasts, keratinocytes stimulation of arachidonic acid metabolism; secretion 
of collagenase, elastase and plasminogen activator; fever 
IL-2 T cells (Th1-like) mitogenic for thymocytes, T and B cells and NK cells; 
enhanced cytotoxic activity of monocytes 
112,113 
IL-3 multi-CSF T cells hemopoietic growth and differentiation factor 114 
IL-4 BSF-I T cells (Th2-likel. mast cells proliferation of T and B cells; induction of IgE and IgG 28,29,31, 
synthesis; induction of MHC class II, CD13 and CD23 Ag 63,115 
expression on mononuclear phagocytes 
IL-5 BCGF-I!, TRF T cells (Th2-like) activation of B cells and eosinophils; chemotactic 116 
for eosinophils 
IL-6 BSF-2, IFN-02, mononuclear phagocytes, B cells, T cells, induction of acute phase proteins; synergistic with IL-l; 117,118 
HSF endothelial cells, fibroblasts, keratinocytes induction of IL-2R on T cells 
IL-7 T cells, fibroblasts mitogenic for thymocytes and T cells; induction of IL-2R 119,120, 
on T cells; induction of IL-l, IL-6, lL-8, TNF-a. 121 
IL-8 NAP-l mononuclear phagocytes, endothelial cells, chemotactic for and degranulation of PMN 122 
epithelial cells, fibroblasts, keratinocytes 
IL-9 P40, MEA T cells growth factor for some T cell lines; production 
of IL-6 by IL-3-dependent mast cell lines 
123,124 
IL-l0 mononuclear phagocytes, T cells (Th2-like)' decreased production of IL-l, IL-6, IL-8, TNF-o:, 125,126 
B cells GM-CSF, PGE2 
IL-11 fibroblasts proliferation and maturation of megakaryocytic and 127 
myeloid precursor cells 
IL-12 NKSF mononuclear phagocytes, B cells induction of IFN-y; augmentation of NK cell-mediated 128,129 
cytotoxicity; initiation of cell-mediated immunity 
IL-13 T cells many of the effects are similar to IL-4 130 
IL-14 HMW-BCGF T cells, certain malignant B cells proliferation of B cells; inhibition of immunoglobulin 131 
secretion 
IL-15 adherent mononuclear phagocytes, epithelia! biological activity resembles that of IL-2 132 
and fibroblast cell lines 
Table 3_ Cellular sources and a selection of effects of human c'{tokines (continuedl. 
Cytokine Other name Cellular source Biological action Reference 
IFN-a virallFN, mononuclear phagocytes, NK cells, B cells, induction of antiviral state; fever 139 
type 1 IFN fibroblasts 
IFN-~ fibroblasts, epithelial cells induction of antiviral state; fever 139 
IFN-y T cells (Th1-like), NK cells enhanced phagocytosis and tumoricidal activity of 
mononuclear phagocytes; induction of MHC class 11 
136,139 
on many cell types; fever 
G-CSF MGI-2 mononuclear phagocytes, fibroblasts, maturation/differentiation of granulocytes 140-143 
endothelial cells 
M-CSF MGF, CSF-1 mononuclear phagocytes, fibroblasts, maturation/differentiation of mononuclear 140,141 
endothelial cells phagocytes 
GM-CSF CSF-2, mononuclear phagocytes, T cells, maturation/differentiation of both granulocytes 140,141, 
pluripoietin-a fibroblasts, endothelial cells, mast cells and mononuclear phagocytes 143 
IGF somatomedin, 
AMDGF 
mononuclear phagocytes growth of tissues 144 
FGF mononuclear phagocytes "Induction of neovascularization; mitogenic 145 
for endothelial cells 
MIP-1 a/j3 mononuclear phagocytes chemokinetic for mononuclear phagocytes and PMN; fever 146,147 
MCP-1 MeAF keratinocytes, lymphocytes, fibroblasts chemotactic for mononuclear phagocytes 148,151 
RANTES T cells migration of blood monocytes and T cells 149-151 
MIP-2 mononuclear phagocytes chemokinetic for PMN 151 
POGF platelets, endothelial celis, epithelial mitogenic for fibroblasts, epithelial cetts, capillary 93,152 
cells, mononuclear phagocytes endothelial cells and arterial smooth muscle cells; 
wound repair; chemotactic for mononuclear phagocytes 
TGF-a epithelial cells, keratinocytes, fibroblasts proliferation of cells; angiogenesis 153 
EGF j3-urogastrone epithelial cells, keratinocytes, fibroblasts proliferation of cells; angiogenesis 153 
TNF-aJ~ cachectin mononuclear phagocytes, T cells necrosis of certain tumors; growth of fibroblasts; 154 
angiogenesis; fever ;;-
TGF-~ mononuclear phagocytes, platelets, inhibition of IL-2 effects and proliferation of certain 100,101 :l g-fibroblasts cells; increased gene expression of collagens 0 
'" 
g. 
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Abbreviations used In Table 3. Cellular sources and a selection of effects of human cytokines. 
AMDGF 
BAF 
BCGF 
BSF 
CSF 
EGF 
ETAF 
FGF 
G 
HSF 
HMW~8CGF 
IFN 
IGF 
IL 
LAF 
M 
MCP 
MCAF 
MEA 
MGF 
MGI 
MIP 
NAP 
NKSF 
PDGF 
PMN 
RANTES 
R 
TNF 
TGF 
TRF 
alveolar macrophage-derived growth factor 
B cell activating factor 
8 celf growth factor 
B cell stimulatory factor 
colony stimulating factor 
epidermal growth factor 
epidermal celt-derived T cell activating factor 
fibroblast growth factor 
granulocyte 
hepatocyte-stimulating factor 
high molecular weight B cell growth factor 
interferon 
insulin-like growth factor 
inter leu kin 
lymphocyte-activating factor 
macrophage 
monocyte chemoattractant protein 
monocyte chemotactic and activating factor 
mast cell enhancing activity 
macrophage/granulocyte factor 
macrophage/granulocyte inducer 
macrophage inftammatory protein 
neutrophil-activating peptida 
natural killer cell stimulatory factor 
platelet-derived growth factor 
polymorphonuclear cells 
regulated upon activation, normal T expressed, and presumably secreted 
receptor 
tumor necrosis factor 
transforming growth factor 
T cell replacing factor 
Although once it was thought that a certain cytokine directed its single activity at one 
particular cell type, it is nowadays appreciated that different cytokines may direct the same 
change in cell function (136,137), that a single cytokine may effect a multitude of 
activities, and that these activities may concern different cell types (138). Furthermore, the 
biologic effect of cytokines are often situation-specific, since they vary depending on the 
concentration of the cytokine, the cellular stage of activation, maturation and differentiati-
on, and the presence of other cytokines or hormones in the local microenvironment (30, 
36,38(39). This context of a particular cytokine determines to a great extent the ultimate 
effects observed. Table 3 summarizes human regulatory proteins that are at present 
accepted cytokines, together with their cellular sources and some of their biological effects. 
It should be emphasized that in this table only the most important effects are selected, and 
that for the purpose of a complete overview of cytokine effects one has to turn to the 
references. 
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1.2.2 Clinical implications 
The important role played by cytokines in numerous physi%gical processes, as 
mentioned above, constitutes a challenge to clinicians to use these molecules in clinical 
settings. Moreover, the genetic material of many of these cytokines has been cloned and 
it is possible to produce huge amounts of pure recombinant cytokines. The cytokines that 
direct normal hemopoiesis are now being used in a variety of clinical protocols, comparable 
to the use of erythropoietin (which is, however, considered to be a hormone, rather than 
a cytokine) to control anemia in chronic renal failure and recently in sickle cell disease 
(155,156). 
G-CSF and GM-CSF are being used in cancer patients with leucopenia induced by 
chemotherapy andlor irradiation (157,160). At present, these cytokines are administered 
subcutaneously and adverse effects are mild in case of G-CSF (local rashes, fever, 
discomfort over bones containing hemopoietic tissue) (161). In some patients, high doses 
of GM-CSF may have more serious side effects such as capillary leak syndrome, fever, 
rashes, pericarditis, and pleural effusion (161). Furthermore, the use of these cytokines 
may entail the risk to convert preleukemic cells to fully neoplastic leukemic cells as also 
leukemic cells may possess cytokine receptors. Recently, aerosolized GM-CSF was used 
in nonhuman primates, and was shown to increase the population of macrophages and 
neutrophils (162). Further studies are needed to determine whether aerosol delivery of GM-
CSF will be of use in the treatment of pulmonary diseases. 
The gravity of thrombocytopenia induced by treatment with high-dose carboplatin in 
cancer patients could be diminished by IL-1a (163). The latter, beneficial application of IL-
1 a contrasts with other more harmful effects of IL-1, as IL-1 is also known to mediate, in 
part, fever, sleep, anorexia, shock, arthritis, colitis, diabetes and atherosclerosis (164). 
Also IL-2 is currently being used in the treatment of various diseases (165-167). It has 
been shown to be of benefit in cancer and infection with HIV (165,166). Recently, IL-2 
was reported to enhance immunity in common variable immunodeficiency which allowed 
stopping of immunoglobulin infusions (167). 
The potential anti-inflammatory effects of IL-4 observed in several in vitro experiments 
are now being tested in in vivo studies (168-170). On the contrary, blocking IL-4 effects 
may also be of therapeutical use, e.g. in the treatment of allergy and asthma. In these 
diseases, disrupted commitment of T cells to Th2 effector functions may underlie the 
aberrant IgE production (171). The importance of IL-4 in these processes has been stressed 
recently, and IL-4 was suggested as a critical drug target (171). 
In addition to IL-4, also IL-5 has been suggested as a key cytokine in diseases as 
allergy and asthma (171). Blocking IL-5 activity has been shown to inhibit eosinophilia and 
bronchial hyperresponsiveness induced by antigen in sensitized animals (172). Therefore, 
also IL-5 may be a future target for antagonists in the treatment of allergic diseases. 
Recently, the local generation of IL-8 was described as a possible therapeutic target 
for attempts to control the adult respiratory distress syndrome (ARDS) (173,174). ARDS 
is characterized by increased capillary permeability and increased numbers of neutrophils 
within the airspaces of the lungs. It has been suggested that IL-8, a neutrophil chemotaxin, 
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is an actual candidate for the initiation and progression of neutrophil-mediated events in 
ARDS 1174). Early appearance of IL-8 in SAL-fluid of patients at risk of ARDS may be an 
important prognostic indicator (174). AM are the principal source of IL-8 within the lungs 
1175,176). 
In summary, single-cytokine therapy is now being evaluated in many clinical trials. As 
the effect of a certain cytokine is greatly determined by the context, sequential or 
concurrent combination cytokine therapy may prove to be superior in the future (177-179). 
On the other hand, blocking harmful cytokine effects may also be of potential clinical use. 
However, one has to realize that, in addition to their antagonizing activities, soluble 
cytokine receptors and anticytokine antibodies can also agonize cytokine activity (181). The 
latter activity may result from an increased half-life time of cytokine-cytokine receptor 
complexes (182). This "double-edged sword" phenomenon may restrict the therapeutic use 
of such agents (181). The effects of recombinant IL-1 receptor antagonist is presently 
studied in clinical trials for treating rheumatoid arthritis, septic shock and chronic myeloid 
leukemias 1180). 
1.2.3 Cytokines and monocytes/macrophages 
Mononuclear phagocytes are able to "communicate" with many other cell types. As 
a result, mononuclear phagocytes are important regulators of complex multicellular 
processes, e.g. inflammation (58,82). Part of this "communication" is mediated by soluble 
or cellular bound cytokines. On the one hand, mononuclear phagocytes are capable of 
secreting various cytokines (Table 3) 1183,184). On the other hand, these phagocytes are 
receptive to many cytokines produced by either themselves or other cell types (Table 2) 
176). 
Effects of cytokines 
The influence of cytokines on mononuclear phagocytes has been demonstrated in early 
events during maturation/differentiation. Generation of CFU-GEMM and CFU-GEM, the 
earliest precursor cells of mononuclear phagocytes, from the pluripotent stem cells (see 
figure 1), is under control of both IL-3 and GM-CSF 1136). Only more mature/differentiated 
stages have been shown to be responsive to M-CSF (137). The presence or absence of 
specific cytokine receptors may underlie the sequential responsiveness for different 
cytokines during cell maturation/differentiation. M-CSF responsiveness may eventually 
result from induction of the c-fms proto-oncogene, which represents the high affinity 
receptor for M-CSF, by GM-CSF 1137). /n vitro, it has also been demonstrated that IL-6 and 
IFN-y are able to potentiate GM-CSF and M-CSF effects 1185). Furthermore, maturation/dif-
ferentiation of mononuclear phagocytes can be modulated by IL-4 (28). 
Besides the effects on maturation/differentiation, some cytokines may induce 
chemotactic responses in mononuclear phagocytes (Table 4). The p-chemokines (e.g. MIP-
1, MCP-1 and RANTES) are chemotactic for mononuclear phagocytes, whereas another 
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related family of cytokines, the a-chemokines (e.g. IL·8 and NAP-2l, is only chemotactic 
for neutrophils and lymphocytes (186). Also TGF, PDGF and TNF may attract mononuclear 
phagocytes (98,152,154). 
As regulators of complex multicellular processes in vivo, many functions of 
mononuclear phagocytes can be affected by activating and inhibitory signals from their 
micro-environment. Some cytokines give mononuclear phagocytes properties which may 
eventually increase the degree of inflammation (Tables 2 and 4). The most important of 
these cytokines are IL-1, IL-7 and TNF (121,137). In the presence of these cytokines, 
mononuclear phagocytesenhancetheproductionof other pro-inflammatory mediators (IL-1, 
IL-6, TNF·a., PAF, PGE,). Other cytokines may eventually result in a decrease of 
inflammatory activities (Tables 2 and 4). 
Table 4. Functions of mononuclear phagocytes which can be modulated by cytokines. 
Function 
maturation/differentiation 
chemotaxis 
pro-inflammatory activities 
anti-inflammatory activities 
Cytokine 
M·CSF, GM·CSF, IL-3, IL-4, IL-6, IFN-'( 
p-chemokines (MIP-1, MCP-1, RANTES), TNF, TGF, PDGF 
Il-1, Il-4, Il-7, IFN-y, TNF-a 
IL-1RA, IL-4, IL-l0, IL-13, TGF, IFN-P 
The most important potential terminators of an inflammatory response are IL-1 RA (180), 
IL-4 (168,169) and IL-1 0 (125,126). They are all able to decrease the production of other 
mediators IIL-1, IL-6, TNF-a, GM-CSF, PGE,) in mononuclear phagocytes. Here, it is 
essential to stress again that the actions of cytokines can only be understood in "context", 
and can not be categorized as pure stimulators or inhibitors. A particular cytokine may have 
either pro-inflammatory or anti-inflammatory properties, subject to additional signals. A 
striking case in point is IL-4, which may induce MHC class II resulting in enhanced antigen 
presenting capacities (62). However, IL-4 may also decrease the production of IL-1 and 
TNF-a, enabling a decrease of the acute inflammatory response (168,169). 
Production of cytokines 
One of the earliest examples of cytokines produced by mononuclear phagocytes are 
IL-1 (137,187) and TNF-a (137,188,189). The IL-1 family consists of three structurally 
related polypeptides (164). The first two are IL-1a and IL-1P, each of which has a broad 
spectrum of both beneficial and harmful biologic actions. The third is IL-1 RA, which inhibits 
the activities of IL-1. Il-1 was originally recognized for its ability to induce proliferation of 
murine thymocytes (187), but is now also known as an important mediator of coagulation, 
inflammation and fibrosis (137, 164). Functions of a great variety of different cell types may 
be modulated by IL-1. IL-1 RA is a specific inhibitor of IL-1 activity that acts by blocking the 
binding of IL-1 to its cell surface receptor. It provides some protection against the disease-
provoking effects of IL-1 (180). TNF-a. was first recognized for its ability to induce 
hemorrhagic necrosis of certain tumors (190). Besides this cytotoxicity, it has variable 
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growth activity for fibroblasts, it modulates angiogenesis, induces release of collagenase 
from structural cells, and produces systemic effects of fever and cachexia (137,154). 
Mononuclear phagocytes are the main source of IL-6. It is the cytokine primarily 
involved in delivering the final signal to hepatocytes for the regulation of protein synthesis 
during the acute phase protein response (191). Furthermore, IL-6 induces the proliferation 
of T cells, as well as the expression of the IL-2R on these cells (117). 
The chemotaxis and degranulation of neutrophils is regulated by IL-8, which is 
produced by mononuclear phagocytes and many other cell types (122). 
IL-10, IL-12 and IL-15 are also produced by mononuclear phagocytes. IL-10 has been 
shown to exhibit anti-inflammatory properties. It inhibits the production of many 
inflammatory cytokines 1125,126). Recently, IL·12 was found to induce the differentiation 
of Th 1 cells from uncommitted T cells (129). Consequently, it may play an important role 
in cell-mediated immunity. The biological activities of IL·15 resemble those of IL-2 (132). 
Upon stimulation with LPS or IL-1, mononuclear phagocytes may produce colony 
stimulating factors, as M-CSF, G·CSF, and GM·CSF (183,192). These factors are important 
regulators of the maturation/differentiation of myeloid cells. 
Mononuclear phagocytes are known to produce IFN-o:. in response to viruses, bacteria, 
and tumor cells (193). IFN-a has antiviral and antimitotic effects, and up-regulates MHC 
class II expression (139). 
By means of the production of TGF-p, mononuclear phagocytes are able to modulate 
many cellular functions, e.g. replication (97). The response of cells to TGF-j3 is complex, 
and depends upon the cell type, state of activation, and exposure to other cytokines (101). 
Cells that respond to TGF-p by undergoing mitosis do so through their ability to secrete and 
respond in an autocrine fashion to PDGF. Mononuclear phagocytes themselves are also able 
to produce PDGF 194,194). 
Some growth factors produced by mononuclear phagocytes are characterized by a high 
affinity for heparin. FGF is mitogenic for endothelial cells and represents a potent inducer 
of neovascularization (145). MIP-1 is produced in response to stimulation with LPS. It is 
chemotactic for neutrophils, and may induce fever (146,147). 
IGF-1 is synthesized by mononuclear phagocytes and other cells in response to growth 
hormone and mediates its trophic actions (144). It stimulates proliferation of a variety of 
structural cell types, including fibroblasts, smooth muscle cells and chondrocytes. AM 
synthesize and secrete a high molecular weight form of IGF-1, which was originally named 
AMDGF 195,96). 
In conclusion, both the production of cytokines by mononuclear phagocytes and the 
numerous effects of cytokines on their function are likely to play an important role in 
inflammatory processes and immune reactions. Everyday, interactions between cytokines 
and these cells seem to become more complex because of new observations (195). Careful 
interpretation of in vitro results will eventually lead to insight into the in vivo processes and 
may open new therapeutic possibilities. 
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1.3 GLUCOCORTICOIDS 
With emphasis on their influence on monocytes/macrophages 
1.3.1 Historical background 
Although glucocorticoids are known by almost everybody as a powerful drug feared 
because of their sometimes impressive adverse effects (196-198), they are still ordinary 
hormones physiologically present in everyone's body (199). They are synthesized in the 
adrenal cortex, secreted and circulating at a concentration that fluctuates in a circadian 
mode (200). In humans the natural glucocorticoid is hydrocortisone (cortisol). It has several 
vital functions (199,201-202). Life would be impossible without functioning adrenal glands, 
unless the absent cortisol is substituted for by exogenous glucocorticoids (199,203). 
Plasma cortisol levels are elevated during periods of stress, probably preventing the body's 
defense reactions against stress from overshooting and preventing needless tissue damage 
(201,202). Just these inhibitory and protective effects of glucocorticoids are being used 
nowadays in the treatment of several diseases. Cortisone, the natural precursor of cortisol, 
was used first in the treatment of rheumatoid arthritis in 1949 (204). Within a few years 
glucocorticoids were also used in the treatment of other diseases and in 1950 their 
beneficial effects in asthma patients were described (205). Cortisone was initially 
administered intramuscularly, but at present glucocorticoids can be administered also orally, 
intravenously or via inhalation (206). Furthermore, synthetic glucocorticoids, much more 
potent than cortisol and without the unwanted mineralocorticoid side effects, have been 
developed (207-209). 
1.3.2 Clinical implications 
After their introduction in the treatment of rheumatoid arthritis, glucocorticoids were 
soon used in the treatment of other diseases with inflammatory or disrupted immunological 
components (210,211). Since 1950 glucocorticoids are being used in the treatment of 
various lung diseases (212). In some pulmonary diseases their use is of undisputable value 
now, whereas in others their use is still controversial (see below and Table 5). In the last 
decade, insight in the cellular and subcellular mechanisms underlying lung diseases has 
increased tremendously thanks to new cellular and molecular biological techniques 
(213,214). With this, also the beneficial effects of glucocorticoids in lung diseases became 
clear at the cellular and subcellular level (215,216). Hopefully, this knowledge will 
eventually help to decide whether or not glucocorticoid treatment will be of use in a 
particular clinical setting. Table 5 gives an overview of pulmonary diseases in which 
glucocorticoids have become a cornerstone of treatment. With regard to the dosage 
scheme of oral glucocorticoid treatment it is generally accepted now that alternate-day 
therapy can prevent or ameliorate the manifestations of Cushing's syndrome, avert or 
permit recovery from hypothalamus-pituitary-adrenal axis suppression, and is as effective 
(or nearly as effective) as continuous therapy (197,240,241). 
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.,. Table 5. lung diseases in which glucocorticoid treatment is generally accepted or under investigation. 
Lung disease 
asthma 
COPO 
tuberculosis: menigitis 
pericarditis 
PCP 
sarcoidosis 
EAA 
fibrosis 
PIE syndrome 
drug induced pneumonitis 
(e.g. methotrexate, amiodarone, 0l) 
ARDS 
aspiration pneumonitis 
neonatal respiratory distress syndrome 
lung transplantation or lung conditions 
secondary to general autoimmune diseases 
(e.g. RA,SLE, scleroderma, Wegener's disease) 
neoplasms 
Comment 
glucocorticoids generally accepted in reducing BHR; important 
role of maintenance treatment with inhaled glucocorticoids 
subgroups of CO PO patients may benefit from glucocorticoids 
use of glucocorticoids controversial 
indications for use of glucocorticoids clear 
early adjunctive treatment with glucocorticoids reduces the risks 
of respiratory failure and death in patients with AIDS and PCP 
glucocorticoids used in hypercalcemia or impaired pulmonary function 
glucocorticoids used to inhibit or delay fibrosis 
glucocorticoids may slow down the progression to end stage fibrosis 
use of glucocorticoids in chronic or recurrent cases 
glucocorticoids may have some benefit, but results are inconsistent 
no benefit from glucocorticoids early in the disease; g!ucocorticoids 
being used in a trial 7 to 14 days after the onset of ARDS 
glucocorticoids may prevent ARDS when administered within 
12-24 hours after aspiration 
glucocorticoids given to mother before parturition 
glucocorticoids prevent rejection or may be used to treat the primary 
disease, usually in combination with other immunosuppressive agents 
{e.g. azathioprine or cyclophosphamide} 
glucocorticoids (in combination with chemotherapy or radiation) used 
as either cytostatic drug or anti-emetic agent 
Abbreviations used: AROS 
BHR 
COPO 
EAA 
: adult respiratory distress syndrome 
: bronchial hyperresponsiveness 
PIE : pulmonary infiltration with blood eosinophilia 
PCP: Pneumocystis carinii pneumonia 
: chronic obstructive pulmonary diseases 
: extrinsic allergic alveolitis 
RA : rheumatoid arthritis 
SLE : systemic lupus erythematosus 
References 
217-219 
220 
221,222 
223 
224,225 
226-228 
227-229 
227,228,230 
228 
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This has been shown in many non"lung diseases, but also in asthma, sarcoidosis and 
rheumatoid arthritis associated lung conditions. If alternate-day therapy is unsuccessful 
because symptoms of the underlying disease occur on the second day, the dosage scheme 
may be changed to a daily single dose early in the morning. Currently, the use of 
(intravenous) high"dose pulse therapy is being studied, but up to now Its benefits remain 
controversial (242). 
Table 6. The influence of glucocorlicoids on the synthesis of proteins with inflammatory effects In human 
celts or tissue. 
Protein 
IL·1p 
IL·2 
IL·5 
IL·6 
IL·B 
TNF-« 
IFN··( 
collagenase 
lipocortins 
nitric oxide 
synthase 
Cell/tissue 
BAl mononuclear phagocytes, 
monocytic cell Iina (U937) 
T lymphocytes 
PBM 
monocytes, endothelial cells, 
fibroblast cell line 
PBM, AM 
lung fragments 
lymphocytes 
transfected cell lines (Hela) 
PBM, AM 
macrophage cell line {J774L 
endothelial cells 
Glucocorticoid effect References 
decreased mRNA expression in vitro; 249,250 
blocking post-transcriptional Il-1 
synthesis 
decreased gene transcription/mRNA 251,252 
stability 
decreased gene expression in vitro 253 
decreased mRNA levels and protein 249,254 
production in vitro 
decreased mRNA levels and protein 255 
production in vitro 
inhibition of mRNA transcription 256 
decreased mRNA expression 257 
decreased gene transcription as a 258-260 
result of GR/AP-l interaction 
induction of mRNA expression 261-270 
in vitro; influence in vivo unclear 
inhibition of mRNA synthesis 271,272 
metallothionein Ita AM increased mRNA expression 265,273 
ICAM·1 
ELAM·1 
GM-CSF 
monocytic and bronchial epithelial decreased mRNA expression 
cell line, endothelial cells 
endothelial cells decreased mRNA expression 
fibroblasts decreased mRNA stabilityl 
mRNA transcription 
245,274 
245 
275 
Although probably all cells in humans possess glucocorticoid receptors, humans are 
relatively insensitive to the effects of glucocorticoids as compared with rodents (243). This 
is of great importance when extrapolating glucocorticoid effects in laboratory animals to 
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humans. One of the first effects of a single dose of glucocorticoids in humans concerns the 
numbers of circulating leukocytes 1244,245). Within 4 to 6 hours a lymphopenia and 
granulocytosis are the result of redistribution of circulating lymphocytes to other lymphoid 
compartments and of delayed egress of granulocytes from the intravascular space, 
respectively. Steroid-altered interactions of lymphocytes and granulocytes with endothelial 
cells through cell membrane proteins may underlie these effects (246). Furthermore, the 
number of blood monocytes is decreased (244,245), These effects were the first observed 
cellular changes induced by glucocorticoids. At present, a lot of subcellular effects of 
glucocorticoids are known and with this knowledge insight in the working mechanisms of 
these drugs have increased greatly (213,214). It IS known now that glucocorticoids are 
able to influence cellular protein synthesis ITable 6) 1247). These proteins include 
inflammatory mediators (e.g. cytokines), membrane-bound proteins (e.g. ICAM-1), and 
enzymes (e.g. collagenase, synthases and phospholipase A2 ) which catalyze the production 
of inflammatory mediators. It should be mentioned that most data are obtained from in vitro 
studies. We understand nowadays that protein mediators (cytokines) and non-protein 
mediators, which production for their part may be modulated by protein mediators, control 
to a great extent inflammatory and immunological processes. All this knowledge seems to 
suggest that the anti-inflammatory working mechanisms of glucocorticoids are clear (see 
chapter 2 for further detailed information). However, there remain still several unanswered 
questions. These concern not only virgin research fields but also our recently obtained data. 
The latter may be exemplified by our current knowledge of lipocortins. In 1986 they were 
first described to be induced by glucocorticoids and to mediate anti-inflammatory effects 
(276). Since then, numerous conflicting results were published regarding the inducibility 
of lipocortins by glucocorticoids in vivo and the biological importance of in vivo lipocortin-
mediated inhibition of phospholipase A, 1261-270). 
Glucocorticoid resistance 
Besides the unwanted adverse effects of glucocorticoids in their clinical use, it was 
also observed that glucocorticoid responsiveness varied among patients (277). Furthermore, 
syndromes of partial resistance to the physiologically most important glucocorticoid, 
cortisol, were recognized (for a recent review 278). Hyposensitivity to the glucocorticoid 
action of cortisol was first described in a family in 1976 (279). This could be explained 
recently by a defect in the glucocorticoid receptor (280,281). The defect was shown to 
result from a mutation in the coding sequence. This mutation turned out to be a point 
mutation with a thymidine substituted for adenine at position 2054 in the ligand-binding 
domain. This led to an amino acid substitution from aspartate to valine at position 641 of 
the receptor, resulting in the synthesis of glucocorticoid receptors that are unable to bind 
their ligand effectively. Furthermore, the molecular basis of two other types of familial 
glucocorticoid resistance has been elucidated, recently (282-284). In one family, a 
heterozygous 4 basepair deletion was found, that eventually led to a 50% decrease in the 
receptor concentration with normal binding affinity (282,283). This reduction was 
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suggested to result from low glucocorticoid receptor mRNA transcription or rapid 
degradation of this mRNA. In another family, a point mutation (in position 2317) led to the 
substitution of valine to isoleucine at amino acid residue 729 again within the ligand-
binding domain of the glucocorticoid receptor, resulting in a decreased affinity for its ligand 
(284; for a recent review 2781. 
In the reported syndromes of familial, partial resistance to cortisol, patients presented 
with various symptoms. Most of these symptoms result from compensatory enhanced 
ACTH levels, which also lead to elevated cortisol concentrations. There are no signs of 
Cushing's syndrome, but excess ACTH secretion also results in increased levels of both 
adrenal steroids with salt-retaining activity and adrenal androgens. This may lead to (mild) 
hypertension, hypokalaemic alkalosis, female masculinization (hirsutism, menstrual 
irregularities, acne), or abnormalities in spermatogenesis. However, clinical manifestations 
may be absent, or nonspecific like chronic fatigue as the only symptom (285). 
The above-mentioned mutations are rare and the clinical observation of variable clinical 
response to therapeutically used glucocorticoids may have (an)other explanation(s) (286). 
The variability can sometimes be explained by variable patient's compliance with taking the 
prescribed dose of glucocorticoids, mostly as a result of fear of adverse effects. Other 
causes may be differences in glucocorticoid pharmacokinetics associated with the presence 
of another disease [e.g. hypo/hyperthyroidism (287,2881], enhanced microsomal activity 
induced by comedication [e.g. phenobarbital or rifampicin (203,2891], decreased 
bioconversion of prednisone (290), hypoalbuminemia (291), or the formation of auto-
antibodies directed against glucocorticoid-induced proteins such as lipocortins (292). Table 
7 shows a summary of theoretical causes of the decreased response to glucocorticoids. 
Airway inflammation is believed to be the main cause of bronchial hyperresponsiveness 
in asthma (84). Therefore, glucocorticoids are frequently used in this disease (217-219). 
Certain asthma patients, however, fail to respond adequately to glucocorticoid therapy and 
have been described as suffering from steroid-resistant asthma (277,300,301,304-312). 
Many mechanisms underlying this apparent resistance have been suggested, but the 
precise nature remains to be elucidated. On the one hand, a defect in the glucocorticoid 
responsiveness of blood monocytes has been hypothesized (304-309). Recently, it has 
been reported that in blood monocytes a defective interaction of the glucocorticoid receptor 
with transcription factors such as AP-1 may underlie the clinical observation of asthmatics 
who are less responsive to glucocorticoid treatment (300,301). On the other hand, rapid 
glucocorticoid clearance (3101. abnormal binding of ligand to its receptor (310,311 I. and 
reduction in receptor numbers (311) have been described in mononuclear cells. Further-
more, a defective response of T cells to glucocorticoids has been reported in steroid-
resistant asthma (302,312). In the patients studied, T cells appeared to be activated 
persistently, despite steroid therapy (312), whereas IL-2 in combination with IL-4 was 
shown to reduce the binding affinity of nuclear glucocorticoid receptors for their ligand in 
mononuclear cells and to reduce the T cell response to glucocorticoids (302), These 
findings suggest that multiple cellular abnormalities may underlie the clinical presentation 
of steroid-resistant asthma, and that inflammation in itself may modulate cellular steroid 
responsiveness via locally produced inflammatory mediators. This mechanism may also 
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explain the acquired, partial glucocorticoid resistance observed in AIDS-patients (313). 
Table 7. Theoretical cellular disturbances underlying decreased glucocorticoid responsiveness. 
Disturbance Comment 
relatively low levels of ligand secondary to enhanced steroid metabolism 
hampered diffusion through cell membrane no reports in literature 
decreased number of functional receptors 
interactions of Oiganded) receptor 
with other proteins in the cytoplasm 
hampered translocation of liganded 
receptor from cytoplasm to nucleus 
altered interactions of liganded 
receptor with DNA or other transcription 
factors in the nucleus 
either decreased number or decreased 
affinity for ligand 
e,g, mutual repression of GR and AP-1 in the 
regulation of collagenase gene expression 
role of heat shock proteins? no reports In 
literature (however, interaction of FK 506 
with hsp 56 potentiates GR-mediated effects) 
1, hypothesized molecular defect in 
glucocorticoid-resistant asthma 
Aeferences 
203,288,289 
293-297 
214 
(298,299) 
300,301 
2. interaction of inflammation-induced 214,302 
transcription factors (e.g, AP-1) with 
GR may antagonize glucocorticoid effects 
3_ mutations in the HRR of MMTV affect 303 
response to glucocorticoids 
hampered transcription no reports in literature 
hampered translation no reports in literature 
posttranslational interference auto-antibodies against lipocortins 292 
Abbreviations used: AP-1 
GR 
HRR 
: activator protein-l 
: glucocorticoid receptor 
: hormone response region 
hsp : heat shock protein 
MMTV : mouse mammary tumor virus 
1.3.3 Glucocorticoids and monocytes/macrophages 
Many cell types in various animals, including man, have been shown to possess 
glucocorticoid receptors. Probably all nucleated cells in man express these receptors and 
thus are potentially glucocorticoid-responsive (314). In this part of the introduction we shall 
focus on the influence of glucocorticoids on one particular cell type, mononuclear 
phagocytes, because of their supposed central role in many physiological and pathological 
processes as discussed in the first part of the introduction. 
The presence of glucocorticoid receptors has been described in PBM, which makes the 
observed effects of glucocorticoids on these cells understandable (315,316). In other 
mononuclear phagocytes the presence of specific glucocorticoid receptors has been found 
to be more difficult to demonstrate (316,317), In human AM, binding assays to determine 
the numbers of glucocorticoid receptors are hampered by high nonspecific binding. In our 
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laboratory, we succeeded to by-pass this nonspecific binding and showed conclusively that 
the effects of glucocorticoids on AM in man are also mediated via glucocorticoid receptors 
(318). 
The effects of glucocorticoids on mononuclearphagocytes are diverse (319-321). Most 
of the effects have been studied in vitro, but extrapolation of such results to the in vivo 
situation may be a tricky operation. Different aspects of mononuclear phagocytes can be 
influenced by glucocorticoids. Effects on antimicrobial activity, accessory function, 
maturationldifferentiation and activation will be discussed here. Furthermore, interactions 
of the immune and endocrine systems at the level of mononuclear phagocytes will be 
mentioned. 
Antimicrobial activity of monocyteslmacrophages has been described to decrease upon 
treatment with glucocorticoids, although some reports seem to contradict these findings 
(319,322-325). In vitro treatment of human macro phages impaired the elimination of 
several bacteria and the fungus Aspergillus (322,323). This effect was glucocorticoid 
receptor-mediated. However, another study showed that reduced antimicrobial activity of 
human monocytes in vitro could only be achieved with high doses of glucocorticoids 
exceeding therapeutic levels (324), whereas in vivo reduced monocyte killing of 
Staphylococcus aureus was observed after a 3-day course of prednisone therapy (319). 
Also in animal studies, antimicrobial actions of glucocorticoids show contradictory results. 
In vivo, glucocorticoids suppress resistance to microbial infection in rodents, but the 
phagocytic and microbicidal activities of macrophages isolated from glucocorticoid-treated 
animals often remain normal (325). Nowadays, it is possible to understand these puzzling 
results, as a result of the explosive growth of knowledge of immune processes and 
cytokines. It has been shown that some cytokines, in particular IFN-y, could antagonize or 
enhance effects of glucocorticoids on mononuclear phagocyte functions (323,326-328). 
The ability of macrophages to inhibit the growth of bacteria has been described to decrease 
upon treatment with glucocorticoids, but was restored by IFN-y (323). However, IFN-y was 
only capable of restoring antimicrobial activities against some, not all, pathogens (323). 
These recent findings may help to understand that results of simplified in vitro conditions 
(effect of an isolated cytokine or hormone) cannot be extrapolated to the complicated in 
vivo processes (many interactions between hormones and cytokines) thoughtlessly. 
Part of the antimicrobial activities of mononuclear phagocytes results from the 
expression of membrane receptors that specifically bind the Fc region of immunoglobulins. 
These FcR greatly enhance the ability of mononuclear phagocytes to recognize and 
eliminate microorganisms that are coated with specific antibodies. Especially IgG 
antibodies, which interact with specific FcyR on the cell membrane of mononuclear 
phagocytes/ are able to increase phagocytosis, and are therefore called opsonins (329). 
Several studies, in man and animals, have shown that glucocorticoids and cytokines, in 
particular IFN-y, are able to modulate the expression of FcyR on mononuclear phagocytes 
(328,330-334). The influence of glucocorticoids may be either a direct effect on FcyR 
expression (332/333), or an indirect mechanism, such as the inhibition of IFN-y production 
{2571. These findings enable us to understand the above-mentioned antagonizing effects 
of IFN-y on the glucocorticoid-mediated modulation of phagocytosis. However, the effects 
39 
CHAPTER 1 
of glucocorticoids on FoyR expression are still not fully understood. Some studies showed 
that glucocorticoids downregulated ForR expression in the monocytic cell lines U937 and 
HL60 (332,333), whereas another study showed that in human monocytes FcyR expression 
was not affected by glucocorticoids alone (334). The model is getting even more 
complicated, as three distinct FoyR have been demonstrated in man and rodents, which 
expression is differentially regulated by IFN-y and glucocorticoids (328,335,336). Murine 
macrophages constitutively express FcyRIl and III. Upon stimulation with IFN-y, the 
expression of FcyRI is greatly induced, whereas the expression of FcyR III and II is 
moderately increased and unaffected, respectively (328). Furthermore, dexamethasone was 
shown to enhance the effects of IFN-y on the expression of FerRI, whilst the effects on 
FcyRIl and III were unaffected by glucocorticoids (328). In human cells, recent in vitro 
findings showed that glucocorticoids inhibited the IFN-y-induced increase in FcyRI on U937 
cells, but that they enhanced the IFN-y-induced increase on blood monocytes (337). In vivo 
however, glucocorticoids slightly decreased FcyRI-expression on monocytes, but induced 
a manifest downregulation of FcyRllla-expression (Dr. P.M. Guyre, personal communica-
tion). 
In addition to the antimicrobial activities, also other functions of mononuclear 
phagocytes are mediated by FcyR (superoxide generation, ADCC, release of cytokines) 
(336), and may therefore also be influenced by glucocorticoids. 
The accessory function of mononuclear phagocytes is vitally important in the 
generation of immune responses. Many aspects of this function are still unknown, but it 
is realized that the expression of MHC class II and the production of both IL-1 and IL-6 by 
mononuclear phagocytes are essential (Figure 3) (60). Glucocorticoids are known to 
interfere with the production of IL-1 and IL-6 both in human monocytes and macrophages 
in vitro (249,254,338,339), and the monocytic cell line U937 (250). However, it has also 
been shown that (in vivo) treatment of patients with rheumatoid arthritis did not influence 
the ability of isolated synovial macrophages to produce IL-1 or TNF (340). This stresses 
again the need for reserve in extrapolating in vitro results to in vivo processes uncondition-
ally. Several reports showed that glucocorticoids decrease MHC class II Ag expression on 
macrophages in mice (325,341)' In mice repression of MHC class II I-Ap gene expression 
by glucocorticoids has been shown to result from preventing the binding of the X box DNA 
binding protein to the X box DNA sequence (342). In rats, even the immunostimulatory 
effects of IFN-y on antigen expression could be reversed by treatment with methylpredniso-
lone (343). Glucocorticoid treatment of human monocytes decreased their antigen 
presenting properties (344). 
Maturation/differentiation of mononuclear phagocytes has also been shown to be 
controlled by glucocorticoids (345,346). Different aspects of maturation/differentiation 
were inhibited by glucocorticoids in vitro. Tumoricidal activity, 5' nucleotidase and acid 
phosphatase activity were found to increase upon maturation, but these increases were 
inhibited when human monocytes were cultured in the presence of cortisol succinate or 
dexamethasone (345). In our laboratory, the maturation-associated increases in RFD9 Ag 
expression and acid phosphatase activity, and decrease in CD14 Ag expression were 
inhibited by dexamethasone in human monocytes in vitro (346). In the monocytic cell line 
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U937, PMA induced maturation, which was inhibited by cortisol (347). In contrast with 
these findings, another study in U937 cells showed that TPA-induced maturation was not 
inhibited by glucocorticoids, whereas TPA-induced activation was (348), 
Activation of mononuclear phagocytes may result in an enhanced capacity to present 
antigens or to kill microbes, both of which have already been described above to be 
downregulated by glucocorticoids. In vitro, activation of mononuclear phagocytes can be 
studied after stimulation with various compounds, e.g. TPA or LPS. Activation of U937 
cells with TPA induced a release of lysozyme and prostanoids, and generated reactive 
oxygen radicals. This TPA-induced activation with concomitant functions was inhibited by 
glucocorticoids (348). LPS-stimulated mononuclear phagocytes produce various cytokines, 
e.g. IL-1 p and TNF-C(. IFN-'f enhanced the TNF·" production, and even overcame the 
inhibition of TNF-a. by dexamethasone (349). Again, these findings stress that in vivo, at 
the site of inflammation, probably multiple cytokines and hormones determine in concert 
the eventual effects on the functions of mononuclear phagocytes. Another study showed 
the influence of glucocorticoids on another aspect of activation with LPS; Upon stimulation 
of the macrophage cell line J774 with LPS, NO synthase was induced, and this induction 
could be inhibited by glucocorticoids (271). This resulted in a decreased formation of N02-
and NO, which may be part of the anti-inflammatory mechanisms of glucocorticoids. 
In addition to the above-mentioned effects of glucocorticoids on (more or less) isolated 
functions of mononuclear phagocytes, it is important to realize that an additional aspect 
of the anti-inflammatory effects of glucocorticoids may be a decreased accumulation of 
mononuclear phagocytes at the site of inflammation. This, in turn, may be caused by a 
decreased production of myeloid precursors in the bone marrow, inhibition of maturati-
on/differentiation as mentioned in the last paragraph, a decreased production of 
chemotactic stimuli by other cell types, and a hampered interaction with endothelial cells 
resulting in decreased diapedesis. 
Recent studies have suggested balanced interactions between immunological processes 
and the endocrine system. Immunological functions of mononuclear phagocytes, in 
particular the production of a great variety of cytokines (e.g. IL-l, IL-6, IL-8 and TNF-a) 
(249,254-256,338,339), are regulated by glucocorticoids, adrenal representatives of the 
hormone system. That part of the mutual influences of the two systems will be discussed 
in detail in chapter 2. Conversely, cytokines may influence mononuclear phagocytes at the 
level of glucocorticoid responsiveness. It was shown recently that IFN-y increased the 
number of glucocorticoid receptors in the murine macrophage cell line RAW 264.7 (350). 
It was suggested that this increase in receptor number may be essential for increasing 
macrophage sensitivity to feedback inhibition by glucocorticoids. Another recent study 
showed that either IL-l p, IL·6 or TNF·" alone induced a rise in the binding of 
glucocorticoids in the monocytic cell line U937 (351). Interestingly, antagonistic effects 
were demonstrated between IL-6 and TNF-C(, and between IL-l p and TNF-C( when they 
were applied simultaneously in U937 cells. It was suggested that local imbalance in the 
ratio of these three cytokines may also influence glucocorticoid responsiveness of 
mononuclear phagocytes in vivo. 
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2.1 INTRODUCTION 
Controlling inflammation is still one of the major aims in medicine. Today, many anti-
inflammatory drugs are available (Table 1), but new agents are still being searched for. 
Table 1. Overview of anti-inflammatory drugs. 
Main groups of anti-inflammatory drugs 
1. Derivatives of salicylic acid 
2. Derivatives of acetic acid 
Derivatives of propionic acid 
Derivatives of oxicam 
Derivatives of pyrazolone 
3. Disease modulating/slow acting agents 
4. Anti-neoplastic drugs 
5. Glucocorticoids (derivates of cor~isol) 
6. Cytokines, cytokine receptors and 
their antagonists 
Examples/comments 
- Aspirin 
- Indomethacin. diclofenac 
- Ibuprofen, naproxen 
- Piroxicam 
- Phenylbutazone 
- Gold, antimalarial compounds (chloroquine), penicillamine 
- Cyclophosphamide, azathioprine, methotrexate 
- Prednisone, dexamethasone 
- Clinical trials recently started 
(e.g. Il-l R antagonist and Il-4) 
Glucocorticoids are powerful anti-inflammatory agents. In humans there is a natural 
production of mainly hydrocortisone by the adrenal cortex, and this steroid hormone at 
physiological levels has several vital effects (1). An excessive production, however, leads 
to a disturbance of a hormonal equilibrium resulting in a salient constellation of symptoms 
and physical features. During periods of stress, plasma hydrocortisone concentration is 
elevated, but paradoxically glucocorticoids are able to inhibit the body's defense systems 
against stress factors. It is proposed that this stress-induced increase in hydrocortisone 
level prevents the body's defense reactions from overshooting and needless tissue damage 
(2). Since 1948 these inhibitory effects of glucocorticoids have been used in the treatment 
of several inflammatory diseases, and up until now no equally potent agent has been found. 
This chapter deals with some recently unraveled molecular mechanisms of 
glucocorticoid actions at the level of synthesis and release of mediators in inflammatory 
processes. With the help of these mechanisms it is possible to understand more clearly why 
some inflammatory lung diseases can be treated with glucocorticoids. On the other hand, 
knowledge of the importance and role of certain mediators in inflammatory lung diseases 
combined with understanding of the basic glucocorticoid influences in inflammation will 
lead to predictions as to whether or not such diseases can be combatted with these 
steroids. Hopefully, it will also create possibilities to eliminate the more serious side effects. 
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2.2 HISTORICAL BACKGROUND 
Today it is impossible to imagine life without glucocorticoids in the treatment of a large 
variety of diseases (3), although not so long ago Philip S. Hench wrote that " ... no supplies 
of compound E are expected for treatment or additional research until sometime in 1950 
at the earliest at which time supplies still will be exceedingly small" (4). In his paper he 
mentioned the use of cortisone, originally termed compound E and first isolated 16 years 
earlier (5). in the treatment of rheumatoid arthritis. Following the footsteps of Hench, 
glucocorticoids were soon introduced in the treatment of other inflammatory diseases 
including some lung diseases, in particular asthma (6), Unfortunately this apparent panacea 
turned out also to have undesirable side effects, just as impressive as the intended 
therapeutic effects (7). 
CH,OH 
I 
c=o 
HO OH (a) 
Figure 1. Structure of hydrocortisone. 
In the beginning, cortisone was used and administered intramuscularly, but because 
of the side effects a search for a more ideal anti-inflammatory therapeutic with fewer side 
effects was initiated. In principal two potentialities were investigated. First, it proved to be 
possible to reduce the mineralocorticoid action, which is one of the causes of the unwanted 
side effects. At the same time, the anti-inflammatory effects could be potentiated. This 
was achieved by the production of synthetic glucocorticoid derivatives instead of isolation 
and separation of steroids from adrenal extracts. All these derivatives have, as does the 
very first administered compound E, the same basic structure as hydrocortisone (cortisol) 
(Figure 1). In humans, hydrocortisone is the most important glucocorticoid, while cortisone 
happens to be its natural precursor. Table 2 shows some glucocorticoid~ with their relative 
potencies. Second, attempts were made to reduce the systemic side effects by delivering 
the glucocorticoids locally to the place of disease. This search led in 1972 to the 
introduction of beclomethasone dipropionate (BOP) as a topical aerosol glucocorticoid in the 
treatment of asthma (8). The absence of significant systemic side effects can be explained 
by the fact that the small part of BOP that is absorbed systemically will be converted 
directly in the liver to the much less potent beclomethasone. Since this success, other 
topical glucocorticoids were introduced in the treatment of some lung diseases and several 
other inflammatory disorders. 
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In the 46 years since the first scientific paper on the clinical application of 
glucocorticoids, much clinical and fundamental research has unraveled some of the basic 
mechanisms through which glucocorticoids influence inflammatory and immunological 
processes. Especially the deeper understanding of influences on the production or secretion 
of mediators enables us to explain clinical (side) effects in a more satisfying way. 
Nevertheless, many riddles remain, and scientists are aware of the great diversity of still 
uncomprehended mechanisms, which together define the outcome of glucocorticoid 
treatment (9). 
Table 2. Relative properties of some glucocorticoids. 
Relative 
mineralocorticoid 
effects 
Cortisone (compound E) ++ 
Hydrocortisone ++ 
Prednisone + 
Prednisolone + 
Methylprednisolone 0 
Triamcinolone 0 
Betamethasone 0 
Dexamethasone 0 
Relative 
anti-Inflammatory 
effects 
0.8 
1.0 
4.0 
4.0 
5.0 
5.0 
20 to 30 
20 to 30 
Equivalent dose 
(mg) when 
systemically 
administered 
25 
20 
5 
5 
4 
4 
0.6 
0.75 
General 
comments 
Natural precursor of 
hydrocortisone 
Natural glucocorticoid in 
humans 
Conversion to prednisolone 
In liver 
long b'lologlc half-life with 
prolonged duration of 
effects and side effects 
Budesonide 
Fluticasone propionate 
0 
0 
Developed for inhalation therapy, Higher affinity for glucocorticoid 
receptors than dexamethasone and betamethasone. No systemic 
effects because of an efficient hepatic first-pass metabolism 
2.3 NUCLEAR MECHANISM 
2.3.1. Introduction 
Most investigators are convinced that a so-called "nuclear mechanism" is responsible 
for most, if not all, of the glucocorticoid effects (10). In this mechanism the leading role 
is played by glucocorticoid receptors. These receptors are not membrane receptors, but are 
believed to be situated in the cytoplasm at least in the absence of glucocorticoids. Addition 
of glucocorticoids leads to a shift from the cytoplasm to the nucleus (11). These 
observations were made in experiments with a monoclonal antibody against the 
glucocorticoid receptor on cell cultures. In vivo there probably exists an equilibrium 
between cytoplasmic- and nuclear-situated receptors. 
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The initial events in the nuclear pathway that prelude the glucocorticoid effects 
concern the passive diffusion of gluGocorticoids through the cell membrane and the specific 
binding to the glucocorticoid receptor, which is associated with at least three types of heat 
shock proteins (hsp) (Figure 2). The unliganded glucocorticoid receptor exists in the 
cytoplasm as a hatera-oligomer and interacts with two molecules of hsp 90 and one 
molecule of hsp 70 (12,13). Hsp 56 presumably does not interact with the receptor itself, 
but interacts with and regulates the function of hsp 90 (14,15). As a result of the binding 
of g/uGocorticoids to their receptors, the receptor molecule undergoes some changes, 
probably expressed in the sterle conformation, and acquires a high affinity for binding to 
specific DNA sequences in the nucleus. The original receptor has now turned into an 
activated (transformed) receptor-ligand complex. Moreover, this activation is accompanied 
by the dissociation of two types of the heat shock proteins (hsp 90 and hsp 56) from the 
receptor (Figure 2). Dissociation of hsp70 from the receptor is thought to take place not 
in the cytoplasm, but at a later stage in the nucleus (16). The precise functions of these 
hsp are not yet clear. Probably, hsp 90 plays a role in transport of the glucocorticoid 
receptor towards the nucleus through interactions with the cytoskeleton (17 118). The same 
cell 
membrane 
? ? 
nuclear 
membrane 
influence at 
mRNA-Ievel 
influence at 
protein-level 
influence on 
inflammation 
I 
I 
clinical effecl 
Figure 2. Hypothetical cellular events after glucocorticoid administration, Glucocorticoids (5), steroid 
hormones, pass the cell membrane and bind to their receptors (R), The unliganded glucocorticoid receptor 
is part of a multi protein complex, that also consists of several heat shock proteins (hsp). Upon binding of 
glucocorticoids to their receptors, some hsp (hsp 56 and hsp 90) dissociate from the receptor in the 
cytoplasm. Others (hsp 70) probably dissociate from the receptor in the nucleus. Furthermore, in the nucleus 
liganded glucocorticoid receptors form homodimers and interact with specific DNA sequences. Eventually, 
this interaction results in modulation of transcription. 
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function has been suggested for hsp 70, whereas hsp 56 may playa role in the regulation 
of hsp 90 function (15), Furthermore, hsp 56 may interact with the immunosuppressive FK 
506, leading to an increased translocation of the glucocorticoid receptor to the nucleus 
(19,20). 
Next, the activated receptor-glucocorticoid complex passes the nuclear membrane, 
"recognizes" a specific DNA sequence, and binds to it (for recent reviews: 21,22). These 
DNA sequences are now recognized as enhancers of DNA transcription (23) and are called 
glucocorticoid response elements (GRE). It is known now that there exist two classes of 
steroid hormone responsive elements in general. One group mediates response to 
glucocorticoids, progestins, mineralocorticoids, and androgens. This group is known as the 
group of glucocorticoid/progesteroneresponse elements (GRE/PRE), and has the consensus 
nucleotide sequence GGTACAnnnTGTYCY (24), The other group mediates response to 
estrogens, thyroid hormones, vitamin 0 3 and retinoic acid, and has the consensus sequence 
GGTCAnnnTGACC (24), The prototype of this group is the estrogen response element 
(ERE). In common with the other response elements, GRE are either palindromic or half-
palindromic sequences. This probably accounts for the fact that in general not one 
activated receptor-ligand complex binds to DNA, but a homo- or hetero-dimer of complexes 
(25,26), Through this binding, the transcription of DNA to mRNA can be influenced at 
places of the genome, mostly far removed from the GRE (27). Steroid hormone response 
elements found in hormonally responsive genes are usually clustered as hormone response 
regions (HRR). Examples of such clusters of binding sites for the same class of steroid 
hormone receptor are found in the HRR of the MMTV (21; Figure 3), the rabbit 
uteroglobuline gene (28), and the chicken lysozyme gene (29), 
-200 
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,'-----------
~~1~ 
HRE 
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HRE 
-100 
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Figure 3, Schematic representation of the mouse mammary tumor virus (MMTV) promoter. The hormone 
response region (HAA) consists of four separate hormone response elements (HRE). HAE 1 and 2 are 
palindromic structures, whereas HRE 3 and 4 are half-palindromes. Furthermore, the binding site for NF-1, 
the two octamer motifs (Oct), and the TATA box are shown. 
Furthermore, HRR may be integrated in the context of a complex array of additional 
sites for other transcription factors (21; Figure 3). The interactions among receptors bound 
to these clusters of response elements and the interactions between these receptors and 
other transcription factors play an important role in steroid hormone response (21,30,31). 
Influence of the GRE-bound receptor-ligand complex on transcription is mediated partially 
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by transcriptjon~activation domains on the receptor. The glucocorticoid receptor contains 
at least three transcription-activation domains, one in the steroid-binding, one in the DNA-
binding, and one in the N-terminal domain (22,32-34). It is generally thought that these 
transcription-activation domains contact transcription factors, whereupon the transcription 
machinery is either activated or deactivated (21,22,35). It is possible to get either an 
increased transcription or a decreased transcription. This regulation at the level of mRNA 
finally results in induction or inhibition of the translation of mRNA to protein. The induced 
or inhibited proteins probably account for many of the clinical glucocorticoid effects, 
although as yet only a few glucocorticoid-regulated proteins have been identified (Table 3). 
The intermediate between administration of glucocorticoids and the clinical effects caused 
by influenced protein synthesis usually takes a minimum of several hours. 
Table 3. Influence of glucocortlcoids on the synthesis of some proteins involved in inflammation. 
Protein 
lipocortins 
Interleukln-1 
Interleukin-2 
Interleukin-3 
Interleukin-5 
Interleukin-6 
Interleukin-B 
TNF-Ct: 
interferowt 
Collagens 
Nuclease 
Inffammatory function of protein 
Regulate the production of 
arachidonic acid metabolites 
by phospholipase A2 inhibition 
Early role in inflammation 
Induces T cell proliferation 
Regulates hematopoiesis 
Induces eosinophilia 
Early role in inflammation 
Chemotactic for neutrophils 
Role in shock, capillary leak 
Activation of mononuclear phagocytes 
Enhanced deposition in fibrosis 
Degrades DNA leading to 
Iymphocytolysis in mice 
2.3.2. Glucocorticoid receptor 
Glucocorticoid effect 
on gene transcription References 
Increase 77-100 
Decrease 103,104 
Decrease 106-108 
Decrease 110 
Decrease 113 
Decrease 116 
Decrease 119 
Decrease 120 
Decrease 107 
Decrease 122-124,126 
Increase 130 
With the nuclear mechanism in mind, it is possible to imagine the glucocorticoid 
receptor (GR) as a protein with different functional domains: one domain with the function 
to bind steroid and another domain with the function to bind DNA (Figure 4). The existence 
of such functional domains has been confirmed by limited proteolysis of crude and purified 
GR (36). Mild digestion with different proteases resulted in different proteolytic fragments, 
some still able to bind glucocorticoids or DNA. At that time, these findings strengthened 
the hypothesis that separate DNA- and steroid-binding domains were present within the 
GR. Apart from the steroid-binding capacity, the steroid-binding domain is nowadays also 
believed to possess a transcription activation function (37). The DNA-binding region 
contains two subregions which are both able to form a "zinc finger" (38/39). The first, N-
terminally located, "zinc finger" is believed to recognize one half of the palindromic GRE 
and to interact with the major groove of the DNA double helix. More precisely, three amino 
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acids at the C-terminal site of this finger are believed to determine DNA binding specificity 
(for a recent review: 38). The second "zinc finger" plays a role in the dimerizatlan of two 
glucocorticoid receptor molecules upon binding to GRE (38,40). The DNA-binding region 
is also known to have a transcription-activation function (33,34). Furthermore, a third 
domain has been recognized by making antibodies against the receptor (immunogenic 
domain in Figure 4) (41). The precise role of this third domain is still uncertain, but it is 
required in transcriptional regulation. A portion of the receptor molecule between the DNA-
binding and steroid-binding domain has been termed "hinge region", because of supposed 
flexibility in determining the three-dimensional structure (Figure 4). 
immunogenic domain 
A 
. 
! transcription-aclivation 
site 1 
hinge region 
,------, 
DNA binding 
domain 
steroid binding 
domain 
) 
,~, ~transcriPtion-activalion 
! site 3 
i Iranscriplion-aclivation 
site 2 
"zinc·finger" II 
"zinc-finger" I 
Figure 4. Linear alignment of the human glucocorticoid receptor. Nand C represent the N-terminal and e-
terminal end of the protein, respectively. 
This subdivision of the GR into three main domains is also visible at the level of DNA. 
This observation was enabled by the cloning of the human GR cDNA (42). Thanks to the 
cloning of other hormone receptors with a transcriptional regulatorY function, it became 
possible to compare these receptors at the DNA and protein level (estrogen receptor (43), 
mineralocorticoid receptor (44), progesteron receptor (45), androgen receptor (46). In 
particular the cloning of the mineralocorticoid receptor needs to be mentioned because it 
also has, added to its aldosteron-binding capacity, a high cortisol-binding capacity, but a 
low dexamethasone-binding capacity. Therefore, this receptor is often referred to as a type 
I corticosteroid binding site, whereas the glucocorticoid receptor, having a high affinity for 
dexamethasone and a low one for aldosteron, is often referred to as a type /I binding site 
(47). 
Comparisons at the level of DNA led to the discovery that there were important 
homologies between the different steroid receptors. The regions of highest homology at the 
DNA level appeared to code for two of the three above-mentioned functional domains at 
the protein level. Because of these regions of similarities, it is thought that steroid receptors 
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in general are built up as variations on a shared theme (48). At the protein level the 
above-mentioned homology among the steroid receptors can be expressed as the 
percentage of identical amino acids. The DNA-binding domains have the highest homology, 
the steroid-binding domains possess a lower homology, whereas the immunogenic domain 
expresses the lowest homology (Table 4). These homologies can be explained functionally: 
to bind cortisol the GR has to possess at least the structure to bind a steroid in general. 
Amino acids stabilizing this structure have to be present also in other steroid receptors, and 
these amino acids represent the homology. Specificity for cortisol is expressed by those 
amino acids that are not homologous. The same thinking concerns the DNA-binding 
domains: to bind DNA a certain protein structure is demanded (the homology). Binding to 
specific GRE in DNA is determined by some of the remaining amino acids, which differ from 
those in other steroid receptors. It is known now which amino acids determine specificity 
for either a GRE or a ERE. Combining the results from three laboratories it became clear 
that three amino acids playa key role in distinguishing between these two response 
elements (38,49-51). These amino acids are located at the C-terminal site of the first zinc 
finger, at positions 458, 459, and 462. It was demonstrated that a three amino acid 
change of Glu-Gly-Ala (EGA) in the ER to Gly-Ser-Val (GSV) completely switched receptor 
specificity from an ERE to a GRE (50). 
Table 4. Comparison of the human glucocorticoid receptor with other human receptors with transcriptional 
regulatory functions concerning the DNA-binding and steroid-bindIng domains. 
Mineralocorticoid receptor 
Progesterone receptor 
Androgen receptor 
Estrogen receptor 
Thyroid hormone receptors 
Retinoic acid receptor 
Vitamin D3 receptor 
Percentage homology with 
the glucocorticoid receptor 
DNA-binding 
domain 
94 
83 
76 
62 
47 
45 
42 
steroid binding 
domain 
57 
54 
50 
30 
17 
<15 
<15 
On the other hand, specificity is also determined by the structure of the response 
elements: the response elements for estrogens differ from the GRE. However, the GRE 
appears to be similar to response elements for progesterone, mineralocorticoids and 
androgens, indicating that hormone-specific gene regulation is not determined by DNA 
binding alone. Additional receptor-protein interactions, which are not fully understood, play 
an important role (21,52). Specific interaction of transcription factors [e.g. nuclear factor 
I (NF I), octamer transcription factor-1 (OTF-1L activator protein-1 (AP-1)] with steroid 
hormone receptors andlor promoters may determine further hormone-specific gene 
regulation not shared with other steroids. Furthermore, the relative levels of expression of 
the different steroid receptors in a particular cell may also determine hormone-specific 
actions. 
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As steroid hormone receptors are phosphoproteins, phosphorylation may also be a way 
to modulate receptor function (53). Receptors are basally phosphorylated in the absence 
of ligand, but a certain degree of hyperphosphorylation is observed in the presence of 
hormone. Phosphorylation may affect intracellular traffic of receptors, but also reutHization, 
transcriptional regulation and interaction of receptors with other molecules are probably 
influenced by the degree of phosphorylation (21,53). 
Steroid receptors belong to a superfamily of DNA~binding proteins able to modulate 
gene expression (54). On one hand, this family concerns proteins (e.g., GR) which need the 
binding of a ligand (e.g., cortisol) before being able to bind to DNA. On the other hand, 
there are supposed to be proteins (products of oncogenes) able to bind to DNA without the 
need for a ligand. Therefore, these proteins can influence the transcription of genes 
continuously in the absence of a ligand. In case these genes concern the production of a 
growth factor, the continuous stimulation of transcription may lead to an overproduction 
of growth factors. This mechanism attractively suggests a relation between oncogene 
products and hormone-independent neoplasms (55). At the moment this superfamily 
concerns the different steroid receptors, the c-erb-A proto-oncogen (identical to the thyroid 
hormone receptor) (56), another thyroid hormone receptor (present in the central nervous 
system) (57), the retinoic acid receptor families (58,59), the vitamin D receptor (60), and 
numerous orphan receptors, e.g. hERR 1 and 2 (61), COUP-TF's and EAR's (for a recent 
review: 62,63). 
The search for the putative ligands of the orphan receptors has recently led to new 
insights into activation of the steroid hormone receptors. It was found that the 
neurotransmitter dopamine stimulated COUP-TF-dependent activation of a target gene 
(62,64). This effect did not appear to be mediated through direct binding of dopamine to 
COUP-TF, but was suggested to result from the interaction of dopamine with its 
membrane-bound receptor. This "cross-talk" between a cell membrane signal transduction 
pathway and the modulation of gene expression by steroid hormones may be mediated by 
phosphorylation of the steroid hormone receptor. These findings shed a new light on the 
ligand-independent activation of steroid hormone receptors and stress the above-mentioned 
significance of phosphorylation for receptor function (53). On the other hand, not all steroid 
receptor systems may be activated by such neurotransmitters. This may apply to the 
glucocorticoid receptor system, as CV1 cells co-transfected with a human glucocorticoid 
expression vector and a target gene were transcriptionally responsive to dexamethasone, 
but totally unresponsive to dopamine (62). Other evidence for "cross-talk" between the 
steroid hormone signalling pathway and signal transduction via cell membrane receptors 
comes from the fields of cytokines (for a recent review: 65) and oncogenes (66-69). 
Recently, IFN-o: was shown to modulate phosphorylation of transcription factors in the 
cytoplasm, which then translocate into the nucleus and regulate transcription (66; Figure 
5). The Ras-dependent signalling pathway was shown to run from the cell membrane to the 
nucleus (67), Growth factors may affect Ras activity, which eventually leads to 
translocation of activated protein kinases into the nucleus, where they phosphorylate 
transcription factors (67; Figure 5). Final regulation of gene transcription is thought to 
depend on the interactions of steroid hormone receptors with transcription factors in the 
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nucleus (69). In addition to these interactions in the nucleus, interactions of the 
glucocorticoid receptor with transcription factors in the cytoplasm have also been 
suggested (70-72). The transcription factor AP-l, a protein complex of the products of the 
c-jun and c-fos proto-oncogenes, was shown to interact with the liganded glucocorticoid 
receptor (73). This interaction prevents translocation of the receptor from the cytoplasm 
into the nucleus (Figure 5). In this way, AP-1 is able to counteract glucocorticoid actions. 
On the other hand, glucocorticoids may antagonize the actions of AP-1. The latter 
represents an important mechanism of the anti-inflammatory effects of glucocorticoids, and 
explains the repressive effects of glucocorticoids on IL-1-induced expression of the 
collagenase gene (74). Recently, direct interactions of glucocorticoid receptors with other 
transcription factors resulting in altered gene expression have been reported (75,76). A 
functional antagonism between the transcription factor NF-KB and the glucocorticoid 
receptor has been demonstrated in the regulation of the expression of the IL-6 gene (75). 
This antagonism resulted from physical association between the two proteins. In epithelial 
cells, it was shown that a direct interaction between the transcription factor CREB and the 
glucocorticoid receptor reduced binding of the latter protein to GRE (76). 
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Figure 5. Hypothetical "cross talk" between different cellular signalling pathways. 
Abbreviations used in this Figure: activator protein (AP); deoxyribonucleic acid (DNA); epidermal growth 
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2.3.3. Glucocorticoid-regulated mediators 
Phospholipase A2 inhibitory proteins 
One group of proteins of which synthesis is thought to be inducible by glucocorticoids 
involves lipocortins (77,78). Upocortin is the proposed unified name of a family of 
phospholipase A2 inhibiting proteins. The first identified inhibitor was isolated from guinea 
pig lungs and peritoneal macrophages, and was named macrocortin (79). In other 
experiments, proteins with phospholipase A2 inhibitory properties were also demonstrable 
and christened as renocortin and lipomodulin (80). Also, the release of stored lipocortins 
can be induced by glucocorticoids (81). Recently, human lipocortin complementary DNA 
has been cloned, and the gene has been expressed in E. coli (82). 
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aspirin 
Figure 6. Interaction sites of steroidal (glucocorticoids) and nonsteroidal (e.g. aspirin) anti-inflammatory drugs. 
In vitro these proteins inhibit phospholipase A2 activity leading to a reduced production 
of arachidonic acid and consequently to a reduced production of arachidonic acid 
metabolites (Figure 6). How inhibition of phospholipase A2 by lipocortins is achieved is still 
a matter of debate. In the beginning it was suggested that lipocortin inactivated the enzyme 
by direct binding. However, a research line involving substrates of viral and growth factor 
receptor tyrosine kinases suggested another possibility (83). This line of research led to the 
discovery of calpactins: proteins with calcium-dependent phospholipid- and actin-binding 
capacity. Eventually, calpactins were found to be equivalent to lipocortins: lipocortin I 
equals calpactin II, and lipocortin II is comparable to calpactin I. Furthermore, recent data 
show that calpactin-mediated inhibition of phospholipase A2 is most probably due to 
Ca2+ -dependent binding of calpactin to phospholipids, the substrate of phospholipase A2 
(84). The discovery of these calpactins expanded the number of potential inhibitors of 
phospholipase A2 (83). Recently, it has been suggested to rename this family of proteins 
"annexins" (85; Table 5). A novel annexin (annexin XII has been identified recently (86). 
Some members of this group of proteins are suggested to be a secretory form (annexin I 
is secreted by macrophages), whereas others are intracellular proteins (annexin II). These 
different forms might be regulated in different ways by glucocorticoids (87). 
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No matter what the exact mechanism of lipocortin action, inhibition of phospholipase 
A2 leads indirectly to an inhibition of both the cyclooxygenasc and the lipoxygenase 
pathway (Figure 6). As a result, the synthesis of all arachidonic acid metabolites 
(prostaglandins, thromboxanes, and leukotrienes) is reduced. In addition, by inhibition of 
phospholipase A, activity, the production of platelet-activating factor (PAF) will also be 
impaired (Figure 6) (88), In contrast, nonsteroidal anti-inflammatory drugs like aspirin are 
only able to inhibit the cyclooxygenase pathway without influencing the production of 
leukotrienes and PAF (89). 
Table 5. Revised nomenclature of lipocortins, calpactins and blood coagulation inhibitors. 
Annexin 
Previous 
terminology 
Annexin 
Previous 
terminology 
lipocortin I 
p35 
Calpactin II 
Chromobindin 9 
GIF 
V 
PAP-l 
Lipocortin V 
35K Calelectrin 
Endonexin II 
PP4 
VAC-a 
35-y Calcimedin 
Calphobindin I 
Anchorin Gil 
II 
Calpactin I 
Lipocortin II 
p36 
Chromo bind in 8 
Protein I 
PAp·IV 
VI 
p6a, p70, 73K 
67K Calelectrin 
Lipocortin VI 
Protein III 
Chromobindin 20 
67K Calcimedin 
Abbreviations used: GIF : glycosylation-inhibiting factor 
PAP : placental anticoagulant protein 
III 
Lipocortin HI 
PAp·1II 
35-a Calcimedin 
VII 
Synexin 
IV 
Endonexin I 
Protein II 
32.5K Calelectrin 
Upocortin IV 
Chromobindin 4 
PAP-II 
PP4-X 
VIII 
VAC-P 
PP placental protein 
VAC : vascular anticoagulant (protein) 
All these phospholipase A2-dependent metabolites are important mediators in 
inflammatory processes (90,91). Therefore, on the basis of in vitro experiments, regulation 
of the expression and activity of lipocortins has been postulated to be at least one of the 
keystones by which glucocorticoids exert their anti-inflammatory actions in vivo. It has 
been shown that monoclonal antibodies against lipocortins block the suppressive effects 
of glucocorticoids on the release of arachidonic acid (92). In some patients suffering from 
autoimmune disease, autoantibodies against lipocortins have been found (92). Probably the 
effective serum level of lipocortin in these patients is inversely related to the severity of 
their disease. Research is focused now on the direct application of lipocortins instead of 
glucocorticoids as a therapeutic in inflammatory diseases. Notwithstanding the over-
whelming data on the action of lipocortins in vitro leading to an attractive general model 
to explain the inhibition of the mediator production by glucocorticoids, there still remain 
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questions about differences between in vivo and in vitro experiments (82,93). After in vivo 
treatment of rats with dexamethasone, rat peritoneal macrophages showed a sixfold 
increase of lipocortin I mRNA (82), whereas in vitro treatment of human cells did not lead 
to a detectable increase of lipocortin I mRNA (93). In both experiments the increase is 
puzzlingly not accompanied by an increase of the protein level. Analyzing these 
experiments, one has to bear in mind that glucocorticoids can affect posttranslational 
processing and compartmentalization of proteins without changing the total protein level 
(94). Moreover, in in vivo experiments with rabbits and healthy human volunteers, 
dexamethasone treatment does not lead to a decrease in the level of eicosanoid metabolites 
in urine (95,96), In contrast, dexamethasone is indeed able to block increased LT84 
production during endotoxin-induced lung injury in pigs in vivo (97). 
Recently, another aspect of the biological activity of lipocortin I was published. It was 
shown that lipocortin I could modulate cell functions by binding to specific cell surface 
receptors on blood monocytes and neutrophils (98). 
In conclusion, it can be said that there is compelling evidence that glucocorticoid-
induced phospholipase A2 inhibitors play an important role in regulating the production of 
inflammatory mediators, although their exact mechanisms of inhibition remain to be 
elucidated. Under certain conditions glucocorticoids can influence the production of 
lipocortins in vitro and in vivo. The precise role of these glucocorticoid-inducible proteins 
as physiological regulators of inflammatory reactions in humans has to be further evaluated 
(for recent reviews: 99,100), 
Interleukin-l 
Another protein with an important immunological and inflammatory role and 
transcription of which is believed to be influenced by glucocorticoids is interleukin-1 (1 01 ). 
Interleukin-1 (IL-1) can be produced by a variety of cell types, but the most important 
source in view of inflammatory processes concerns antigen-presenting cells. The lungs 
harbor a large number of antigen-presenting cells, represented mostly by dendritic cells and 
alveolar monocytes/macrophages. Therefore, a large source of IL-1 is potentially present 
in the lung, although alveolar monocytes/macrophagesdiffer in their ability to produce IL-1, 
probably related to differences in cell maturation (102). IL-1 is able to influence many 
different target cells, among which are cells with important inflammatory properties (101). 
In this respect, the influence of IL-1 on cytokine production and proliferation of T 
lymphocytes is important, whilst polymorphonuclear leukocytes and macrophages have 
been reported to be chemotactically attracted to IL-1 and to become activated. 
Since many years, it is known that glucocorticoids inhibit IL-1 release from murine 
peritoneal macrophages (103). Recently, it was reported that pharmacological doses of 
dexamethasone could block transcription of the IL-1 gene in a bacterial toxin-stimulated 
human monocytic cell line, U937 (104). It was also shown in this study that higher doses 
of dexamethasone could block IL-1 release. This was not due to an enhanced degradation 
of IL-1 mRNA, but most likely to an elevation of cAMP levels. It is therefore conceivable 
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that in vivo anti~inflammatory actions of glucocorticoids may also, at least partly f be caused 
by suppression of IL-1 expression. 
Interleukln-2 
Interleukin-2 (lL-2), also termed T cell growth factor, is a protein of which the most 
important immunological function is to enable the proliferation of activated T cells. 
Activated T cells possess the dimeric, high affinity IL-2 receptor and show clonal expansion 
upon stimulation with IL-2 (105). In addition, IL-2 is able to enhance the cytolytic activity 
of natural killer cells. 
Glucocorticoids have been shown to suppress directly the production of this 
Iymphokine in vitro, and at methylprednisolone concentrations over 10 Ilg/ml the induction 
of the IL-2 receptor was also inhibited in vitro (106). Glucocorticoids are now known to 
inhibit the IL-2 production at the level of mRNA (107). These data strongly suggest that 
in vivo regulation of IL-2-driven immunological processes can be a mechanism through 
which glucocortlcoids exert their anti-inflammatory and immunosuppressive actions. 
Unfortunately, one has also to bear in mind that the effects of glucocorticoids in vitro 
can be dependent upon the choice of cell type. It has been shown that glucocorticoids 
exert different actions on the proliferation of a murine helper and a cytolytic T cell clone 
after addition of IL-2 or IL-4 (108). It was shown that the IL-2-driven proliferation of a 
cytolytic clone did not respond to glucocorticoids, while the proliferative response to IL-4 
could be blocked by glucocorticoids. In contrast, addition of glucocorticoids to a (Th2-type) 
helper clone blocked the IL-2-driven proliferation, while the IL-4-driven proliferation was not 
affected. In this view, the in vivo actions of glucocorticoids on concerted lymphocyte 
functions are probably even more complex. 
Interleukin-3 
Interleukin-3 (IL-3) has been described to be produced by human activated T cell clones 
(109). Probably IL-3 plays a significant role in the rapid expansion of hemopoietic cells in 
response to immunological stress. Recently, IL-3 expression was also shown to be under 
control of glucocorticoids, at least in cloned murine T lymphocytes (110). 
Because experiments were done with a murine helper T cell clone incapable of 
producing IL-2, the possibility that IL-3 mRNA is regulated by glucocorticoid-regulated IL-2 
concentrations could be ruled out. 
Interleukin-5 
Interleukin-5 (IL-5) has been shown to be a potent and specific growth factor for 
eosinophilic granulocytes (111). Because of the eosinophilia seen in bronchial asthma, IL-5 
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has been suggested to playa key role in the pathogenesis of asthma. It was also shown 
that anti-IL-5 monoclonal antibodies inhibited BAL eosinophilia and airway 
hyperresponsiveness in an animal model (112). In human mononuclear ce/ls, using the peR-
technique, it was shown that dexamethasone (10·s-10·'M) suppressed IL-5 mRNA 
expression in vitro (113). These effects may be a mechanism of the beneficial effects of 
glucocorticoids in asthma. 
Interleukin-6 
Another cytokine believed to contribute to the process of inflammatory responses is 
interleukin-6 (IL-6), Different inflammatory stimuli like LPS, IL-1 and IFN-y induce IL-6 
transcription in monocytes (114). IL-6 promotes growth of B cells, plasma cells, T cells, 
and induces acute phase proteins in hepatocytes (115). Dexamethasone (1 0-9-1 a-6M) was 
shown to inhibit IL-6 production at the transcriptional level in human monocytes, 
endothelial cells and fibroblasts (116), 
Interleukin-8 
The cytokine interleukin-8 (lL-8) has been implicated as a major chemotactic and 
activating factor for neutrophils. Mononuclear phagocytes are the predominant source of 
IL-8 in various inflammatory diseases. It was shown that dexamethasone decreased IL-8 
mRNA levels in both LPS-stimulated human peripheral blood monocytes and alveolar 
macrophages (119). It is not known whether glucocorticoids decrease IL-8 mRNA synthesis 
or accelerate its decay (119), 
Tumor Necrosis Factor-(X 
Tumor necrosis factor-a (TNF-a) has been described to be a central cytokine in 
inflammation (117). Many of its effects are caused by the induction of other mediators, and 
it plays a role in leucocyte chemotaxis and activation, shock, capillary leak syndrome, 
necrosis and many other aspects of inflammatory diseases (118). It was shown in mice and 
human lung fragments that dexamethasone (1 O"M) inhibited the transcription of TNF-a, 
providing an additional mechanism for the anti-inflammatory and immunosuppressive 
effects of glucocorticoids (120), 
Interferon-y 
Interferon-y OFN-y) belongs to a family of proteins first recognized by their antiviral 
properties. It is produced by activated T lymphocytes and is able to increase the numbers 
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of monocyte and macrophage Fe receptors, thereby augmenting some immunological 
functions of monocytes and macrophages. Furthermore, it is capable of inducing class I and 
class 1/ histocompatibility antigens (1 21 ). Dexamethasone inhibits in vitro the accumulation 
of IFN-y mRNA in human, phytohemagglutinin-stimulated peripheral blood lymphocytes 
(107). It is not yet known whether this inhibited accumulation is mediated through a direct 
effect on the IFN-y gene transcription or whether it is regulated by another 
glucocorticoid-induced mediator. 
2.3.4. Other glucocorticoid-regulated proteins 
Besides the above-mentioned regulation of lipocortin and cytokines, the genes of other 
proteins with important functions in inflammatory processes have been proven to be under 
regulation of glucocorticoids. These regulations take place at the level of DNA transcription 
and can be explained by the nuclear working mechanism of glucocorticoids. 
Collagen 
Glucocorticoids have been shown to inhibit the synthesis of collagen in many in vitro 
models (122,123). The exact mechanism by which this inhibition takes place has been a 
matter of debate. Some studies suggest that transcriptional regulation by glucocorticoids 
causes the decrease in mRNA (122), while other studies propose a change in the half-life 
of mRNA (123). Recently these two views were united when it was shown that 
dexamethasone both decreases the transcription of the collagen gene in vitro and appears 
to lead to a posttranslational effect on the procollagen mRNA content (124). Analyzing the 
above-mentioned studies one has to keep in mind the possible influence of the used 
glucocorticoid and its concentration on the ultimate results. In one study, dexamethasone 
was used at the concentration of 1 x 10~7 M, while in another 250 x 10-7 M was used. 
Cortisol at 100 x 10-7 M was also used in some experiments. The mechanism of collagen 
inhibition may depend on the glucocorticoid concentration. Although in some pulmonary 
diseases the use of glucocorticoids is debatable (125), in pulmonary diseases with active 
collagen secretion leading to restriction of lung volume, the use of glucocorticoids to 
diminish the production of collagen seems tenable, especially in view of the 
above~mentioned in vitro results. In late stage adult respiratory distress syndrome (ARDS), 
lung edema is no longer present. Instead, extensive collagen formation with the 
development of fibrosis takes place. EVen early stages of some forms of ARDS are 
characterized by active collagen synthesis in the pulmonary interstitium (126). 
Administration of dexamethasone especially during the late stage of AROS may thus be 
useful. This is demonstrated in Figure 7 showing the results of dexamethasone 
administration in a patient who developed ARDS after a pneumococcal pneumonia. 
Dexamethasone application resulted in a downregulation of collagen formation with an 
increase in lung compliance allowing a successful weaning of the ventilator. 
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Figure 7. Illustration of the influence of 
dexamethasone on the late (proliferative) phase 
with newly formed collagen and fibrosis in a 
patient with adult respiratory distress syndrome 
(ARDS), A 40-year-old female admitted with a 
pneumonia developed ARDS. Because of 
deteriorating lung function parameters, 
dexamethasone (16 mg/day) was given on day 
26. This resulted in a down regulation of fibrosis 
and clinical improvement. The dead-space 
ventilation decreased resulting in a decreased 
physiological dead space/tidal volume (VDP-"IV,1 
ratio. The compliance of the lung increased as 
indicated by the increase in total static 
compliance (TSC), whereas the lung volume 
increased as indicated by the increase in 
functional residual capacity (FRC). 
The collagenase family, a group of metalloprotease enzymes, is involved in the 
degradation of collagen and other basal membrane constituents, In inflammatory diseases, 
tissue damage may be caused by the action of metalloproteases (e.g. damage to cartilage 
in rheumatoid arthritis) (127). Inflammatory cytokines as Il-1 and TNF-a induce the 
expression of some metalloprotease genes (128,129). This effect is mediated via the 
transcription factor AP-1. Glucocorticoids bound to their receptor are known to interact 
with AP-1 in the cytoplasm, thus preventing the gene expression of collagenase (70-72). 
This anti-inflammatory action of glucocorticoids results from modulation of transcription 
without binding of the receptor-steroid complex to DNA. 
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Nuclease 
In man, cells are relatively corticosteroid resistant, compared with rodents such as mice 
and rats (9), In these rodents, gluGocorticoids cause lymphocyte depletion resulting from 
cell death and shrinkage of lymphoid tissue, while in man this kind of cell death can only 
be observed in glucocorticoid treatment of certain lymphatic leukemias. The central event 
in this cytolytic process concerns degradation of the genome, and it was hypothesized that 
steroid-induced cell death was dependent upon the induction of a protein. In rats this 
protein has now been identified as a nuclease (130). Whether the induction of such a 
protein also plays a role in man in the treatment of glucocorticoid-responsive diseases, in 
particular the treatment of inflammatory lung diseases, has still to be evaluated. 
ICAM-I (CD 54) 
The intercellular adhesion molecule-1 (ICAM-1; CD54) represents a member of the 
immunoglobulin gene-like superfamily and plays a role in cellular interactions. It interacts 
with integrin receptors on other cell types and mediates diapedesis and infiltration of tissue 
by inflammatory cells. Regulation of the expression of these interaction-regulating proteins 
may modulate inflammation (131). Recently, it was shown that glucocorticoids are able to 
downregulate ICAM-1 expression in both a human monocytic and bronchial epithelial cell 
line (132). The mechanism of this effect is not clear yet. It has been suggested that ICAM-
1 mRNA expression may be regulated by transcription factors. A direct interaction of the 
steroid-glucocorticoid receptor complex with these transcription factors, in the absence of 
GRE, may eventually downregulate ICAM-1 mRNA expression. 
Neutral endopeptidase (CD 10) 
Neutral endopeptidase [NEP, EC 3.4.24.11, common acute lymphoblastic leukemia Ag 
(CALLA), CDlO] belongs to the group of ectoenzymes, so-called because of their 
extracellularly located catalytic sites. The physiological function of these enzymes is being 
unraveled nowadays. NEP has been reported to process a number of biologically active 
peptides (133), including neuropeptides (134). It has been suggested that NEP may 
modulate neurogenic inflammation (e.g. in asthmatic lungs) by enzymatic degradation of 
neuropeptides (e.g. substance P) (134). Glucocorticoids have been shown to increase NEP 
expression in airway epithelial cells (135), although a recent study could not reproduce 
these findings (136). This increase in expression may represent an increased activity to 
terminate inflammation, and may be an actual working mechanism of glucocorticoids. 
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2.4 NONNUCLEAR MECHANISM 
Because some glucocorticoid actions appear faster than could be expected through the 
above-mentioned influence on mRNA production, some investigators have postulated that 
giucocorticoids are also able to influence cellular events without interfering with nuclear 
processes (137,138). One of the actions concerns the inhibition of ACTH release that 
begins minutes after administration of glucocorticoids. Probably such effects are 
attributable to an interference of steroid (whether or not bound to the glucocorticoid 
receptor~ see Figure 2) with protein phosphorylation or to an interaction with the cell 
membrane leading to a change in intracellular Ca2+. An important role of intracellular Ca2+ 
concerns the activation of a cAMP-dependent protein kinase which is able to phosphorylate 
lipocortin. Upon phosphorylation lipocortin is inactivated, leading to an increase in 
phospholipase A2 activity and an increase in arachidonic acid products. Therefore, besides 
their regulation of lipocortin synthesis at mRNA level, it also seems possible that 
glucocorticoids exert action on arachidonic acid metabolism via a nonnuclear mechanism 
mediated by interference with Ca2+ entry into the cell and lipocortin phosphorylation. 
2.5 OTHER ANTI-INFLAMMATORY ACTIONS 
Besides the already mentioned basic effects of glucocorticoids on the production of 
some inflammatory mediators (arachidonic acid metabolites, IL-1, IL-2, IL-3, IL-5, IL-6, TNF-
a, IFN-y) and two specific proteins (collagen and nuclease), there exist numerous other 
effects influencing the inflammatory process, which are not yet fully clarified (9). 
Glucocorticoids exert an effect on the cellular distribution in peripheral blood. A 
lymphocytopenia occurs in man 4-6 hours after glucocorticoid administration (139). This 
results from a redistribution of the peripheral blood lymphocytes (mostly T lymphocytes) 
into other body compartments, especially the bone marrow. Probably in this way fewer 
lymphocytes are available to leave the circulation at a site of inflammation. 
There are also glucocorticoid effects on the other cellular components of peripheral 
blood. Uke the induced lymphocytopenia, the monocytopenia probably results from a 
redistribution of monocytes, although in animal models a decreased release from the bone 
marrow has also been described (140). Another important contribution to the 
anti-inflammatory action of glucocorticoids concerns the decreased influx of neutrophilic 
granulocytes to the site of inflammation leading to a neutrophilia (141). The precise 
underlying mechanisms of this hampered accumulation are unknown, but it partially 
depends on decreased margination of the neutrophils and is probably the most important 
anti-inflammatory factor at pharmacological glucocorticoid doses. Probably, glucocorticoids 
alter cellular surfaces leading to a disturbance of neutrophil-endothelium interactions and 
preventing regression from the microvasculature to the site of inflammation. Actually, it 
was shown recently that glucocorticoids (at nanomolar concentrations) inhibited the 
expression of adhesion molecules by endothelial cells (142). Glucocorticoids may thereby 
interfere with the traffic of leukocytes into inflamed areas. Effects on cellular distribution 
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in blood can therefore also be explained as mediated via the nuclear mechanism of 
glucocorticoids and their influence on transcription of adhesion proteins. Furthermore, it 
Was shown in hamsters that dexamethasone in hibited leukocyte diapedesis, but not 
leukocyte rolling or adhesion. This dexamethasone-induced inhibition of leukocyte 
transmigration appeared to be mediated by lipocortin I (143). 
Stabilization of lysosomal membranes, thereby leading to an inhibition of the release 
of lysosomal contents, has been proposed to be an important anti-inflammatory factor of 
glucocorticoid treatment (137). However, this inhibition was achieved at very high doses 
on isolated rabbit liver Iysosomes and was not reproducible on isolated Iysosomes from 
human neutrophils (144). Lysosomal release from intact human cells proved to be 
inhibitable (145), Whether this mechanism plays a role at glucocorticoid concentrations 
during treatment is still a matter of debate. 
Vasoconstriction can be achieved by glucocorticoids.ln this way the vascular response 
to inflammation can be compensated for as some inflammatory mediators are capable of 
producing vasodilatation (146). It is possible that inhibition of the production of arachidonic 
acid metabolites is responsible for this phenomenon, but a still controversial antagonism 
of the kinin system has also been proposed (147). 
Many inflammatory mediators cause an increase in vascular permeability (148) leading 
to edema. Glucocorticoids reduce formation of edema by a still unknown mechanism. 
Because formation of some edema-causing mediators requires the presence of neutrophils, 
it has been suggested that inhibition of the interaction between neutrophils and vascular 
endothelium can be a mechanism through which glucocorticoid-induced edema inhibition 
takes place (149). 
Alveolar macrophages are believed to secrete a mediator responsible for an increase 
of mucus secretion (150). This mediator is newly synthesized after cell surface activation 
of macrophages.lt was called macrophage-derived mucus secretagogue (MMS), and it was 
shown not to be a derivative of arachidonic acid. In vitro studies on human airways have 
described the inhibition of mucus secretion by glucocorticoids (151). It is not yet known 
whether these two findings may be combined, leading to the hypothesis that 
glucocorticoids are able to reduce the macrophage production of the above-mentioned 
secretagogue by inhibition of gene transcription. 
2.6 CONCLUSION AND FUTURE RESEARCH 
Since the first clinical application of glucocorticoids in the treatment of rheumatoid 
arthritis, the use of these drugs has been extended to the fight against a large variety of 
other inflammatory diseases, including several lung diseases. During the past 46 years both 
basic and clinical investigations have expanded our insight into their working mechanisms, 
although many questions remain. Nowadays, glucocorticoids are known to exert many of 
their effects by influencing the transcription of genes, and many proteins encoded by these 
genes playa role at different levels in inflammatory processes. On the other hand, one 
realizes that inflammatory processes usually represent a complex of interactions between 
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many different cell types, inflammatory mediators, and other secretory products. Because 
of this involvement of many different cell types and cell products an anti-inflammatory 
agent intervening at the level of one specific cell type or cell product would be of little 
value. This explains, in part, why glucocorticoids, with their wide range of effects on 
cellular events, have proved to be such successful anti-inflammatory drugs. Unfortunately, 
their broad range of effects has also proved not to be restricted to beneficial ones, given 
their impressive side effects, while glucocorticoid responsiveness seems to vary among 
individuals. Future investigations face the arduous task of adapting the working mecha-
nisms of these hormones in order to diminish side effects, while leaving enough of their 
many influences to maintain their strong anti-inflammatory action. This task would be made 
easier by a better understanding of the molecular working mechanisms of glucocorticoids. 
Furthermore, the recently discovered "cross-talk" between membrane-associated protein 
receptors and intracellular steroid hormone receptors may also have therapeutical 
implications. 
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Introduction to the experimental work 
Since the idea that organisms are made up of cells, doctors have been aimed at 
understanding diseases by searching for disturbances of cellular processes. Concurrently, 
the realization dawned upon doctors that recovery of derailed cellular processes was 
accompanied by recovery of the patient. Furthermore, ft became clear that medicines were 
able to influence this process of recovery of "diseased cells". This search for relations 
between cell function and disease has led to many victories in the history of medicine and 
have realized new and powerful methods of treatment, stressing the importance of basic 
sciences and knowledge. Although it is almost unavoidable for our understanding to 
simplify the complex reality of cellular disturbances underlying diseases, one has to take 
care not to overestimate the role of one single cell type in a particular disease. It is realized 
now that different cell types are able to interact with each other. Therefore, medical 
intervention has to concentrate preferably on influencing cellular interactions, rather than 
on only one cell type. 
Nowadays, great efforts are made and a lot of money is spent to find new ways to 
influence specifically cellular functions or interactions. Monocytes/macrophages are being 
studied all over the world because of their supposed crucial role in several diseases, partly 
for their own specific properties and partly for their ability to interact with and influence 
other cell types. The great variety of cellular functions of mononuclear phagocytes 
described in chapter 1.1 support the idea that these cells are essential in many physiologi-
cal and pathological processes. Because of these cellular properties and their abundance 
in the lung, mononuclear phagocytes should be considered as pivotal cells in many lung 
diseases, including asthma. In chapters 1.2, 1.3 and 2 it is shown that glucocorticoids and 
cytokines can modulate functions of mononuclear phagocytes. Consequently, the course 
of the diseases in which mononuclear phagocytes are central cells may be influenced by 
the clinical application of glucocorticoids or cytokines. Since 1949, glucocorticoids are 
being used successfully in the treatment of many inflammatory diseases, including asthma, 
but the clinical use of cytokines is still in its infancy. 
The base of the investigations presented in this thesis was the central role of 
mononuclear phagocytes in the chronic airway inflammation, which underlies many of the 
clinical symptoms in asthma. The purpose of the investigations was to get more insight into 
the influence of glucocorticoids and cytokines on the phenotype and function of these cells, 
since glucocorticoid- or cytokine-induced modulation of monocyte/macrophage functions 
may be relevant to the treatment of asthmatic patients. In vitro experiments concerning 
these aspects are described in chapters 4 and 5. In chapter 6, studies are described in 
which it was analyzed whether in vivo treatment of asthma patients with inhaled 
glucocorticoids was associated with effects on peripheral blood monocytes and alveolar 
macrophages similar to the effects described in our in vitro studies. 
The precise working mechanisms of glucocorticoids in the inhibition of inflammation 
are still incompletely understood. Therefore, the investigations presented here were started 
to gain more insight into their cellular working mechanisms. With regard to cytokines, their 
clinical application as anti-inflammatory drugs is less clear compared to glucocorticoids, and 
therefore, the in vitro studies presented here were done to search for effects which may 
be of use to modulate inflammation in vivo. In most experiments, we focussed on the 
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effects of IL-4, as this cytokine has been described previously to have potential anti-
inflammatory effects. 
Chapter 4 describes the effects of cytokines in vitro on the expression of cell 
membrane proteins, the function and the proliferative activity of monocytes/macrophages. 
Especially the influence of IL-4 on aminopeptidase-N is described, and it is shown that ILA-
mediated effects are determined partly by the maturation stage of mono-
cytes!macrophages. Furthermore, it is shown that in vivo the lungs create an environment, 
probably through local production of cytokines, in which monocytes/macrophages re-
acquire proliferative activity. 
Chapter 5 is a compilation of four in vitro studies concerning the effects of 
glucocorticoids on some functional aspects of monocytes/macrophages. An earlier 
described effect of IL-4 on the maturation of monocytes/macrophages is confirmed in our 
studies. We investigated the influence of glucocorticoids on this IL-4 effect, and based on 
our findings we hypothesized a balanced in vivo regulation of the phenotype and function 
of monocytic cells by cytokines and steroid hormones. Furthermore, we focussed on the 
gene expression of two proteins with pro- and anti-inflammatory properties, respectively, 
and its regulation by IL-4 and glucocorticoids. Additional, direct evidence for specific 
effects of glucocorticoids on monocytes/macrophages comes from the development of an 
assay to detect glucocorticoid receptors in these cells conclusively. 
Chapter 6 describes some cellular effects during glucocorticoid therapy. The in vitro 
influences of glucocorticoids on monocytesl macrophages, as described in chapters 4 and 
5, were reason to investigate whether in vivo treatment with glucocorticoids resulted in 
cellular effects comparable with the in vitro findings. 
Chapter 7 discusses the significance of the presented experimental data in the context 
of the literature. In addition, the clinical use of cytokines, in particular the applicability of 
the described potential anti-inflammatory properties of IL-4, are discussed in the context 
of recent clinical studies. Special attention is paid to the understanding that the anti-
inflammatory properties of both glucocorticoids and cytokines are based on the modulation 
of cell functions via modulation of gene expression. New openings for improvement of the 
treatment of inflammatory lung diseases including asthma, may be the specific modulation 
of the expression of only the genes relevant to inflammation. 
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INTRODUCTION: 
DIFFERENCES IN EXPRESSION OF MONOCYTE/MACROPHAGE 
SURFACE ANTIGENS IN PERIPHERAL BLOOD AND 
BRONCHOALVEOLAR LAVAGE CELLS' 
Henk C. Hoogsteden1, Peter Th.W. van Hap·2, Johanna M. Wijkhuijs2, Wim HOp3 
and Chris Hilvering I 
From the Departments of Pulmonary Medicine', Immunologr, and BiostatisticsJ , University Hospital 
Rotterdam-Dijkzigt and Erasmus University Rotterdam, The Netherlands . 
• This chapter is an updated summary of the manuscript "Differences in expression of 
monocyte/macrophage surface antigens in peripheral blood and bronchoalveolar lavage cells in interstitial lung 
diseases ", published in: Lung 1993; 171: 149-160, 
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SUMMARY 
Peripheral blood monocytes (PBM) are generally considered as precursors of various 
populations of tissue macrophages, e.g. alveolar macrophages (AM). These macrophages 
differ from their precursors in morphology and function. Monoclonal antibodies can be used 
to study differences in the expression of cell membrane antigens. In this study, differences 
in the expression of cell surface antigens between PBM and AM (isolated from 
bronchoalveolar lavage fluids) from healthy volunteers were evaluated. 
In blood monocytes, the percentages of cells expressing the antigens recognized by 
CD14, CD33 and Max 3, respectively, were higher than in AM, On the other hand, the 
percentages of AM expressing RFD9 antigen were higher than blood monocytes expressing 
this antigen. 
These data suggest that upon migration of PBM to the alveoli, the expression of some 
cell membrane antigens is reduced, whereas the expression of other antigens is 
upregulated. These changes in expression eventually determine the phenotype of AM and 
may be considered as maturation-associated. Our findings may be used to study and 
influence maturation of mononuclear phagocytes in vitro. 
INTRODUCTION 
AM represent a heterogeneous population of mononuclear phagocytes (1-3). This 
heterogeneity is believed to represent differences in maturation and activation. A 
continuous influx of PBM maintains, probably in addition to local proliferation, the local 
population of AM (4-6). PBM leave the circulation, pass the lung interstitium and mature 
into AM. At each level of this migratory process, PBM are thought to pass through different 
stages of maturation. The presence of different maturation stages may be visualized by 
studying the expression of cell surface antigens. Different stages of the life cycle of 
mononuclear phagocytes are characterized by the expression of different cell surface 
antigens or combinations of different antigens. Expression of these different antigens is 
related to different cellular functions of the respective stages of the life cycle. Monoclonal 
antibodies (mAb) are useful to detect these differences in expression of surface antigens 
(7). Other cellular qualities to study the existence of different maturation stages or, in a 
more general sense, different subpopulations among AM may be their morphology, density, 
motile capacity and immunological functions (1). 
Activation at all stages of maturation may also contribute to the cellular heterogeneity 
of mononuclear phagocytes. Activation may influence the expression of cell surface 
antigens, cell function and cell morphology. Whether differences in differentiation stages 
also determine the heterogeneity of AM remains controversial. Some studies appear to 
demonstrate that subpopulations of AM arise from distinct bone marrow precursors. After 
this differentiation process in the bone marrow, these different lineages should mature 
independently. Dendritic cells, which are also found in bronchoalveolar lavage (BAL) fluid, 
may represent such a distinct lineage (8). However, recent studies in humans showed that 
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also dendritic cells may originate from PSM (9,10). Therefore, differentiation does not 
appear to contribute to the cellular heterogeneity of SAL monocytes/macrophages in 
humans. 
Activation is obviously a cellular response to extracellular stimuli. These environmental 
stimuli may be mediated via direct intercellular contact, interactions between cells and 
extracellular matrix, or soluble factors, e.g. cytokines. With regard to maturation, the 
importance of environmental stimuli is less self-evident. Maturation may be considered as 
an autonomous cellular process which takes place independently of extracellular influences. 
However, recent studies have shown conclusively that maturation of monocytes/macropha-
ges can be modulated by environmental factors in vitro, suggesting that also maturation 
in vivo may be under the influence of extracellular stimuli (11,12). Furthermore, differences 
in phenotype between monocytes/macrophages from different tissues are thought to result 
from environmental differences created by the tissue where these cells reside (13). 
This study was partly designed to investigate differences in the expression of 
monocytic cell surface antigens on PBM and AM in healthy volunteers. Differences were 
suspected because of the above-mentioned migration of PBM to the lung, which is 
associated with maturation of PBM into AM. Differences were studied with mAb. 
MATERIALS AND METHODS 
Subjects and bronchoalveolar lavage 
BAl fluid (8AlF) was obtained from 10 healthy volunteers. This group consisted of non-smoking 
individuals without chest abnormalities and with normal chest X-ray films and lung functions. Approval for 
alf lavage studies was obtained from the Medical Ethics Committee of the Erasmus University/University 
Hospital Rotterdam. 
SAL was performed with a bronchoscope placed in wedge position in the middle lobe, Four aliquots of 
50 ml sterile saline were infused and aspirated Immediately in a siliconized specimen trap placed on melting 
ice, Immediately after coltection of the BAlF the various laboratory analyses were carried out. All standard 
washings of SAL celfs were performed with phosphate-buffered saline WBS) (300 mosmol; pH 7.B) 
supplemented with 0,5% heat-inactivated bovine serum albumin (BSA) (Organon Teknika, Boxtel, The 
Netherlands). Washing centrifugations were performed for 5 min at 4°C with a force of 400 g, 
Immunologic characterization of BAl cells 
The BAl cells were immunologically characterized by use of the following mAb: C03(leu·4), C04(leu-
3a), C08(leu-2al (Becton Dickinson, San Jose, CAl, C013(Q20) (Dr. C,E, van der Schoot, Amsterdam, The 
Netherlands), CD14(My3) (Coulter Clone, Hialeah, Fl), U26 (Dr, R, Winchester, NY!, C068(Y2/131) (Dr, O,Y, 
Mason, Oxford, UK), Max3 and Max24 (Dr, F. Emmrich, Erlangen, FRG)' AFD9 (Dr, l. Poulter, London, UK), 
CD6B(Ki-M6), C06B(Ki-M7) and Ki-M8 (Behring, Marburg, FAG), 
For immunologic staining, 50 ~tI of the cell suspensions (B x 106 cells per mil were incubated for 30 min 
at 4°C with 50 ,t! of the relevant, optimally-titrated antibody. As a control, cells were incubated with normal 
mouse serum (NMS). After this incubation the cells were washed twice and subsequently incubated with a 
fluorescein isothiocyanate (FITC)-conjugated goat-anti-mouse immunoglobulin antiserum (Nordic 
Immunological laboratories, Tifburg, The Netherlands), Subsequently the cells were washed twice and the 
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cell pellet was mounted in glycerol/PBS (9:1), containing 1 mg p-phenylenediamine per ml (BDH Chemicals, 
Poole, UK) to prevent fading of Fife. Coversllps were sealed to the slide with paraffin wax mixed with 
ceresin (BDH Chemicals), The fluorescence was evaluated using Zeiss fluorescence microscopes equipped 
with phase contrast facilities. The phase contrast facilities were used to evaluate the morphology of the cells 
(lymphocytes, small monocyte-like macrophages and mature macrophages) and for discrimination between 
labeled cells and contaminating fluorescent particles. In this way it was possible to determine which 
proportion of the monocytes and macrophages expressed the various Immunologic markers. For each 
immunologic marker at least 300 cells were evaluated. 
Immunologic characterization of PB cells 
Mononuclear cells (MNC) from PB were isolated by Flcoll density centrifugation (Ficot! Paque, density: 
1.077 g/cm3 , Pharmacia, Uppsala, Sweden) for 15 min at room temperature at a centrifugal force of 1,000 
g. All standard washings and immunologic stainings of MNC from PB were done as described above for BAl 
cells. Forward and sideward light scatter signals were used to differentiate between lymphocytes and 
monocytes and made It possible to analyze expression of the relevant Ag on PBM by FACScan analysis. 
Statistical analysis 
Comparisons of cellular parameters from BAlF and PB were done with Wilcoxon's test. Five percent 
was considered as the limit of statistical significance. 
RESULTS 
Some characteristics of the BALF from healthy volunteers are shown in Table 1. The 
majority of BAL cells was found to be monocytes/macrophages as determined by May-
Grunwald Giemsa staining. A small percentage (1 %) of this population resembled blood 
monocytes, and was thought to represent immature macrophages (Figure 1). Around 6% 
of the total cell population concerned lymphocytes, whereas less than 2% concerned 
granulocytes. 
Table 1. Total and differential cell counts in BAlF from healthy volunteers. 
Recovered BALF 
Recovered volume in ml 
Total cell recovery x 106 
Differential cell count (%): 
Macrophages 
Granulocytes 
lymphocytes 
Monocyte-like cells 
a. Mean with standard deviation in parentheses. 
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("~1O) 
122.0 (23.9)a 
8.9 (5.2) 
93.1 (7.7) 
1.9 (2.9) 
5.9 (7.7) 
1.0 (0.1) 
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Figure 1. May-GrOnwald Giemsa staining of cells present in the SAL fluid from a healthy volunteer. The 
majority of the cells Is macrophage (mature mononuclear phagocyte). A small percentage of the cell 
population resembles blood monocytes (arrows), and Is thought to represent Immature macrophages. 
Table 2. Immunologic characterization of PBM and BAL monocytes/macrophages from healthy volunteers. 
Monoclonal BAL 
antibody PBM monocytes!macrophages 
% % x 104/ml 
CD1310201 78.3 129.1)' 68.4 116.6) 5.2 11.3)' 
CD141My3) 89.0 110.1) 49.3 123.3)' 3.5 10.9) 
C0331My9) 89.3 18.7) 42.9 134.4)' 3.1 11.21 
CD68IKi-M6) 0.2 10.3) 2.2 12.6) 0.2 10.2) 
CD6BIKI-M7) 52.4 129.51 50.6 16.01 4.8 15.61 
CD681Y2/1311 27.4 116.8) 45.0 119.6) 4.5 11.7) 
U26 93.7 16.51 91.7 17.61 7.0 11.4) 
Max3 96.6 11.81 81.6 117.01' 6.4 11.51 
Max24 92.0 14.21 93.0 15.9) 7.2 11.61 
Ki-M8 79.4 16.41 82.7 18.61 7.6 12.11 
RFD9 0.3 10.61 84.9 123.31' 5.8 10.91 
a. Mean with standard deviation in parentheses. 
b. The absolute numbers of celts are given as positive macrophages x 104/ml recovered BAL fluid. 
c. Different from PBM (p<O.Ol). 
d. Different from PBM (p<O.05). 
The immunologic characterization of monocytes/macrophages in BAL fluid and PBM is 
shown in Table 2. An important difference between AM and PBM was the higher 
percentage of PBM positive for some mAb used: CD14, CD33 and Max 3. Statistical 
analysis indicated that these differences were significant. The percentages of PBM positive 
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for two of the mAb used, RFD9 and CD68, appeared to be lower than the percentages of 
AM positive for these markers. Both the percentages of RFD9+ and CD68 (Ki-M6)+ PBM 
were less than 0.5%, whereas RFD9+ and CD68 (Ki-M6)+ AM represented 85% and 2.2% 
of the total cell popUlation in BALF I respectively. However I only the difference in 
expression of RFD9 Ag between PBM and AM was statistically significant. 
DISCUSSION 
In this study the expression of a panel of monocytic antigens was analyzed on PBM and 
AM. The background of this study is the hypothesis that a continuous influx of PBM into 
the lungs maintains, at least partially I the local population of AM. This migration is 
associated with phenotypic and functional changes, which are considered to represent 
maturation of PBM (12). Some of the mAb used in this study recognize cell surface 
antigens with known functions, whereas others react with proteins with still unknown 
functions. 
CD13 antibodies recognize a cell membrane-bound glycoprotein, aminopeptidase-N (Ee 
3.4.11.2), involved in the metabolism of regulatory peptides (14). The expression and the 
functional enzyme-activity of CD13 Ag can be modulated by cytokines Ii? vitro. As part of 
these findings, IL-4 was shown recently to increase C013 Ag expression (15) in addition 
to its effect on PBM maturation (11, chapter 5.2). However, no differences in the 
expression of CD13 Ag were observed between PBM and AM in this study. One 
explanation may be that IL-4 has only a transient effect on CD13 Ag expression (15), 
whereas the effects on PBM maturation (visualized by changes in the expression of CO 14 
and RFD9 Ag) are long-lasting (chapter 5.21. 
CD 14 antibodies recognize three or four distinct epitopes on a 55 kOa cell membrane 
glycoprotein (16). This glycoprotein may function as a receptor for LPS. The binding of LPS 
to the CO 14 glycoprotein can be enhanced markedly in the presence of LPS-binding protein 
(LBP). Only a minor population of AM, i.e. the monocyte-like cells (Figure 1), expressed 
CD14 Ag, in contrast to the majority of PBM. This small population of AM was thought to 
represent newly arrived monocytes, which had finished their migration from the vasculature 
to the alveolar compartment. It may be hypothesized that upon maturation of PBM to AM, 
C014 Ag expression decreases. This decrease is also seen during in vitro maturation, and 
can be accelerated by IL-4 (chapter 5.21. 
C033, U26, Max 3, Max 24 and Ki-M8 antibodies are known to recognize cell 
membrane antigens on monocytes/macrophages, but the functions of these antigens have 
to be elucidated still (17,18). The expression of CD33 and Max 3 Ag may be related to the 
maturation stage of monocytes/macrophages, as in this study the expression in PBM was 
found to be higher than in AM. 
RFD9 Ag were nearly absent from PBM, whereas the majority of AM expressed this Ag. 
Further studies are necessary to determine whether only the small RFD9+ subpopulation 
of PBM migrates to the lungs, or RFD9 Ag becomes progressively expressed upon migration 
of PBM to the lungs. 
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The three mAb CD68(Ki-M6), CD68(Ki-M7) and CD68(Y2/131) are pan macrophage 
antibodies (19-21). The markers recognized by these mAb are restricted to cells of the 
monocyte/macrophage system, and these antigens are mainly confined to lysosome and 
phagosome structures. For CD68(Ki-M6) and CD68(Ki-M7), a stepwise increase in 
cytoplasmic expression has been described during maturation of monocytes into 
macrophages, in vitro as well as in vivo (19-21). In our study we did not perform 
immunoperoxidase stainings on cytocentrifuge preparations (in which cytoplasmic 
expression of antigens can easily be detected), but instead incubated cells in suspension 
in order to analyze differences in cell surface expression between the different C06S mAb. 
In this way, we demonstrated that these markers are not strictly cytoplasmic. Surface 
expression was also found by Cordell et a!. (22). Our findings are also in line with the 
findings of Parwaresch et al. (19) and Kreipe et al. (21) that the expression of CD68 is 
increased in more mature cells. We found lower percentages of C068+ macrophages than 
in their studies because with our technique we detect cell-surface markers, whereas in the 
other studies an alkaline phosphatase technique was used that detects cell-surface as well 
as intracytoplasmatically located antigens. 
In conclusion, this study shows that PBM and AM differ in the expression of cell surface 
Ag as demonstrated with mAb. These findings help us to understand maturation of 
mononuclear phagocytes. Further studies are needed to evaluate whether influencing 
maturation and Ag-related cellular functions may be useful in the treatment of pulmonary 
diseases. 
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CHAPTER 4.2 
SUMMARY 
IL-4 up-regulates various monocytic properties, which are associated with pro-
inflammatory functions. Paradoxically, IL-4 may also act as an anti-inflammatory agent by 
down-regulating the production of several inflammatory mediators. As the activity of some 
mediators has recently been shown to be regulated by peptidases, we examined whether 
IL-4 was able to modulate the expression of a cell membrane associated peptidase, 
aminopeptidase-N (CD13). IL-4 caused a dose-dependent increase in the expression of 
CD13 Ag on highly purified human blood monocytes. Maximal expression was observed 
around 48 h of culture. This IL-4-induced increase was completely blocked by anti-IL-4 
antiserum. Furthermore, the increase in surface expression was preceded by increased 
mRNA levels of CD13, which was maximal around 24 h of culture. Additionally, we 
observed that also CD13-mediated leucine-aminopeptidase activity of monocytes was 
induced by IL-4. Also other CD13-expressing cells were sensitive to IL-4, since CD13 Ag 
expression and CD13 mRNA levels were up-regulated in human alveolar macrophages and 
endothelial cells upon IL-4 treatment. The increased expression of cell membrane 
aminopeptidase-N represents a potentially increased cellular ability to inactivate 
inflammatory mediators. Therefore, these findings represent further evidence of IL-4-
mediated anti-inflammatory actions. We postulate that up-regulation of aminopeptidase-N 
expression may be an indirect working-mechanism of IL-4 to modulate the action of 
bioactive peptides. This mechanism as such may underlie, at least partially, the anti-
inflammatory effects of IL-4 in vivo. 
INTRODUCTION 
IL-4 was originally characterized by its ability to effect differentiation of resting B 
lymphocytes (11. More recently, it has been shown that IL-4 may also display a wide range 
of effects on several cell types (2). It can act as a growth factor for activated T 
lymphocytes, thymocytes, NK cells (3-5), and mast cells (5,6). In addition, monocytic cells 
can also be influenced by IL-4, which is reported to induce monocyte maturation (7). 
Furthermore, some of the actions of IL-4 on monocytic cells are considered to be 
stimulatory. IL-4 increases expression of MHC class" Ag (7), increases antigen-presenting 
capacity (8), and induces FCERllb expression (9). On the other hand, IL-4 also appears to 
inhibit some parameters of monocyte activation. Thus, IL-4 inhibits superoxide production 
(101, inhibits the release of PGE2 (11), IL-1 P (11-14), IL-6 (12,15,16), IL-8 (17), TNF-o: 
(11-13), and up-regulates the production of IL-1 R antagonist (14,18). Based upon the latter 
findings, it was suggested that IL-4 may have anti-inflammatory properties (11-19). 
During our studies on the influence of cytokines on monocytes/macrophages, we 
observed that IL-4 was also able to modulate the expression of aminopeptidase-No Initially, 
this enzyme (EC 3.4.11.2, gp150, CD131 was designated as a marker for subpopulations 
of hemopoietic cells (20-23). Currently, it is generally accepted that many other cell types 
(including fibroblasts, the renal tubular and intestinal epithelium (24,25), endothelial cells 
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(26,27), and synaptic membranes of cells of the centra) nervous system (28)) express this 
enzyme. Comparable to the role of neutral endopeptidase (EC 3.4.24.11). it is hypothesized 
that aminopeptidase-N also plays an important role in modulating the activity of bioactive 
oligopeptides (29-32). Accordingly, aminopeptidase-N may playa role in regulation of 
inflammatory and immunological responses. Modulation of the expression of 
aminopeptidase-N may therefore influence these oligopeptide-mediated responses. In this 
report, we demonstrate that IL-4 is able to up-regulate the expression of CD13 Ag on 
monocytic cells. Up-regulation is also seen in non-monocytic cells (Lc. endothelial cells), 
although this was less pronounced. This up-regulation is accompanied by an increase in 
aminopeptidase-activity, indicating that cells activated by IL-4 may acquire potential anti-
inflammatory properties. 
MATERIALS AND METHODS 
Isolation of PBM 
Human PBM were isolated from 500 ml blood from healthy volunteers as described elsewhere (33). 
Briefly, mononuclear cells were separated by density centrifugation with a blood component separator. Next, 
the mononuclear cells were fractionated into lymphocytes and monocytes by centrifugal elutriation. The 
monocyte preparation was over 95% pure as judged by May·Grunwald Giemsa staining and contained more 
than 98% viable cells as judged by trypan' blue exclusion. Lymphocytes and granulocytes constituted less 
than 2% and 3% of the monocyte preparation, respectively. Before analysis of the surface membrane 
determinants the cells were washed twice with a PBS solution (300 mosmol; pH 7.8) supplemented with 
0.5% heat-inactivated BSA (Organon Teknika, Oss, The Netherlands). Before isolation of total RNA or 
detection of LAP activity the cells were washed twice with a PBS solution. 
Isolation of AM 
Afllavage studies were approved by the Medical Ethics Committee of the Erasmus University/University 
Hospital Dijkzigt, Rotterdam. BAL was performed in healthy, nonsmoking volunteers after premedication with 
thiazinamium and local anesthesia using a lidocaine (2%, w/v) spray. The bronchoscope was placed in wedge 
position in the right middle lobe, and four aliquots of 50 ml sterile saline solution were infused and aspirated 
immediately in a siliconized specimen trap placed on melting 'ice. Immediately after collection, the BAL fluid 
was strained through a sterile nylon gauze to trap large mucous particles, whereafter the BAl cells were 
isolated by centrifugation at 4°C at a force of 400 x g. More than 90% of the SAL cells appeared to be 
macrophages as judged by May·Grunwald Giemsa staining. Refore analysis of the surface membrane 
determinants the cells were washed twice with PBS/0.5% BSA. Before isolation of total RNA or detection 
of LAP activity the cells were washed twice with a PBS solution. 
Isolation of EC 
Human EC were isolated from umbilical cord vein by collagenase digestion as described elsewhere (34). 
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Cell lines 
THP-l celfs (35) were used as control cells because of their CD13 mRNA and CD13 Ag expression. 
They were obtained from The American Type Culture Collection (Rockville, MOl and maintained according 
to their instructions. 
Recombinant IL-4, rll-2, rIFN")'. GM-CSF, LPS and anti-IL-4 antiserum 
Human r1L-4 was a generous gift from Dr. H.F.J, Savelkoul from our department and Dr. K, Arai (DNAX 
Research Institute, Palo Alto, CAl. Human rlL-2 was obtained from Eurocetus (Amsterdam, The Netherlands), 
Human rIFN-'f (specific activity 107 U/mg) and human rGM-CSF (specific activity 107 U/mg) were kindly 
provided by Drs. p, Trotta and S. Naghabhushan (Schering-Plongh Corp, Bloomfield, NJI. LPS (E. coli 
0127:88) was purchased from oifco Laboratories (Detroit, MI). A polyclonal rabbit anti-IL-4 antiserum was 
used to block the biologic activity of IL-4, as has been described elsewhere (36). 
Culture of cells 
PBM and AM were cultured in a modified Iscove's medium (GIBCO, Paisley, U.K.) as described 
elsewhere (37), In which BSA was replaced by human serum albumin, In some experiments this medium was 
supplemented with 2% autologous heat-inactivated serum, The culture medium was found to be endotoxin 
free (defined as less than 1.0 ng endotoxin/ml as quantified by the limulus amoebocyte lysate assay). P8M 
(2-4 x 106 Iml) and AM (1-2 x 106 Iml) were cultured at 37°C, 5% C02, and 100% humidity in Teflon bags 
(Janssen's MNL, St-Niklaas, Belgium) for 1 to 7 days. For detection of surface membrane determinants, 
isolation of total RNA, or detection of LAP activity, cells were harvested from the Teflon bags and separated 
from the culture supernatant by centrifugation. Subsequently, the cells were washed twice with either 
PBS/0.5% BSA/O.5% sodium azide when cells were used for detection of surface membrane determinants, 
or PBS when cells were used for isolation of total RNA or detection of LAP activity. The viability as 
determined by propidium iodide or trypan blue exclusion exceeded 85%. The numbers of cells recovered after 
culture in the presence of rIL-4, rIL-2, or anti-IL-4 antiserum did not differ significantly. 
EC were cultured in flat bottom B-well plates as described elsewhere (38). For detection of CD13 Ag 
expression, plates were washed twice with PBS (37"C) to remove nonviable, nonadherent EC. Thereafter, 
EC were incubated (5 min, 37"C) with a collagenase solution (Worthington, Biochemical Corporation, NJ) to 
harvest adherent cells. From this point, EC were handled as PBM and AM. For isolation of total RNA, plates 
were washed twice with PBS (37°C). Thereafter, adherent celts were homogenized with 0.5 ml of solution 
o and transferred to 1.6-ml Eppendorf tubes. From this point, EC were handled as PBM and AM. 
Detection of surface membrane determinants 
For immunofluorescence stainings of PBM, AM and EC the following mAb were used: CD13 
(020(fgG2a), Dr. C. E. van der Schoot, CLB, Amsterdam, The Netherlands: My7 (lgG1), Coulter Clone, 
Hialeah, FL): CD23 (TOl (lgG1), Biotest, Dreieich, Germany; Leu-20 (IgG 1), Becton Dickinson, San Jose, CAl. 
Isotype matched control antibodies were directed against idiotypic determinants on a 8 cell lymphoma cell 
line and did not react with monocytes, macrophages or endothelium. Fifty ~1I of the EC, P8M, or AM cell 
suspension (2 x 106 celis/mil were incubated for 30 min at 4°C with 50 ~ll of one of the, optimally titrated, 
mAb. Incubation was performed in U-bottom 96-weU microtiter plates. After three washings the cells were 
incubated with FITC-Iabeled GAM F(ab'h (De Beer Medicals 8. V., Hilvarenbeek, The Netherlandsl for 30 min 
at 4°C. After another three washings the cell pellets were resuspended for analysis of the fluorescence 
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intensity by means of a FACScan (Becton Dickinson). The fluorescence intensities of Ag expression are 
expressed as a ratio relative to the background fluorescence intensity of cells stained with an isotype 
matched control antibody. A value of 1.0 reflects fluorescence equivalent to background. When fluorescence 
intensity was determined on cultured cells, background fluorescence was determined on simifarly cultured 
cells. 
All standard washings were performed with PBS/O.5% BSA/0.5% sodium azide. 
Preparation of total cellular RNA and Northern blot analysis 
Total cellular RNA was isolated from THP-l cells, freshly isolated or cultured PBM and AM, and cultured 
EC largely according to Chomczynski and Sacchi (39). Briefly, cells (5-10 x 106 ) were homogenized with 0.5 
ml of solution 0 in a 1.5-ml Eppendorf tube. Sequentially, 50 ~1I of 2 M sodium acetate (pH 4_0), 0.5 mt of 
water-saturated phenol, and 0. 1 ml of chloroform were added to the homogenate, with thorough mixing after 
the addition of each reagent. The final suspension was cooled on ice for 15 min. Samples were centrifuged 
at 10,000 x g for 15 min at 4"C. The aqueous phase was transferred to a fresh tube containing 0.6 ml of 
isopropanol, and then placed at 4"C for at least 6 h to precipitate RNA. RNA was recovered by centrifugation 
(10,000 x g, 15 min, 4"C)' dissolved in 0.3 to 0.5 ml solution D, and precipitated again with 1 volume of 
isopropanol. After centrifugation (10,000 x g, 15 min, 4"C), the RNA-pellet was washed in 0.6 to 1.0 ml 
75% ethanol and eventually dissolved in 25 to 50 ~U RNase-free water_ Total RNA (5-20 ~tg) was separated 
by electrophoresis in a 1 %-agarose gel (40), subsequently vacuum transferred {41 I onto a nylon membrane 
(NY-13 Ni Schleicher and Schuell, Dassel, Germany), fixed to the membrane with a 254 nm UV crosslinker 
(Stratal/nker, Stratagene, La Jolla, CAl and hybridized with a CD 13 probe, which was labeled according to 
the Klenow-oligonucleotide method (42). The CD13 cDNA probe was prepared as described elsewhere (43). 
Prehybridization and hybridization of RNA blots were performed as described elsewhere (40). After 
hybridization the blots were washed and exposed to Fuji NIF·RX films (Fuji Photo Film Co., Tokyo, Japan) 
with intensifying screens. The quality and the amounts of RNA applied were controlled by rehybridization of 
the blots with a GAPDH probe. This probe was a 0.7 kb EcoRI - Pstl fragment (44). 
Semiquantification of CD13 mRNA levels 
The relative density for bands on autoradiograms was estimated by laser scanning densitometry lvideo 
densitometer model 620, Bio-Rad Laboratories, Rlchmond, CAl. Each gel containing RNA from kinetic IL-4 
experiments with PBM, AM or EC also contained a series of 7 1:2 dilutions (O.5-32 ~Ig) of total RNA isolated 
from CD13 mANA + THP-1 cells. As the Jinear relation between band density on autoradiograms and the 
quantity of CD13 mRNA is only limited, we related the density of a particular CD13 band from PBM, AM or 
EC to bands of comparable density in the dilution series of CD13 bands from THP-1 cells. In this way, it was 
possible to quantitate, indirectly but in a linear way, CD13 bands of different density from P8M, AM or EC, 
whether or not exposed to IL-4 during different periods of time. CD13 mRNA levels are expressed in units, 
where a value of X represents the level of CD13 mRNA (present in the quantity electrophorized total RNA) 
which is identical to the revel of CD13 mRNA in X ~Ig of THP-l total RNA. If X is greater than the quantity 
of electrophorized total RNA, the particular cell sample contained relatively more CD13 mRNA than THP-l 
cells. The same procedure was applied to estimation of GAPDH band densities. 
For final interpretation of CD13 mRNA levels, i.e. to compensate for differences in RNA loading per lane 
or culture-induced influences on general mRNA levels, CD13 mRNA levels were related to GAPDH mRNA 
levels. 
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Functional assay for LAP·actlvity 
The presence of aminopeptidase-N activity on PBM was detected largely as described elsewhere (45). 
Briefly, the assay was performed in triplicate in flat bottom wells of 96-well microtiter plates. Fifty ~lI of a 
cell suspension (0.5·1,0 x 106 cells/ml) were incubated with 50 ~tr of L-Ieucine-p-nitroanilide (Sigma) (8.36 
mM) for 30 min at 3JOC. After this incubation enzymatic activity was blocked by addition of 35 ~tl of a 30% 
(v/v) acetic acid solution. The increase in specific absorbance at 405 nm (as a result of accumulation of free 
p-nitroanilidel was determined by using a Titertek Multiskan MeC plate reader (LC,N. Biomedicals B,V., 
Amsterdam, The Netherlands), Aminopeptidase-N activity was expressed as the production of p-nitroanilide 
in 30 min by 106 cells (nmol/30 min x 106 celts). 
In some experiments cells were pre-incubated with the CD13 mAb WM15 (lgG 1, Or. E_ J. Favaloro, 
Westmead, Australia) for 30 min at 4°C to block C013-mediated LAP-activity. As a control procedure, celts 
were pre-incubated with an isotype-matched control antibody. After this pre-Incubation, celts were directly 
assayed for their LAP-activity as described above. 
RESULTS 
Il-4 up-regUlates CD13 Ag expression on human monocytes 
Freshly isolated PBM expressed CD13 Ag, However, even after one day of culture, 
expression of CD13 Ag was found to increase significantly upon IL-4 treatment (Figure 1, 
closed circles). This increase was consistently seen in all experiments (n:::: 9). Maximal 
increase was observed around day 2 of culture. To a limited extent, CD13 Ag expression 
was also enhanced in control cultures of PBM (Figure 1, open circles). These findings could 
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Figure 1_ Kinetics of the effect of IL-4 on the cell membrane expression of CD13 Ag on human PBM. 
Monocytes were cultured without (0) or with (lID) 100 U IL-4/ml. On the ordinate is given the relative 
fluorescence, i.e. the ratio between the mean linear fluorescence intensity of cells labeled with CD13 mAb 
and the mean linear fluorescence intensity of cells labeled with an IgG2a control antibody. Data of a 
representative experiment out of five is shown. 
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not be explained by an increase in cell-size as there was only a limited rise in forward light 
scatter signal after 2 days, and CD13 Ag expression decreased upon further culture while 
cell-size increased gradually. After more than 2 days of culture, expression of CD13 Ag 
diminished, but even after 7 days of culture expression was higher than the expression on 
freshly isolated PBM or PBM cultured in medium without IL-4. This IL-4-induced increase 
was dependent on the concentration of IL-4 and could be blocked by anti-IL-4 antiserum 
(Table 1). We also studied whether other cytokines were able to affect CD13 Ag 
expression comparable to IL-4. Therefore, we cultured PBM for 2 or 3 days with either IL-2, 
IFN-y, GM-CSF or LPS. Neither LPS nor these cytokines were able to induce any additional 
increase in CD13 Ag expression as compared with the spontaneous increase observed 
when cells were cultured in mock-medium (Table 2), Taken together, these results suggest 
that the transient increase in CD13 Ag expression upon culture with IL-4 is specific for IL-
4. 
Table 1. Influence of IL-4 on the expression of the CD13 Ag on blood monocytes can be blocked by anti-
Il-4 antiserum." 
Days of Culture Medium 
a 
3 35.2 
Medium + 
IL·4 1100 U/mll 
17.3 
94.8 
Medium + 
IL·4 1100 U/mlJ + 
anti-IL-4 
17.3 
34.3 
a. Freshly isolated monocytes or monocytes cultured either in mock medium or in the presence of IL-4 alone 
or both tl-4 and antHL-4 were labeled with Q20(C013) and FITC-conjugated GAM Flab')2' A 
representative experiment out of seven is shown. 
b. Data are expressed as relative fluorescence, Le. the ratio between the mean linear fluorescence intensity 
of celfs labeled with the relevant antibody and the mean fluorescence intensity of cells labeled with the 
isotype-matched control antibody. 
IL-4 increases CD13 mRNA levels in human monocytes 
To investigate whether increased CD13 Ag expression required enhanced mRNA levels, 
total RNA was prepared from freshly isolated PBM, and PBM after culture without or with 
IL-4. Total RNA was size-separated by electrophoresis and hybridized with the "P-Iabeled 
CD13 eDNA probe and, at a later point of time, the "P-Iabeled GAPDH cDNA probe. 
Analysis of the CD13 mRNA levels showed that culture of PBM with IL-4 caused a 
consistent and marked additional increase in CD13 mRNA level as compared with the 
spontaneous increase in control cultures (Figure 2). Maximal induction of CD13 mRNA was 
seen around day 1 of culture. Semiquantlfication of the mRNA levels revealed that the level 
of CD13 mRNA after 1 day of culture in medium without IL-4 was more than 10 times as 
high as the level in freshly isolated PBM. After 1 day of culture in medium with IL-4, the 
level of CD13 mRNA was more than 30 times as high (Table 3). Culture of PBM for a 
111 
CHAPTER 4.2 
longer period of time revealed that the level of CD13 mRNA gradually diminished after day 
1 of culture. Without IL-4, the level of CD13 mRNA decreased to the level of freshly 
isolated PBM after 5 days of culture. With IL-4, the level of CD13 mRNA also decreased, 
but was still markedly increased even after 5 days of culture (Figure 2 and Table 11. These 
results indicate that IL-4 specifically increased the level of CD13 mRNA, and that maximal 
induction of CD13 mRNA preceded maximal IL-4-induced expression of CD13 Ag on the 
cell surface by one day. 
+ 
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. 288 
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Figure 2, Kinetics of the IL-4-induced up-regulation of CD13 mRNA expression in human PBM. Total RNA was 
prepared from freshly isolated monocytes (lane 1), and from cells cultured in the absence (lanes 2, 4 and 6) 
or preSence (lanes 3, 5 and 7) of 100 U IL-4/ml. Each lane contains 5 ~lg of total RNA. RNA was size-
separated by electrophoresis, transferred onto a nylon membrane, hybridized with the 32P-labeled CD13 eDNA 
probe, and exposed for 72 hours (upper panel, A). The lower panel (8) shows the same membrane 
rehybridized with the GAPDH eDNA prohe, which was used as the internal standard for RNA content, 
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Influence of Il-4 on LAP activity of cultured human monocytes 
To determine whether the IL-4-induced up-regulation of CD13 mRNA levels and CD13 
Ag expression in PBM was accompanied by a functional increase in aminopeptidase 
activity, we studied whether PBM cultured with IL-4 would degrade a chromogenic 
substrate more efficiently than PBM cultured without IL-4. Initially, freshly isolated and 
shortly cultured PBM were assayed for their capacity to degrade l-Ieucine-p-nitroanilide. 
These experiments revealed a decrease in LAP activity after 1 or 2 days of culture whether 
or not in the presence of IL-4, although in all experiments LAP activity was significantly 
higher in the IL-4-treated PBM than the nontreated PBM (data not shown!. As also other 
membrane enzymes may display LAP-like activity comparable to CD13 Ag (Dr. E. Favaloro, 
unpublished data), we tried to make our assay more specific for LAP activity due to C013 
Ag. Therefore, we pre-incubated cultured PBM with the mAb WM-15, which has been 
described to block LAP activity due to CD13 Ag (231 or, as a control procedure, with an 
isotype-matched control antibody. Furthermore, we studied the kinetics of the effect of IL-4 
on LAP activity in more detail. After culture of PBM without IL-4 we observed an 
unchanged or slightly decreased total (i.e. after pre-incubation with a control antibodyl LAP 
activity despite the invariably observed increases in CD13 mRNA level and CD13 Ag 
expression (Figure 3, open circles of panels A and C). After 1 day of culture with IL-4, PBM 
showed only a slight increase or a slight decrease in total LAP activity (Figure 3, closed 
circles of panels A and C). Upon further culture, however, a gradual increase in total LAP 
activity was seen. Maximal total LAP activity was seen around 60 hours of culture with IL-
4. Culture with IL-4 for more than 60 hours resulted in a decrease of total LAP activity. 
During the whole culture period, total LAP activity of PBM cultured with IL-4 was higher 
than total LAP activity of PBM cultured without IL-4. This was observed in all our 
experiments (n ~ 4). 
CD13-specific LAP activity of PBM cultured without IL-4 (i.e. the decrease of LAP 
activity after pre-incubation with the mAb WM-15) also decreased upon culture (Figure 3, 
open circles of panels B and D), while this enzyme activity of PBM cultured with IL-4 
showed a transient increase which was maximal around 60 hours of culture (Figure 3, 
closed circles of panels 8 and 0). The apparent discrepancy between the increased CD13 
Ag expression already seen after 1 day of culture with IL-4 and the initially unchanged LAP 
activity was also observed. Since mAb WM-15 has been reported to block CD 13-mediated 
LAP activity completely, but was unable to block all LAP activity of PBM in our 
experiments, we concluded that in our experiments also other enzymes displayed LAP-like 
activity. How expression and function of these other enzymes are influenced by IL-4 is 
unclear. 
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Table 2. Influence of Il-2, IFN--y, GM-CSF and LPS on the expression of the CD13 Ag on blood monocytes as compared with the influence of IL-4.a 
Days of Medium Medium + Medium + Medium + Medium + Medium + 
Culture IL-2 IFN-y GM-CSF LPS IL-4 
0 39.3b 39.3 39.3 39.3 39.3 39.3 
3 59.1 61.6 24.9 48.9 55.4 143.6 
a. Freshly isolated monocytes or monocytes cultured either in mock medium or in the presence of one of the indicated cytokines OL-2, IFN-y, GM-CSF, 
IL-4J or LPS were labeled with 020 (CD131 and FITC-conjugated GAM F(ab'lz. A representative experiment out of three is shown. 
b. Data are expressed as relative fluorescence, calculated as described in the footnote to Table 1. 
Table 3. Time course of the influence of IL-4 on the level of CD13 mRNA in human PBM.~ 
Medium Medium + IL-4 
CD13 mRNA CD13 mRNA 
Days of CD13 mRNA GAPDH mRNA relative to CD13 mRNA GAPDH mRNA relative to 
Culture level level GAPDH mRNA level level GAPDH mRNA 
0 <2' 5.2c <O.4~ <2 5.2 < 0.4 
1 34.2 6.8 5.0 >70 4.4 >15.9 
2 7.2 3.1 2.3 37.6 4.1 9.2 
5 <2 4.7 <0.4 34.5 2.5 13.8 
a. Total RNA was prepared from freshly isolated PBM and PBM cultured in medium either without or with 100 U IL-4/ml. After fractionation of 5 ~g 
RNA in an agarose gel, transfer to a nylon membrane, hybridization with the CD13 or GAPDH cDNA probe, and exposure to a film, the relative 
radioactivity for bands on the autoradiogram was estimated by laser scanning densitometry. Results in this table are derived from the autoradiograms 
shown in Figure 2. A representative experiment out of three is shown. 
b. Data represent expression of CD13 mRNA in PBM relative to the expression in THP-' cells. A value of X represents the level of CD13 mRNA present 
in the Quantity of total RNA used for electrophoresis (i.e. 5 J..l.g), which is identical to the level of CD13 mRNA present in X ~g of total RNA isolated 
from THP-l cells (see Materials and Methods for further explanation). 
c. Data represent expression of GAPDH mRNA in PBM relative to the expression in THP-' cells. Interpretation of the data is identical to the interpretation 
as described in footnote b. 
d. Data represent the ratio between the CD13 mRNA (footnote b) and GAPDH mRNA (footnote c) levels. 
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Figure 3. Kinetics of the influence of IL-4 on the LAP activity of human PBM. Monocytes were assayed for 
their LAP activity directly after isolation (0 hours of culture) and after culture without (OJ or with ( .. ) 100 
U Il-4/mt. Total LAP activity (panels A and C) represents enzyme activity of PBM which were pre-incubated 
with an fgG1 control antibody, CD13-specific LAP activity (panels B and OJ is calculated by subtracting the 
remaining LAP activity of PEM which were pre-incubated with the mAb WM-15 from the total LAP activity, 
and assumes that after pre-incubation with WM-15 the only aminopeptidase activity detected is that which 
is not mediated by CD13 Ag. 
Influence of Il-4 on the expression of CD13 Ag and CD13 mRNA levels in cultured human 
AM 
We have demonstrated earlier that freshly isolated AM express CD13 Ag (43). Upon 
culture, a spontaneous and transient increase in CD13 Ag expression was observed, 
comparable with PBM. Likewise, IL-4 induced a more substantial increase in CD13 Ag 
expression with a maximum around day 2 of culture (Figure 4, right-hand panel). We 
studied also the kinetics of the effect of Il-4 on CD13 mRNA levels in AM. As in PBM, we 
observed an IL-4-induced rise in the level of C013 mRNA. This increase was significantly 
larger than the spontaneous increase, which was seen upon culture without IL-4 (Figure 
5, lanes 2 and 3). Furthermore, this increase was already seen after 5 h of culture and was 
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maximal after 1 day of culture. The level of C013 mRNA decreased upon further culture. 
After 4 days of culture, the level of C013 mRNA in AM cultured with IL-4 did not differ 
anymore from the level in AM cultured without ILA (Figure 5, lanes 8 and 9). 
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Figure 4. Influence of IL-4 on the expression of CD13 Ag on human EC and AM. The left-hand panel 
represents Ee, which were stained with CD13 mAb and FITe-labeled GAM F(ab'h, either after a culture 
period of 2 days in medium without (C) or with (0; bold histogram) 100 U Il-4/ml. Histogram A represents 
EC stained with an IgG2a control antibody and FITe-labeled GAM F(ab')2' Dna representative experiment out 
of two is shown. The right-hand panel represents AM, which were also stained after a culture period of 2 
days in medium without (e) or with (0; bold histogram) 100 U Il-4/mL Histogram A represents AM stained 
with an JgG2a control antibody and FllC-labeled GAM Flab');!, whereas histogram B represents staining of 
freshly isolated AM with CD13 mAb and FIlC-labeled GAM F(ab')2' One representative experiment out of 
seven is shown. In both the left-hand and right-hand panel, fluorescence intensity of 7500 cells was 
determined on a log scale with a FACScan, 
Influence of IL-4 on the expression of C013 Ag and C013 mRNA levels In cultured human 
EC 
In our experiments we could confirm, as has been demonstrated elsewhere (26,27L 
that human endothelial cells in in vitro culture expressed C013 Ag. Already after 13 h of 
culture in the presence of IL-4 (100 U/ml) we found a slight increase in the expression of 
CO 13 Ag (relative fluorescence increased from 100 ± 11 % to 122 ± 7 % (n = 211. Maximal 
increase of CD13 Ag expression was observed between 24 and 48 h of culture, The left-
hand panel of Figure 4 shows the maximal IL-4-induced expression of C013 Ag of one 
representative experiment (relative fluorescence increased from 7,9 (100%) to 18.8 
(238%)). Incubation for more than 48 h resulted in a decrease of the expression of C013 
Ag. Therefore, the transient induction of CD13 Ag expression in human EC resembled the 
kinetics observed in our experiments with PBM and AM. Moreover, IL-4 also increased 
C013 mRNA levels in EC comparable with the increase seen in PBM and AM (Figure 6). 
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Figure 5. Kinetics of the IL-4·jnduced up-
regulation of CD13 mRNA expression in human 
AM. Total RNA was prepared from freshly 
isolated macrophages (lane l)f and from 
macrophages cultured either in the absence Hanes 
2, 4, 6 and 8) or presence (lanes 3, 5, 7 and 9) 
of 100 U IL-4/ml, Each lane contains 6 ~lg of total 
RNA. ANA was electrophorized, transferred onto 
a nylon membrane, hybridized with the 32P-labeled 
CD13 eDNA probe, and exposed for 26 hours 
(upper panel, AI. The lower panel fB) shows the 
same blot rehybridized with the GAPDH eDNA 
probe, which was used as the internal standard 
for ANA content. 
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Figure 6. Kinetics of the IL-4-induced up-
regulation of CD13 mRNA expression in human 
EC. Total RNA was prepared from EC cultured 
either in the absence of IL-4 (lanes 1, 3, 5, 7 and 
9) or for 13h, 25h, 2, 3, and 4 days in the 
presence (lanes 2, 4, 6, 8, and 10) of 100 U IL-
4/ml. Each lane contains 6 ~tg of total RNA. RNA 
was electrophorized, transferred onto a nylon 
membr.ane, hybridized with the 32P-labeled CD13 
eDNA probe, and exposed for 3 days (upper panel 
A). The lower panel 8 shows the same blot 
rehybridized with the GAPDH cDNA probe, which 
was used as the internal standard for RNA 
content. 
Although IL-4 was initially described as a B cell stimulatory factor, it is now also 
known to have regulatory activity on human monocyte/macrophage functions. IL-4 may 
activate PBM to express FCBRilb and MHC class II Ag 17-9). and may thus contribute to 
inflammatory processes. Paradoxically, IL-4 has also been reported recently to display anti-
inflammatory functions. The monocyte production of several cytokines and reactive oxygen 
species is suppressed by IL·4 (10-18), and the capacity to lyse tumor cells and 
microorganisms is decreased (10,46,47). Furthermore, IL-4 may control the accumulation 
of monocytes in areas of inflammation by enhancing apoptosis in stimulated monocytes 
(19). Evidence that IL-4 may exhibit anti-inflammatory properties is accumulating and the 
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first results of the use of IL-4 in vivo have been published recently (48,49). 
In the present study, it is shown that IL-4 up-regulates the expression of CD13 Ag on 
monocytes!macrophages, and thus may be a newly described mechanism in modulating 
inflammation. The transient induction of CD13 Ag by IL-4 resembles the earlier reported 
ILA-induced up-regulation of FceRilb on P8M (9,50). Maximal induction was seen after 2 
days of culture. Kinetics of the IL-4-induced up-reguration of CD13 mRNA revealed maximal 
levels after 1 day of culture, indicating that peak mRNA levels preceded peak CD13 Ag 
expression. The increased CD13 mRNA levels may result from either IL-4-increased 
transcription or mRNA stability. Future nuclear run-off transcription experiments and mRNA 
half-life experiments may clarify this point. Indirect evidence that most IL-4 effects occur 
at the transcriptional level comes from other studies which described influences of IL-4 on 
mRNA transcription of IL-1Ra (51), IL-2 (52), IL-6, CD23, type I and III procollagen. 
Functionally, we observed an IL-4-induced increase in LAP activity more or less 
coinciding with the IL-4-induced expression of CD13 Ag. Although PBM cultured in mock-
medium also exhibited a slight, spontaneous increase in CD13 Ag expression and CD13 
mRNA level, this was not accompanied by an increase in LAP activity in our experiments. 
This may be due to a negative influence on the optimal functional enzyme structure when 
cells are isolated from the in vivo environment and transferred to the artificial in vitro 
culture conditions. Nevertheless, IL-4-treated PBM exhibited a higher LAP activity than 
untreated PBM, indicating that IL-4 is able to increase the capacity of PBM to degrade 
aminopeptidase substrates. Not all LAP activity appeared to be due to the presence of 
CD13 Ag, as the mAb WM-15 was unable to block LAP activity totally. This was 
demonstrated earlier (53) and may indicate that also other cell membrane enzymes display 
aminopeptidase-N-like activity. A more specific assay for measuring peptidase activity due 
to aminopeptidase-N-activity (which is not available yet) would address this issue 
appropriately. 
PBM cultured in mock-medium exhibited a slight, spontaneous increase in CD13 mRNA 
and CD13 Ag. These increases in expression are unlikely to be caused by contaminating 
amounts of IL-4, as culture of PBM in the presence of both IL-4 and anti-IL-4 antiserum 
reduced CD13 Ag expression to the levels of PBM cultured in mock-medium, and not to the 
levels of freshly isolated PBM. Furthermore, this spontaneous increase could not be 
explained by either serum components or LPS or cellular adherence, as culture of PBM 
under serum-free conditions gave similar results, culture in the presence of LPS did not 
result in a more pronounced increase and PBM were cultured under nonadherent conditions 
in Teflon bags. 
Recently, it was described that activity of cell membrane peptidases could be 
modulated by cellular environmental factors. Werfel et al. demonstrated that the cell 
membrane expression of CD13 Ag was rapidly increased on PBM upon stimulation with 
C5a (54). This increase was observed within minutes, indicating translocation of an 
intracellular pool of CD13 Ag to the cell surface. Together with our results presented here, 
this suggests that different mechanisms induce increased cell membrane expression of 
CD13 Ag. Rohrbach and Conrad reported that LAP activity in cultured P8M was enhanced 
by the presence of T lymphocytes (55). Although they did not speculate on the mechanism 
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by which LAP activity was increased, we think that their results can be explained by the 
production of IL-4 by activated T lymphocytes, which is consistent with our own results. 
Kondepudi and Johnson studied another cell type and another cell membrane peptidase 
(56). They reported that several cytokines increased neutral endopeptidase activity in lung 
fibroblasts, and they suggested that up-regulation of this peptidase may limit inflammation 
in the pulmonary interstitium. In their study several cytokines were shown to increase 
neutral endopeptidase activity in human lung fibroblasts, but our results show that IL-4 
uniquely upregulates CD13 Ag expression/aminopeptidase-N-activity in human monocytes/ 
macrophages. Our conclusion is supported by others who have shown that IFN-y and IL-1 0 
were without effect on CD13 Ag expression in human monocytes (57). 
Originally, the cell membrane glycoprotein (gp 150) defined by CD13 mAb has been 
regarded as a marker for subpopulations of hemopoietic cells (20-23). Nowadays, it is 
known to be expressed by a number of different cell types, including fibroblasts, the renal 
tubular and intestinal epithelium (24,25), endothelial cells (26,27), and synaptic membranes 
of cells of the central nervous system (28). Recently, the gene for this protein has been 
cloned, leading to the recognition of this protein as aminopeptidase-N (EC 3.4.11.2) (58). 
Aminopeptidase-N belongs to the group of ectoenzymes, so-called because of their 
extracellularly located catalytic sites (25,29,30). It has been speculated that the actual, 
physiological substrate(s) of these ectoenzymes may be either membrane-bound, soluble 
or part of the extracellular matrix. Another member of this group, neutral endopeptidase (EC 
3.4.24.11, common acute lymphoblastic leukemia Ag, CD1O), has been studied 
extensively. This enzyme has been reported to process a number of biologically active 
peptides (59), including IL-1~ (60), substance P (29,61), en kephalin (62), C5a (63), and 
FMLP (64). Less is known about the physiological substrate(s) of aminopeptidase-N, but 
substrates comparable to those of neutral endopeptidase have been suggested (31). This 
is strengthened by the findings that different peptidases may be able to process the same 
peptide, or that inactivation of biologically active peptides may require sequential hydrolysis 
by a battery of distinct ectoenzymes in a multistep fashion (29,30). In the central nervous 
system the role of aminopeptidase-N, together with other cell surface peptidases, is 
believed to inactivate neuropeptides (28). Comparatively, the action of neuropeptides at 
places of neurogenic inflammation (e.g. neurogenic inflammation in asthmatic lungs) is 
thought to be terminated, at least partially, by enzymatic degradation (65,66). It has been 
reported that neutral endopeptidase is able to inactivate the neuropeptide substance P, 
which plays an important role in the pathogenesis of asthma (61). As hydrolysis of a 
particular peptide may result from the single action of different peptidases, and inactivation 
of biologically active peptides may need sequential hydrolysis by both endo- and 
exopeptidases (29,30), aminopeptidase-N may, in concert with neutral endopeptidase, play 
a role in modulating inflammation in inflammatory dIseases like asthma. 
As IL-4 has also been described in PBM to down-regulate cell membrane proteins such 
as CD14 Ag3 and the three Fcy R (47), and the physiological substrate of ectoenzymes may 
be membrane-bound, IL-4-induced up-regulation of aminopeptidase-N may, in the same cell, 
playa decisive role in processing other cell membrane-bound Ag. Transfection experiments 
in CD14 + or Fcy R+ cells using cDNA coding for enzymatically active aminopeptidase-N 
119 
CHAPTER 4.2 
may clarify this issue. 
The role of monocytes and macrophages in initiating and amplifying immunological and 
inflammatory responses has been described extensively (67,68). Both cell types may 
generate a variety of pro-inflammatory mediators and cytokines (68). On the other hand, 
it has been reported that macrophages may also be able to down-regulate inflammation 
(69). This down-regulation may be (partially) mediated by cell membrane peptidases. The 
IL-4-induced increase in LAP activity, as described here, may be a new, additional anti-
inflammatory mechanism of IL-4. 
Partly comparable to the role of monocytes and macrophages, EC are nowadays 
recognized as cells which actively participate in a variety of physiological processes, such 
as inflammation and hemostasis (27,70). Inflammation is characterized by perturbation of 
EC integrity, leading to increased vascular permeability. Several inflammatory peptides may 
be responsible for the increase in vascular permeability. A balanced regulation of production 
and degradation of these peptides determines the final development of localized edema. 
Recently, it was shown that neutral endopeptidase plays an important role in modulating 
the edema-forming effects of bradykinin (70). In view of the effects on aminopeptidase-N 
activity, IL-4 may therefore suppress indirectly the inflammatory response by increasing the 
capacity of EC to degrade pro-inflammatory peptides. 
In conclusion, our results show that IL-4 is able to increase the expression of CD13 
Ag on monocytes, macro phages and endothelial cells. We postulate that up-regulation of 
CD13 Ag expression may be an indirect working-mechanism of IL-4 to modulate the action 
of bioactive peptides. 
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CHAPTER 4.3 
SUMMARY 
IL-4 has multiple biologic activities and it has been shown to have effects on Band T 
lymphocytes, mast cells, NK cells and monocytes. We studied the influence of IL-4 on the 
expression of cell membrane determinants, in particular aminopeptidase-N (CD13) and 
Fc"Rllb (CD23), on human peripheral blood monocytes. We compared the response of 
monocytes with the response of human alveolar macrophages and monocytic cell lines 
(U937 and THP1), as mature and more immature representatives of the mononuclear 
phagocyte system, respectively. A dose-dependent increase of the expression of CD13 Ag 
was observed when monocytes were cultured with IL-4. Kinetic analyses revealed that this 
induction was maximal after 2-3 days of culture and resembled the kinetics of IL-4-induced 
expression of FCERlib on monocytes. This IL-4-induced increase was absent when 
monocytes were cultured with IL-4 and an anti-IL-4 antiserum. Concomitantly, an IL-4-
induced increase in leucine-aminopeptidase activity could be observed. Northern blot 
analysis showed that incubation of monocytes with IL-4 induced a marked increase in 
CD13 mRNA. Alveolar macrophages also exhibited an increase in CD13 Ag expression 
when exposed to IL-4. Surprisingly, IL-4 was unable to induce expression of FcsRllb on 
alveolar macrophages. U937 and THP1 cells did not show an induction of CD13 Ag when 
cultured in the presence of IL-4. However, IL-4 did induce the expression of FcsRllb on both 
cell lines, suggesting the presence of functional IL-4 R. 
Our data demonstrate that IL-4 increases the expression of CD13 Ag on monocytes. 
This IL -4-induced increase can also be observed in more mature monocytic cells such as 
alveolar macrophages, but is absent in immature cells such as U937 or THP1 cells. This is 
functionally accompanied by an increase in leUcine-aminopeptidase activity, and may be 
part of the general activation of monocytesl macrophages by IL-4. In conclusion, the data 
suggest that IL-4 responsiveness, in particular the induction of CD 13 Ag and FcsRllb 
expression, may be dependent on the stage of maturation of monocytes/macrophages. 
INTRODUCTION 
Initially, IL-4 was described to act as a differentiation factor for resting B lymphocytes 
(1). Nowadays, IL-4 has been shown to have a variety of effects on different cell types. 
It may act as a growth factor for activated T lymphocytes, thymocytes, NK cells (2-4), and 
mast cells (4,5). It may modulate the expression of cell membrane determinants, as FCERllb 
(CD23) and class II MHC antigen (Ag) on B lymphocytes (6,7) and monocytes (8,9), and 
IL-2R (CD25) on B lymphocytes (10). Furthermore, it has been shown that IL-4 is able to 
stimulate monocyte maturation accompanied by modulation of maturation markers as CD14 
and RFD9 (see chapter 5.2 of this thesis). In the course of studying the influence of IL-4 
on monocytes/macrophages we observed that IL-4 is also able to regulate the expression 
of another myeloid antigen, CD 13 Ag. 
Originally, the cell membrane glycoprotein (gp150) defined by CD13 mAb was seen 
as a marker for subpopulations of hemopoietic cells (11-14). Currently, it is known to be 
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present on many nonhemopoietic tissues, including fibroblasts, the intestinal and renal 
tubular epithelium (15,16), and on synaptic membranes of the central nervous system (171. 
As the glycoprotein has been identified as aminopeptidase-N (EC 3.4.11.2) (14,18), it has 
been suggested that this cell membrane enzyme may playa role in modulating. the activity 
of bioactive oHgopeptides (19). In the knowledge that the effects of cytokines on a certain 
cell type may depend on the maturation or differentiation stage of the cell (20,211, we 
studied the influence of IL-4 on the expression of the CD13 Ag on PBM as well as AM and 
monocytic cell lines (U937 and THP1), which can be regarded as more mature and 
immature representatives of the mononuclear phagocyte system, respectively. In this 
report, we demonstrate that IL-4 is able to induce a strong increase in expression of the 
CD13 Ag. This induction can be demonstrated on PBM and AM, but not on U937 and 
THP1 cells. 
MATERIALS AND METHODS 
Isolation of PBM 
Human PBM were isolated from 500 ml blood from healthy volunteers as described elsewhere (22). 
Briefly, mononuclear cells were separated by density centrifugation with a blood component separator. Next, 
the mononuclear cells were fractionated into lymphocytes and monocytes by centrifugal elutriatlon. The 
monocyte preparation was over 95% pure and contained more than 98% viable cells as judged by Trypan 
blue exclusion. Lymphocytes and granulocytes constituted less than 2% and 3% of the monocyte 
preparation, respectively. Before analysis of the surface membrane determinants the cells were washed twice 
with a PBS saluHon (300 masma!; pH 7.8) supplemented with 0.5% heat-inactivated BSA (Organon Teknika, 
Oss, The Netherlands). 
Isolation of AM 
All lavage studies were approved by the Medical Ethics Committee of the Erasmus University/University 
Hospital Dijkzigt, Rotterdam. SAL w,as performed in healthy, nonsmoking volunteers after premedication with 
thiazinamium and local anesthesia using a lidocaine (2%, w/v) spray. The bronchoscope was placed in wedge 
position in the right middle lobe, and four aliquots of 50 ml sterile saline solution were infused and aspirated 
immediately In a sillconized specimen trap placed on melting ice. Immediately after collection the BAL fluid 
was strained through a sterile nylon gauze to trap large mucous particles, whereafter the BAL cells were 
isolated by centrifugation at 4°C at a force of 400 x g. More than 90% of the BAL cells appeared to be 
macrophages as judged by May-Grunwald Giemsa staining. Before analysis of the surface membrane 
determinants the cells were washed twice with PBS/O.5% BSA, 
CelllJnes 
U937 cells, originally described by Sundstrom et a1. (23) were maintained at concentrations of 0,25-1 ,0 
x 106/ml in RPMI 1640 medium (Flow Laboratories, Irvine, UK) supplemented with FCS (GIBCO, Paisley, UK) 
110%)' penicillin G sodium (102 U/ml; Gist-Brocades, Delft, The Netherlands), and streptomycin-sulfate (0,1 
mg/ml; Biochrom KG, Berlin, Germany). THPl cells (24) were obtained from the American Type Culture 
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Collection (Rockville, MOl and maintained according to their instructions. In some experiments, to culture 
U937 and THPl cells under the same conditions as PBM or AM, cells were maintained in a modified Iscave's 
medium (see below). 
Culture of cells 
Generally, U937 and THPl cells were cultured as described above. In some experiments they were 
cultured as PBM and AM. paM and AM were cultured in a modified Iscave's medium (GIBCO, Paisley, UK) 
as described previously (25), in which BSA is replaced by human serum albumin supplemented with 2% 
autologous heat-inactivated serum, The culture medium was found to be endotoxin-free (defined as tess than 
1.0 ng/m! of endotoxin as quantified by the Limulus amoebocyte lysate assay). PBM (4 x 1GB/ml) and AM 
(1-2 x 10s/ml) were cultured at 37°C, 5% CO2 and 100% humidity in Teflon bags (Janssen's MNL, St-
Niklaas, Belgium) for 1 to 7 days. For detection of surface membrane determinants, cells were harvested 
from the Teflon bags and culture supernatant was removed after centrifugation. Subsequently, the cells were 
washed twice with PBS/O.5% BSA/O.5% sodium azide. The viability as determined by propidium iodide 
exclusion exceeded 85%. No significant differences in the numbers of cells recovered after culture in the 
presence of rll-4 or anti-ll-4 antiserum could be observed. 
rll-4, rll·2 and antHl-4 antiserum 
Human rll-4 was a generous gift from Dr. H.F.J. Savelkoul (Erasmus University, Rotterdam, The 
Netherlands) and Dr, K. Arai (DNAX Research Institute, Palo Alto, CAl. A polyclonal rabbit anti-ll-4 antiserum 
was used. This antiserum blocks the biologic activity of IL-4, as has been described earlier (26). Human rlL-2 
was obtained from Eurocetus (Amsterdam, The Netherlands). 
Detection of surface membrana determinants 
For immunofluorescence staining of PBM and AM the following monoclonal antibodies (mAb) were used: 
CD13 (Q200gG2a), Dr. C. E. van der Schoot, Amsterdam, The Netherlands; My7 (lgG1) Coulter Clone, 
Hialeah, FL); CD23 {TOl (lgG 1), 8iotest, Dreieich, Germany; Leu-20 (lgG 1), Becton Dickinson, San Jose, CA), 
Iso type matched antibodies which were directed against idiotypic determinants on a 8 cell lymphoma cell line 
and did not react with monocytes were used as control antibodies. Fifty ~II of the PBM or AM celt suspension 
(2 x lOS cells/m1) were incubated for 30 min at 4° C with 50 ~ll of one of the, optimally titrated, mAb. 
Incubation Was performed in 96-welr microtiter plates, After three washings the cells were incubated with 
FITC-Iabeled GAM F(ab')2 (De Beer Medicals B,V., Hilvarenbeek. The Netherlands) for 30 min at 4°C, After 
another three washings the cell pellets were resuspended for analYsis of the fluorescence intensity by means 
of a FACScan (Becton Dickinson), The fluorescence intensities of Ag expression are expressed as a ratio 
relative to the background fluorescence intensity of cultured cells stained with an isotype matched antibody, 
where a value of 1,0 reflects fluorescence equivalent to background, 
For immunological staining of U937 and THPl cells, the cell suspension (2 x 10Blm1) was preincubated 
for 10 min at 4°C with a solution of normal horse serum (final concentration 5%, v/vl. Without this 
preincubation, interpretation of the immunological stainings with the relevant mAb was troublesome because 
of high aspecific binding. After this preincubation, the cells were stained with the relevant mAb as described 
above for P8M and AM. 
All standard washings were performed with PBS/O,5% BSA/O.5% sodium azide. 
128 
CD 13 and CD23 expression ;n monocytes/macrophages 
Preparation of total cellular RNA and Northern blot analysis 
Total cellular RNA was isolated from U937 and THP1 cells, and freshly isolated or cultured PBM and 
AM largely according to Chomczynski and Sacchi (27). Briefly, cells were washed twice in PBS. Cells (5-10 
x 106) were homogenized with 0.5 ml of solution 0 in a 1.5-ml Eppendorf tube. Sequentia1Jy, 50 pI of 2M 
sodium acetate (pH 4.0), 0.5 ml of water-saturated phenol, and 0,1 ml of chloroform were added to the 
homogenate, with thorough mixing after the addition of each reagent. The final suspension was cooled on 
ice for 15 min. Samples were centrifuged at 10,000 x g for 15 min at 4°C. The aqueous phase was 
transferred to a fresh tube containing 0,5 ml of isopropanol, and then placed at 4°C for at least 6 h to 
precipitate RNA, RNA was recovered by centrifugation (10,000 x g, 15 min, 4°C), dissolved in 0.3 to 0.5 
ml solution 0, and precipitated again with 1 volume of isopropanol. After centrifugation (10,000 x g, 15 min, 
4°C), the ANA-pellet was washed in 0,6 to 1.0 ml 75% ethanol and eventually dissolved in 25 to 50 pI 
RNase-free water. Total RNA (10-20 pg) was separated by electrophoresis in a l%-agarose gel (28), 
subsequently vacuum transferred (29) onto a nylon membrane (NY-13 N; Schleicher and Schue II, Dassel, 
Germany), fixed to the membrane with a 254 nm UV crosslinker (Stratalinker, Strata gene, La Jolla, CAl and 
hybridized with the CD13 probe, which was labeled according to the Klenow-oligonucleotide method (30), 
Prehybridizatlon and hybridization of ANA blots were performed as described elsewhere (28), After 
hybridization the blots were washed and exposed to Fuji NIF-RX films (Fuji Photo Film Co., Japan) with 
intensifying screens, 
Preparation of CD13 cDNA probe 
Total ANA was extracted from AM, which were obtained from a healthy individual. The eDNA was 
synthesized with reverse transcriptase (31) and subsequently amplified by using the PCR method as 
described elsewhere (32), For the PCR-mediated amplification, synthetic oligonucleotide primers were 
designed according to the published CD13 cDNA sequence (18), The CD13 upstream primer, aacggaa 
TTCCAGAGTGTGAGGAGATGGTC, including an aspecific 5' tail (underlined) with an EcoRI restriction site, 
and the CD13 downstream primer, tgtgtctaga CTTCACCCACTTGATGTTGGCTT, including an aspecific 5' 
tail (Underlined) with a Xbafrestriction site, were used in the PCR-reaction. The obtained 562 base pairs PCR-
product was electrophorized in a 0.7%-a9arose gel, and the band containing the probe was cut out of the 
gel. The probe was electrophoretically recovered from the agarose gel fragment by using a separation 
chamber (Biotrap; Schleicher and Schuell) and cloned in the pUC19 vector with EcoRt and Xbaf restriction 
enzymes. Sequence analysis of the cloned PCR-fragment confirmed that the isolated probe represented the 
expected CD13 sequence. 
Functional assay for amlnopeptidase-N activity 
The presence of aminopeptidase-N activity on PBM, U937 or THPl ce!1s was detected largely as 
described earlier (33). Briefly, the assay was performed in wells (in triplicate) of 96-well microtiter plates. 
Cells were washed twice in PBS. Fifty pI of a cell suspension (1-3 x 106 cells/mil were incubated with 50 
,II of L-feucine-p-nitroanilide (Sigma) (8.36 mM) for 30 min at 3JOC. After this incubation enzymatic activity 
was blocked by addition of 35 pI of a 30% (v/v) acetic acid solution and the increase in specific absorbance 
at 405 nm (as a resuft of accumulation of free p-nitroanilide) was determined by using a Titertek Multiskan 
MCC plate reader (I.C.N. Biomedlcals B,V" Amsterdam, The Netherlands). Am'mopeptidase-N activity was 
expressed as the production of p-nitroanilide in 30 min by 106 cells (nmol/30 min x 106 cells). 
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RESULTS 
CD13 and CD23 surface expression on U937 cells, THP1 cells, PBM and AM 
U937 cells cultured in medium containing RPMI 1640 and 10% FCS do not express 
the CD13 Ag. On the other hand, THP1 cells and freshly isolated PBM or AM clearly 
express this Ag (Figure 1). The CD23 Ag could not be demonstrated on either one of these 
cell sources (data not shown). 
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Figure 1. Expression of the CD13 Ag on human monocytic cell lines (U937 and THP1), freshly isolated paM 
and AM. The fluorescence intensity of 7500 cells Was determined on a log scale with a FACScan, The left-
hand histogram in each of the four panels represents cells stained with an IgG2a control antibody and Flle-
labeled GAM F(ab'h, whereas the right-hand histogram represents cells stained with Q20 (CD13) and FlrC· 
labeled GAM F(ab')2' 
Influence of IL·4 on the expression of the CD13 Ag on human monocytes 
Highly purified PBM were cultured for 3 days, As compared with the expression 
directly after isolation, the expression of the CD13 Ag was enhanced after culture (Figure 
2). This increase was consistently seen in all our experiments (n:::: 7). It could only partially 
be explained by an increase in cell-size as there was only a limited rise in forward light 
scatter signal. Besides this spontaneous increase in CD13 Ag expression upon culture, IL-4 
caused a considerable further increase (Figure 2). Compared with the control cultures, IL-4 
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induced a 2- to 3-fold further increase in CD13 Ag expression. This further increase was 
dependent on the concentration of IL-4 (maximal increase was found at a concentration of 
50 U IL-4/mll (data not shown) and could be blocked by the anti-lL-4 antiserum, adding 
proof to the specificity of the induction (Table 1). PBM cultured in the presence of both IL-4 
and the anti-IL-4 antiserum exhibited the same spontaneous but small up-regulation of 
CD13 Ag as PBM cultured in mock-medium (Table 11. In addition, IL-2 did not induce a 
further increase in CD13 Ag expression (Table 1). Because IL-4 is known to have 
longlasting (MHC class II Ag (9). CD14 Ag, RFD9 Agi and transient (CD23 Ag (8)1 effects 
on the expression of cell membrane determinants, we studied the kinetics of.the influence 
of IL-4 on CD13 Ag expression. 
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Figure 2. Effects of Il-4 on the expression of the C013 Ag on blood monocytes. Cells were stained with Q20 
(C013) and FITC-Iabeled GAM F(ab'h either directly after Isolation (B), or after a culture period of 3 days in 
modified Iscove's medium without (C) or with (0; bold histogram. 100 U IL-4/ml. Histogram A represents 
monocytes stained with an IgG2a control antibody and FITC-Iabeled GAM F(ab')2' Fluorescence intensity of 
7500 cells was determined on a log scale with a FACScan. A representative experiment out of seven is 
shown. 
Table 1. Influence of Il·4 on the expression of the CD13 Ag on blood monocytes can be blocked by anti-
Il·4 antiserum.a 
Days of Culture Medium Medium + Medium + Medium + 
IL-2 11000 U/ml) IL·4 1100 U/ml) IL-4 1100 U/ml) + 
anti-tl-4 
a 17.3b 17.3 17.3 17.3 
3 35.2 36.7 94.8 34.3 
a. Freshly isolated monocytes or monocytes cultured either in mock medium or in the presence of Il-2, Il-4 
alone or both Il-4 and anti-ll-4 were labeled with Q20(CD13) and FITC-conjugated GAM F(ab'h. A 
representative experiment out of seven Is shown. 
b. Data are expressed as relative fluorescence, i.e. the ratio between the mean linear fluorescence intensity 
of cells labeled with the relevant antibody and the mean fluorescence intensity of cells labeled with the 
isotype·matched control antibody. 
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Influence of IL-4 on the expression of the CD13 Ag on human monocytes during a culture 
period of 7 days 
An up-regulation of the determinant recognized by CD 13 was already observed after 
day of culture (Figure 3 and Table 2). This increase was observed in medium without 
IL-4, but was much more substantial when PBM were cultured with IL-4. Maximal induction 
of CD13 Ag was seen after 2-3 days of culture. Thereafter, expression of CD13 Ag 
diminished. However, even after 7 days of culture expression of CD13 Ag Was higher than 
the expression on freshly isolated PBM. During the whole culture period, PBM cultured in 
the presence of IL-4 exhibited a higher expression of CD13 Ag than PBM cultured in 
medium without IL-4. 
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Figure 3. Kinetics of the effect of IL-4 on the membrane expression of CD13 Ag on human monocytes. 
Monocytes were cultured without (0) or with (e) Il-4 (100 UJmlJ. Fluorescence intensity of 7500 cells was 
determined with a FACScan. On the ordinate is given the relative fluorescence, calculated as described in 
the footnote to Table 1_ Data of a representative experiment out of three are shown. 
We compared the transie~t induction of CD13 Ag by IL-4 with the known lransient 
induction of FceRllb (CD23) and the IL-4-induced downregulation of CD14 Ag (Table 2). 
Also in our experiments we observed a transient induction of FceRllb by IL~4. Maximal 
expression was seen after 2 to 3 days of culture, coinciding with the maximal induction of 
CD13 Ag expression. In contrast, downregulation of CD14 Ag by IL-4 seemed to be a long-
lasting phenomenon. Expression of CD14 Ag was almost completely lost after 2 days of 
culture in the presence of IL-4 and reexpression was not observed even after 7 days of 
culture. This indicates that IL-4 has transient and sustained effects. The transient IL-4 
effects probably reflect a temporary change in state of activation, while the 10ng~lasting 
effects may regard monocyte maturation (see chapter 5.2 of this thesis). 
As there are indications that the maturation/differentiation state of the cell may 
determine its susceptibility to influences of IFN-y or TNF-a (21), we investigated whether 
more mature and immature representatives of the mononuclear phagocyte system respond 
to lL-4 in the same way as PBM. 
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Table 2. Time course of the Influence of IL-4 on the expression of the C013, CD14, and CD23 Ag on 
human blood monoeytes. a 
Days of Culture Medium 
CD13 CD14 CD23 
o 9.4 
30,0 11.0 1.1 
2 56,2 1.0 
3 47,8 
5 22,5 10.4 1.0 
6 20,2 7,0 1.0 
7 11.4 5,1 0,8 
CD13 
5,8 
75,7 
192,8 
155,1 
56,7 
31,6 
23,9 
Medium + 
IL-4 (100 U/mll 
CD14 
9.4 
7,6 
1.8 
1.0 
1.1 
1.3 
CD23 
1.1 
3,6 
6,6 
2,1 
1.2 
1.1 
a. Monocytes were labeled with either Q20 (C013), or UCHMl (C014), or TOl (CD23). followed by labeling 
with FITC-conjugated GAM F(ab'h either directly after isolation or after 1, 2, 5, 6, or 7 days of culture 
with or without IL-4. A representative experiment out of three is shown. 
b. Data are expressed as relative fluorescence, calculated as described in the footnote of Table 1. 
c. Not determined. 
Influence of IL-4 on the expression of the C013 Ag on U937 cells, THP1 cells and human 
AM 
U937 cells are known to express FCERllb upon culture in the presence with IL-4 (34). 
In our studies, we could also demonstrate induction 0 f a weak expression of FCERilb by 
IL-4. This induction appeared to be transient and was maximal after 3 days of culture. On 
the other hand, culture with IL-4 did not result in induction of CD13 Ag (Figure 4), Neither 
culture in RPMI 1640 supplemented with 10% FCS and r1L-4 nor culture in modified 
Iscove's medium supplemented with rlL-4 revealed induction of CD13 Ag expression on 
U937 cells, Although on PBM C013 Ag expression increased after only 1 day of culture 
with 30 U IL-4/ml, induction of CD13 Ag expression on U937 cells could not be detected 
even after 2-3 days of culture with 100 U IL-4/ml. 
Human AM were found to express CD13 Ag constitutively (Figure 1), Upon culture, this 
expression increased and this increase appeared to be maximal after 2 to 3 days of culture 
(Figure 4), With respect to the kinetics of increase in CD13 Ag expression during culture, 
PBM and AM appeared to be comparable. Moreover, IL-4 caused a further increase in CD 13 
Ag expression similar to that observed in PBM (Figure 4 and 5). Maximal expression was 
observed after 2 to 3 days of incubation, After 4-5 days, expression of CD 13 Ag on AM 
cultured with IL-4 was almost identical to the expression on AM cultured without IL-4. 
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However, expression after 4-5 days of culture was still higher than expression on freshly 
isolated AM. These data indicate that, besides the basal culture-induced increase in CD13 
Ag expression, ILA induced an additional transient up-regulation of CD13 Ag on AM. On 
the other hand, IL-4 was unable to induce FCERllb expression on AM (Figure 4). Because 
an IL-4-induced increase of CD13 Ag expression was observed only in constitutively CD13-
positive cells (PBM and AM) and not in constitutively CD13-negative cells (U937), we 
examined whether IL-4 was able to modulate expression on THP1 cells, which are, like 
U937 cells, immature monocytic cells but constitutively express CD13 Ag. In THP1 cells, 
eXpression of CD13 Ag was not changed, neither when these cells were cultured in RPM I 
1640 supplemented with 10% FCS and r1L-4 nor when they were cultured in modified 
Iscove's medium supplemented with rlLA (data not shown). On the other hand, THP1 cells 
were able to respond to IL-4, just as expression of FcsRllb was induced on U937 cells (data 
not shown). 
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Figure 4. Time course of the influence of IL-4 on the membrane expression of the C013 and CD23 Ag on 
the monocytic cell line U937 and human alveolar macrophages. Cells were cultured either without (OJ or 
with (OJ 30 U lL-4/ml. Fluorescence intensity of 7500 cells was determined with a FACScan. On the ordinate 
is given the relative fluorescence, calCUlated as described in the footnote to Table 1. Both data of U937 cells 
and macro phages represent one representative experiment of four. 
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Figure 5. Effects of lL-4 on the expression of the CD 13 Ag on alveolar macrophages. Cells were stained with 
Q20 (CD13) and FITC-Iabeled GAM Fiab')2 either directly after isolation (8), or after a culture period of 2 days 
in modified Iscove's medium without (C) or with (0; bold histogram) 30 U IL-4/ml. Histogram A represents 
macro phages stained with an IgG2a control antibody and FITC-Iabeled GAM F(ab')2' Fluorescence intensity 
of 7500 ceUs was determined on a log scale with a FACScan. A representative experiment out of three is 
shown. 
IL-4 increases LAP activity of human monocytes 
To determine whether the IL-4-induced up-regulation of C013 Ag reflects a functional 
increase in aminopeptidase activity of PBM , we studied whether IL-4 enhanced the capacity 
of PBM to degrade L-Ieucine-p-nitroanilide. PBM cultured for 2 days showed a decrease in 
LAP activity compared with freshly isolated PBM, despite an increase in CD13 Ag 
membrane expression (Table 3). These apparent contradicting data may be explained by 
preliminary observations that also other membrane enzymes (which may be down-regulated 
upon culture) can display peptidase-activity comparable to CD13 Ag (Dr. E. Favaloro, 
personal communication). On the other hand, PBM cultured for 2 days with IL-4 exhibited 
a higher activity to degrade L-Ieucine-p-nitroanilide than PBM cultured without IL-4 (Table 
3). These data add proof that IL-4 is able to increase the functional activity of PBM to 
degrade L-Ieucine-p-nitroanilide. U937 celis, which do not express CO 13 Ag, exhibited a 
20-fold lower capacity to degrade L-Ieucine-p-nitroanilide, while THP1 celis, which do 
express C013 Ag, had a capacity comparable with freshly isolated PBM (data not shown). 
To obtain more direct evidence for the influence of IL-4 on the expression of CD13 Ag and 
because IL-4 has been described to induce C023 mRNA (35), we investigated the effect 
of IL-4 on C013 mRNA. 
135 
CHAPTER 4.3 
Table 3. Influence of IL-4 on the LAP activity of human monocytes, related to the expression of the CD13 
Ag.a 
Days of 
Culture 
o 
2 
Experiment 1 
Medium Medium + IL-4 
LAP 
231 b 
108 
CD13 LAP CD13 
3.S" 
17.0 
231 3.8 
229 158.2 
Experiment 2 
Medium 
LAP 
171 
108 
CD13 
5.1 
14.1 
Medium + Il-4 
LAP 
171 
199 
CD13 
5.1 
189.4 
a. Monocytes were assayed for their LAP activity directly after isolation and after 2 days of culture with or 
without 100 U of IL-4/ml. Monocytes of the same donor were also labeled with 020 and FITC-conjugated 
GAM F(ab')2 directly after isolation and after two days of culture with or without 100 U IL-4/ml. 
b. Data represent enzymatic activity and are expressed as the rate of accumulation of p-nitroaniHde, nmol/3D 
min x 106 cells, 
e, Data are expressed as relative fluorescence, calculated as described in the footnote of Table 1, 
IL-4 increases the expression of CD13 mRNA 
Total RNA was isolated from freshly isolated human PBM, and PBM cultured for 2 days 
with or without IL-4. Total RNA was separated by electrophoresis and hybridized with a 
32P-labeled CD13 cDNA probe. The results in Figure 6 show that IL-4 induced a strong 
increase in the level of CD13 mRNA in PBM (Figure 6, lane 2). PBM cultured for 2 days in 
mock-medium exhibited a small, spontaneous increase in the level of C013 mRNA (Figure 
6, lane 3). CD13 mRNA was not detectable in U937 cells, while the level of CD13 mRNA 
in THP1 cells resembled the level in freshly isolated PBM and AM. 
DISCUSSIDN 
Initially, it was thought that a certain cytokine directed its single activity at one 
particular cell type, Nowadays, it is generally accepted that different cytokines can regulate 
the same immune activity, that a single cytokine may effect a multitude of activities and 
that these activities may be directed at multiple cell types (36-39), Moreover, recent 
reports describe that the responsiveness of a certain cell type to a particular cytokine may 
depend on the stage of maturation/differentiation of that cell type (21). IL-4 was originally 
described as a B cell growth factor, but is now also known to influence T lymphocytes, NK 
cells, and monocytes as well, Some of the many effects of IL-4 can also be brought about 
by other cytokines (38,39). The data presented here widen the range of activities of IL-4 
and show that IL-4 responsiveness of monocytic cells depends on their stage of maturation, 
It has been reported by different investigators that IL-4 is able to modulate the 
expression of several cell surface determinants. IL-4 is able to induce a transient expression 
of FERllb (CD23) on PBM (8) and monocytic cell lines (35). Furthermore, IL-4 enhances the 
expression of class II MHC Ag on PBM (9) and AM (P.Th.W. van Hal, unpublished 
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Figure 6. Induction of CD13 
mRNA by Il-4 in human 
peripheral blood monocytes. 
Total ANA was isolated from 
freshly isolated monocytes (lane 
1 I, and from cells cultured for 2 
days in the presence (lane 2, + I 
or absence (lane 3,-1 of Il-4. 
Each of these three lanes 
contains 10 pg of total ANA. 
Lanes 4 to 9 contain 1, 2, 4, 8, 
16 and 32 ~tg of ANA from the 
CD13+ cell tine THP1, 
respectively. lanes 10 and 11 
contain 10 and 20 ~tg of RNA 
from the CD13- cell line U937, 
respectively. lane 12 contains 5 
pg of total RNA from freshly 
isolated alveolar macrophages. 
RNA was separated by 
electrophoresis, transferred onto 
a nylon membrane and 
hybridized with the 32P-labeled 
CD13 cDNA probe (upper 
panel). The lower panel shows 
ethidiumbromide staining of the 
gel after electrophoresis to 
visualize loading per lane. 
observations), downregulates the expression of FcyR on PBM (40), and modulates 
maturation markers on PBM (see chapter 5.2 of this thesis). Our data indicate that IL-4 is 
also able to increase the expression of the CD13 Ag. This increase appears to be transient 
and resembles the kinetics of IL-4-induced FCERlib expression. Furthermore, IL-4 increases 
the level of CD13 mRNA and raises the capacity to degrade L-Ieucine-p-nitroanilide. Besides 
these IL-4-induced increases, a small and spontaneous up-regulation of CD13 Ag was 
observed following culture of monocytes in mock-medium. It is unlikely that this 
spontaneous up-regulation is due to contaminating amounts of IL-4, as culture of PBM in 
the presence of both IL-4 and the anti-IL-4 antiserum reduced CD13 Ag expression to the 
levels of PBM cultured in mock-medium, and not to the levels of freshly isolated PBM. 
Furthermore, this spontaneous increase could not be explained by serum components or 
adherence, as culture of PBM in serum-free medium gave similar results (data not shown) 
and PBM were cultured under nonadherent conditions in Teflon bags, respectively. As 
culture of PBM in mock-medium induces also a spontaneous increase in MHC class II 
expression (9), it appears that in our system activation takes place, most likely because of 
medium components, e.g., low levels of LPS. The spontaneous increase in CD13 Ag 
expression may be part of this activation. 
To our knowledge this is the first report on ILA-induced expression of CD13 Ag, 
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although recently Rohrbach et al. (41) reported that leucine-aminopeptidase IEC 3.4.11.2 
and identical to CD 13 Ag) activity in cultured PBM was enhanced by the presence of T 
lymphocytes. They found that the majority of increase occurred during the first day of 
culture, while they saw a further slight increase up until day 6 of culture. Although they 
did not confirm their data with immunofluorescence staining for CD13 Ag and did not 
speculate on the mechanism by which leucine-aminopeptidase activity increased, we think 
that their results can be explained by the production of IL-4 by activated T lymphocytes, 
thus being consistent with our own results. 
Surprisingly, induction of CD13 Ag by IL-4 could not be achieved on immature 
monocytic cell lines, such as U937 and THP1. We confirmed the earlier observations that 
IL-4 is able to induce FCERllb expression on these cell lines. Therefore, unresponsiveness 
to IL-4 concerning the induction of CD13 Ag can not be explained as a result of absence 
of functional IL-4 R. On the other hand, AM, just like PBM, increased their expression of 
CD13 Ag upon culture with IL-4. AM and PBM constitutively express CD13 Ag, while 
U937 cells lack this Ag. Therefore, one could speculate that IL-4 is only able to enhance 
actual expression of CD 13 Ag, while it is unable to induce expression on a CD13-negative 
cell type. If so, one would expect an increase in expression of CD13 Ag on THP1 cells, 
which are constitutively positive for this marker, upon culture with IL-4. This, however, 
could not be demonstrated in our experiments. We therefore propose, that immature 
monocytic cells are unable to enhance CD13 Ag expression upon culture with IL-4 despite 
the presence of functionallL-4 R, and that the ability to enhance CD13 Ag expression after 
culture with IL-4 is only acquired upon maturation. On the other hand, it may also be 
possible that the cell lines in question are unable to upregulate CD 13 Ag because of cell 
line-related properties other than immaturity, e.g. altered state of (de)activation. 
An analysis of the literature showed that others also indicated that cytokine effects are 
variable depending on the cell type andlor the stages of differentiation. Kawabe et al. (34) 
mentioned that CD23 Ag could be upregulated by IL-4 on normal B lymphocytes, but not 
on EBV-transformed B Iymphoblastoid cell lines. Littman et al. (39) found that IL-4 did not 
stimulate undifferentiated HL-60 cells to produce C2. However, when these cells were first 
pre-incubated with vitamine 03 to induce monocytic differentiation, they did produce C2 
in response to IL-4. Recently, Watanabe et al. (21) demonstrated that TNF-cx enhanced IFN-
y-induced MHC class II Ag expression in immature cells, such as U937 cells, while TNF-cx 
had no effect on IFN-y-induced MHC class II Ag expression in TPA-differentiated U937 
cells. They also proposed that cytokine effects depend on the maturation stage of cells. 
As IL-4 was able to induce FCERlib expression on U937 cells and PBM, we were surprised 
to see that it was unable to induce expression on AM, Although there are some reports 
showing expression of FCERllb on AM 142,43). it seems unlikely from our study that IL-4 
plays a decisive role in this expression, at least as an isolated factor. Bieber et al. (44) were 
able to induce FCERlib on a subpopulation of human epidermal Langerhans cells, but they 
used IL-4 in a high dose 11000 U/ml) and in combination with IFN-y 11000 U/ml). However, 
it should be emphasized that we cannot exclude the possibility that IL-4 in combination 
with other cytokines may be able to induce FCERllb on AM, or that IL-4 is able to induce 
FCERlib on a small (immature) subpopulation of AM, as FACScan analysis is inappropriate 
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for detecting positive subpopulations constituting less then 1 ~2% of the total cell 
population. Nevertheless, virtually the whole population of U937 cells and PBM express 
Fc,Rllb after culture with IL-4, whereas virtually the whole population of AM does not 
respond. These findings suggest that upon maturation the ability to express Fc,Rllb during 
culture with IL-4 is lost. This notion is supported by the findings of Te Velde et al. (45), 
who demonstrated that IL-4~matured PBM do not re-express FcsRllb upon renewed addition 
of IL-4 on day 4 of culture. 
In conclusion, our findings reveal a new property of IL-4, namely an up-regulation of 
the expression of CD13 Ag on monocytic cells. As the CD13 Ag represents 
aminopeptidase-N activity, this up-regulation may be part of an IL-4-induced activation of 
monocytic cells. Furthermore, our findings provide a model to explain the paradoxical 
effects of cytokines on a certain cell type. Positive or negative effects of a cytokine on a 
single cell type may be related to differences in stage of maturation, differentiation or 
activation. 
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SUMMARY 
A continuous influx of peripheral blood monocytes (PBM) to the lung is thought to 
maintain the local population of alveolar macrophages (AM) . However, local proliferation 
of a small subpopulation of AM has been demonstrated in animal studies and in humans. 
AM exhibit a great heterogeneity with regard to their morphology (cell size, shape of 
nucleus), immunophenotype (expression of CD14 Ag and RFD9 Ag), and function. Part of 
this heterogeneity may be explained by the presence of different maturation stages of AM, 
ranging from small immature, CD14' RFD9' PBM·like cells to large, CD14- RFD9' mature 
AM. These findings prompted us to study whether proliferation of PBM and AM is related 
to their stage of maturation. 
The expression of the proliferation marker Ki-67 was studied in AM from both healthy 
volunteers and patients suffering from sarcoidosis. Using double immunofluorescence 
staining, we studied proliferation of immature, CD14 + AM, and mature, RFD9+ AM in 
sarcoidosis, and we compared this with PBM. A significantly larger percentage of AM in 
general expressed Ki-67 Ag in sarcoidosis (3.0 (median); range 1.1 - 5.51 as compared 
with healthy volunteers (0.8; 0.2 - 1.3). In sarcoidosis, proliferation was observed in both 
the immature and the mature sUbpopulation of AM. Proliferating PBM were rarely observed 
(less than 0.2% of the CD14' mononuclear cells (MNC)] both in healthy volunteers and 
sarcoidosis patients. A small subpopulation of PBM showed a weak expression of RFD9 Ag 
(less than 1 % of MNC). Interestingly, proliferation of PBM was concentrated in this 
subpopulation (15% of the RFD9+ MNC). 
These data show that even mature AM, which are generally thought to be terminally 
differentiated cells with little capacity to replicate, are able to proliferate, whereas a 
relatively very low percentage of their precursors in the blood circulation proliferates. 
Furthermore, the findings suggest that lung tissue in sarcoidosis creates an environment 
which promotes proliferation of monocytic cells. 
INTRODUCTION 
Pulmonary alveolar macrophages (AM) were originally recognized as phagocytosing 
scavenger cells (1), but nowadays they are also known to initiate and regulate inflammatory 
and immunological processes in several lung diseases (2-4). AM are thought to represent 
more mature cells of the mononuclear phagocyte system, and to be derived from peripheral 
blood monocytes (PBM](5,6). As AM are continuously lost (mainly through a transport from 
the peripheral airways, via the trachea to the pharynx), the local AM population must be 
constantly replenished. This may be enabled either through a continuous influx of PBM 
from the vasculature, or through local proliferation of AM, or a combination of these 
processes. Historically, the former vision was described first (7,8), whereas the second and 
latter ideas evolved more recently (9,10). In mice, it was shown that AM renewal may be 
accounted for by local proliferation alone, and that the influx of PBM was not needed to 
sustain AM (10). Also in human studies, local proliferation of a small subpopulation of AM 
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has been demonstrated (11). Moreover, in some inflammatory lung diseases and in the lung 
of smokers an increase in the number of proliferating AM has been reported (12,13). These 
latter findings may indicate that inflammation, or in general the focal environment of AM, 
is able to modulate the capacity of AM to proliferate. The local environment may be 
determined by local cytokines, direct cell contact of AM with other inflammatory cells, or 
contact with extracellular matrix molecules (14,15). Recent studies on rat and murine AM 
suggested the significance of cytokines as M-CSF and GM-CSF in in vitro proliferation of 
AM (16-181. In contrast to murine AM, human AM were reported not to respond to M-CSF, 
but GM-CSF was shown to be a likelY candidate as a promotor of local proliferation of AM 
in the lungs (191. 
Human AM represent a heterogenous population of cells with regard to their 
morphology (cell size, shape of nucleus, ratio of cytoplasm: nucleusl(15,201, the 
expression of cell membrane proteins (CD14 and RFD9 Ag)(21 I and their function 
(expression of acid phosphatase, Ag presenting capacity, response to 
cytokines){15,21,22). The majority of this population is generally considered as more 
mature mononuclear phagocytes as compared with PBM. As mitotic activity is believed to 
diminish upon maturation, it is expected that proliferation would be more abundant among 
the immature, monocyte-like AM. However, a recent study suggested that proliferating AM 
were not monocyte-like but appeared mature (19). 
The purpose of this study was to' evaluate as to whether or not proliferation of human 
AM is related to their stage of maturation and is restricted to the more immature AM. Our 
findings show that both immature and mature AM may be able to proliferate, whereas a 
relatively low percentage of PBM proliferate. Furthermore, it is suggested that lung tissue 
in sarcoidosis creates an environment which induces proliferation of monocytic cells. 
MATERIALS AND METHODS 
Isolation of mononuclear cells 
Peripheral blood samples were obtained from non-smoking healthy volunteers and sarcoidosis patients. 
Mononuclear cells (MNC) were isolated by Ficoll-Paque (density 1.077 g/ml; Pharmacia, Uppsala, Sweden) 
density centrifugation for 15 min at room temperature with a centrifugal force of 1,000 g. All standard 
washings of cells were performed with phosphate-buffered saline (PBS; 300 mosmo!; pH 7.8) supplemented 
with 0.5% heat-inactivated bovine serum albumin (BSA; Organon Teknika, Oss, The Netherlands). Washing 
centrifugations were performed with a force of 400 9 at 4°C for 5 min. 
Isolation of AM 
All lavage studies were approved by the Medica! Ethics Committee of the Erasmus University/University 
Hospital Dijkzigt, Rotterdam. Bronchoalveolar lavage (BAL) was perfo(med in healthy, non-smoking volunteers 
(n = 12) or patients suffering from sarcoidosis (n == 12) after premedication with thiazinamium and local 
anesthesia using a lidocaine (2°/", wlvl spray. The bronchoscope was placed in wedge position in the right 
middle lobe, and four aliquots of 50 ml sterile saline solution were infused and aspirated immediately in a 
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siliconized specimen trap placed on melting ice. Immediately after collection, the BAL fluid was strained 
through a sterile nylon gauze to trap large mucous partictes, whereafter the BAL cells were isolated by 
centrifugation at 4°C at a force of 400 g. In the healthy volunteers, more than 90% of the BAL cells 
appeared to be macrophages as judged by May-Grunwald Giemsa staining. Before analysis 9f the surface 
membrane determinants or expression of the proliferation marker Ki-67, the cells were washed twice with 
PBS/O.5% BSA. 
Double immunofluorescence staIning 
Double immunofluorescence stainings were performed for either the mature monocyte/macrophage 
marker RFD9 [(not clustered), Dr. loW. Poulter, london, UK] or the immature monocyte/macrophage marker 
CD14 (UCHM1, Dr. P.C.L. Beverly, London, UK; My4, Coulter Clone, Hia!eah, FL) and the proliferation marker 
Ki-67 (Dakopatts, Danmark). In some staining experiments also the T lymphocyte marker CD3 (Leu-4, Becton 
Dickinson, San Jose, CAl was used. Both RFD9, UCHM1, My4, and Leu-4 recognize cell membrane 
determinants, whereas Ki-67 reacts with a nuclear antigen present in proliferating cells (23). Ki-67 recognizes 
an antigen that is associated with chromosomes (24). This antigen is expressed in the G" S, G2 and M phase 
of continuously cycling cells, but is absent in Go cells (231. fifty pi of the MNC or AM cell suspension (10 
x 106 and 8 x 106 cells/ml, respectively) were incubated for 30 min at 4°C with 50 ~1I of the optimally titrated 
biotinylated monoclonal antibody against one of the cell membrane markers (or NMS as a control). After two 
washings, cells were incubated (30 min, 4°C) with tetra methyl rhodamine isothiocyanate (TRITCHabeled 
streptavidin. The labeled cells were washed twice and cytocentrifuge preparations were made. These 
preparations were fixed in methanol (30 min, 4°C) and subjected to indirect immunofluorescence staining 
with Ki-67 (or IgG 1 as a control) and a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
immunoglobulin antiserum (Nordic Immunological Laboratories, Tilburg, The Netherlands). Subsequently, the 
slides were washed twice and mounted in glycerol/PBS (9: 1) containing phenylenediamine (80H Chemicals, 
Poole, UK) (1 mg/ml) to prevent fading of the fluorescence. The fluorescence was evaluated using Zeiss 
fluorescence microscopes (Carl Zeiss, Oberkochen, Germany) equipped with phase contrast facilities and filter 
combinations for the evaluation of both FITC and TRITC. At least 500 cells positive for one of the cell 
membrane markers (either CD3, CD14, or RFD9) were evaluated for the expression of Ki-67 Ag. In some 
experiments, the expression of cell membrane Ag was determined in Ki-6J+ cells. There, at least 200 Ki-67 f 
cells were screened, which implied that 1-2 x 104 cells were evaluated. 
Statistical analysis 
Differences in the expression of KI-67 Ag or the various cell membrane Ag between subject groups were 
tested with the Mann-Whitney U test. Within group differences in the Ag expression between different cell 
types were tested with the Wilcoxon matched-pairs signed-ranks test. A p value less than 0.05 was 
considered statistically significant. 
Subject popUlation 
BAL fluid was obtained from 14 patients with sarcoidosis. The diagnosis was based on the Clinical 
history, physical examination, radiologic findings and the presence of non-caseating granulomas on histologic 
examination of biopsy specimens. Only those patients were included in this study when cellular analysis of 
BAL fluid revealed specific findings of alveolitis, Le. at least 15% T lymphocytes (CD3-positive cells) and a 
CD4/COB-ratio equal to or higher than 4.0. The CD4/CDB-ratio of blood T lymphocytes did not exceed 2.5. 
The patients did not receive glucocorticoids or other medication and did not smoke. For our studies on 8AL 
cells, the cont(Ol group consisted of 12 healthy, nonsmoking volunteers without chest abnormalities and with 
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normal chest X·ray films and lung functions, Another comparable control group (n = 8) was used In our 
studies on blood MNC, 
RESULTS 
Ki-67 Ag expression by AM 
It was demonstrated earlier that the number of AM expressing Ki-67 Ag was higher in 
smokers or patients suffering from sarcoidosis than in healthy, nonsmoking volunteers 
(12,13). In those studies, expression of Ki-67 Ag was demonstrated by immuno-enzyme 
staining, In the present study an immunofluorescence staining technique was used and a 
similar increase in Ki-67+ AM was found in sarcoidosis patients (Table 1). In healthy 
volunteers, only 0,8% of the AM expressed the proliferation marker, whereas in sarcoidosis 
this percentage was almost four times higher (3,O%), This difference was statistically 
significant (p<0.0005). Upon evaluation of AM for expression of the Ki-67 Ag, we found 
that expression could be observed in both small, monocyte-like AM (with a low cytoplasm 
: nucleus ratio) and large AM (with a high cytoplasm: nucleus ratio), This, against 
expectations, suggested that proliferation was not restricted to the more immature, small 
AM. 
Table 1. Expression of Ki-67 Ag in AM from healthy volunteers and patients suffering from sarcoidosis,' 
Ki-67 
healthy volunteers 
In= 121 
0,8 (Q,2-1.3)b 
sarcoidosis 
In= 141 
3.011.1-5.51' 
a, Expression of Ki-67 Ag was determined by evaluating at least 1000 AM, Lymphocytes, granulocytes and 
epithelial cells were excluded on morphogical criteria, 
b, Data are expressed as median percentage (range)_ 
c, Statistically different from healthy volunteers (p < 0,0005), 
Ki-67 Ag expression by immature and mature AM 
Heterogeneity among AM can be explained partly by differences (Tables 2 and 31 in 
maturation stage, Maturation of monocytes/macrophages is accompanied by changes in 
the expression of cell membrane determinants. Mature AM are positive for RFD9, whereas 
virtually all immature AM, comparable to PBM, do not express the RFD9 Ag (211. Only a 
small subpopulation of PBM (0,4%1 has been reported to express RFD9 Ag with a low 
intensity (21), In contrast, immature AM and PBM express the CD14 Ag, whereas mature 
AM do not (21), The combined application of a maturation-associated marker and Ki-67 
revealed that both CD 14 + and RFD9 + AM could express the proliferation-associated marker 
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(Tables 2 and 3), (This could only be demonstrated in patients suffering from sarcoidosis, 
because the low expression of Ki-67 Ag in AM from healthy volunteers hampered the 
combined evaluation of Ki-67 Ag with cell membrane markers). These findings confirmed 
the above-mentioned conclusion that also the more mature, RF09+ AM may express the 
Ki-67 Ag (Figure 11. The expression of Ki-67 Ag in mature RFD9+ AM was in the same 
range as in immature CD14 + AM (Table 2), Therefore, we were also interested to find out 
to what extent PBM, the precursors of both mature and immature AM, expressed the Ki-67 
Ag. 
Figure 1. Double immunofluorescence staining of BAL cells for AFD9 and Ki-67 Ag. 
A: Phase contrast picture, which enables morphological differentiation between monocytes!macrophages, 
granulocytes and lymphocytes. In this picture only monocytes!macrophages are seen. 
B: Immunofluorescence staining of the ceff membrane marker RFD9 ITRITC labeled}. Most 
monocytes!macrophages strongly express this marker; some ceffs exhibit a weak signal, whereas one 
cell does not express RFD9 Ag larrow). 
C: Immunofluorescence staining of the proliferation marker Ki-67 (FITC labeled). Antigen recognized by this 
monoctonal antibody is located in the nucteus. One cell, which also expresses AFD9 Ag Isee 8), 
expresses Ki-67 Ag. 
Ki-67 Ag expression by PBM 
MNC were isolated from healthy volunteers and patients suffering from sarcoidosis, 
and tested for expression of Ki-67 Ag in PBM. In the MNC samples derived from control 
subjects, expression of Ki-67 Ag could not be detected in the CD14 (UCHM 11+ cells (Table 
41. At least 500 CD14 (UCHM1)' cells were screened in all control subjects (n~81. Use 
of another monoclonal antibody also clustered within CD14 (My4) revealed that a very low 
percentage (0,2%1 of My4 + cells expressed Ki-67 Ag (Table 41. When T lymphocytes, as 
determined by the expression of CD3 Ag, were evaluated for the expression of Ki-67 Ag, 
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Table 2. Expression of Ki-67 Ag In blood MNC versus mature and immature subpopulations of AM in 
sarcoidosis (n == 5). 
subpopulation of cells 3 
CD14+ MNC (23 ± 7)b 
RFD9' MNC 1<1) 
CD14+ AM (9 ± 6)d 
AFD9+ AM (40 ± 16) 
Ki-67 
0,0 10,0 - 0,0)' 
14,5 12,0 - 46.0) 
1,811,0- 2,2) 
2,310,7 - 4,3) 
a. At least 500 cells positive for either CD14 (UCHM1) or RFD9 were evaluated for expression of Ki-67 Ag. 
b. In parentheses is shown the mean percentage ± S.D. of CD14 (UCHM1)+ or RFD9+ cells in the total 
population of MNC. 
c. Data are expressed as median percentage (range). 
d. In parentheses is shown the mean percentage ± S.D. of CD14 (UCHM1)+ or RFD9+ 
monocytes/macrophages in the total population of BAL cells. 
Table 3. Expression of different cell membrane Ag in the Ki-67+ subpopulatlon of blood MNC and AM in 
sarcoidosis (n = 5).a 
Ki-67+ cells 
blood MNC 
CDI4IUCHM1) 
0,0 
10,0 - 1.0)' 
RFD9 
10,5 
13,0 - 38,0) 
AM 
CDI4IUCHM1) 
24.4 
112-48,91 
RFD9 
81.6 
155,2 - 84,01 
a. Expression of the relevant cell membrane marker was determined by evaluating at least 200 Ki-67+ blood 
MNC or AM. 
b. Data are expressed as median percentage (range). 
a higher percentage of Ki-67+ cells was found as compared with CD14+ myeloid cells 
(Tables 4 and 5), 
Conversely, MNC expressing Ki-67 Ag were screened with regard to their cell 
membrane marker (Table 5). At least 200 Ki-67+ cells were evaluated in'each subject. As 
only a small percentage (1-2%) of the MNC expressed Ki-67 Ag, the screening of 200 
positive cells implied that 1-2 x 104 cells were evaluated. Only a minor part of the Ki-67+ 
population expressed CD14 Ag. In the healthy volunteers, less than 1 % (median 0.3%) 
was positive for CD14 (UCHM1), whereas 1,5% of the Ki-67+ cells was also positive for 
CD14 (My4), Most of the Ki-67' cells turned out to be CD3', i.e, T lymphocytes (Table 
5), 
In the subpopulations of MNC derived from sarcoidosis patients, the expression of 
Ki~67 Ag was not significantly different from the expression in healthy volunteers (Table 
4). When the expression of Ki-67 Ag in CD14 (UCHM1)' MNC was compared with CD14 
(UCHM1)+ AM in sarcoidosis, expression of this proliferation marker was clearly higher in 
AM (Tables 2 and 3), This difference could not be tested statistically, as the number of 
subjects was too small for the Wilcoxon matched-pairs signed-ranks test becoming 
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significant. In sarcoidosis patients, we also evaluated the expression of Ki-67 in RFD9+ 
MNC. Less than 1 % of MNC expressed the RFD9 Ag with low intensity (Table 2). 
Interestingly, within this cell population there was a distinct subpopulation positive for Ki-
67 (Table 2 and 3). 
Table 4. Expression of KI·67 Ag In blood MNC and different subpopulatlons of MNC in sarcoidosis {n=51 
and healthy volunteers (n = 8). 
percentage of KI-67+ cells 
(sub)poputation of 
blood MNC 
total population" 
CD14 (UCHM1)+ cellsd 
CD14 (My4)+ cells 
CD3 (Leu-4) + cells 
sarcoidosis 
1.0 10.4 . 1.71'" 
0.0 10.0·0.01' 
0.0 10.0·0.01' 
0.5 (0.2 - 4.21' 
healthy volunteers 
1.610.2 -1.71 
0.0 (0.0·0.01 
0.2 (0.0 - 0.21 
0.6 (0.0 - 1.81 
a, At least 1000 MNC (not further characterized with cell membrane markers) were evaluated for expression 
of Ki-67 Ag. 
b. Data are expressed as median percentage (range). 
c. Not significantly different from healthy volunteers. 
d. At least 500 cells positive for the different cell membrane markers were evaluated for expression of KI-67 
Ag. 
Table 5. Expression of different cell membrane Ag in the Ki-67 + subpopulatio!l of blood MNC In sarcoidosis 
(n = 5) and healthy volunteers (n "" 8).a 
sarcoidosis healthy volunteers 
CD14 C0141 CD3 CD14 C014 CD3 
IUCHMll (My4 (UCHMll (My41 
Ki-67+ cells 0.0 0.5 77.0 0.3 1.5 58.5 
(0.0 - 1.0)b." (0.0·2.i:))' (50.6 . 87.01' (0.0 - 3.01 (1.0 - 4.01 (28.5 - 84.51 
a. Expression of the relevant cell membrane marker was determined by evaluating at least 200 Ki-67+ blood 
MNC. 
b. Data are expressed as median percentage (range), 
c. Not significantly different from healthy volunteers. 
DISCUSSION 
In this study, we have demonstrated that in the lung proliferation of AM is not 
restricted to the immature, monocyte~like and CD14 + subpopulation, and that a substantial 
number of the larger I more mature and RFD9 + AM also expressed the proliferation marker 
Ki-67. Moreover, we showed that proliferation is clearly more abundant among CD14 + AM 
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than CD14 + PBM. These findings suggest that (part of the) PBM, upon entering the lung 
tissue maintain or re-acquire their proliferative activity in spite of the changes in their 
phenotype which suggest maturation/differentiation. We also showed that a small 
subpopulation of PBM (less than 1 % of MNC) expressed the RFD9 Ag. Just within this 
RFD9+ subpopulation of PBM, proliferation appeared to be concentrated. Proliferation, Le. 
expression of Ki·67 Ag, was beyond the detection limit in the CD14 (UCHM1)+ MNC, 
whereas 15% of the RFD9+ MNC exhibited proliferative activity. These findings may 
suggest that RFD9 Ag playa role in the proliferation of monocytesimacrophages, although 
its precise function is still unknown (25). 
Current concepts on the origin of tissue macrophages suggest that these cells derive 
from PBM (1,5,6), although also local proliferation of tissue macrophages has been 
demonstrated (9,10-13). Accordingly, AM are generally thought to represent terminally 
differentiated cells with no or very little capacity to replicate. The general idea implies that 
upon leaving the circulation, PBM mature or differentiate to AM via interstitial monocytes 
and loose their ability to proliferate. Therefore, one would expect that the proliferating 
subpopulation of AM, if any, is more immature, and resembles PBM. Surprisingly, we found 
in sarcoidosis that both the mature (RFD9+) and immature (CD14 +) subpopulation of AM 
exhibited proliferative activity, whilst CD14 + AM had a much higher proliferative activity 
than CD14 + PBM. These findings indicate that lung tissue creates an environment which 
appears to induce proliferation of migrated PBM. Prior to their appearance in the alveolar 
lumen, PBM migrating from the circulation have to pass the interstitial compartment. It 
would be interesting to compare the proliferative activity of these interstitial 
monocytes/macrophages with PBM and AM, and to relate proliferation to the expression 
of cell surface markers. 
Here, we also confirmed the findings of others (12,13) that the proliferative activity 
of AM is higher in sarcoidosis than in healthy volunteers. An enhanced number of 
proliferating AM could be due to the local presence of a growth factor which is normally 
absent, or to a changed cellular responsiveness to local growth factors which are 
constitutively present. Recently, Kreipe et al. showed that the increased proliferation of AM 
in sarcoidosis may be explained by the increased presence of younger and higher c-fms-
expressing AM (12). It is known that PBM express c-fms transcripts (26), whereas AM 
from non-inflamed lungs show only reduced levels of c-fms RNA (27). Kreipe et al. 
suggested that the combination of constitutive production of M-CSF by AM and the 
increased numbers of younger and higher c-fms-expressing AM may result in an enhanced 
mitotic activity of AM (12). In contrast, our findings indicate that both immature, i.e. 
younger, and more mature AM show mitotic activity. Furthermore, we showed that PBM, 
which are known to express the c-fms protein, exhibit only very low mitotic activity as 
compared with AM. Therefore, it must be concluded that either there is no M-CSF in the 
environment of PBM, or c-fms expression is not related to the proliferation of 
monocytes/macrophages in the lung environment. With our findings of proliferation in the 
RFD9+ subpopulation of PBM, it would be worthwhile to study the expression of c-fms 
transcripts and the response to growth factors in the various sUbpopulations of PBM. 
Nakata et a!. studied the proliferation of human AM In vitro in the presence of either M-CSF 
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or GM-CSF (19). They found that GM-CSF increased the proportion of proliferating AM, in 
contrast to M-CSF. This GM-CSF effect could be abrogated by an antibody against GM-
CSF. Furthermore, they showed that human lung conditioned medium contained GM-CSF. 
Itoh et al. found high levels of GM-CSF mRNA in SAL cells from sarcoidosis patients 
compared with subjects suffering from extrinsic allergic alveolitis (28). It may therefore by 
hypothesized that in sarcoidosis increased expression of GM-CSF results in an increased 
population of proliferating AM, although the trigger of GM-CSF production is still unknown. 
In addition to the contribution of local proliferation to the accumulation of 
monocytes/macrophages in pulmonary inflammation, prolonged survival may also playa 
substantial role. Recently, it was shown that GM-CSF, and to a lesser degree M-CSF, 
enhanced survival of human monocytes in vitro (29), 80th epithelial oell- and fibroblast-
conditioned medium contained GM-CSF and M-CSF activity f suggesting that the lung 
environment in vivo may be a potential source of GM·CSF and M-CSF. 
Summarizing the findings of different studies in humans, it is suggested that in the lung 
both GM-CSF and M-CSF may enhance survival of newly arrived PBM, whereas GM-CSF 
(and not M-CSF) may induce the proliferation of more mature AM. Differential responses 
of PBM and AM on GM-CSF therapy were also observed in vivo, recently, although the 
influence on cell proliferation was not studied (30). 
The data presented here show only a limited expression of Ki·67 Ag in human PBM, 
suggesting that PBM have only a minute proliferative activity. However, RFD9+ PBM 
represent a small sUbpopulation with a much higher proliferative activity than the majority 
of PBM which are CD14 +. Furthermore, a higher percentage of AM expressed Ki-67 Ag as 
compared with PBM. Even the CD14' AM, which resemble PSM most, have a higher 
mitotic activity than PBM. It may therefore be concluded that upon leaving the circulation 
and entering lung tissue, monocytes enter an environment which seems to induce 
proliferation. This environment may be determined by local production of GM~CSF, whether 
or not in combination with other cytokines or tissue factors. This idea is in line with the 
conclusions of Nakata et al. and Itoh et al. (19,28). Future studies, which should unravel 
differences in local environmental factors of different organs, will lead to a better 
understanding of cellular processes as proliferation, maturation, differentiation and 
activation, and may eventually enable clinical intervention where these cellular processes 
are disturbed. 
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-----------------------CHAPTER5.1-----------------------
INTRODUCTION 
CHAPTER 5.1 
Nowadays, we know that modulation of cellular functions underlies the clinical and 
therapeutical effects of glucocorticoid treatment in inflammatory diseases. The beneficial 
effects of gluGocorticoids in asthma result from the inhibition of the chronic airway 
inflammation, which is considered as a major base of the clinical symptoms, especially 
bronchial hyperresponsiveness. Furthermore, we understand that inflammation in asthma 
results from the concerted actions of a variety of different cell types including mononuclear 
phagocytes, lymphocytes, eosinophils, neutrophils, mast cells, epithelial cells, and others. 
The response of these cells to gluGocorticoids requires the presence of functional and 
specific glucocorticoid receptors. A still increasing number of inflammatory cell functions 
is being shown to be affected by glucocorticoids. 
In this chapter, we shall focus on cellular effects of glucocorticoids in two 
representatives of the mononuclear phagocyte system, i.e. peripheral blood monocytes and 
alveolar macro phages, obtained from healthy volunteers. These cells are believed to play 
a central role in different aspects, i.e. initiation, perpetuation and inhibition, of inflammatory 
processes. Therefore, mononuclear phagocytes represent an important target cell for 
glucocorticoids. A better understanding of the cellular working mechanisms of glucocorti~ 
coids may enable us to find new ways to by-pass their unwanted "side" effects, or to 
recognize glucocorticoid-resistent individuals. 
In this chapter, we aim 
1. to study the effects of glucocorticoids on the expression of cell surface antigens in 
blood monocytes in vitro, 
2. to study the effects of glucocorticoids on the gene expression of IL-l p (a pro-inflamma-
tory cytokine) and Iipocortin-1 (a potential anti-inflammatory protein) in blood monocytes 
and alveolar macrophages in vitro, 
3. to compare IL-4 effects with the anti-inflammatory effects of glucocorticoids, because 
also IL-4 has been resorted to exhibit various potential anti-inflammatory effects, 
4. to demonstrate the presence of specific glucocorticoid receptors in human alveolar 
macrophages. 
We studied the effects of the synthetic glucocorticoid dexamethasone on the 
expression of cell membrane antigens in peripheral blood monocytes. Upon culture of these 
cells, changes in the expression of cell membrane antigens appeared to correlate with cell 
maturation. In some maturation experiments, we shall show the combined effects of both 
glucocorticoids and IL-4, because this cytokine was found to accelerate monocytic 
maturation. The results of these combined effects will be discussed in the light of the 
recently described evidence of cross-talk between the cytokine and the steroid signalling 
pathways. Furthermore, we will show that human alveolar macrophages may be an actual 
cellular target of gJucocorticoids. Both the application of the glucocorticoid antagonist RU 
38486 and the development of a specific receptor assay provided conclusive evidence of 
receptor-mediated effects of glucocorticoids in human alveolar macrophages. 80th IL-1 P 
and Iipocortin-1 gene expression were modulated by glucocorticoids. Since some of the 
pleiotropic IL~4 effects appear to be anti-inflammatory, we compared those effects with the 
anti-inflammatory effects of glucocorticoids. 
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CHAPTER 5.2 
SUMMARY 
In vitro culture of peripheral blood monocytes (PBM) induces changes in the 
morphology and functions of these cells. The nature of these changes suggests that 
cultured PBM progressively exhibit characteristics of more mature mononuclear phagocytes. 
[n this study, the expression of cell surface antigens fAg} and the intracellular enzyme acid 
phosphatase was studied in various maturation stages of mononuclear phagocytes, i.e. in 
both freshly isolated and cultured human PBM, and freshly isolated alveolar macrophages 
(AM). Furthermore, we tried to modulate the maturation-associated changes with IL-2, IL-4, 
and dexamethasone. 
Almost all freshly isolated PBM expressed the CD14 surface membrane determinant, 
but were negative for RF09. In contrast, almost all AM were positive for RF09, whereas 
only a minority was positive for CD14. Both cell types were negative for CD23. 
Furthermore, AM were strongly positive for endogenous acid phosphatase, whilst PBM 
were virtually negative. Upon culturing in control medium, PBM became progressively 
positive for RFD9 and part of the PBM lost the CD14 Ag. In addition, PBM became positive 
for endogenous acid phosphatase. These data strongly suggested in vitro maturation of 
PBM towards a cell type resembling AM. IL-4 induced both an accelerated maturation of 
PBM and a transient expression of CD23 Ag, whereas IL-2 had no effects. Maturation was 
partly inhibited by dexamethasone. Dexamethasone inhibited, in a dose-dependent way, 
also the IL-4-accelerated maturation and IL-4-induced expression of CD23 Ag, and these 
effects were counteracted by the glucocorticoid antagonist RU 38486. This suggests that 
glucocorticoid receptors are involved in mediating the antagonizing influence of 
dexamethasone on the IL-4 effects. 
In conclusion, our findings support the conclusions that maturation of PBM can be 
achieved in vitro, that IL-4 accelerates and dexamethasone slows down this maturation 
process, whilst dexamethasone is also able to counteract the IL-4 effects. Maturation of 
monocytic cells in vivo may therefore represent a fine-tuned process, regulated by mUltiple 
factors including IL-4 in concert with steroid hormones. It is hypothesized that interactions 
between the signalling pathways of IL-4 and glucocorticoids may occur at the level of 
transcription factors. One of the working mechanisms of therapeutical glucocorticoids in 
inflammatory diseases, in which mononuclear phagocytes playa role as immune effector 
cells, may be modulation of the maturation of monocytic cells. 
INTRDDUCTION 
Both peripheral blood monocytes (PBM) and tissue macrophages belong to the 
mononuclear phagocyte system, which is widely distributed throughout many tissues [1,21. 
Current concepts on the origin of tissue macrophages suggest that these cells derive from 
PBM {1-4]. PBM are able to leave the circulation and enter almost every tissue [4]. Upon 
leaving the vasculature, PBM mature into tissue macrophages, and acquire, depending on 
the tissue in which they reside, a site-specific morphological and immunological phenotype 
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[5,6J. Alveolar macrophages (AM) are considered to be more mature representatives of the 
mononuclear phagocyte system and are mainly derived from PBM [3,7,81. Both the 
morphological and immunological phenotype and the functions of AM differ from PBM [6,9· 
11 I. It is believed that during their migration from blood to alveoli PBM undergo a 
maturation process resulting in a change of their phenotype. The precise nature of the in 
vivo stimuli leading to these changes is still unknown. 
In vitro studies have suggested that cytokines, e.g. IL·4, GM·CSF and IFN·y, may be 
among the central factors that direct the changes in phenotype and function which 
accompany maturation [12-161. Comparatively, local in vivo production of these cytokines 
may play an important part in the physiological maturation of PBM in tissues, e.g. the lung. 
Furthermore, at sites of inflammation or immune responses, inflammatory cytokines and 
mediators may also alter the phenotype, and, concomitantly, the function of monocytic 
cells [61. In addition, in vitro studies have shown that maturation of PBM can be influenced 
by glucocorticoids [17-20]. Glucocorticoids may inhibit the production of inflammatory 
mediators and cytokines, as a result of which an indirect effect of these hormones on PBM 
is imaginable [17]. However, also a direct influence of glucocorticoids on the maturation 
of PBM has been suggested [18-20J. Further studies are needed to understand the various 
mechanisms underlying the maturation of mononuclear phagocytes. 
The available findings and hypotheses prompted us to study in more detail the effects 
of human r1L-4 and dexamethasone on the maturation of PBM in vitro. We also studied the 
effects of rIL-2, because functional IL-2 receptors have been described on freshly isolated 
PBM recently [21,22]. In vitro culture of PBM is known to be associated with maturation 
and may therefore be considered as a model to study maturation associated changes in 
phenotype and effects of various stimuli [12,23,24). Here, the immunological phenotype 
and function of PBM during culture were compared with those of AM. The results of this 
study demonstrate that IL-4 accelerates the maturation of PBM in vitro, whereas 
glucocorticoids inhibit maturation and counteract the IL-4 effects. The results support the 
hypothesis that both cytokines and steroid hormones are involved in a balanced regulation 
of the phenotype and function of monocytic cells in vivo. 
MATERIALS AND METHODS 
Isolation of PBM 
Human peripheral blood monocytes were isolated from 500 ml blood from healthy volunteers as 
described earlier [25]. Briefly, mononuclear cells were separated by density centrifugation with a blood 
component separator. Next, the mononuclear cells were fractionated into lymphocytes and monocytes by 
centrifugal elutriation. The monocyte preparation was over 95% pure and contained more than 98% viable 
cells as judged by trypan blue exclusion. Lymphocytes and granulocytes constituted less than 2% and 3% 
of the monocyte preparation, respectively. 
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Isolation of AM 
All lavage studies were approved by the Medical Ethics Committee of the Erasmus University/University 
Hospital Dijkzigt, Rotterdam. Bronchoalveolar lavage (BAL) was performed in 10 healthy, non-smoking 
volunteers after premedication with thiazinamium and local anesthesia using a lidocaine (2%, w/v) spray. The 
bronchoscope was placed in wedge position in the right middle lobe, and four aliquots of 50 ml sterile saline 
solution were infused and aspirated immediately in a siliconized specimen trap placed on melting ice. 
Immediately after collection, the SAL ftuid was strained through a sterile nylon gauze to trap large mucous 
particles, whereafter the BAl cells were isolated by centrifugation at 4°C at a force of 400 g, More than 
90% of the BAL cells appeared to be macrophages as judged by May-GrUnwald Giemsa staining_ Before 
analysis of the surface membrane determinants the cells were washed twice with a phosphate-buffered saline 
solution (PBS; 300 mosmol; pH 7,8) supplemented with 0.5% heat-inactivated bovine serum albumin (BSA) 
(Organon Teknika, Oss, The Netherlands1-
Detection of surface membrane determinants 
For immunofluorescence stainings of PBM and AM the following monoclonal antibodies (mAb) were 
used: C013 [Q20 (lgG2a); Dr_ C.E, van der Schoot, Amsterdam, The Netherlands], CD14 [UCHMl (lgG2a); 
Dr, P_C_L. Beverly, London, U.K,], CD23 {TUl (lgGl); 8iotest, Dreieich, Germany) and AFD9 (lgGl; Or. L.W. 
Poulter, London, U,K.). lsotype matched antibodies which were directed against idiotypic determinants on 
a B cell lymphoma cell line and did not react with monocytes were used as control antibodies. Fifty ~d of the 
PBM cell suspension {2 x 106 celis/mil was incubated for 30 min at 4°C with 50 ~d of one of the, optimally 
titrated, mAb, Incubation was performed in wells of 96-wells microtiter plates, After three washings PBM 
were incubated with a FITC-Iabeled goat anti mouse-immunoglobulin antiserum (Nordic, Immunological 
Laboratories, Tllburg, The Netherlands) for 30 min at 4°C, After another three washings cell pellets Were 
resuspended for analysis of the fluorescence intensity by means of the FACScan {Becton Dickinson}. The 
fluorescence intensities are expressed as a ratio relative to the background fluorescence intensity of cells 
stained with an isotype matched control antibody, where a value of 1.0 reflects fluorescence equivalent to 
background, 
For immunological staining of AM 50 ~tI of the cell suspension {8 x 106/mll was incubated for 30 min 
at 4°C with 50 fll of the relevant, optimally titrated mAb, After this incubation, the cells were washed twice 
and subsequently incubated with a FITC-Iabeled goat anti mouse-immunoglobulin antiserum for 30 min at 
4°C, After two washings the cell pellet was mounted in glycerol/PBS (9:1), containing p-phenylenediamine 
{1 mg/mll (BoH Chemicals, Poole, U.K,) to prevent fading of FITC. Coverslips were sealed to the slide with 
paraffin wax mixed with ceresin (BD~ Chemicals). Fluorescence was evaluated using Zeiss fluorescence 
microscopes, equipped with phase contrast facilities, For each mAb at least 200 cells were evaluated, 
All standard washings were performed with PBS/0.5% BSA/0,5% sodium azide. 
Monocyte cultures 
PBM were cultured in a modified Iscove's medium as described previously (26), in which BSA was 
replaced by human serum albumin, In some experiments this medium was supplemented with 2% autologous 
heat~inactivated serum. The culture medium was found to be endotoxin-free (defined as less than 1,0 ng/ml 
of endotoxin as quantified by the Umulus amebocyte lysate assay), PBM (4 x 106 /mll were cultured at 3JOC, 
5% CO 2 and 100% humidity in Teflon bags (Janssen's MNL, St-Niklaas, Belgium) for 1 to 6 days, For 
detection of surface membrane determinants, PBM were harvested from the Teflon bags and culture 
supernatant was removed after centrifugation. Subsequently, the PBM were washed twice with PBS/0,5% 
BSA/0,5% sodium azide. The viability as determined by trypan blue exclusion exceeded 85%, No significant 
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differences in the numbers of cells recovered after culture in the presence of different supplements could be 
observed. 
Cytokines 
r1L+4 was a generous gift from Dr. K. Ara! (DNAX Research Institute, Palo Alto, CA, USAl. rlL-2 was 
kindly provided by Eurocetus (Amsterdam, The Netherlandsl. 
Anti r1L-4 
A polyclonal rabbit anti-IL-4 antiserum was used. This antiserum, as has been described earlier [27), 
blocks the biologic activity of IL-4. 
Dexamethasone 
Dexamethasone micronisatum used in these experiments was obtained from Duchefa b.v. {Haarlem, The 
Netherlandsl. A stock solution of 2 x 10.3 M dexamethasone in ethanol was prepared. The concentration of 
ethanol during culture was less than 0.25% in each experiment. 
RU 38486 
The glucocorticoid antagonist RU 38486 (28] was kindly provided by Roussel Uclaf (RomainviUe, 
Francel. A stock solution of 2 x 10·3M RU 38486 in ethanol was prepared. The concentration of ethanol 
during culture was less than 0.25% in each experiment. 
StaIning for endogenous acid phosphatase 
Activity of endogenous acid phosphatase was determined using the Burnstone method [29J. Briefly, 
cytocentrifuge preparations of AM, freshly isolated and cultured PBM were incubated in a mixture of naphthol 
AS-BI phosphate (Sigma, St. Louis, MO) as substrate and diazotized pararosaniline (Sigma) as coupling agent 
in acetate-barbiturate buffer (pH 5.0) at 37°C for 30 min. After washing in PBS the slides were mounted in 
glycerin-gelatin (Merck, Darmstadt, Germany) and evaluated using tight microscopy. 
RESULTS 
Immunophenotype of freshly isolated PBM and AM 
The most prominent differences in immunophenotype between PBM and AM concerned 
the expression of RFD9 and CD14 IUCHM1) antigen lAg) ITable 1). RFD9 was virtually 
absent on the PBM, whilst 85% of the AM expressed this membrane antigen. In contrast, 
most of the PBM were positive for CD14 IUCHM1), whereas only 23% of the AM was 
positive. 
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Table 1. Percentages of freshly isolated PBM and AM positive for various cell membrane determinants. 
C014 (UCHMll 
C023 (TOll 
RF09 
87 ± gc 
o ± 1 
o ± 1 
AM" 
23 ± 15 
o ± 1 
85 ± 23 
a. Freshly isolated peripheral blood monocytes were stained with specific mAb and FITe-labeled goat anti 
mouse-immunoglobulin antIserum as detailed under Materials and Methods. Cells were evaluated with a 
FACScan. 
b. Freshly isolated alveolar macrophages (AM) were stained as described in footnote a. Cells were evaluated 
using a Zeiss fluorescence microscope equipped with phase-contrast facilities. 
c. Data are expressed as mean ± SD of 10 independent experiments. 
Effects of IL-21 IL-4 and dexamethasone on the expression of various surface membrane 
determinants by PBM 
PBM were cultured for 60 hours in the presence of either IL-4 (100 U/ml), IL-2 (1000 
U/ml) or dexamethasone (5 x 10.7 M), or without either of these supplements. After culture 
without any supplements, the expression of RFD9 was greatly enhanced (Figure 1 and 
Table 2). This increase was consistently seen in all our experiments irrespective of donor 
(n = 6). It could only partially be explained by an increase in cell-size as the forward light 
scatter signal was changed to a very small extent (data not shown). In most experiments, 
analysis of the histograms showed the loss of CD14 Ag expression by 35-40% of the PBM 
after culture (Figure 1 and Table 2). This finding appeared to be donor dependent as the 
loss of CD14 expression was not observed in all experiments. No differences between 
CD14 + and CD14 - monocytes were observed when forward and sideward scatter signals 
were compared. 
When IL-4 was added to the culture medium, the changes in CD14 and RFD9 Ag 
expression were much more pronounced. All our experiments revealed one homogenous 
CD14- population after culture in the presence of jL~4. In addition to the earlier reported 
upregulation of CD23 Ag by Il-4 [30), which was also seen in our experiments, IL-4 also 
upregulated the CD13 Ag (31). 
Il-2 had no effects on the expression of CD14, CD23 or RFD9 Ag (Table 2). Culture 
of PBM in the presence of dexamethasone (5 x 10.7 M) did not result in the expression of 
RFD9 Ag. In addition, the whole monocyte population exhibited a relatively lower 
expression of CD14 Ag, but a CD14-negative subpopulation was not observed (Figure 1 
and Table 2). 
The above-mentioned results were reason for us to study the maturation of PBM at 
different times during culture, either with or without addition of IL-4 or dexamethasone, 
separately or in combination with each other. 
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Table 2. Effects of In vitro culture and the Influence of cytokines and glucocorticoids on the expression of 
surface membrane markers on human blood monocytes. 
culture time C014 C023 RF09 
(hours) (UCHM1) (T01) (not clustered) 
Control 0 17.0a 0.6 1.2 
Control 60 15.9/1.7' 1.1 6.2 
lLA (100 U/m]) 60 1.5 2.5 10.5 
lL-2 (1000 U/ml) 60 21.5/2.0' 0.8 6.7 
Dexamethasone (5 x 10-7 M) 60 5.8 0.9 1.5 
a. Data are expressed as relative fluorescence of the whole monocyte population, I.e. the ratio between the 
mean linear fluorescence intensity of cells labeled with the relevant antibody and the mean fluorescence 
intensity of cells labeled with the isotype-matched control antibody. A representative experiment out of 
4 is shown. 
b. Calculation of one value of relative fluorescence is not possible because both a bright positive (66% of 
the whole cell population) and a negative (34% of the whole cell population) monocyte population were 
observed. 
c. Calculation of one value of relative fluorescence is not possible because both a bright positive (70% of 
the whole cell population) and a negative (30% of the whole cell population) monocyte population were 
observed. 
Culture conditions CD14 (UCHMt) days of culture 
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Figure 1. Effect of IL-4 or dexamethasone on the 
expression of the CD14 and RFD9 Ag on human 
monocytes after 3 days of culture. The fluorescence 
intensity of 7500 cells was determined on a fog scale 
with a FACScan. On the abscissa and on the ordinate 
are given fluorescence intensity and number of cells, 
respectively. Relative fluorescence was determined as 
described in the footnotes of table 2, and is stated in 
the right upper corner of each histogram. When a 
histogram revealed both a positive and negative 
population, relative fluorescence of both these 
populations was determined. In parentheses is shown 
the percentage of negative and positive cells, 
respectively. One representative experiment out of 
four is shown. 
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Influence of IL-4 and dexamethasone on the expression of the CD14 Ag on PBM during a 
culture period of 6 days 
The down-regulation of the determinant recognized by CD 14 was already observed 
after 1 day of culture in the presence of IL-4 (100 U/ml) (Figure 2). This down-regulation 
became more pronounced upon further culture. Even after 6 days of culture re-expression 
of the CD14 Ag could not be detected, indicating that this IL-4 effect was not transient. 
This IL-4-induced down-regulation could be blocked by an anti-IL-4 antiserum, indicating 
the specificity of the down-regulation by IL-4. Culture with mock-medium typically revealed 
that only part of the cell population lostthe CD 14 Ag. Notably, this negative subpopulation 
could be demonstrated until 2-3 days after start of the culture, but could not be observed 
anymore after 6 days of culture. Only one positive population was seen at that point of 
time. 
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Figure 2. Time course of the inhibition 
of ILA-induced down-regulation of the 
CD14 Ag expression on human 
monocytes by dexamethasone. 
Monocytes were cultured for 1, 2, 3 
and 6 days without or with 100 U IL-
4/ml and/or dexamethasone (5 x 10.7 
M). Fluorescence intensity was 
determined as described In the legend 
of figure 1. On the abscissa and on 
the ordinate are given fluorescence 
intensity and number of cells, 
respectively. Relative fluorescence 
was determined as described In the 
footnotes of table 2, and is stated in 
the right - upper corner of each 
histogram. When a histogram revealed 
both a positive and negative 
population, relative fluorescence of 
both these populations was 
determined. In parentheses is shown 
the percentage of negative and 
positive celis, respectively. One 
representative experiment out of three 
is shown. 
When dexamethasone (5 x 10-7 M) was added to the culture medium the appearance 
of a negative subpopulation was less pronounced and usually seen on day 1 of culture only 
(Figure 2). Culture of PBM in the presence of both dexamethasone and IL-4 revealed that 
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the IL-4-induced down-regulation of the CD14 Ag was inhibited. The vast majority of the 
cells retained the- CD14 Ag. This inhibition by dexamethasone was most evident during the 
first 3 days of culture. Furthermore, this inhibition was dependent on the dexamethasone 
concentration and was virtually absent when dexamethasone was used in a concentration 
of 5 x 10.9 M (data not shown). RU 38486 (5 x 10.6 M), an antagonist of glucocorticoids, 
restored the IL-4-induced down-regulation of the CD14 Ag when cells were cultured with 
IL-4 and dexamethasone (Table 3). 
Influence of Il-4 and dexamethasone on the expression of the CD23 Ag on PBM during a 
culture period of 6 days 
Freshly isolated PBM did not express the CD23 Ag and upon culture this antigen was 
not acquired spontaneously (Figure 3). However, it has been shown that IL-4 is able to 
induce its expression [26J. Here we confirm that IL-4 (100 U/ml) is able to induce a 
transient expression of this antigen. Culture of PBM in the presence of dexamethasone (5 
x 10'7 M) was without effect on the expression of the CD23 Ag. On the other hand, 
induction of CD23 Ag by ILA was blocked by dexamethasone. When PBM were cultured 
with IL-4, dexamethasone and RU 38486, the ILA-induced expression was restored (Table 
3). 
4 CD23(T01) 
o 2 3 4 5 6 
days of cullure 
Figure 3. Dexamethasone inhibits the IL-4-induced expression of CD23 Ag on human monocytes. Cells were 
cultured in medium alone (0), or in medium supplemented with either 100 U IL-4/ml (e), 5 x 10-7 M 
dexamethasone (6.) or both IL-4 and dexamethasone ( .... ). Relative fluorescence was determined as described 
in the footnotes of Table 2. A representative experiment out of three is shown. 
Influence of IL-4 and dexamethasone on the expression of the antigen recognized by RFD9 
on PBM during a culture period of 6 days 
The antigen recognized by RFD9 was not present on freshly isolated PBM. Upon 
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culture PBM became progressively positive for this marker (Figure 4), The appearance of 
this marker was greatly accelerated by addition of IL-4 to the culture medium. From these 
IL-4 experiments there seemed to exist a plateau-value for the expression of RFD9 Ag and 
this value was already reached after 3 days of culture. This level of expression was not 
(yet) reached after 6 days of culture in medium without IL-4. Dexamethasone alone 
appeared to have only a minor effect during the lirst 3 days, but the expression 01 RFD9 
Ag at day 6 was eventually hall the expression of the control cells. On the other hand, 
dexamethasone totally blocked the accelerated appearance 01 RFD9 Ag induced by IL-4. 
This inhibitory effect 01 dexamethasone on the IL-4-induced expression 01 RFD9 was 
dependent on the concentration of dexamethasone (data not shown) and could be 
antagonized by RU 38486 (Table 3). 
RFD9 
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Figure 4. Kinetics of the effects of IL-4 and dexamethasone on the expression of RFD9 Ag on human 
monocytes. Cells were cultured in medium alone {OJ, or medium supplemented with either 100 U IL-4/ml 
(0), 5 x 10-7 M dexamethasone (b.) or both IL-4 and dexamethasone (A). Relative fluorescence was 
determined as described in the footnotes of Table 2. One representative experiment out of three is shown. 
Influence of IL~4 and dexamethasone on the expression of endogenous acid phosphatase 
in PBM 
It has been shown that endogenous acid phosphatase is abundant in more mature 
monocytes/macrophages {32]. Human alveolar macrophages were highly positive for 
endogenous acid phosphatase (Figure 5A)' whilst freshly isolated PBM exhibited only very 
low levels 01 this enzyme (Figure 5B). In vitro culture 01 PBM revealed that these cells 
became progressively positive for endogenous acid phosphatase (Figure 5C), suggesting 
maturation of the cells. Activity of this enzyme could be enhanced by culture in the 
presence 01 IL-4 (100 U/ml) (Figure 5D). Dexamethasone (5 x 10.7 M) prevented the 
additional enhancement 01 enzyme activity caused by IL-4 (Figure 5E). On the other hand, 
RU 38486 (5 x 10.6 M) restored the inlluence of IL-4 on acid phosphatase activity when 
cells were cultured with IL~4 and dexamethasone (Figure 5F). 
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Table 3. Effect of dexamethasone on the IL-4~induced changes in the expression of surface membrane determinants on human monocytes and the 
antagonizing effect of RU 38486. 
control IL~4 (100 U/ml) 
day 0 day 1 day 2 day 3 day 1 day 2 day 3 
CD13 (Q20) 36.4" 92.7 67.0 70.3 216.0 177.1 127.2 
CD14 (UCHM1) 28.8 22.8 40.5 16.4 19.7 4.8 1.6 
CD23 (Til1) 1.2 1.4 1.6 1.2 3.5 6.5 3.2 
RFD9 1.3 1.2 3.3 6.0 1.2 8.3 14.1 
lL~4 (100 U/m]) + 
dexamethasone (5 x 10.7 M) 
day 1 day 2 day 3 
117.4 74.6 36.0 
19.6 16.0 6.5 
1.4 1.6 1.4 
1.4 2.5 2.4 
IL~4 (100 U/ml) + 
dexamethasone (5 x 10.7 M) 
+ RU 38486 (5 x 10-6 M) 
day 1 day 2 day 3 
160.6 173.9 122.2 
15.6 5.3 1.6 
3.4 6.1 6.1 
1.3 7.7 19.5 
a. Data are expressed as the relative fluorescence described in the footnotes of Table 2. One out of two separate experiments is shown. 
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Figure 5. Effects of IL-4, dexamethasone and RU 38486 on the activity of intracellular acid phosphatase in 
human blood monocytes. Freshly isolated human alveolar macrophages were highly positive for endogenous 
acid phosphatase (A), whilst freshly isolated blood monocytes (B) were virtually negative for this enzyme, 
After 2 days of culture, enzyme activity in blood monocytes was enhanced (C). Further enhancement was 
achieved after 2 days of culture with IL-4 (lOO U/m!) (0)_ This IL-4-induced increase could be antagonized 
by dexamethasone (5 x 10-7 M) (E), whereas RU 38486 (5 x 10-6 M) restored full IL-4-induced enzyme 
activity {Fl, Culture in the presence of RU 38486 (5 x 10-6 MJ alone was without effect (data not shown), 
DISCUSSION 
The present study indicates that interactions between cytokines and glucocorticoids 
may occur at the level of the maturation of mononuclear phagocytes. We describe that, in 
vitro, IL-4 modulates the immunophenotype and function of PBM, resulting in more mature 
cells which resemble AM. Dexamethasone is shown to antagonize these IL-4 effects, The 
significance of these observations is twofold. First, a better understanding of the 
maturation process of mononuclear phagocytes may lead to possibilities to influence this 
process, This may be important in the treatment of diseases, in which cellular maturation 
is derailed or affected, Second, they stress the importance of "cross-talk" between 2 
different signalling systems: that of steroid hormones and that of cytokines [33,34J. 
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The maturation of mononuclear phagocytes was studied here by means of the 
expression of cell membrane markers and endogenous acid phosphatase. Freshly isolated 
PBM were positive for CD 14 and negative for both RFD9 and endogenous acid 
phosphatase, whereas AM were positive for RFD9 and the phosphatase. A small 
subpopulation of the AM expressed the CD14 Ag. These differences seem to indicate that 
the phosphatase and RFD9 Ag are up-regulated when PBM leave the circulation, whilst 
CD14 Ag is down-regulated. During in vitro culture, PBM gradually expressed the RFD9 Ag 
and part of PBM lost the CD14 Ag, suggesting in vitro maturation. The in vitro down-
regulation of CD14 Ag in the absence of cytokines, has also been described previously 
[35]. Bazil et al showed in their study, just as we did in ours, that the spontaneous 
decrease in CD14 Ag expression appeared to be donor-dependent (35]. Other studies 
observed upregulation [36,371 or unchanged expression [381 of the CD14 Ag. These 
discrepancies may result from the choice of monoclonal antibody, as the glycoprotein 
recognized by COlA mAb has 3 or 4 distinct epitopes [39]. Here we used UCHM1, as this 
mAb yielded the best way to discriminate between PBM and AM. Furthermore, the 
discrepancies may result from differences in the culture medium, the way of isolating PBM 
or the purity of the analyzed cells. The PBM used here were highly purified according to a 
procedure which did not activate the cells (40), and they were cultured under serum-free 
conditions, ruling out influences of unidentified serum factors on maturation. 
In sarcoidosis, local production o"f IFN-y has been suggested to cause down-regulation 
of the CD14 Ag on AM [41J, as IFN-y has been shown to down-regulate this antigen in 
vitro [35,42,43J. Here we showed that also IL-4 is able to down-regulate the CD14 Ag, 
adding proof that some IFN-y effects are similar [16J to IL-4 effects, although in other 
aspects these cytokines appear to have antagonizing effects [16]. This IL-4-induced down-
regulation of CD 14 Ag has been reported previously r although the investigators did not 
interpret this finding in terms of PBM maturation [44]. Te Velde et al mentioned the 
influence of IL-4 on the maturation of PBM (13]. Here, we confirm her findings, and we 
further show that 2 other features of maturation, the expression of RFD9 Ag and 
endogenous acid phosphatase, occur faster and are more pronounced in the presence of 
IL-4. 
Thinking of maturation as an irreversible process, it was surprising to see in our in vitro 
study that after prolonged culture without IL-4, PBM re-expressed CD14 Ag comparable 
to expression directly after isolation, despite high expression of RFD9 Ag and acid 
phosphatase. In view of the recently proposed functions of CD14 Ag (see below), also this 
finding may indicate that CD14 is not an ideal maturation marker. Probably, expression of 
CD 14 Ag represents a certain functional stage, whether or not associated with maturation. 
CD14 mAb recognize a 55 kD glycoprotein. Because it maps to chromosome 5 within 
a region containing other genes encoding cytokines (lL-3, IL-4, IL-5, GM-CSF, M-CSFJ and 
receptors fc-fms), it may function as a receptor important for myeloid differentiation 
[39,45,46J. It is absent from stem cells, myeloid cells of very early differentiation states 
and some mature tissue macrophages [46). On the other hand, it has been reported that 
the protein may be involved in phagocytosis [471. Recently, it was suggested that the 
CD14 Ag could function as a receptor for complexes of LPS and LPS binding protein 
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[39,48,49J. The IL-4-induced down-regulation of the CD14 Ag may explain why IL-4 
inhibits LPS-induced secretion of IL-jp, TNF-ct and IL-B [50,51J: down-regulation of the 
receptors for complexes of LPS and LBP may thus lead to LPS-unresponsiveness. 
Another role for CD 14 Ag in the regulation of T cell proliferation has been proposed 
by Lue et al [52]. They suggested that monocytes may deliver a negative signal to T cells 
through interaction with a putative ligand for CD 14 Ag on T cells. If their model is correct, 
one should expect that IL-4 is able to intensify T cell proliferation as a result of diminished 
negative regulatory monocyte-T cell interactions. 
Originally, RFD9 has been described to recognize an antigen present on germinal center 
and granuloma macrophages [53,54]. The function of this antigen has not been established 
yet, but from our studies the antigen may be considered as a maturation marker. Although 
this antigen has been reported by Noble et al [54J to be present on only a minority (18 ± 
8%1 of macrophages in SAL fluid, our study demonstrates that virtually all AM are positive 
for this marker and that it makes a clear distinction between PBM, which are all negative, 
and AM. This apparent discrepancy in results may be due to differences in experimental 
conditions, as in our study unfixed cells were analyzed in suspension using 
immunofluorescence staining, whilst in other studies immunoperoxidase staining was 
performed on fixed samples. 
IL-4 has been shown to be a cytokine with pleiotropic biologic effects, also affecting 
monocytes. Te Velde et al indicated that IL-4 seems to be able to induce monocyte 
maturation [13). On the other hand, IL-4 is also able to modulate the phenotype and 
function of monocytes, paradoxically resulting in features of both activation (increased 
expression of MHC class II Ag (13], increased expression of cell-membrane aminopeptidase-
N [31], increased antigen-presenting capacity [55J and induction of FcoRilb [30]) and de-
activation (inhibition of superoxide production [56), inhibition of the release of PGE2 (571, 
IL-1 p, IL-B [50J and TNF-ct [50,51]). Here we provide further evidence for a role of IL-4 in 
the maturation of monocytes. These IL-4 effects seemed to be long-lasting, as they could 
still be observed after 6 days of culture. This is in contrast with the transient IL-4 effects 
on the expression of FCERllb [30] and aminopeptidase-N [311, which are maximum after 2-3 
days of culture. These findings suggest two working mechanisms of IL-4 in vitro. Effects 
on cell maturation seem to be sustained, whereas influence on the activation-state of PBM 
seems to be transient. 
Glucocorticoids are hormones with potent anti-inflammatory actions, which mainly 
result from either a decreased or increased transcription of inflammatory and anti-
inflammatory proteins, respectively [581. Recently, it was suggested that glucocorticoids 
may modulate monocyte differentiation [18-20], Using mAb against cell membrane 
determinants we have provided further evidence that monocyte maturation is inhibited by 
dexamethasone. In our study, also the IL-4-accelerated maturation and the IL-4-induced 
expression of CD23 Ag could be antagonized by dexamethasone in a dose-dependent way. 
These results suggest that also in vivo the concerted actions of glucocorticoids and 
cytokines may regulate the maturation and activation of mononuclear phagocytes. It seems 
likely that dexamethasone exerts its effects via glucocorticoid receptors, as RU 38486 
could effectively reverse the influence of dexamethasone on the IL-4 effects. Recently, it 
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was suggested that the regulation of transcription mediated by glucocorticoids may interact 
with various cytokine effects [33,34,59,60]. The signal transduction pathway of cytokines 
is thought to include the phosphorylation and activation of transcription factors [61]. Part 
of the "cross-talk" between the glucocorticoid and cytokine actions has been shown to 
result from the interaction of transcription factors with glucocorticoid receptors [60,621. 
Recent studies also reported the interaction between IL-4 and glucocorticoid effects 
[63,64]. Zubiaga et al showed that IL-4 antagonized the glucocorticoid-induced apoptosis 
of murine Th2 cells, and that protein kinase C may be involved {63]. Also synergism 
between IL-4 and glucocorticoids has been reported [64], underlining the complexity of 
"cross-talk". Therefore, further studies are needed to unravel the precise mechanism of the 
IL-4/dexamethasone antagonism observed here, and should focus on the phosphorylation 
of transcription factors and their interaction with glucocorticoid receptors. 
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SUMMARY 
Mononuclear phagocytes are key regulators of immune and inflammatory responses. 
This function results, to a great extent, from their ability to produce a large variety of 
mediators, e.g. the cytokine IL-1. It is not clear yet whether the capacity of mature 
mononuclear phagocytes like alveolar macrophages (AM) to release IL-1 is limited as 
compared with the relatively immature peripheral blood monocytes (PBM). This lack of 
clarity queries whether the inhibition of AM to produce IL-1 is an actual anti-inflammatory 
mechanism of glucocorticoids in the lung. Further studies are needed to clarify this issue. 
In this study f IL-1 P gene expression was studied in freshly isolated and cultured human 
AM, and compared with PBM and PMA/LPS-stimulated U937 cells. Furthermore, the 
influences of glucocorticoids and IL-4 on IL-1 p gene expression were studied. AM and PBM 
were cultured under serum-free conditions. Northern blot analysis was used to study mRNA 
expression, whereas dot blot analysis was applied to semiquantitate mRNA levels. 
Freshly isolated AM showed low levels of IL-1 jl mRNA as compared with stimulated 
U937 cells. However, upon culture AM exhibited a great capacity to increase IL-1 jl mRNA 
levels, which increased 64-128 fold after 1 day of culture. Thereafter, IL-1 jl mRNA 
decreased, but even after 3 days of culture levels were still higher than in freshly isolated 
AM. Both AM from smokers and nonsmokers exhibited comparable kinetics of IL-1 jl mRNA 
expression. Freshly isolated PBM were found to have higher IL-1 jl mRNA levels than freshly 
isolated AM, but showed a smaller increase upon culture. Furthermore, this increase in PBM 
was not as long lasting as in AM. Both glucocorticoids and IL-4 were able to inhibit the 
culture-associated increase in IL-1 p mRNA levels. The glucocorticoid-induced inhibition was 
counteracted by the glucocorticoid antagonist RU 38486, indicating that this inhibition was 
mediated via specific glucocorticoid receptors. 
These results show conclusively the relatively great capacity of AM to increase their 
expression of the IL-1 p gene, and stress the potential role of AM in inflammatory lung 
diseases. Part of the anti-inflammatory mechanisms of glucocorticoids can be explained by 
their influence on IL-1 jl mRNA expression in AM. The effects of IL-4 on IL-1 jl mRNA 
expression stress the potential role of IL-4 as an anti-inflammatory cytokine in vivo. 
INTRODUCTION 
Initially, IL-1 was described as a factor in culture supernatants of human peripheral 
blood adherent leukocytes that promoted thymocyte proliferation (1). Then it was found 
that monocytic cells rather than lymphocytes produced this factor, and that besides 
thymocytes also other target cells are susceptible to IL-1 (2). Nowadays, the IL-1 family, 
which includes IL-1 cr, IL-1 jl and IL-1 RA, is known to have a broad range of actions in 
inflammatory and immune responses, and to be produced by a diverse array of cell types 
and tissues (3,4), 
AM have been suggested to play an important role in the pathogenesis of several 
inflammatory lung diseases (5,6). On the one hand, AM may downregulate local 
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inflammation in the lung (7), e.g. through the production of IL-1 RA (8). On the other hand, 
AM may exhibit critical pro~inflammatory activities. Direct tissue injury may result from 
secretion of proteolytic enzymes and oxygen radical species (9). Furthermore, AM are able 
to secrete powerful pro-inflammatory cytokines as TNF and IL-1 (3). These two cytokines 
act in a synergistic fashion in inducing inflammation, shock, or even death. Initially, the 
proinflammatory activities of AM appeared relatively limited, as the production of IL -1 P by 
both freshly isolated and LPS-stimulated AM was found to be much smaller than by PBM 
(10,11). However, recent studies showed that AM contain a relatively large reservoir of 
intracellular pro~IL~1P after stimulation with LPS. These findings turned AM again into 
potential, powerful inducers of inflammation, and stressed that differences in IL~ 1 
production by freshly isolated AM and PBM may be based on the method applied to 
measure the IL-1 protein (12, 13). Moreover, culture conditions (in particular the presence 
of serum factors in culture medium) may interfere with the kinetics of Il-1 protein or mRNA 
production. The extent of IL-1 production by AM remains therefore controversial. 
Consequently, also the supposed crucial role of AM in initiating pulmonary inflammation 
and the supposed macrophage-mediated working mechanism of anti-inflammatory drugs 
may have to be reconsidered. 
These conflicting results prompted us to study the kinetics of IL-1P gene expression 
in freshly isolated human AM and AM cultured under serum-free conditions. Furthermore, 
we studied the effects of dexamethasone, a known anti-inflammatory drug, and IL-4, a 
potential anti-inflammatory cytokine,· on IL-1 p gene expression. 
MATERIALS AND METHODS 
Isolation of monocytes/macrophages 
Human AM were obtained as described elsewhere (14). BAL was performed in healthy volunteers, both 
smokers and non-smokers. All lavage studies were approved by the Medical Ethics Committee of the Erasmus 
University/University Hospital Dijkzigt, Rotterdam. At least 90% of the BAL cells appeared to be 
monocytes/macrophages as judged by May-Grunwald Giemsa staining. Human PBM were isolated from 500 
mt blood from healthy volunteers as described elsewhere (15). The monocyte preparation was over 95% pure 
as judged by May-Grunwald Giemsa staining. After isolation, some of the AM or PBM were used for 
preparation of total RNA, whereas the rest of the cells were cultured in the presence of either IL-4, 
dexamethasone (a synthetic glucocorticoid), RU 38486 (a glucocorticoid receptor antagonist), a combination 
of dexamethasone and RU 38486, or without one of these additions. 
Cell lines 
U937, a human monocytic cell line, originally described by Sundstrom and Nilsson (16) was maintained 
as described previously (14). To induce IL-1P production, celis were stimulated with PMA/LPS as described 
earlier (17). Unstimulated and PMA/LPS-stimulated U937 cells served as negative and positive controls, 
respectively, with regard to the presence of IL-1P mRNA. 
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Recombinant IL·4, dexamethasone and RU 38486 
Human r1L-4 was a generous gift from Dr. H.F.J. Savelkoul from our department and Dr. K. Ara! (DNAX 
Research Institute, Palo Alto, CAl. Dexamethasone was purchased from Duchafa b.v. (Haarlem, The 
Netherlands). The glucocorticoid antagonist RU 38486 was kindly provided by Roussel Uclaf tRomainville, 
France). 
Culture of cells 
PBM and AM were cultured under serum-free conditions as described elsewhere (14) for up to 7 days. 
In most experiments cells were maintained in T75 Falcon tissue culture flasks (Becton Dickinson, Plymouth, 
UK), whereas in some experiments cells were cultured under non-adherent conditions in Teflon bags 
(Janssen's MNL, St-Niklaas, Belgium). For isolation of total RNA from cells cultured in Teflon bags, cells were 
separated from culture supernatants by centrifugation under RNase-free conditions. Subsequently, cells were 
washed twice with PBS. Cell pellets were homogenized with 0.5 ml of solution D (18) and cooled to 4"C on 
iced water. If cells were cultured under adherent conditions, they were washed twice with PBS, then 
homogenized in the culture flasks with 0.5 ml of solution D and cooled as described above. 
Preparation of total cellular RNA, Northern blot and dot blot analysis 
Total cellular RNA was isolated from U937 cells, freshly isolated or cultured AM and PBM largely 
according to Chomczynski and Sacchi (18). For Northern blot analysis, total RNA (5-20 ~lgl was separated 
by electrophoresis in a 1 %-agarose gel, subsequently vacuum transferred onto a nylon membrane (NY-13N; 
Schleicher and SchueH, Dassel, Germany), and hybridized with an IL-l p probe, which was labeled according 
to the Klenow-oligonucleotide method (19). This IL-l P cDNA probe, a 1.3 kb Pst I fragment, was kindly 
provided by Genetics Institute (Cambridge, MAl. After hybridization, the membranes were washed and 
exposed to Fuji NIF-RX films (Fuji Photo Film Co., Tokyo, Japan) with intensifying screens. The quality and 
amounts of RNA applied were controlled by rehybridization of the blots with a GAPDH probe (20). For dot 
blot analysis, a series of total RNA dilutions was vacuum transferred onto a nylon membrane (see below). 
Thereafter, the membrane was handled as described for Northern blot analysis. 
Semlquantification of IL-1{J mRNA levels by RNA dot blotting 
Dot blotting was largely performed as described previously (211. Briefly, 1 volume of total RNA Was 
dissolved in 1 volume 15 x sse (1 x SSC = 0.15 M NaCI/15 mM Nacitrate, pH = 71 and 0.5 volume 37% 
formaldehyde, and incubated for 15 min at 60"C. Next, serial 1:2 or 1 :1.58 dilutions of total RNA in 
15 x SSC were applied with a Biodot microfiltration apparatus onto a nylon membrane, which had been 
soaked in 20 x sse. A serial dilution of total RNA from PMA/lPS~stimulated U937 cells was used as a 
reference and was also applied to each membrane containing serial dilutions of RNA from experiments with 
AM or PBM. After aspiration, RNA was fixed to the membrane with a 254 nm UV crosslinker. 
Prehybrldization, hybridization, washing, and autoradiography were performed as described above for 
Northern blotting. Semiquantification of IL-l p mRNA levels in the different AM and PBM experiments was 
achieved by comparison of the serial dilutions of RNA from AM or PBM with the serial dilutions of reference 
RNA from stimulated U937 cells. 
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RESULTS 
U937 A B 
• 0.1 0.3 3 10 3D' _ To51105' 
o 1 0 1 
kb 
1.6-
--w .... ........  . j 
2 3 4 5 6 - 7 8 9 10 
1.2-
subject 
~gRNA 
day 
-288 
-18S 
lane 
-288 
-18S 
Figure 1. Expression of Il-l p mANA in AM from two nonsmoking 
subjects A and 8 as compared with PMA/LPS-stimulated U937 
celts. Lanes 1 to 6 contain 0.1 f 0.3, 1, 3, 10, and 30 Ilg, 
respectively, of total RNA from U937 cells, and were used as a 
reference to estimate expression of IL-1J3 mRNA in freshly isolated 
(lanes 7 and 9) or cultured (lanes 8 and 10) AM. IL-lf3 mANA 
expression in freshly isolated AM turned out to be many times 
lower than in AM cultured for 1 day. Therefore, lanes 7 and 9 were 
loaded with 1 0 ~lg, whereas lanes 8 and 10 were loaded with 5 pg 
of total ANA. The upper panel shows hybridization with the IL-l p 
eDNA probe. The lower panel shows the same membrane 
rehybridized with the GAPDH eDNA probe. 
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Figure 4. Expression of lL-l p 
mRNA In freshly isolated and 
cultured AM from a smoking 
subject. lanes were loaded with 
15 119 of total RNA obtained from 
freshly isolated AM or AM cultured 
for 2 hours, or 1, 2, 3 or 7 days. 
The upper panel shows 
hybridization with the IL-1P eDNA 
probe, whereas the lower panel 
shows the same membrane 
rehybridized with the GAPDH 
cDNA probe. 
Levels of IL-1/3 mRNA in freshly isolated AM and PBM as compared with PMA/LPS-
stimulated U937 cells 
Freshly isolated AM expressed IL-l p mRNA, but in all our experiments (n ~ 7) this basal 
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expression appeared low (16-64 times as low) as compared with PMA/LPS-stimulated 
U937 cells (Figures 1 and 2). IL-l P mRNA expression in these U937 cells was used as a 
reference expression in all experiments. Freshly isolated PBM also expressed IL-l p mRNA. 
Their basal expression was consistently higher than the basal expression in AM, and was 
comparable with the expression in PMA/LPS-stimulated U937 cells (Figure 3). Basal 
expression of IL-1 P mRNA in AM from nonsmokers did not differ from basal expression in 
AM from smokers (data not shown). 
119 RNA 
16 8 4 2 1/2 
•••• 
••••• 
I 
1/4 1/8 1/16 
AM dayO 
AM day 1 
U937 
relative 
IL-1P mRNA 
expression 
1/32 
4 
1 
Figure 2. Semiquantification of IL-1P mRNA expression by dot blot analysts in AM from a smoking subject 
as compared with PMA/LP$-stimulated U937 cells. Serial 1:2 dilutions of total RNA {isolated from freshly 
isolated AM (day 0), AM cultured for 1 day (day 11. and U937 cells] were applied to the wells. Blots were 
probed with the lL-l P eDNA probe. The right column indicates IL-l p mRNA expression relative to expression 
in PMA/lPS-stimulated U937 cells. 
119 RNA relative 
IL-1P mRNA 
8 4 2 1 1/2 1/4 1/8 1/16 expression 
PBM day 0 1 
• • PBM day 1 4 
.. 
• 
U937 1 
Figure 3. Semiquantification of ll-1P mRNAexpresslon by dot blot analysis in PBM from a healthy volunteer 
as compared with PMA/lPS-stimulated U937 cells. Dot blot procedures are the same as mentioned in the 
legend to Figure 2. The right column indicates 1l-1P mRNA expression relative to expression in PMA/lPS-
stimulated U937 cells. 
182 
IL -1 {3 gene expression in mononuclear phagocytes 
Kinetics of Il-111 mRNA expression in cultured AM and PBM 
Upon culture of AM, a consistent marked increase in IL-1 p mRNA expression was 
observed in all our experiments (n:::: 7). Already after 2 hours of culture an increase in IL-1 p 
mRNA level was observed (Figure 4, lane 2). Semiquantitative analysis of Il-1P mRNA 
expression revealed that already after 2 hours of culture expression in AM almost equalled 
the expression in PMA/lPS-stimulated U937 cells (Figure 5). Maximal levels of Il-1 p mRNA 
were observed after 1 day of culture. On this day, levels were higher than in PMA/lPS-
stimulated U937 cells and were 64-128 times as high as compared with levels in freshly 
isolated AM (Figures 4 and 5). After 3 days of culture, levels of Il-1P mRNA were still 
higher than the levels in freshly isolated AM (Figure 4). Both in AM from smokers and 
nonsmokers a significant increase in IL-1 P mRNA upon culture was seen, which was 
maximal on day 1 of culture. Culture of PBM also revealed an increase in IL-1 p mRNA 
expression, although this increase was not seen in every experiment and was not as large 
as in AM (data not shown). Furthermore, in PBM the culture-associated increase in IL-1P 
mRNA expression was not as lasting as in AM. Already after 2 days of culture, Il-1 p mRNA 
levels were comparable with freshly isolated PBM. 
16 8 
/.lg RNA 
4 2 1 1/2 1/4 1/8 1/16 
••• 
••••• 
U937 
AM dayO 
AM 2h 
AM day 1 
relative 
IL-1f3 mRNA 
expression 
1 
1/64 
1/4 
2 
Figure 5. Semiquantification of IL-l p mRNA expression by dot blot analysis in AM from the same subject as 
in Figure 4. Serial 1:2 dilutions of total RNA [isolated from freshly isolated AM (day 0), AM cultured for 2 
hours (2h). AM cultured for 1 day (day 1), and U937 cells] were applied to the wells. The right column 
indicates IL-1P mRNA expression relative to the expression in PMA/LPS-stimulated U937 cells_ 
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Influence of dexamethasone on the kinetics of IL-1,8 mRNA expression in cultured AM 
Culture of AM in the presence of dexamethasone inhibited the culture~associated 
increase in IL-1 p mRNA levels. As compared with the IL-1 p mRNA expression in freshly 
isolated AM, there was still an increase in expression after 1 day of culture, but this 
increase was consistently and markedly smaller than the increase in AM cultured without 
dexamethasone (Figures 6 and 7), Semiquantification of IL-l P mRNA expression in a 
representative experiment out of seven is shown in Figure 7. After 1 day of culture, IL-l p 
mRNA expression increased 160 fold (line 1). Culture in the presence of dexamethasone 
reduced this increase to 40 times (line 4) (75% reduction). After 2 days of culture these 
increases were 40 and 16 fold, respectively (lines 7 and 10) (60% reduction). This 
dexamethasone-associated inhibition of increase in IL-1 f3 mRNA expression was mediated 
through glucocorticoid receptors, as RU 38486 antagonized this effect of dexamethasone 
(Figure 6, lane 3; Figure 7, line 3): culture of AM in the presence of both dexamethasone 
and RU 38486 revealed the same increase in IL~ 1 i3 mRNA expression as compared with 
control cultures (Figure 6, lane 3 and 1, respectively; Figure 7, line 3 and 1, respectively). 
days of culture 
dexamethasone 
RU 38486 
kb 
+ + 
+ + 
2 3 4 
2 
+ +' 
+ + 
5 6 7 8 
-28$ 
-18$ 
234-5678 lane 
Figure 6. Northern blot analysis of the effects of dexamethasone on Il+ 1 P mRNA expression in cultured AM. 
Total RNA was prepared from AM cultured in either control medium (lanes 1 and 5), RU 38486 (5 x 10-6 M; 
lanes 2 and 6), dexamethasone (5 x 10.7 M; lanes 4 and 8), or both RU 38486 and dexamethasone (lanes 
3 and 7). Each lane was loaded with 5 ~lg of total RNA. The left panel shows hybridization with the IL-l p 
eDNA probe. The right panel shows ethidiumbromide staining of the gel after electrophoresis to visualize 
equal loading per lane. 
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Figure 7. Semiquantification of Il-1 P mRNA expression by dot blot analysis in dexamethasone-treated AM 
from the same subject as tn Figure 6. Serial 1: 1.58 dilutions of total RNA (obtained from freshly Isolated AM 
(day 0)' AM cultured for 1 day (day 1), AM cultured for 2 days (day 2), and U937 cellsJ were applied to the 
wells. AM were cultured in either control medium (- -I, medium with RU 38486 (+ -), medium with 
dexamethasone (- +), or medium with both RU 38486 and dexamethasone (+ +). The right column 
indicates IL-1 P mRNA expression relative to the expression in PMA/LPS-stimulated U937 cells. 
Influence of IL-4 on the kinetics of IL-l11 mRNA expression in cultured AM and PBM 
Culture of PBM in the presence of IL-4 revealed a reduction in IL-1P mRNA expression 
as compared with the control cultures, as was described previously (22). This reduction 
was most evident on day 1 of culture (data not shown). This IL-4 effect was also observed 
in AM. In those cells, the IL-4-mediated suppression was even more distinct, probably as 
a result of the higher IL-1 p mRNA levels during culture as compared with PBM. Even on day 
3 of culture, the inhibitory effect of IL-4 on IL-1 p mRNA expression was still observed in 
AM (Figure 8, lines 6 and 7). Semiquantification of the effects of IL-4 on IL-1P mRNA 
expression in a representative experiment out of 3 is shown in Figure 8. IL-1 P mRNA 
expression increased 128 fold after 1 day of culture (line 2). IL-4 inhibited this increase, 
which resulted in only an 8 fold increase (more than 90% reduction) after 1 day of culture 
(line 3). 
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I1g RNA IL·4 relative 
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Figure 8. Semiquantification of IL-'f3 mRNA expression by dot blot analysis in IL-4-treated AM. Serial 1:2 
dilutions of total RNA (prepared from freshly isolated AM (day 0), AM cultured for 1, 2 or 3 days (day 1, 2 
and 3, respectively)' and U937 cells I were applied to the wells. AM were cultured in either control medium 
H or in the presence of 100 U IL-4/ml (+). The far right column indicates IL-lf3 mRNA expression relative 
to the expression in PMA/lP$-stimulated U937 cells. 
DISCUSSION 
Monocytes!macrophages are considered as a pivotal cell type in the initiation and 
perpetuation of inflammation in several diseases. This vision is concluded from their ability 
to function as antigen presenting cells, to secrete a great variety of inflammatory 
mediators, and to influence other inflammatory cells (5,6,23). Against this background, AM 
have been studied extensively to elucidate their role in (inflammatory) lung diseases. This 
cellular knowledge is being used in medicine to understand how glucocorticoids may exert 
their clinical anti-inflammatory 'effects (24). Furthermore, products that exhibit potential 
anti-inflammatory effects in vitro may be applied in the treatment of diseases, eventually. 
A good example of the latter is represented by IL-4 which has been shown to have 
potential anti-inflammatory effects in vitro (22,25,26), and is being used in clinical studies 
nowadays (27,28). 
In this study, the regulation of IL-1 p gene expression was analyzed in human AM. The 
literature shows conflicting data as to whether or not AM are an important source of IL-1 p. 
Recent findings suggest that IL-1 p production by AM has been underestimated because 
conventional ELISA's are unable to detect the 35 kDa pro-IL-1 p molecule (12,13). These 
findings strengthened the potential role of AM in inflammation, and prompted us to re-
examine the expression of the IL-1 p gene in AM. In this study, three aspects of IL-1 p gene 
expression in AM were evaluated. First, we studied the kinetics of IL-1 p mRNA expression 
186 
IL ~ 1 (3 gene expression in mononuclear phagocytes 
in cultured AM from smokers and nonsmokers. Second, we examined the influence of 
glucocorticoids on this expression. Third, we evaluated the effects of IL-4. 
The basal expression of the IL-1 p gene in freshly isolated AM appeared relatively low 
as compared with freshly isolated PBM or stimulated U937 cells. These findings correspond 
to the conclusions of Wevers et al (10) . However, AM showed an increased expression 
upon culture, eventually resulting in higher expressions of IL-l p mRNA than in PBM and 
U937 cells. This may indicate that also in vivo, under certain conditions, AM may be able 
to increase the production of IL-1 p to a greater extent than any other cell type. The role of 
AM in the initiation of inflammation in the lung may therefore be more important than it 
was suggested on the basis of former studies (10). PBM also showed a transient increase 
in IL-l p mRNA expression upon culture, but this increase was less pronounced and of 
shorter duration. These findings stress the functional differences between AM and PBM. 
Differences in the stage of maturation/differentiation within the mononuclear phagocyte 
system, to which both AM and PBM belong, may underlie such functional differences (14). 
The spontaneous increase in IL -1 P mRNA upon culture of AM and PBM may result from 
mRNA stabilization or an increased transcription. The ultimate trigger of this spontaneous 
increase remains unknown. Serum components were excluded, as cells were cultured in 
serum-free medium. Cellular adherence as a cause is also unlikely, as the spontaneous 
increase was observed both during culture in flasks (adherent conditions) and during culture 
in Teflon bags (non-adherent conditions). It has been reported that culture of PBM under 
both non-adherent and serum-free conditions induced a spontaneous increase in MHC class 
II (29) and CD13 Ag expression (25). It appears that in those culture systems, and also 
ours, PBM and AM become activated. This activation may result from e.g. cellular products 
or low levels of LPS. 
AM from smokers and nonsmokers differ in morphology, immunophenotype and 
function (30,31). It was shown previously that smoking decreased IL-1 secretion by LPS-
stimulated AM, and it was suggested that smoking impaired the release of intracellular IL-1 
rather than the production of IL-1 (31). We found no differences in the expression of IL-1 p 
mRNA between AM from smoking and nonsmoking subjects. These results are consistent 
with the idea that smoking decreases IL-l production via a post-transcriptional mechanism. 
Upon culture, AM from both smokers and nonsmokers showed a transient increase in IL-1 p 
mRNA levels. Even with the technique of mRNA semiquantification used in our 
experiments, we were unable to detect differences between AM from smokers and 
nonsmokers. 
Part of the anti-inflammatory effects of glucocorticoids has been shown to result from 
modulation of the production of various inflammatory cytokines (32,33). Expression of IL-1 
by U937 cells and PBM has been reported to decrease upon treatment with glucocorticoids 
(34,35). In the current study, these findings were confirmed in more mature mononuclear 
phagocytes, i.e. AM. This effect of glucocorticoids was mediated via glucocorticoid 
receptors, as RU 38486 antagonized the decrease in IL-1P mRNA levels. Either reduced 
transcription or increased mRNA instability may underlie the glucocorticoid-mediated 
decrease in IL-1p mRNA levels. In PBM, only stability of IL-1P mRNA was markedly 
decreased by dexamethasone (35), whereas in U937 cells expression of IL-1 was inhibited 
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both transcriptionally and post-transcriptionally (34). The mechanism of glucocorticoid-
mediated IL-1j3 mRNA decrease in AM is currently being studied in our laboratory. AM are 
nowadays considered as a potential reservoir of intracellular IL-1 p as a result of large 
amounts of pro-IL-1 13. This reservoir may be activated and released in the presence of the 
appropriate milieu (13). Therefore, modulation of IL-1 p gene expression by glucocorticoids 
in AM may be of more importance than previously considered. Our findings indicate that 
in the lung part of the anti-inflammatory actions of glucocorticoids may be mediated via 
AM. 
IL-4 was recently found to modulate the gene expression (22) and secretion (22,36) 
of cytokines. In those studies, it was demonstrated that IL-4 suppressed LPS-induced 
mRNA and protein accumulation for IL-1 P in human PBM. Little is known about the effects 
of IL-4 on AM. Results in PBM can not be extrapolated on AM thoughtlessly, because it has 
been reported that effects of cytokines on target cells may depend on their stage of 
maturation (14). The results on PBM presented here confirm the results of Vannier et al 
(22). In addition, we show that also in AM IL-4 suppresses IL-1P gene expression. Time-
course experiments demonstrated that IL-4 reduced IL-1 P levels for a prolonged period of 
time (> 3 days). This IL-4-mediated inhibition of the spontaneous, culture-associated 
increase in IL-1 p mRNA levels may be due to decreased transcription or enhanced 
degradation of IL-1f3 mRNA. Future nuclear run-off transcription experiments and mRNA 
half-life experiments may clarify this point. Indirect evidence that IL-4 modulates 
transcription comes from other studies which described IL-4 effects on mRNA transcription 
of IL-1 RA (37) and IL-2 (38). However, IL-4 may also accelerate mRNA decay, as was 
demonstrated in recent studies on MIP-a (39). Our findings may be considered as further 
evidence of the potential anti-inflammatory properties of IL-4. 
Recently, Galve-de Rochemonteix et al described the effects of IL-4 on the regulation 
of IL-1a, IL-1P and IL-1RA production by AM (8). In that study, AM were obtained from 
patients with pulmonary cell carcinoma immediately after surgery. AM were cultured in the 
presence of 5% FCS. A transient increase in IL-1 p mRNA levels was shown upon culture 
of AM with a peak at 3 h. Furthermore, IL-4 was shown to increase IL-1 RA production and 
IL-1RA mRNA levels, but IL-4 did not affect the IL-1P production or IL-1P mRNA levels. In 
our study, AM were obtained from healthy volunteers and were cultured in medium without 
serum. A spontaneous, transient increase in IL-1P mRNA was demonstrated with a peak 
at day 1 of culture. After 1 day, IL-1 p mRNA levels were 64-128 fold higherthan in freshly 
isolated AM. Even after 3 days of culture, levels were still higher than in freshly isolated 
AM. These different results may arise from differences in either the patient population 
(healthy volunteers versus cancer patients), the method of performing SAL (whether or not 
after surgery), or the culture conditions (whether or not in the presence of serum). 
Furthermore and in contrast to the previous study, in our study a consistent decrease in IL-
1 P mRNA was induced by IL-4. This discrepancy in findings may also result from the above 
mentioned differences between the two studies. An important factor may be the presence 
of serum in the culture medium, as serum factors (e.g. glucocorticoids or cytokines) may 
antagonize IL-4 effects. 
In conclusion, the results of this study stress that AM are potential modulators of 
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inflammation as illustrated by their ability to increase steady state IL-1 p mRNA levels 
substantially under certain environmental condition. Furthermore, both glucocorticoids and 
IL-4 were shown to decrease IL-1 p mRNA levels. These findings help us to understand the 
anti-inflammatory mechanisms of glucocorticoids in the lung, and stress the potential role 
of IL-4 as an anti-inflammatory cytokine. 
ACKNOWLEDGMENTS. We gratefully acknowledge Prof. Dr. R. Benner and Prof. Dr. C. Hifvering for their 
continuous support and advices; Dr. S.F. Smith (London) for critically reading the manuscript; Mr. T.M. van 
as for excellent assistance in preparing the figures; and Mrs. J.M.J. van £verdingen-Quartel for expert 
secretarial help. This investigation was supported in part by a grant from Glaxo Holland B. V. (A.P') and from 
the NWO Council for Medical Research. 
REFERENCES 
1. Gery I, Gershon RK, Waksman BH. Potentiation of the T-Iymphocyte response to mitogens. J Exp Med 
1972; 136: 128·142. 
2. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin 1. Immunol 
Today 1986;7:45-56. 
3. Dinarello CA. The proinflammatory cytokines interleukin-l and tumor necrosis factor and treatment 
of the septic shock syndrome. J Infect Dis 1 991; 163: 1177-1184. 
4. Dinarello CA, Wolff SM. The role of interleukin-l in disease. New Engl J Med 1993;328:106-113. 
5. Sibille V, Reynolds HV. Macrophages and polymorphonuclear neutrophifs in lung defense and injury. 
Am Rev Respir Dis 1990;141:471-501. 
6. Fels AOS, Cohn ZA. The alveolar macrophage. J Appl Physiol 1986;60:353-369. 
7. Holt PG, Oliver J, Bilyk N, McMenamin e, McMenamin PG, Kraal G, Thepen T. Downregulation of the 
antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar 
macro phages. J Exp Med 1993; 177:397-407. 
8. Galve-de Rochemonteix B, Nicod lP, Chicheportiche R, lacraz S, Baumberger C, Dayer J-M. 
Regulation of interleukin-lra, interleukin-la, and interleukin-1J3 production by human alveolar 
macro phages with phorbol myrrstate acetate, lipopolysaccharide, and interleukin-4. Am J Respir Cell 
Mol BioI 1993;8: 160-168. 
9. Nathan CF. Secretory products of macrophages. J Clin Inve-st 1987;79:319-326. 
10. Wewers MO, Rennard SI, Hance AJ, Bitterman PB, Crystal RG. Normal human alveolar macro phages 
obtained by bronchoalveolar lavage have a limited capacity to release interleukin-l. J Crin Invest 
1984;74:2208·2218. 
11. Kern JA, Lamb RJ, Reed JC, Elias JA, Daniele RP. Interle-ukin-l-beta gene expression in human 
monocytes and alveolar macrophages from normal subjects and patients with sarcoidosis. Am Rev 
Respir Dis 1988; 137: 1180-1184. 
12. Wewers MD, Pope HA. Il-1P measurements using proll-1P specific ELISA confirm alveolar 
macrophage as potential reservoir of intracellular Il-1 p. Am Rev Respir Dis 1993;147:A230. 
13. Herzyk OJ, Berger AE, Allen IN, Wewers MD. Sandwich ELISA formats designed to detect 17 kDa 
IL-lf3 significantly underestimate 35 kDa Il-lp. J Immunol Meth 1992;148:243-254. 
14. Van Hal PThW, Hopstaken-Broos JPM, Wijkhuijs JM, Te Velde AA, Figdor eG, Hoogsteden HC. 
Regulation of aminopeptidase-N (CD13) and FCf.:Rllb (CD23) expression by Il-4 depends on the stage 
of maturation of monocytes/macrophages. J Immunol 1992;149:1395-1401. 
15. Figdor CG, Bont WS, Touw I, De- Roos J, Roosnek EE, De Vries JE. Isolation of functionally different 
human monocytes by counterflow centrifugation elutriation. Blood 1982;60:46-53. 
189 
CHAPTER 5.3 
16. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line 
(U-937). Int J Cancer 1976;17:565-677. 
17. Baldarl CT, Telford JL. The intracellular precursor of IL-l P is associated with microtubules in activated 
U937 cells. J ImmunoI1989;142:785-791. 
18. Chomczynski P, Sacchi N, Single-step method of RNA isolation by acid guanidinium thiocyanate-
phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159. 
19. Van Oongen JJM, Walvers-Tettero (lM. Analysis of immunoglobulin and T cell receptor genes. Part 
I: Basic and technical aspects. Clin Chim Acta 1991 ;198:1·92. 
20. Benham FJ, Hodgkinson S, Davies KE. A glyceraldehyde-3-phosphate dehydrogenase pseudogene on 
the short arm of the human X-chromosomes defines a multigene family. EMBO J 1984;3:2635-2640. 
21. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the mdr 
1 gene in blast cells from patients with acute myelocytic leukemia is assoclated with decreased 
anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990;45:263-268. 
22. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: Interleukin 
4 suppresses inter leu kin 1 production but up-regulates gene expression and synthesis of interleukin 
1 receptor antagonist. Proc Nat! Acad Sci USA 1992;89:4076-4080_ 
23_ Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory 
cells. Science 1987;236:551-557. 
24. Russo-Marie F. Macrophages and the glucocorticoids. J Neuroimmunol 1992;40:281-286. 
25. Van Hal PThW, Hopstaken-Broos JPM, Prins A, Favaloro EJ, Huijbens RJF, Hilvering C, Figdor CG, 
Hoogsteden HC. Potential indirect anti-inflammatory effects of IL-4. Stimulation of human monocytes, 
macrophages, and endothelial cells by IL-4 increases aminopeptidase-N activity (CD13; EC 3.4.11.2J. 
J ImmunoI1994;153:2718-2728_ 
26. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli OS, Hamilton JA. Potential antiiflammatory effects 
of interleukin 4: Suppression of human monocyte tumor necrosis factor a, lnterleukin 1, and 
prostaglandin E2 • Proc Natl Acad Sci USA 1989;86:3803-3807. 
27. Maher OW, Davis I, Boyd AW, Morstyn G_ Human interleukin-4: An immunomodulator with potential 
therapeutic applications_ Prog Growth Factor Res 1991;3:43-56. 
28. Wong HL, Lotze MT, Wahl LM, Wahl SM. Administration of recombinant lLA to humans regulates 
gene expression, phenotype, and function in circulating monocytes. J ImmunoI1992;148:2118-2125. 
29. Te Velde AA, Klomp JPG, Yard BA, De Vries JE, Figdor CG. Modulation of phenotypic and functional 
properties of human peripheral blood monocytes by IL-4. J Immunol 1988;140: 1548-1554. 
30_ Hoogsteden HC, Van Hal PThW, Wijkhuijs JM, Hop W, Verkaik APK, Hilvering C. Expression of the 
CD11/CD18 cell surface adhesion glycoprotein family on alveolar macro phages in smokers and 
nonsmokers. Chest 1991;100:1567-1571. 
31. Soliman OM, Twigg HL. Cigarette smoking decreases bioactive interleukin-6 secretion by alveolar 
macrophages_ Am J Physiol 1992;263:L471-L478. 
32_ Munck A, Mendel DB, Smith L1, Orti E_ Glucocorticoid receptors and actions. Am Rev Respir Dis 
1990;141 :S2~Sl o. 
33. Van Hal PThW, Hoogsteden HC. Inflammatory mediators and glucocorticoids_ In: Bray MA, Anderson 
WH, eds_ Mediators of pulmonary inflammation. New York: M Dekker, Inc. 1991:593-617. 
34. Knudsen PJ, Dinarello CA, Strom T8. Glucocorticoids inhibit transcriptional and posttranscriptional 
expression of interleukin-1 in U937 cells. J Immunol 1987; 139:4129-4134. 
35. Amana Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1u, 
interleukin-1 p, and interleukin-6: Mediation by decreased mRNA stability. Mol Pharmacol 
1993;43: 176-182. 
36. Te Velde AA, Huijbens RJF, Heije K, De Vries JE, Figdor CG. lnterleukin-4 tlL-4) inhibits secretion of 
IL-1P, tumor necrosis factor a, and IL~6 by human monocytes. Blood 1990;76:1392-1397. 
37. Orino E, Sone S, Nii A, Ogura T_ IL-4 up-regulates IL-l receptor antagonist gene expression and its 
production in human blood monocytes. J Immunol 1992;149:925-931. 
190 
IL-lf3 gene expression in mononuclear phagocytes 
38. Schwarz EM, Salgame P, Bloom BR. Molecular regulation of human interleukin 2 and T-cell function 
by interleukin 4. Proc Nat! Acad Sci USA 1993;90:7734-7738. 
39. Standiford T J, Kunkel SL, Liebler JM, Burdick MD, Gilbert ARt Strieter RM. Gene expression of 
macrophage inflammatory protein-1 alpha from human blood monocytes and alveolar macrophages 
is inhibited by interJeukin-4. Am J Respir Cell Mol Bioi 1993;9:192-198. 
191 

-----------------------CHAPTER5.4-----------------------
INVERSE MODULATION OF LlPOCORTlN-1 (ANNEXIN-1) AND IL-1f3 GENE 
EXPRESSION BY DEXAMETHASONE IN CULTURED HUMAN 
BRONCHOALVEOLAR MACROPHAGES' 
Peter Th.W. van Hal,,2, Arie Prins', Susan F. Smith3 and Henk C. Hoogsteden2 
From the Departments of Immunology' and Pulmonary Medicine2, Erasmus University Rotterdam and 
University Hospital Rotterdam-Dijkzigt, The Netherlands, and the Department of Medicinrr, 
Chafing Cross and Westminster Medical School, London U.K. 
'This chapter is submitted for publication. 
CHAPTER 5.4 
SUMMARY 
Glucocorticoids are powerful anti· inflammatory drugs, which are used in the treatment 
of many diseases including certain inflammatory lung diseases. Modulation of transcription 
of both pro- and anti-inflammatory proteins in a variety of cell types is nowadays 
considered as the most important working mechanism of glucocorticoids. Alveolar 
macrophages (AM) are thought to have a central function in the regulation of inflammatory 
processes in the lung. On the one hand, they may initiate or perpetuate inflammation by 
production of certain cytokines, e.g. IL-1. On the other hand, they may inhibit inflammation 
via the production of proteins with potentially anti-inflammatory properties, e.g. lipocortins. 
As AM express glucocorticoid receptors, the inflammatory activities of AM may be 
regulated by glucocorticoids. The glucocorticoid-mediated induction of lipocortin gene 
expression could be demonstrated in only a few reports, and therefore requires further 
study. 
Here we have focussed on the gene regulation of an anti-inflammatory protein, 
lipocortin-1, by glucocorticoids in human AM, and we compared this, under the same 
experimental conditions, with the gene regulation of a pro-inflammatory cytokine IL-1 p. AM 
were obtained from healthy volunteers by bronchoalveolar lavage and cultured for up to 3 
days under serum-free conditions. Northern blot and dot blot analysis were employed to 
study mRNA expression and to semiquantitate mRNA levels. Lipocortin-1 mRNA in AM was 
compared with BEAS S6 cells, whereas IL -1 P gene expression in AM was compared with 
peripheral blood monocytes (PBM) or PMA/LPS-stimulated U937 cells. 
Freshly isolated AM contained low levels of IL-1 p mRNA as compared with PBM and 
U937. Upon culture, AM exhibited a large, but transient increase in IL-1 p mRNA levels. 
After one day of culture, levels had increased 64 to 128 fold. After 3 days of culture, IL-1 p 
mRNA levels were still higher than in freshly isolated AM. Dexamethasone inhibited this 
culture-associated increase. Upon culture, PBM also showed a transient increase in IL-1 p 
mRNA, which was much smaller than in AM. Under the same experimental conditions, 
dexamethasone induced an increase in lipocortin-1 mRNA in AM, but only after one day of 
culture. The glucocorticoid antagonist RU 38486 counteracted the effects of 
dexamethasone on both IL-1 p and Iipocortin-1 mRNA levels, indicating that these effects 
were receptor-mediated. 
These results show that part of the anti-inflammatory activity of glucocorticoids in the 
lung can be explained by their influence on lL-1 p and lipocortin-1 mRNA expression in AM. 
Furthermore, effects of glucocorticoids on lipocortin-1 mRNA were only seen up to one day 
of culture, whereas effects on IL-1f3 mRNA were still observed after 3 days of culture. 
These differences between kinetics of IL-1 p and Iipocortin-1 mRNA regulation indicate that 
glucocorticoids can regulate different target genes differently. These data may clarify the 
results in the literature with regard to the induction of lipocortins by glucocorticoids. 
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INTRODUCTION 
Pulmonary diseases with a major inflammatory component are usually treated, although 
sometimes with varying degrees of success, with anti-inflammatory drugs. Glucocorticoids 
are extremely powerful anti-inflammatory drugs which have been used clinically since 1949 
(1). It is known that glucocorticoids can influence many aspects of the different cell types 
regulating the inflammatory processes in certain lung diseases (2), but their subcellular 
working mechanisms are, even today, only partially understood (3,4). The cell types 
involved in inflammatory processes interact with each other extensively, either through 
direct cell-cell contact or soluble mediators, both of which mechanisms can be modulated 
by glucocorticoids (5-8). However, further studies on the working mechanisms of 
glucocorticoids are needed in order to understand these mechanisms more fully and thus 
develop treatment strategies with fewer unwanted side effects. 
Central to inflammatory and immunologic processes are mononuclear phagocytes. In 
these cells, glucocorticoids are thought both to inhibH the production of inflammatory 
mediators such as"IL-l (9,10) and to induce anti-inflammatory proteins such as lipocortins 
(11-13). IL-1 has been proposed to playa key role in inflammatory diseases (14,1 5), and 
the anti-inflammatory effects of glucocorticoids are likely to include interaction with IL-l 
production (9, 1 0). One member of the Iipocortin (annex in) family, Iipocortin-1 (annexin-l L 
has been described as inducible by glucocorticoids in rat peritoneal macrophages (11). If 
so, induction of this protein may represent one working mechanism of glucocorticoids, as 
lipocortin-l has been shown to possess anti-inflammatory activity (for a recent review: 16). 
Many studies confirmed this hypothesized mechanism (12,13,17), and also recent studies 
showed the involvement of lipocortin-1 in the anti-inflammatory action of glucocorticoids 
(18,19). However, some authors failed to reproduce the glucocorticoid-mediated induction 
of Iipocortin-1 (20-22), and therefore further studies are needed to understand the nature 
of the conflicting data on the inducibility of lipocortins by glucocorticoids. 
Alveolar macrophages (AM), a special type of mononuclear phagocytes, are known to 
exhibit both pro- and anti-inflammatory properties which make them potent regulators of 
inflammatory processes in lung diseases (23-25). Furthermore, there is evidence that AM 
possess functional glucocorticoid receptors (26). However, many of the hypothesized 
working mechanisms of glucocorticoids in human AM are extrapolated results from studies 
in other mononuclear cells. Therefore, further studies in human AM are needed to elucidate 
the precise working mechanisms of glucocorticoids in the treatment of lung diseases in 
which AM are a major cellular component. 
In this study we have focussed on the influence of glucocorticoids on the kinetics of 
gene expression of Jipocortin-l and IL-1 P in both freshly isolated and cultured human 
alveolar macrophages. Glucocorticoids were shown to increase transiently levels of 
lipocortin-1 mRNA as well as to reduce levels of IL-1 p mRNA. 
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MATERIALS AND METHODS 
Isolation of monocytes/macrophages 
Human AM were obtained as described elsewhere (27). BAl was performed in healthy volunteers, both 
smokers and nonsmokers. None of these volunteers were being treated with glucocorticoids at the time of 
investigation. BAl was performed between 8.30 and 11.30 a.m, to minimize the influence of the 
physiological circadian rhythm of cortisol. All lavage studies were approved by the Medical Ethics Committee 
of the Erasmus University/University Hospital Dijkzigt, Rotterdam. At least 90% of the BAl cells appeared 
to be monocytes/macrophages as judged by May-Grunwald Giemsa staining. Human PBM were isolated from 
500 ml blood from healthy volunteers as described elsewhere (28). The monocyte preparation was over 95% 
pure as judged by May-Grunwald Glemsa staining. After isolation, some of the AM or PBM were used for 
preparation of total RNA, whereas the rest of the cells were cultured in the presence of either a synthetic 
glucocorticoid (in casu dexamethasone), a glucocorticoid antagonist (in casu RU 38486), a combination of 
dexamethasone and RU 38486, or without one of these additions, 
Cefllines 
U937, a human monocytic ceflline, originally described by Sundstrom and Nilsson f29}, was maintained 
as described previously (27), To induce IL-1P production, cells were stimulated with PMA/LPS as described 
previously (30). Unstimulated and PMA/LPS-stimulated U937 cells served as negative and positive controls, 
respectively, with regard to the presence of IL-1P mRNA. BEAS S6 cells, a human bronchial epithelial cell 
line, were kindly provided by Dr. M.M. Verheggen from our department. They were maintained as described 
earlier {31}, and were used as a positive control with regard to the presence of Jipocortin-1 mRNA. 
Dexamethasone and RU 38486 
Dexamethasone was purchased from Duchefa b.v. (Haarlem, The Netherlands). The glucocorticoid 
antagonist RU 38486 was kindly provided by Roussel Uclaf (Romainville, France). Stock solutions in ethanol 
of 2 x 10.3 M RU 38486 and 2 x 10-3 M dexamethasone were used for preparation of final solutions in culture 
medium. 
Culture of cells 
PBM and AM were cultured as described elsewhere (27) for up to 3 days. Culture media were serum-
and glucocorticoid-free (unless indicated). In most experiments cells were maintained in T75 Falcon tissue 
culture flasks (Becton Dickinson, Plymouth, UK), whereas in some experiments cells were cultured under non· 
adherent conditions in Teflon bags (Janssen's MNl, St-Niklaas, Belgium). For lsolatlon of total RNA from cells 
cultured in Teflon bags, cells were separated from culture supernatants by centrifugation under RNase-free 
conditions. Subsequently, cells were washed twice with PBS. Cell pellets were homogenized with 0.5 ml of 
solution D (32) and cooled to 4°C on iced water. If cells were cultured under adherent conditions, they were 
washed twice with PBS, then homogenized in the culture flasks with 0,5 ml of solution D and cooled as 
described above. 
Probes 
The IL~1P cDNA probe was kindly provided by Genetics Institute (Cambridge, MA). This probe was a 
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1.3 kb Pst I fragment, and hybridized to a RNA species of 1.6 kb. The Iipocortin-l cDNA probe was kindly 
provided by Dr. B.P. Wallner (Biogen Research Corp, Cambridge, MA). This probe was a 1,3 kb Eco RI 
fragment and hybridized to a RNA species of approximately 1.4 kb, The GAPDH probe was a 0.7 kb Eco RI-
Pst I fragment, hybridizing to a 1.2 kb band (33). 
Preparation of total cellular RNA, Northern blot and dot blot analysis 
Total cellular RNA was isolated from U937 cells, and freshly isolated or cultured AM and PBM largely 
according to Chomczynski and Sacchi (32). For Northern blot analysis. total RNA (5-20 pg) was separated 
by electrophoresis in a 1 %-agarose gel, subsequently vacuum transferred onto a nylon membrane (NY-13N; 
Schleicher and Schue II, Dassel, Germany), fixed to the membrane with a 254 nm UV crosslinker and 
hybridized with the Il-1 j3 or Iipocortin-l probe, which were labelled using to the Klenow-oligonucleotide 
method (34). After hybridization, the blots were washed and exposed to Fuji NIF-RX films (Fuji Photo Film 
Co., Tokyo, Japan) with intensifying screens, In some experiments, hybridization of the membrane with the 
IL-l j3 probe was followed by rehybridization with the Jipocortin-l probe. This procedure excluded differences 
in mRNA levels caused by differences in the amount of applied RNA. and enabled us to relate IL-1P and 
lipocortin-l mRNA levels in the same samples. The quality and amounts of RNA applied were controlled by 
rehybridization of the blots with the GAPDH probe, For dot blot analysis, a series of total RNA dilutions was 
vacuum transferred onto a nylon membrane (see below). Thereafter, the membrane was handled as described 
for Northern blot analysis, 
Semiquantification of IL-lfJ and lipocortin-l mRNA levels by RNA dot blotting 
Dot blotting was largely performed as described previously (35). Brieffy, 1 volume of total RNA was 
dissolved in 1 volume 15 x SSC (1 x SSC = 0.15 M NaCI/15 mM Nacitrate, pH = 7) and 0.5 volume 37% 
formaldehyde, and incubated for 15 min at 60°C. Next, serial 1:2 or 1: 1.58 dilutions of total RNA in 
15 x SSC were applied with a Biodot mlcrofjltration apparatus onto a nylon membrane, which had been 
soaked in 20 x SSC, A serial dilution of total RNA from PMA/LPS-stimulated U937 celis was used as a 
reference and was applied to each membrane containing serial dilutions of RNA from experiments with AM 
or PBM, After aspiration, RNA was fixed to the membrane with a 254 nm UV crosslinker. Prehybridization, 
hybridization, washing, and autoradiography were performed as described above for Northern blotting, 
Semiquantification of IL-1P or lipocortin-l mRNA levels in the different AM and PBM experiments was 
achieved by comparison of the serial dilutions of RNA from AM or PBM with the serial dilutions of reference 
RNA from stimulated U937 and BEAS S6 celis, respectively. Arbitrarily, the expression of IL-l p mRNA in AM 
after one day of culture without dexamethasone and the expression of lipocortin-l mRNA in freshly isolated 
AM were set at 100%. 
RESULTS 
Kinetics of IL-1P mRNA expression in cultured AM 
Freshly isolated AM expressed IL-1 p mRNA, but at low levels as compared with 
PMA/LPS-stimulated U937 cells or freshly isolated PBM. However, upon culture this 
expression increased tremendously. Northern blot analyses revealed a transient increase in 
the expression of IL-1 p mRNA (Figure 1), which was seen in all our experiments (n = 111. 
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15 - 5 15 15 15 ~gRNA Figure 1. Expression of IL-l j3 mRNA in AM 
0 1 1 2 3 day of culture from a smoking subject. The upper panel 
kb shows hybridization with the lL-l p eDNA 
probe. IL-l/3 mRNA expression in cultured 
-288 AM was many fold higher than in freshly 
isolated AM. Therefore, both 5 and 15 Jtg of 
total ANA from AM cultured for one day 
(lanes 2 and 3, respectively) were used in 
this Northern blot analysis. For the same 
reason, exposure time to the film after 
-18S hybridization was restricted to two hours and 
1.6- e 40 min in this experiment, even though it 
was, consequently, not possible to 
demonstrate the presence of IL-l J3 mRNA in 
freshly isolated AM (lane 1). The lower panel 
shows the same membrane rehybridlzed with 
the GAPDH eDNA probe. 
2 3 4 5 lana 
kb , 
-28S 
-18S 
1.2- • 
Maximal expression was observed after one day of culture (Figure 1, lane 3). Thereafter, 
expression of IL-l p mRNA diminished, but even after 3 days of culture expression was still 
higher than in freshly isolated AM. Expression of GAPDH mRNA remained unchanged 
during culture, although in some experiments we observed a slight increase in GAPDH 
mRNA expression (lower panel of Figure 1). To semiquantitate the kinetics of IL-jp mRNA 
expression during culture, dot blot analysis was performed. With this technique, it was 
seen in AM from both smokers and nonsmokers that after one day of culture IL-l p mRNA 
expression was 20 to 500 fold as high as compared with the expression in freshly isolated 
AM (Figures 2, 3 and Table 1). Usually, the expression after one day of culture was higher 
than the expression in stimulated U937 cells. 
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119 RNA relative 
I IL-1P mRNA 
8 4 2 1 1/2 1/4 1/8 1/16 expression 
AM day 0 1/16 
•• • • • • AM day 1 16 
•• • • AM day 2 4 
• • AM day 3 1 
.. • !Ilk U937 1 
Figure 2. Semiquantification of IL-l p mRNA expression by dot blot analysis in AM from the same smoking 
subject as in Figure 1, and comparison with PMA/lPS-stimulated U937 cells. Serial 1 :2 dilutions of total ANA 
[isolated from freshly isolated AM (day 0)' cultured AM {for 1, 2, or 3 days, respectively} and U937 cells] 
were applied to the wells. 810ts were probed with the IL-l p cDNA probe. The right column indicates IL-l p 
mRNA expression relative to the expression in PMA/LPS-stimulated cells. 
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Figure 3. Relative expression of IL-1 p mRNA in freshly isolated and cultured human AM (n = 7), and the 
influence of glucocorticoids on this expression. The expression at day 1 of culture without dexamethasone 
is arbitrarily set at 100%. Subject numbers correspond with subject numbers in Figure 6. 
*: not determined. 
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Influence of dexamethasone on the kinetics of IL-lli mRNA in AM during culture 
Culture of AM in the presence of dexamethasone reduced the increase in IL-1 p mRNA 
expression as compared with AM cultured in control medium. This inhibition was already 
seen after one day of culture (n = 7; Figure 4A). To semiquantitate this influence of 
dexamethasone on IL-1 p mRNA expression, dot blot analysis was performed. After one day 
of culture in the presence of dexamethasone, IL-1{3 mRNA levels were 16 to 50% of the 
levels in AM cultured for one day in control medium [Figures 3 and 5 (upper pane!), and 
Table 1]. The effect of dexamethasone was also observed after two days of culture [n =4; 
Figures 3, 4A and 5 (upper panel)], and even after four days of culture (n = 2; data not 
shown), This inhibitory effect of dexamethasone was concentration dependent (data not 
shown) and could be antagonized with RU 38486 [Figures 4A and 5 (upper panel), and 
Table 1]. In most experiments, dexamethasone was used in a concentration of 5 x 10-7 M, 
which was non-toxic and resulted in maximal effects. RU 38486 was always used in a 
tenfold excess. 
Table 1. Influence of dexamethasone on the kinetics of IL-1P gene expression in cultured human AM.a 
culture conditions 
subjectb days of dexamethasone RU 38486 RU 38486 
culture + 
dexamethasone 
3 0 0.4 
3 1 100d 16 100 63 
3 2 25 10 16 16 
4 0 0.4 
4 1 100d 35 100 63 
4 2 25 1 16 10 
a. Total RNA was prepared from freshly isolated or cultured AM. Each sample was dot-blotted in 1 :1.58 
dilutions. Relative IL-1P mRNA expression in each sample was determined by comparison with the 
expression in stimulated U937 cells. 
b. Subject numbers correspond with subject numbers in Figures 3 and 6, and Table 2. 
c. Either freshly isolated AM or AM cultured in control medium. 
d. Expression after 1 day of culture in control medium was arbitrarily set at 100%. 
Kinetics of Iipocortin-1 mRNA expression in cultured AM 
Freshly isolated AM expressed Iipocortin-1 mRNA. This expression was of equal 
magnitude to expression in the epithelial cell line BEAS S6. Whereas expression of IL-1 p 
mRNA increased upon culture, Iipocortin-1 mRNA expression showed no such a 
spontaneous increase [Figures 4C, 5 (lower panel) and 6]. 
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days of cullure 
dexamethasone 
RU 38486 
kb 
days of culture 
dexamethasone 
AU 38486 
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14- •• 1111 
-
-
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2 
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A 
-288 
-18S 
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C 
-285 
-18S 
234-56781ane 
B 
-285 
-185 
2 3 4 - 5 6 7 8 lane 
Figure 4. Northern blot analysis of the effects of dexamethasone on JL-l p mRNA (panel A) and Jipocortin-l 
mRNA (panel C) expression in cultured AM. Total RNA was prepared from AM cultured in either control 
medium (lanes 1 and 5), RU 38486 (5 x la-6M; lanes 2 and 6), dexamethasone (5 x lO-7M; lanes 4 and 8)' 
or both RU 38486 and dexamethasone (lanes 3 and 7). Each lane was loaded with 5 Jig of total RNA. Panels 
A and C show hybridization of the same membrane with the IL-l j3 and lipocortin-l cDNA probes, respectively. 
Panel 8 shows ethidiumbromide staining of the gel after electrophoresis to visualize equal loading per lane. 
Influence of dexamethasone on the expression of Iipocortin-1 mRNA in AM 
After one day of culture in the presence of dexamethasone (5 x 10-7 M), expression 
of Iipocortin-1 mRNA was found to be consistently higher than expression in AM cultured 
201 
CHAPTER 5,4 
119 RNA RU dexa ~~~~----~~~~------------,j ,-, ,-, 
10 6.3 4 2.5 1.6 1 0.6 0.4 0.25 0.16 
• 
• 
• • 
• Ij 
••••• jI;\ 
••••••• 
••••••• 
••••••• 
• • • • • !II 
119 RNA 
4 2.5 1.6 0.6 0.4 0.25 0.16 
••••• 
••• fj 
•••• !II 
•••• " 
••••. '" 
••••• 
• • • •• •••.. "" 
•••••• 
•••••• fj. 
+ 
+ + 
+ 
+ 
+ + 
+ 
RU dexa 
+ 
+ + 
+ 
+ 
+ + 
+ 
AM day 1 
U937 
relative 
IL-1P mRNA 
expression 
16 
16 
16 
4 
AM day 0 0.1 
AM day 2 
AM day 1 
BEAS 
AM day 0 
AM day 2 
4 
4 
4 
1.6 
relative 
expression of 
lipocorlin I mRNA 
0.63 to 1 
0.63 to 1 
1.6 
0.63 
1 
Figure 5, Semiquantification of IL~ 113 mANA (upper panel) and lipocortin-l mANA (lower panel) expression by 
dot blot analysis in dexamethasone-treated AM_ AM are from the same smoking subject as in Figure 4_ Serial 
1 :1.58 dilutions of total ANA [obtained from freshly isolated AM (day 0), cultured AM {for 1 and 2 days, 
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respectively), and control cell lines (U937 in the upper, and BEAS S6 in the lower pane1)] were applied to the 
wells. AM were cultured in either control medium (- -), medium with RU 38486 (+ -I, dexamethasone (+ -
), or both RU 38486 and dexamethasone (+ +). The right columns in A and B indicate IL-l p and Iipocortin-1 
mRNA expression relative to the expression in PMA/LPS-stimulated U937 cells and BEAS S6 celis, 
respectively. The upper panel shows hybridization with the lL-1j3 cDNA probe, whereas the lower panel 
shows the same membrane rehybridized with the Iipocortin-1 cDNA probe. 
in control medium [n = 5; Figures 4C, 5 (lower panel) and 61. Dot blot analysis to 
semiquantitate the expression of Iipocortin-1 mRNA revealed a 60 to 150% increase after 
one day of incubation with dexamethasone as compared with the control experiment 
(Figure 6 and Table 2). This dexamethasone-induced increase in mRNA expression could 
be antagonized by RU 38486 [Figures 4B and 5 (lower panel), and Table 21. In contrast to 
the effect of dexamethasone on IL-1P mRNA expression, which was still present on day 
2 of culture, Jipocortin-l mRNA expression was elevated in only 2 of the 3 subjects studied 
after two days of Incubation with dexamethasone (Figure 6). A consistent dexamethasone-
induced increase in mRNA expression, as was observed on day 1, was not observed on day 
2. 
~ 
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E '" 
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3 4 5 6 7 3 4 5 6 7 subject 
2 
+ 
days 01 cuiture 
dexamethasone 
Figure 6. Relative expression of Iipocortin-1 mRNA in freshly isolated and cultured human AM (n=5), and 
the influence of glucocorticoids on this expression. The expression in freshly isolated AM is arbitrarily set at 
100%. Subject numbers correspond with subject numbers in Figure 3. 
*: not determined. 
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Table 2. Influence of dexamethasone on the kinetics of Iipocortln-1 gene expression In cultured human AM,a 
culture conditions 
subjectb days of - , dexamethasone RU 38486 RU 38486 
culture + 
dexamethasone 
3 0 load 
3 1 100 250 100 80 
3 2 63 158 158 100 
4 0 10Qd 
4 1 40 250 159 100 
4 2 100 100 159 100 
a. Total RNA was prepared from freshly isolated or cultured AM. Each sample was dot-blotted in 1:1.5B 
dilutions. Relative expression of lipocortin-l mRNA in each sample was determined by comparison with 
the expression in the epithelial call line 8EAS S6. 
h. Subject numbers correspond with subject numbers in Figures 3 and 6, and Table 1. 
c. Either freshly isolated AM or AM cultured in control medium. 
d. Expression in freshly isolated AM was arbitrarily set at 100%. 
DISCUSSION 
This study shows that gluGocorticoids are able to induce lipocortin-1 mRNA in human 
alveolar macrophages in vitro, but that this induction is time-dependent, which may explain 
the conflicting results from the literature. Using the glucocorticoid antagonist RU 38486 
it was shown that these effects are mediated via glucocorticoid receptors. Furthermore, 
under the same in vitro conditions IL-1 p gene expression .was downregulated by 
glucocorticoids. These findings are important because glucocorticoids are widely used anti-
inflammatory agents. Their precise working mechanisms are still largely unknown, although 
recent studies have unravelled some of their cellular effects (2,3,7,8). It is known that 
glucocorticoids can modulate mRNA transcription, resulting in either increased or decreased 
protein synthesis. Many inflammatory proteins, in particular inflammatory cytokines, are 
downregulated by glucocorticoids 17,8}. Downregulation of IL-l P gene expression by 
glucocorticoids, which has been demonstrated previously in human monocytes and the 
human monocytic cell line U937 (9,10), was confirmed in human AM in this study. The 
glucocorticoid-mediated induction of lipocortins was once proposed as an important aspect 
of the working mechanisms of glucocorticoids, but since then only some studies showed 
a clear induclion of lipocortin-l mRNA, whereas others did not (11-13, 17-22,36,37). The 
reason for these apparent contradictory results may be obvious differences in experimental 
conditions [in vitro (13,20) versus in vivo studies (12,13,38)], differences in cell lype 
studied (monocytes/macrophages, epithelial celisL differences in species studied [rats 
(11,17), mice (13,21), or rabbits (38) versus humans (12,20,39)], or still others [e.g. 
differences in differentiation state of the cells studied (40) or differences in culture 
conditions]. Here we show that the glucocorticoid-induced upregulation of Iipocortin-1 
mRNA occurs over a defined time course, which may explain why it has not been observed 
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in all previous studies. 
In early studies in rats, it was shown that glucocorticoids induced lipocortin-1 mRNA 
in peritoneal macrophages in vivo (11 ). However, it is unclear whether glucocorticoids had 
the same effects in humans. Studies on steroid-inducibility in vivo are difficult in man 
because of the presence of endogenous glucocorticoids; effects of administered 
glucocorticoids will be superimposed upon the physiological effects of endogenous 
glucocorticoids, and may therefore be difficult to detect. These limitations can be bypassed 
in animal studies by adrenalectomy or treatment with glucocorticoid antagonists (41). Only 
few studies describe effects of chronic treatment with glucocorticoid antagonists in man 
(16,42). However, recently it was shown that glucocorticoids could induce lipocortin-1 in 
vivo in peripheral blood leukocytes (12), SAL cells (39), and SAL-fluid (43). Ambrose et al 
showed that human AM contain lipocortin~ 1, and their levels of lipocortin-1 were higher 
than in peripheral blood monocytes (39). They suggested that expression of Iipocortin-1 
may be dependent of the maturation state of mononuclear phagocytes, which was also 
suggested in a study on U937 cells (40). Furthermore, they showed that glucocorticoids 
increased the amounts of lipocortin-1 in a dose-dependent manner, although the highest 
dexamethasone concentrations used in that study are generally accepted as in vast excess 
of therapeutic doses and toxic (39). Lipocortin-1 mRNA levels were not studied. These 
findings at the protein level of lipocortin~ 1 contrast with studies which failed to 
demonstrate effects of dexamethasone on the expression of Iipocortin-1 mRNA in human 
AM (20). To explain the observed induction of Iipocortin-1 in other studies, Bronnegard et 
al suggested that this may result from posttranslational effects of glucocorticoids (20). On 
the other hand, gJucocorticoids were shown to induce both expression of Iipocortin-1 
mRNA and secretion of Iipocortin-1 in U937 cells (10,40). 
These apparent contradictory findings suggest that experimental conditions may 
determine whether glucocorticoid effects on Iipocortin-1 gene expression will be observed 
or not. Serum factors in the culture medium or pretreatment with cytokines or LPS may 
modulate the cellular response to glucocorticoids with regard to lipocortin-1 gene 
expression (36,37). In the current study, monocytes and AM were cultured under serum-
free conditions, and thus we can exclude the presence of unidentified serum factors which 
were previously suggested to synergise with glucocorticoids to promote lipocortin-1 
induction (36). Compelling evidence that the induction of Iipocortin~1 mRNA in our study 
is glucocorticoid-specific, comes from the observed antagonizing effects of the 
glucocorticoid antagonist RU 38486. Furthermore, our results show that incubation time 
determined whether a glucocorticoid-induced modulation of expression will be observed or 
not. This is illustrated by our findings that the glucocorticoid effects on IL-1 p mRNA 
expression were observed for 4 days, but those on Iipocortin-1 for only 24 hours. The 
kinetics of lipocortin-1 mRNA or protein induction in vitro is sparsely described in other 
studies (13,20,39). Bronnegard et al studied lipocortin-1 mRNA expression in human 
alveolar macrophages treated for 6 hours with dexamethasone (20). Induction of lipocortin~ 
1 mRNA was not observed, but they did not mention whether mRNA expression was 
studied after longer incubations. On the other hand, metallothionein II mRNA was induced 
after 6 hours culture in the presence of dexamethasone. The latter is mentioned as their 
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positive control, but it is clear from the differences between IL-1 13 and Iipocortin-1 mRNA 
kinetics shown here that gluGocorticoids can regulate different target genes differently. 
Ambrose et al studied the induction of Iipocortin-1 at the protein level in human alveolar 
macrophages (39). Kinetics were not mentioned, but they observed an increase after 24 
hours of incubation. Wong et al described time-course experiments in mouse fibroblasts 
(13). As in this study, they found the largest increase in Iipocortin-1 mRNA level after 24 
hours of incubation with dexamethasone. In in vivo experiments, effects of gluGocorticoids 
on Iipocortin-1 expression appear to be faster. Wallner et al showed induction of lipocortin-
1 mRNA within 2 hours (11). Peers et al described an increase in the amount of Iipocortin-1 
protein even within 30 min, which may suggest a mechanism different from the classic 
nuclear working mechanism of glucocorticoids (44). Summarizing, all these results stress 
the importance of time-course experiments in lipocortin studies. 
The results presented in this study clearly demonstrate that glucocorticoids influence 
the gene expression in AM with regard to proteins involved in inflammatory processes. 
Gene expression of the pro-inflammatory cytokine IL-l P is down-regulated by 
glucocorticoids. whilst under the same experimental conditions glucocorticoids increase 
lipocortin-l gene expression. To our knowledge, this is the first time that these two 
aspects of the anti-inflammatory actions of glucocorticoids have been demonstrated 
together in vitro in human AM. Furthermore, these findings strongly suggest that one of 
the ways in which glucocorticoids may modulate lipocortin-l levels is by regulation of gene 
transcription. 
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SUMMARY 
Alveolar macrophages (AM) play a major role in the regulation of inflammatory 
responses in the lung, and are thought to be a primary target for glucocorticoid therapy. 
The variable clinical response to glucocorticoids in the treatment of various inflammato-
ry lung diseases may be explained by a variable cellular response of AM to glucocorti-
coids, although literature is conflicting about the presence of specific glucocorticoid 
receptors in human AM. The present study was designed to determine whether human 
AM possessed a single class of functional glucocorticoid receptors. Established 
methods, which use a 3H-labeled ligand to estimate glucocorticoid receptor numbers per 
cell and the dissociation constant of these receptors, were hampered by extremely high 
nonspecific binding when AM were analyzed. Typically, the nonspecific binding was 80-
95% of the total binding. As receptor numbers could be easily determined in other cell 
types, this high nonspecific binding appeared to be typical of AM and may be caused by 
phagocytosed dust, carbon particles or tobacco smoke products. To reduce this 
nonspecificity, we eventually introduced an immunoprecipitation procedure after 
incubation of AM with various concentrations of 3H-labeled dexamethasone, with the 
intention to precipitate the ligand-receptor complex excluding ligand bound to nonspeci-
fic binding sites. This resulted in an adequate reduction of the nonspecific binding to 
only 10-20% of the total binding. Using this procedure, AM were found to have 3.9 ± 
2.0 x 103 (mean ± SO; n = 3) specific glucocorticoid receptors per cell and the dexame-
thasone Kd was 7.0 ± 1.5 nM (mean ± SO; n = 3). For comparison, the monocytic cell 
line U937 and the uterine cervix carcinoma cell line NHIK 3025 were studied. These cell 
lines were found to have 6.8 ± 0.9 x 10' (mean ± SD; n=4) and 19.2 ± 2.5 x 10' 
(mean ± SO; n = 3) glucocorticoid receptors per cell, respectively. Their dexamethasone 
Kd'S were 3.5 ± 0.5 nM and 3.1 ± 0.6 nM, respectively. Furthermore, it was shown in 
this study that glucocorticoid-induced inhibition of cell spreading upon culture of AM 
was dependent on the dexamethasone concentration and could be antagonized by the 
glucocorticoid antagonist RU 38486. These observations demonstrate that also human 
AM express a single class of specific glucocorticoid receptors, through which cellular 
effects of glucocorticoids are mediated. We therefore conclude that AM may be an 
actual, direct target for glucocorticoid therapy in inflammatory lung diseases. Further 
studies are needed to confirm the putative role of the glucocorticoid receptor system in 
AM in the clinical responsiveness to glucocorticoids. 
INTRODUCTION 
Since the identification of the macrophage, its classical and most important 
function was considered to phagocytose waste and foreign particles (1). Accordingly, 
alveolar macrophages (AM) in the lungs of heavy smokers contain large amounts of 
phagocytosed carbon particles and tobacco smoke products (2,3). In addition to this 
scavenger function, macrophages are nowadays known to have important immunologi-
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cal functions, which turn macrophages into a central cell type in initiating and perpetua-
ting inflammation (3,4). These functions require interactions with other cells and 
molecules, and may take place through the release of numerous secretory products (e.g. 
cytokines, enzymes, and biologically active lipids) and the expression of several surface 
receptors (e.g. cytokine receptors, MHC class II, and adhesion molecules). Therefore, 
AM are thought to playa major role in airway inflammation in lung diseases as asthma 
and chronic obstructive pulmonary diseases (COPD) (3-6), although there is evidence 
that other cell types (T lymphocytes, bronchial epithelium, mast cells and granulocytes) 
may also contribute to the inflammatory reaction (7-9). 
Glucocorticoids are frequently used in the treatment of inflammatory lung diseases. 
The precise nature of their working mechanism is still unknown (1 0, 11). Because of the 
above-mentioned role of AM in airway inflammation and because the function of 
monocytes/macrophages can be influenced by glucocorticoids (12,13), glucocorticoids 
may suppress airway inflammation by influencing AM. Other evidence for a monocy-
te/macrophage-mediated effect of glucocorticoids in asthma stems from studies in 
which a cellular defect of the monocyte/macrophage lineage was suggested in glucocor-
ticoid-resistant asthmatic patients (14,15). However, it remains to be elucidated 
whether the reported effects of glucocorticoids on monocytes/macrophages result from 
a direct, glucocorticoid receptor-mediated (16,17) or a non receptor-mediated (18) 
mechanism. Another actual possibility concerns an indirect effect via mediators released 
by other, glucocorticoid sensitive ce:Il types. To substantiate a direct monocyte/macrop-
hage-mediated effect of glucocorticoids, evidence for specific, saturable and functional 
glucocorticoid receptors in these cells is still a prerequisite. Studies which describe 
estimations of the number of glucocorticoid receptors in human AM are rare, ambiguous 
regarding the presence of a single class of high affinity glucocorticoid receptors, and are 
severely hampered by nonspecific binding (19-211. In this report a procedure for the 
estimation of glucocorticoid receptors in human AM is described and it is shown that 
these receptors are functional. The method employs precipitation of the ligand-receptor 
complex with a receptor-specific monoclonal antibody. The major advantage of this 
immuno receptor assay comes from the by-passing of nonspecific binding. As the 
number and quality of steroid receptors in target cells may determine the extent of 
glucocorticoid responsiveness (22,23), this assay create new openings for studies on 
the role of glucocorticoid receptors, or transcription factors interacting with them, in the 
variable clinical response to glucocorticoids (24). 
MATERIALS AND METHODS 
Cell lines 
U937 cells, an immature monocytic cell line and originally described by Sundstrom et al. (25) were 
maintained at concentrations of 0.25-1.0 x 106 /ml in RPMI 1640 medium (Flow laboratories, Irvine, UK) 
supplemented with FCS (10%; GIBCD, Paisley, UK). penicillin G sodium (102 U/ml; Gist-Brocades, Delft, 
The Netherlands) and streptomycin-sulfate (0.1 mgfmf; Biochrom KG, Berlin, Germany). The cell line NHIK 
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3025, derived from a carcinoma of the human uterine cervix and originally described by Nordbye and 
Oftebro (26), was cultured in DMEM supplemented with FCS (10%), penicillin G sodium (102 VIm!), 
streptomycin-sulfate (0.1 mg/mll and non-essential amino acids. 
Isolation of AM 
All lavage studies were approved by the Medical Ethics Committee of the Erasmus University/Uni-
versity Hospital Dijkzigt, Rotterdam, Bronchoalveolar lavage (BAL) was performed in healthy, smoking 
volunteers after premedication with thiazinamium and local anesthesia using a lidocaine (2%, w/v) spray. 
The bronchoscope was placed in wedge position in the right middle lobe, and four allquots of 50 ml 
sterile saline solution were infused and aspirated immediately tn a siliconized specimen trap placed on 
melting ice. Immediately after collection the SAL fluid was strained through a sterile nylon gauze to trap 
large mucous particles, whereafter the SAL celts were isolated by centrifugation at 4°C at a force of 400 
g. More than 90% of the BAL cells appeared to be macrophages as judged by May-Grunwald Giemsa 
staining. 
Culture of AM 
AM were cultured in a modified Iscove's medium (GIBCQ, Paisley, UK) as described previously (27), 
in which BSA is replaced by human serum albumin supplemented with 2% autologous heat-inactivated 
serum. The culture medium was found to be endotoxin-free (defined as less than 1.0 ng/ml of endotoxin 
as quantified by the Umulus amoebocyte lysate assay). AM (1-2 x 106/ml) were cultured at 37"C, 5% 
CO2 and 1 00% humidity under adherent conditions in flat bottom wells of 24-wells culture plates (Becton 
Dickinson, NJ) for 1 to 4 days. 
Steroids 
Nonradioactive dexamethasone was obtained from Duchefa b.v. (Haarlem, The Netherlands). A 
stock solution of 2 x 10-3 M dexamethasone in ethanol was prepared. 3H-Iabeled dexamethasone 
(1,2,4,6,7 [3HI dexamethasone; specific activity 81 Ci/mmol) was purchased from Amersham (Bucking-
hamshire, UK). The glucocorticoid antagonist RU 38486 was kindly provided by Roussel Uclaf (Romainvil-
fe, France). A stock solution of 2 x 10-3 M RU 38486 in ethanol was prepared. The concentration of 
ethanol during culture of AM wa!? less than 0.25% in each experiment. The concentration of ethanol 
during incubations for the receptor assay was less than 1 % in each sample. 
Glucocorticoid receptor assay without immunopreclpitation procedure 
Glucocorticoid receptor density and dissociation constant were determined according to established 
methods (28,29). A whole cell assay, rather than a binding assay on cellular extracts, was chosen for, as 
the former assay requires smaller numbers of cells (cellular yields from BAL are limited) and minimizes 
proteolysis which may lead to loss of receptors. Freshly isolated AM, U937 or NHIK cells were washed 
with a phosphate-buffered saline solution (PBS) (300 mosmol; pH 7.4) and resuspended at a density of 8-
10 x 106 cells/m!. A series of seven 1:2 dilutions (200 pI) of 3H-labeled dexamethasone was prepared. 
For measurements of nonspecific binding, a parallel series of 1:2 dilutions of JH·labeled dexamethasone 
plus a 100-fold excess nonradioactive dexamethasone was prepared. Incubation was initiated by adding 
200 j..Il of the cell suspension to each of the 14 tubes. Final concentrations of 3H-labeled dexamethasone 
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were 0.5-32 nM. Incubations were carried out in polypropylene tubes for 90 min at 21"C. These 
conditions were shown earlier to allow adequate equilibration between free and receptor-bound steroid 
(28). After this incubation of the cells, three 100 ~ll aliquots of each Incubation mixture (determination in 
triplicate) were transferred to separate tubes. Fifty pi of the incubation mix.ture was used to verify the 
concentration of 3H-labe/ed dexamethasone. One ml of ice-cold PBS was added to each 1 00 ~tI aliquot 
and the samples were centrifuged (400 g, 5 min, 4"C). Supernatants were removed and cell pellets were 
resuspended in 1 ml of ice-cold PBS and left on ice for 30 min to reduce nonspecific binding. Next, the 
samples were centrifugated and the supernatants were discarded. The cell pellets were transferred to 
scintillation vials and radioactivity was determined by liquid scintillation counting. Specific binding was 
calculated as the difference between the totally bound radioactivity and the nonspecifically bound 
radioactivity at each glucocorticoid concentration. Nonspecific binding was calculated from the aliquots 
containing the 100-fold excess nonradioactive dexamethasone, assuming that nonspecific binding was 
nonsaturable and linearly related to the concentration of free glucocorticoid. 
Immuno glucocorticoid receptor assay 
Freshly isolated AM, U937 cells or NHIK cells were washed once and resuspended in TEG buffer (40 
mM Tris-HCI, 1 mM EDTA, 10% glycerol; pH 7.4). Cells (200 pi; 8-10 x 10s/mll were incubated with 
200 pi of 3H-labeJed dexamethasone (final concentration 1-32 nM) in polypropylene tubes for 90 min at 
21"C. Nonspecific binding was determined in a parallel series of incubation of cells with radio labeled 
dexamethasone plus a 100-fold excess nonradioactive dexamethasone. After this incubation, two 150 pi 
aliquots of each incubation mixture (determination in duplicate) were transferred to separate 1.5-ml 
Eppendorf tubes. Fifty pI of the incubation mixture was used to verify the concentration of 3H-labeled 
dexamethasone. All subsequent procedures were performed at 0-4"C, unless otherwise indicated. Next, 
250 pi of a solution of protease inhibitors (tinal concentrations bacitracin (Aldrich Chemie, Brussels, 
Belgium) 500 ~IM, phenylmethylsulfonylfJuoride 600 ,1M (Sigma, St, louis, MO), dithiothreitof 10 mM 
(Sigma), leupeptlne 500 ,1M (Sigma)) was added to each 150 'Il aliquot. The samples were treezed/tha-
wed (-196"C/10°C) three times to lyse cells. Thereafter, the samples were centrifuged (15.000 g, 15 
min, 4"C) and supernatants were frozen (-20°C) and used for immunoprecipitation later. Pellets were 
resuspended in 1 mf NaOH (1 M), incubated at 60°C for 30 min and frozen (-20"C) for determination of 
DNA content Jater. 
Agarose coated with goat anti mouse-immunoglobulin antibodies (Sigma) was incubated with the 
monoclonal antibody F52.24.4 overnight (4"C) with rotation (The monoClonal antibody F52.24.4 was 
raised against the homologous part of the DNA-binding domain of different steroid hormone receptors. 
Details about the generation and characterization of this monoclonal antibody are described elsewhere 
(30)]. After this incubation the agarose was centrifuged (400 9, 5 min) and washed three times with 
PBS. The agarose was resuspended in PBS and 100 pI of this solution was added to the thawed 
supernatants and incubated with rotation for 2 hours at 4"C. Thereafter, 0.5 ml PBS was added to the 
incubation mixture. Subsequently, the samples were centrifuged {2200 g, 1 min, 4"C} and washed with 1 
ml of PBS three times. Finally, the tips of the Eppendorf tubes -containing the pellets were cut off, and 
radioactivity was determined by liquid scintillation counting. 
RESULTS 
Glucocorticoid receptors in cell lines 
Previous studies have reported the presence of glucocorticoid receptors in U937 
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cells (31). In our assay conditions using the unadapted receptor assay, we could also 
demonstrate specific binding of 3H-labeled dexamethasone to these cells. A typical 
binding curve is shown in figure 1 A. The binding data were replotted according to the 
Scatchard technique and these replotted data generated a straight line (Figure 1 B). This 
suggested that dexamethasone is binding to a single class of receptor sites of uniform 
affinity and allowed to estimate the total number of specific binding sites per cell (R; x 
intercept) and the equilibrium dissociation constant (Kd; negative inverse of the slope). 
U937 cells appeared to have 17.1 ± 5.6 x 10' (mean ± SD; n=4) sites per cell, while 
the Kd was 5.3 ± 1.0 nM (n = 4) (Table 1). It was shown earlier (32) that NHIK cells also 
contain specific binding sites for glucocorticoids. In the present study NHIK cells 
showed to have far greater numbers of specific binding sites per cell than U937 cells, 
86.0 ± 6.3 x 10' (n=3). The Kd was not different from the Kd in U937 cells, 4.4 ± 1.9 
nM (n=3) (Table 1). 
Table 1. Numbers of glucocorticoid receptors and their Kd values In U937 cells. NHIK cells and alveolar 
macrophages (AM).a 
R' 
K, • 
U937 
18.2 ± 5.1 c 
5.3 ± 1.0 
NHIK 
86.0 ± 6.3 
4.4 ± 1.9 
AM 
n.d. d 
n,d. 
a. Glucocorticoid receptor density and Kd value were determined using the established receptor assay 
without immunoprecipitation procedure as described In the section Materials and Methods. 
b, R: number of binding sites per cell (x 103 ). 
C, Results are shown as mean ± standard deviation of four (U937 and AM) or three (NHIK) independent 
experiments. 
d. Using the unadapted assay, number of binding sites and dissociation constant could not be determined 
in alveolar macro phages. 
e. Kd: dissociation constant (nM), 
Glucocorticoid receptors in alveolar macrophages 
There are some reports concerning glucocorticoid receptors in human alveolar 
macrophages (19-21). However, those reports are all hampered by a high nonspecific 
binding, which, fundamentally, makes hard conclusions impossible. In this study, it was 
not possible to estimate reliably the number of glucocorticoid receptors or their 
dissociation constant in AM using the unadapted receptor assay. In many experiments 
the nonspecific binding was as high as the total binding (Table 2). Additional wash 
procedures after the 90 min incubation, the use of androgens as antagonist, or cell 
membrane lysis were all unsuccessful in reducing nonspecific binding adequately (data 
not shown) . To circumvent these difficulties, we introduced an immuno receptor assay 
in our studies. Using this assay, the effects of nonspecific binding were by-passed and 
reliable estimation of specific binding in AM proved to be possible (Table 3 and figure 
2). AM from healthy volunteers showed to have 3.9 ± 2.0 x 10' specific binding sites 
per cell (n = 3). The corresponding Kd was 7.0 ± 1.5 nM (n = 3). 
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Figure 1. (A) Binding curves of 3H-labeled dexamethasone for U937 cells as determined with the receptor 
assay without immunoprecipitation procedures. The specific binding {OJ is represented by the difference 
between the total binding (e) and nonspecific binding (III). On the ordinate is given the binding of 3H_ 
labeled dexamethasone (dpm/l00 ,t! of incubation mixture). (B) Scatchard plot of the specific binding of 
3H-labeled dexamethasone to U937 cells. On the abscissa is given the amount of specifically bound 3H_ 
labeled dexamethasone (dpm/100 pi of incubation mixture), while on the ordinate is given the ratio of the 
amount of specifically bound 3H-labeled dexamethasone (B.l to the amount of free 3H-labeled dexametha-
sone (F). One representative experiment out of four is shown. The negative inverse of the slope and the x 
intercept were used to calculate the dissociation constant (Kdl and the number of glucocorticoid receptors 
per cell (R)' respectively. 
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Table 2. Binding of 3H-labeled dexamethasone In alveolar macrophages. 
Concentration of Total Nonspecific Specific Specific binding 
JH-labeJed dexamethasone (nM) binding binding binding x 100% Total binding 
0.5 286 • 237 49 ' 17 
1.0 607 523 84 14 
2.0 1,333 1,127 206 15 
4.0 2,060 2,186 
8.0 4,645 4,318 327 7 
16.0 9,696 8,882 814 8 
32.0 21,599 18,923 2,676 12 
a. Data are given as counts per minute and determined using the established assay without immunopreci-
pitation procedure as described in the section Materials and Methods. One representative experiment 
out of ten is shown. 
b. Specific binding should be calculated by subtracting the nonspecific binding from the total binding. 
c. Calculation of specific binding is not possible, because total and nonspecific binding are virtually 
identical. 
Table 3. Binding of 3H-labeled dexamethasone In alveolar macrophages using the Immuno receptor 
assay. 
Concentration of Total Nonspecific Specific Specific binding 
x 100% 3H-labeled dexamethasone (nM) binding binding binding Total binding 
1.0 167 a 36 131 b 79 
2.0 288 46 242 84 
4.0 466 66 400 86 
8.0 743 99 644 87 
16.0 950 186 764 80 
32.0 1,236 308 928 75 
a. Data are given as counts per minute. One representative experiment out of three is shown, 
b. Specific binding should be calculated by subtracting the nonspecific binding from the total binding. 
Characterization of the immuno receptor assay 
To compare the characteristics of AM as obtained with the immuno receptor assay 
with those of U937 cells and NHIK cells, both cell lines were also put to the immuno 
receptor assay. Under the conditions of this assay, U937 and NHIK cells showed to 
have 6.8 ± 0.9 x 10' (n~4) and 19.2 ± 2.5 x 10' (n~3) specific binding sites per cell, 
respectively. The K;s were 3.5 ± 0.5 nM (n~4) and 3.1 ± 0.6 nM (n~3). respectively 
(Table 4). To test whether the immuno receptor assay could discriminate between small 
differences in number of specific binding sites per cell, we estimated the number of 
glucocorticoid receptors per cell in a mixture (1: 1) of NHIK and U937 cells. This mixture 
produced 12.1 ± 2.2 x 10' (n ~ 3) specific binding sites per cell (expected number 13.0 
± 1.3 x 10') and 3.0 ± 0.3 nM as Kd (Table 4). Therefore, our immuno receptor assay 
proved to produce reliable results and enabled to determine at least a difference of 5300 
receptors per cell. 
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Figure 2. (AI Binding curves of 3H-/abeied dexamethasone for human alveolar macrophages (AM) as 
determined with the immuno receptor assay. The specific binding (0) is represented by the difference 
between the total binding {OJ and nonspecific binding (.). (B) Scatchard plot of 3H-labeled dexametha-
sone specifically bound to human AM. On the ordinate is given the ratio of the amount of specifically 
bound 3H-labeled dexamethasone (Bsl to the amount of free 3H-labeled dexamethasone (F). In both (AI 
and (8) the data from table 3 are used. One representative experiment out of three is shown. The 
negative inverse of the slope and the x Intercept were used to calculate the dissociation constant (Kd) 
and the number of glucocorticoid receptors per cell (A), respectively. 
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Table 4. Numbers of glucocorticoid receptors and their Kd values in U937 cells, NHIK celfs and alveolar 
macrophages (AM) as estimated in the immuno receptor assay. 
U937 NHIK U937 + NHIK AM 
11 :11 
R' 6.B± 0.9 b 19.2 ± 2.5 12.1±2.2 3.9 ± 2.0 
K ' , 3.5 ± 0.5 3.1 ± 0.6 3.0 ± 0.3 7.0 ± 1.5 
a, R: number of binding sites per cell ex 103). 
b. Results are shown as mean ± standard deviation of four (U937) or three (NHIK, U937 + NHIK, AM) 
independent experiments. 
c. Kd: dissociation constant (nM). 
Glucocorticoid receptors in alveolar macrophages are functional 
As specific glucocorticoid receptors were clearly demonstrated in AM when the 
immuno receptor assay was used, we were interested to find out whether these 
receptors were functional or not. Several studies report influences of glucocorticoids on 
AM functions, but it is not known whether these influences are either mediated directly 
via glucocorticoid receptors in the AM themselves, or via mediators released by other 
cell types, or have to be considered as non-receptor mediated influences. 
AM cultured under adherent conditions exhibited a specific morphology. Freshly 
isolated AM appeared round upon examination with phase contrast microscopy, but 
after three days of culture most of the AM were spread or spindle-shaped (Figure 3A). 
However, only few AM were spindle-shaped when they were cultured in the presence 
of dexamethasone (5 x 10.7 M) (Figure 3B). Spreading and appearance of cellular 
protrusions seemed to be inhibited by glucocorticoids. This inhibitory effect of dexame-
thasone on the culture-induced change in morphology was dependent on the concentra-
tion of dexamethasone and could be antagonized by RU 38486 (5 x 10·' M). a known 
antagonist of glucocorticoids (Figure 3C). This suggests that dexamethasone exerted its 
effect via glucocorticoid receptors. 
DISCUSSION 
Studies on glucocorticoid receptors in human alveolar macrophages are rare and 
conflicting with respect to the presence of a single class of high affinity receptors (19-
21). Established methods to determine the dissociation constant and receptor density 
are hampered by high nonspecific binding (20), which makes it impossible, or at least 
unreliable, to calculate specific binding as the difference between total and nonspecific 
binding. Studies on glucocorticoid receptors are easily affected by nonspecific binding, 
because the affinity of the receptor for its ligand is relatively low as compared with 
other steroid receptors. 
Also in our study it was impossible to determine numbers of glucocorticoid 
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Figure 3. Phase contrast morphology of human alveolar macrophages (AMI cultured for three days in 
vitro under adherent conditions (A). More than 70% of the AM exhibit a spindle-shaped morphology. The 
acquisition of this morphology is inhibited by dexamethasone (5 x 10.7 Ml (8). Most cells retain the 
rounded morphology of freshly isolated AM. Culture in the presence of both dexamethasone (5 x 10.7 MJ 
and RU 38486 (5 x 10.6 Ml resulted in the same percentage of spindle-shaped AM as culturing in medium 
without supplements (Cl. Culture in the presence of RU 38486 (5 x 10-s M) alone had no effect on the 
morphology of AM (data not shown). 
receptors and th~ir Kd values in AM from healthy volunteers using an established 
glucocorticoid receptor assay, which did yield excellent results when a monocytic or an 
uterine cervix carcinoma cell line was used. Nonspecific binding was extremely high in 
AM and often in the same range as total binding. Also a recent study by Lacronique et 
al. (20) reported high nonspecific binding (85-90% of total bindingl. Their results 
seemed to indicate non saturable receptors in AM, although they mentioned that their 
results may be caused by methodologic problems. If human AM would indeed possess 
non saturable glucocorticoid receptors, they would represent an exceptional cell type, as 
both AM of other species (33,34) and human peripheral blood monocytes (the precur-
sors of AM) (33,35,36) do contain a single class of high affinity receptors. 
From our first experiments we learned that AM, especially from smokers, showed a 
high nonspecific binding. AM from smokers are known to contain large amounts of 
carbon particles. As carbon/charcoal is able to bind steroids in general (37), we 
reasoned that this could act as a second pool of high affinity binding sites besides the 
hypothesized glucocorticoid receptor in AM. Also other dust particles inhaled by 
smokers and nonsmokers and phagocyoszed by AM may disturb the outcome of the 
receptor assay, because they may bind the applied steroid nonspecifically. Theoretically, 
nonspecific binding can be reduced by stringent wash procedures or cell membrane lysis 
after the 90 min incubation, or by the use of nonspecific steroid antagonists after the 
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90 min incubation. None of these methods proved to be successful in reducing 
nonspecific binding in human AM. Eventually, high nonspecific binding, which interfered 
with reliable estimation of specific binding sites, CQuid be circumvented effectively by 
introducing immunoprecipitation of glucocorticoid receptors after incubation with the 
radioactive ligand. With this, the nonspecific binding in AM was reduced .to only 10-
20% of the total binding. However, estimation of the numbers of glucocorticoid 
receptors per cell in U937 and NHIK cells revealed that specific binding sites seemed to 
be underestimated when the immuno receptor assay was used. In U937 and NHIK cells 
only 40% and 22% of the specific binding sites could be demonstrated respectively, 
when the immuno receptor assay was used in stead of the established method. This 
apparent underestimation may be caused by two factors. First, the immuno receptor 
assay implies more procedures which may lead to partial loss of complexes of receptors 
and their ligand. Second, part of the radioactivity may be bound to the pellet atter cell 
lysis and this is not put to immunoprecipitation. As the established receptor assay was 
inappropriate for studies on human AM, we accepted a possible, partial loss of signal 
and considered the advantage of low nonspecific binding and reproducible specific 
binding as first interest in our studies. Eventually, this enabled us to determine indispu* 
tably specific binding sites in human AM. Recently, a method in studies on estrogen 
receptors in rats also involving immunoprecipitation was described elsewhere (38). The 
authors also reported the small background of nonspecific binding as a major advantage 
of their method. 
Ozaki et a!. (19) could demonstrate saturable glucocorticoid receptors in AM, but 
they did not mention to what extent binding appeared to be nonspecific. In their assay, 
AM were incubated with 3H*labeled prednisolone for 2 hours at 4Q C. In the present 
study AM were incubated with 3H*labeled dexamethasone for 90 min at 21QC. 80th 
incubation temperature and choice of ligand determine the Kd value and may influence 
nonspecific binding. We did not use prednisolone in this study, but triamcinolone used 
in some of our experiments gave similar results as dexamethasone (data not shown). 
The study of Ozaki et al. (19) showed that human AM contained 9.8 ± 4.1 x 10' 
specific binding sites for 3H*labeled prednisolone per cell. The Kd value of these cells 
was 9.0 ± 4.9 nM. In patients with IPF they found a reduced numbsr of specific binding 
sites per cell (3.2 ± 2.0 x 103), although Lacronique et al. (20) could not demonstrate a 
difference in the pattern of dexamethasone binding by AM between normal subjects and 
IPF patients. These apparent discrepancies may be explained by methodologic problems 
resulting from high nonspecific binding. In the present study this problem was elimina* 
ted, and AM from healthy volunteers showed to have 3.9 ± 2.0 x 10' specific binding 
sites per cell. 
High nonspecific binding of glucocorticoids in AM in vivo may have therapeutical 
consequences. If part of the effects of therapeutic glucocorticoids in inflammatory lung 
diseases is mediated via the glucocorticoid receptors of AM, nonspecific binding to 
phagocytosed carbon may interfere with the binding to receptors. The presence of a 
large number of nonspecific binding sites may contribute to the need of higher therapeu* 
tical doses to achieve clinical improvement or may function as a depot. 
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We also provided evidence that the glucocorticoid receptors in AM are functional. In 
mice it was shown that glucocorticoids inhibit phagocytosis and cell spreading in 
cultures of resident peritoneal macrophages (39). It was suggested that the membrane 
function required for phagocytosis and spreading was disrupted by a steroid-induced 
factor. In the present study it was shown that also human AM in culture demonstrate 
marked changes in morphology. Furthermore, inhibition of these morphological changes 
upon culture of AM could be achieved by glucocorticoids. This inhibition was dependent 
on the concentration of dexamethasone and could be antagonized by RU 38486. These 
findings strongly suggest that dexamethasone exerts this effect by binding to glucocor-
ticoid receptors. 
In summary, we demonstrated that human AM possess a single class of high 
affinity glucocorticoid receptors, which can be saturated. To our knowledge, this is the 
first time glucocorticoid receptors are described in human AM, without the comments 
that high nonspecific binding may have influenced interpretation of the specific binding. 
Strong reduction of the nonspecific binding proved to be a prerequisite feature of the 
method to determine receptor numbers. The method may prove to be helpful in studies 
on glucocorticoid responsiveness in inflammatory lung diseases. Furthermore, it was 
shown that these glucocorticoid receptors were functional, which is consistent with the 
hypothesis that AM are a direct target for glucocorticoid therapy in many inflammatory 
lung diseases. 
ACKNOWLEDGMENTS. We gratefully acknowledge Prof. Dr. R. Benner for his continuous support and 
advice, Dr. A.O. Brinkman for his advice and Mr. C.A. Berrevoets for his help in developing the immuno 
receptor assay, Mr. T.M. van Os for excellent photographic assistance, and Mrs. H.J. Efsenbroek-de 
Jager and Mrs. J.M.J. van Everdingen·Quartel for their punctual secretarial help. 
REFERENCES 
1. Ham AW, Cormack DH. The origins, morphologies, and functions (including immunological functions) 
of the cells of loose connective tissue. In: Ham AW, Cormack DH, Histology. Philadelphia, JB 
lippincott Company, 1979, 225-259. 
2. Marcy TW, Merrill WW. Cigarette smoking and respiratory tract infection. Clin Chest Med 
1987;8:381-391. 
3. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. 
Am Rev Respir Dis 1990;141 :471-501. 
4. Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory 
cells. Science 1987;236:551-557. 
5. Herscowitz HB. In defence of the lung: paradoxical role of the pulmonary alveolar macrophage. Ann 
Allergy 1985;55:634-648 
6. Fels AOS, Cohn ZA. The alveolar macrophage. J Appl Physiol 1986;60:353-369. 
7. Rochester el, Rankin JA. Is asthma T-cell mediated? Am Rev Respir Dis 1991;144:1005-1007. 
8. Marini M, Soloperto M, Mezzetti M, Fasoli A, MattoH S. Interleukin-l binds to specific receptors on 
human bronchial epithelial cells and upregulates granulocyte/macrophage colony-stimulating factor 
synthesis and release. Am J Respir Cell Mol Bioi 1991 ;4:519-524. 
221 
CHAPTER 5.5 
9. Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic 
applications in asthma. Am Rev Raspir Dis 1990;141 :S59~S69. 
10. Munck A, Mendel DB, Smith lI, OrU E. Glucocorticoid receptors and actions. Am Rev Raspir Dis 
1990; 141 :82-81 o. 
11. Van Hal PThW, Hoogsteden He. Inflammatory mediators and glucocorticoids. In: Bray MA, Anderson 
WH, ads., Mediators of pulmonary inflammation. New York, M Dekker Inc, 1991, 593-617. 
12. Rinehart JJ, Sagone AL, Balcerzak SP, Ackerman GA, LoBuglio AF. Effects of corticosteroid therapy 
on human monocyte function. New Eng J Mad 1975:292:236-241. 
13, Guyre PM, Munck A. Glucocorticoid action on monocytes and macrophages. In: Schleimer RP, 
Claman HN, Oronsky A, eds., Anti-inflamm'ltory steroid action: basic and clinical aspects. San 
Diego, Academic Press Inc, 1989, 199-225. 
14. Poznansky MC, Gordon ACH, Douglas JG, Krajewki AS, Wyllie AH, Grant IWa. Resistance to 
methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic 
patients. Clin Sci 1984;67:639-645. 
15. Poznansky MC, Gordon ACH, Grant IWB, Wyllie AH, A cellular abnormality in 91ucocorticoid 
resistant asthma, Clin Exp Immunol 1985;61: 135-142, 
16. Beato M, Gene regulation by steroid hormones. Cell 1989;56:335-344. 
17. Miesfeld Rl. Molecular genetics of corticosteroid action. Am Rev Respir Dis 1990;141:S11-S17. 
18. Duval 0, Durant S, Homo·Delarche F. Non-genomic effects of steroids. Interactions of steroid 
molecules with membrane structures and functions. Biochim Biophys Acta 1983;737:409-442. 
19. Ozaki T, Yasuoka S, Nakayama T, Tsubura E. Glucocorticoid receptors in human alveolar macropha-
ges and peripheral blood cells. Clin Exp Immunol 1982;47:505-511. 
20, lacronique JG, Rennard SI, Bitterman PB, Ozaki T, Crystal RG. Alveolar macro phages in idiopathic 
pulmonary fibrosis have glucocorticoid receptors, but glucocorticoid therapy does not suppress 
alveolar macrophage release of fibronectin and alveolar macrophage derived growth factor. Am Rev 
Respir Dis 1984; 130:450-456. 
21. Van Hal PThW, Mulder E, Hoogsteden HC, Hilvering C, Benner R. Glucocorticoid receptors In 
alveolar macro phages: methodological aspects of the determination of the number of glucocorticoid 
receptors per celt. Agents Actions 1989;26: 128-131, 
22. Lippman M. Clinical implications of glucocorticoid receptors in human leukemia. Am J Physiol 
1982;243:El03-El08. 
23. Homo-Delarche F. Glucocorticoid receptors and steroid sensitivity in normal and neoplastic human 
lymphoid tissues: a review. Cancer Res 1984;44:431-437, 
24. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, Kay AB. Glucocorticoid resistance 
in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics. and 
inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 
1991; 144:1 016-1 025. 
25. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell 
line (U-9371. Int J Cancer 1976;17:565-577. 
26_ Nordbye K, Oftebro R. Establishment of four new cell strains from human uterine cervix.!. Exp Cett 
Res 1969;58:458-460. 
27. Yssel H, De Vries JE, Koken M, Van Blitterswijk W, Spits H. Serum-free medium for generation and 
propagation of functional human cytotoxic and helper T cett clones. J Immunol Meth 1984;72:219-
227. 
28, Steiner AE, Wittliff JL A whole-cell assay for glucocorticoid binding sites in normal human 
lymphocytes. Clin Chem 1985;31: 1855-1860. 
29. Crabtree GR, Smith KA, Munck A. Glucocorticoid receptors. In: Catovsky 0, ed. Methods in hemato-
logy: the leukemic celL New York, Churchill livingstone, 1981, 252-269. 
222 
Glucocorticoid receptors in macrophages 
30. Veldscholte J, Berrevoets CA, Zegers NO, Van der Kwast TH, Grootegoed JA, Mulder E. Hormone-
induced dissociation of the androgen receptor-heat-shock protein complex: Use of a new monoclonal 
antibody to distinguish transformed from non transformed receptors. Biochemistry 1992;31 :7422-
7430. 
31. Kontula K, Andersson lC, Paavonen T, Myllyla G, Teerenhovi l, Vuopio P. Glucocorticoid receptors 
and glucocorticoid sensitivity of human leukemic cells. Int J Cancer 1980;26: 177-183. 
32. Mulder E, Peters MJ, De Vries J, Van der Molen HJ, 0stgaard K, Eik-Nes KB, Oftebro R. Androgen 
receptor specificity and growth response of a human cell line (NHIK 3025). Mol Cell Endocrinol 
1978;11 :309-323. 
33. Werb Z, Foley R, Munck A. Interaction of glucocorticoids with macrophages: identification of 
glucocorticoid receptors in monocytes and macrophages. J Exp Med 1978;147:1684-1694. 
34. George SC, Gudewicz PW, Jaffe RC. Glucocorticoid binding to normal and activated alveolar lung 
cells. lung 1980;157:57-64. 
35. Lippman M, Barr R. Glucocorticoid receptors in purified subpopulations of human peripheral blood 
lymphocytes. J Immunol 1977; 118: 1977-1981. 
36. Lane SJ, lee TH. Glucocorticoid receptor characteristics in monocytes of patients with corticoste· 
raid-resistant bronchial asthma. Am Rev Respir Dis 1991; 143:1 020-1024. 
37. Heimer GM, England DE. Enterohepatic recirculation of oestriol: inhibition by activated charcoal. 
Acta Endocrinoi 1986; 113:93-95. 
38. Bettini E, Maggi A. A rapid method for the quantitation of estrogen receptors in small amounts of 
tissue. J Imm Methods 1991;144:87-91. 
39. Becker J, Grasso RJ. Suppression of phagocytosis by dexamethasone in macrophage cultures: 
inability of arachidonic acid, indomethacin, and nordihydroguaiaretic acid to reverse the inhibitory 
response mediated by a steroid-inducible factor. Int J Immunopharmac 1985;7:839-847. 
223 

------------ CHAPTER 6 ------------
MONOCYTES/MACROPHAGES AND GLUCOCORTICOID THERAPY 
6.1 Introduction 
6.2 Cell surface antigen expression by peripheral blood monocytes in allergic asthma: 
results of 2.5 years therapy with inhaled beclomethasone dipropionate 
6.3 Eicosanoids and Hpocortin-1 in SAL-fluid in asthma: effects of smoking and inhaled 
glucocorticoids 

-----------------------CHAPTER6.1-----------------------
INTRODUCTION 
CHAPTER 6.1 
In chapters 1.3, 2.3, 2.4 and 2.5, we discussed new insights in the cellular and 
subcellular working mechanisms of glucocorticoids. In chapter 5, we presented data on the 
modulation of phenotype and function of human mononuclear phagocytes by 
gluGocorticoids in vitro, suggesting that glucocorticoids may exert their clinical effects, at 
least partly, by influencing monocytes and macrophages in vivo. Therefore, we were 
interested to find out whether treatment of asthmatic patients with inhaled glucocorticoids 
resulted in effects on peripheral blood monocytes and alveolar macrophages similar to the 
effects observed in vitro. These ideas to study the cellular in vivo effects of inhaled 
gluGocorticoids were discussed with the Dutch Chronic Non-Specific Lung Disease Study 
Group, who compared in a 2.5 year study the effects of inhaled glucocorticoids with 
inhaled anticholinergic agents (1,2). At the end of this long-term trial, we were allowed to 
analyze both characteristics of the bronchoalveolar lavage fluid and the expression of cell 
membrane antigens on peripheral blood monocytes. Moreover, we were able to correlate 
our findings with lung function parameters, e.g. FEV1 and PC20. The major clinical 
conclusion from this study was: "the addition of an inhaled glucocorticoid - but not an 
inhaled anticholinergic agent - to maintenance treatment with a P2-agonist (terbutaline) 
substantially reduced morbidity, hyperresponsiveness, and airways obstruction in patients 
with a spectrum of obstructive airways disease" (1). The precise cellular base of these 
clinical glucocorticoid effects has still to be elucidated. 
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SUMMARY 
At present inhaled glucocorticoids are widely accepted as the therapy of choice in 
chronic asthma. Treatment with inhaled glucocorticoids significantly sUPPfesses local 
airway inflammation in asthmatics, but may also have systemic effects, e.g. a reduction 
of the number of circulating hypodense eosinophils or a down-modulation of HLA-DR 
antigen (Ag) expression by T lymphocytes in peripheral blood. However, the effect of 
long-term therapy with inhaled glucocorticoids on peripheral blood monocytes (PBM)' 
which are the precursors of the most numerous cell type in the lung, the alveolar 
macrophage, have not yet been evaluated. We therefore investigated the expression of 
various cell surface Ag on PBM from non-smoking patients with allergic asthma who 
were treated for 2.5 years with a P2-agonist plus either inhaled glucocorticoids 
(beclomethasone dipropionate, BDPI (n=4) or an anticholinergic (AC) or placebo (n=8). 
We compared the results with healthy volunteers (n = 7). Long-term treatment of allergic 
asthmatics with inhaled BOP, but not AC or placebo therapy, was associated with a 
significantly lower CDllb Ag expression (p<O.04) and higher expression of CD13, 
CD14 and CD18 Ag (p<O.05, p<O.02 and p<O.04, respectively) when compared with 
the healthy control subjects (n = 71. In addition, PBM of asthmatic patients treated with 
inhaled BDP expressed an almost two-fold higher level of CD14 Ag on their cell surface 
than PBM of patients treated with AC or placebo. No significant differences in the 
expression of CD16, CD23, CD25, CD32 and CD64 Ag or HLA-DR were observed 
between PBM from the different patient groups or healthy controls. Taken together, this 
study shows that the expression of at least several cell surface Ag on PBM from allergic 
asthmatics differs, after long-term therapy with inhaled BOP, from patients treated with 
AC or placebo. 
INTRODUCTION 
One of the major histopathological findings in asthma is chronic inflammation of the 
airways. In bronchial mucosal biopsies, this inflammation is characterized by an 
accumulation of mononuclear phagocytes, eosinophils, mast cells and T lymphocytes 
(1-41. These inflammatory cells have also been described in the bronchoalveolar lavage 
fluid (BALF) (5-7), which, in addition, has been shown to contain elevated levels of 
various inflammatory mediators (7,8). It is generally believed that the airway inflamma-
tion in asthma results from the concerted actions of the different types of inflammatory 
cells and their products, and underlies some of the clinical symptoms (1,3,5). 
The most numerous cell type in both the normal and asthmatic lung is the alveolar 
macrophage (AM). This cell type is nowadays known to playa central role in initiating, 
perpetuating, and reducing inflammatory processes (9-12). Monocytes and 
macrophages recovered from BALF of asthmatics are highly activated (13-15), manifest-
ed in the release of a large variety of mediators which in turn modulate the inflammatory 
responses of eosinophils, mast cells and T cells (7, 16). Furthermore, it has been 
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reported that AM of asthmatic patients express elevated levels of low affinity receptors 
for IgE (CD23) (17), which are capable of inducing cellular activation in reponse to 
specific allergen. 
At present, glucocorticoids are the most effective therapy for controlling airway 
inflammation and clinical symptoms in chronic asthma (18,19). The precise mechanisms 
by which glucocorticoids reduce airway inflammation are not yet fully understood, but it 
is known that they modulate gene expression by binding to specific glucocorticoid-
responsive elements in DNA (20,21). One of the major mechanisms by which 
glucocorticoids inhibit inflammation is direct suppression of cytokine production by 
mononuclear phagocytes and T cells (22) or the induction of anti-inflammatory proteins 
such as lipocortin-1 (23). Additionally, glucocorticoids inhibit the production of pro-
inflammatory mediators indirectly by suppressing the activity of several enzymes 
involved in the production of these mediators. 
Therapy with inhaled glucocorticoids for one to 4 months results in a significant 
decrease in the numbers of macrophages, eosinophils, mast cells, and T cells in the 
bronchial epithelium and submucosa of asthmatic patients (24-27). Only mild systemic 
effects have been reported with a daily dose of 1000-2000 fig of inhaled 
glucocorticoids. Numbers of peripheral blood eosinophils have been shown to be 
reduced after treatment with inhaled glucocorticoids (19,28). The effect of long-term 
treatment with inhaled glucocorticoids on peripheral blood monocytes (PBM), the 
precursors of AM, has not yet been evaluated. Identification of the effects of therapy 
with inhaled glucocorticoids on peripheral blood ceHs may be important, as increased 
numbers of eosinophils and activated T cells are detected in blood of asthmatic patients, 
in addition to the infiltration of inflammatory cells in the airways (29,30). 
In this report, we analyzed the expression of various cell surface Ag by PBM of non-
smoking patients with allergic asthma who were treated for 2.5 years with an inhaled 
P2-agonist plus either inhaled beclomethasone dipropionate (BOP), or an anticholinergic 
or placebo. The patients were participants in the Dutch double-blind placebo-controlled 
CNSLD study (31,32). Our data indicate that PBM of patients treated with inhaled BDP, 
in contrast to PBM of patients treated with anticholinergic or placebo, show significant 
changes in the expression of CD11b, CD13, CD14 and CD18 Ag. In addition, PBM of 
patients treated with inhaled BDP expressed significantly more CD14 Ag on their cell 
surface than PBM of patients who were treated with bronchodilator or placebo. 
MATERIALS AND METHODS 
Subjects 
Twelve non-smoking allergic asthmatic patients (participating in the Dutch double-blind placebo-
controlled CNSLD study) (31,32) and 7 healthy volunteers were studied. The characteristics of each 
patient are described in Table 1. The diagnosis of asthma was made according _ to the criteria of the 
American Thoracic Society (33) and was based on a history of attacks of breathlessness and wheezing 
without chronic cough or sputum production. Chronic was defined as more than three months per year. 
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At entry to the study, all patients showed a 20% decrease In FEV 1 resulting from inhalation of a 
provocative concentration of histamine of ~ 8 mg/ml (32,34). Allergy was defined as at least 2 positive 
wheal and flare reactions to skin prick tests with 12 common aeroallergens, or a positive test to house 
dust mite (32). All patients but one had a baseline reversibility ;:.:10% of predicted (one patient had a 
reversibility of 4%). Control subjects (3 male, median age 27; 4 female, median age 23) were healthy 
volunteers, taking no medication, who had no history of allergy or asthma and who had negative skin 
prick tests. Ethical approval for the study protocol was obtained from the Medical Ethics Committees of 
the participating centres. AU subjects gave written informed consent. 
Table 1. Patient characteristics. 
Patient 
number 
Gender 
glucocorticoid group 
M 
2 F 
3 F 
4 F 
median 
anticholinergic/placebo group 
2 
3 
4 
5 
6 
7 
8 
median 
Study design 
F 
M 
M 
M 
M 
M 
F 
M 
Age 
(years) 
36 
44 
45 
60 
44.5 
41 
42 
24 
44 
50 
57 
38 
26 
41.5 
Baseline 
FEV1 
(% of predicted) 
46.3 
75.0 
49.2 
59.7 
54.5 
54.3 
48.7 
61.5 
63.5 
65.1 
81.6 
57.0 
90.0 
62.5 
After 2.5 years 
FEV1 
(% of predicted) 
64.5 
88.5 
69.6 
90.3 
79.1 
53.1 
56.5 
54.7 
66.3 
62.7 
42.3 
43.6 
61.5 
55.6 
Baseline 
pe20 
(mg/ml) 
0.13 
0.06 
0.05 
0.06 
0.06 
0.03 
0.24 
0.19 
0.02 
0.28 
0.14 
0.13 
0.13 
0.14 
After 2.5 
years pe zo 
(mg/ml) 
1.46 
0.45 
0.21 
0.96 
0.71 
0.04 
0.87 
0.58 
0.05 
0.18 
0.04 
0.06 
0.02 
0.06 
Details of the study design have been described previously (32). Briefly, after a double-blind 
randomization patients were treated with the P2-agonist terbutaline (2 puffs of 250 fig q.i.d.) plus either: 
(A) inhaled glucocorticoids BOP, 2 puffs of 100 )1g q.i.d., (B) the anticholinergic bronchodilator 
(ipratropium bromide), 2 puffs of 20 tlg q.i.d., or (e) placebo q.i.d. At the end of the study, no significant 
differences with regard to FEV1 and pe20 were found between the groups receiving either ipratroplum 
bromide or placebo. Therefore, the data of these groups were pooled for analysis as one single group 
(designated as anticholinergic/placebo group). Heparinized venous blood of patients was collected after 
completing 2.5 years of treatment. Heparinized blood of healthy volunteers served as control. 
Isolation of peripheral blood mononuclear cells 
Mononuclear cells from heparinized venous blood were isolated by Ficol! density centrifugation 
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(Ficoll Paque; density 1.077 g/ml; Pharmacia, Uppsala, Sweden) for 15 min at room temperature 
(centrifugal force 1000 g). Peripheral blood mononuclear celfs (PBMNC) were washed twice at 4 °C using 
PBS (300 mosmol; pH 7.8) supplemented with 0.5% heat-inactivated BSA (Organon Teknika: Turnhout, 
Belgium) and 0.05% w/v NaN3 (PBS/BSA/NaN3). The cell concentration was adjusted to 5xl06 cells/ml. 
Immunofluorescence staining 
Monoclonal antibodies (mAb) used in this study are listed in Table 2. CD11 and CD18 mAb were 
used because of the central role of leukocyte adhesion molecules in the recruitment of blood cells to 
inflammatory sites (35). Cell surface aminopeptidase-N can be recognized by C013 mAb, and may playa 
role In the inactivation of some inflammatory mediators (3B,37). CD14 mAb were used because they 
recognize the receptor for LPS binding protein, which may determine the cellular responsiveness to 
bacterial products (38). mAb recognizing Fcy receptors (C016, CD32, C064) were used because these 
receptors playa role in the response of cells to specific antigens (39). The presence of low affinity 
receptors for IgE, recognized by CD23 mAb, may lead to activation of cells in response to specific 
allergens (40). Both the expression of the a-chain of the IL-2 receptor (CD25) and HLA-DR are markers of 
cellular activation (27). RFD9 recognizes a cell membrane determinant present on alveolar macrophages, 
but virtually absent on blood monocytes, and may be used as a marker of maturation (41). Irrelevant 
isotype-matched antibodies were used as controls. Reagents were diluted to optimal concentration in 
PBS/BSA/NaN3 • All incubations (30 min each) were carried out on ice. Each incubation was followed by 
two washes with PBS/BSA/NaN3 at 4°C. For single-colour stainings, aliquots of 2.5xl05 PBMNC (in a 
volume of 50 l-\I) were first incubated with 50 fIl mAb, washed, and subsequently incubated with FITC-
conjugated goat anti-mouse Ig (GAM-FITC; CLB, Amsterdam, The Netherlands). After the last washing 
procedure, the cells were resuspended in PBS/BSAlNaN3 • For two-colour stainings, 50 ~II PBMNC were 
incubated with both a FITC-conjugated and PE-conjugated mAb, washed and eventually resuspended in 
FACSFlOW™ (Becton Dickinson, Sunnyvale, CAl. 
Flow cytometry 
Flow cytometric analyses were performed using a FACScan flow cytometer (Becton Dickinson) 
equipped with a 488 nm argon laser. Residual erythrocytes, dead cells and debris were excluded from 
analysis by electronic gating on the basis of forward and perpendicular light scatter. At least 7,500 
events were acquired. Cell surface fluorescence was analyzed after setting scatter gates on either the 
monocyte or lymphocyte fraction. Within the monocyte gate, cell surface fluorescence was expressed as 
molecules equivalent to soluble FITC (MESF). MESF values (xl04) were obtained by interpolating cell 
surface fluorescence to a standard curve prepared using microspheres of known fluorescence intensities 
(Flow Cytometry Standards, Research Triangle Park, NC). MESF values were corrected for background 
fluorescence by subtracting the MESF values obtained with isotype-matched control antibodies. Within 
the lymphocyte gate, results were expressed as the percentage of positively stained cells relative to an 
isotype-matched control antibody. Subpopulations of T lymphocytes were identified by two-colour 
labelling. 
Statistical analysis 
Differences between groups in either the percentage of positively stained lymphocytes or the level 
of cell surface fluorescence by monocytes were compared using the two-tailed Mann-Whitney U test. 
Differences associated with p values < 0.05 were regarded as statistically significant. 
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Table 2. Monoclonal antibodies used in this study. 
mAb clone (isotype) 
C03 Leu-4 (l9G,) 
C04 Leu-3a (lgG,) 
COS Leu-2a (l9G,) 
COllb 44 (igG,1 
CD13 020 (igG,,1 
CD14 UCHMl IlgG,,1 
CD15 VIM·05(igMI 
C016 leu-l1 b (19M) 
C01S LFA·ll1 (igG,1 
C020 B1 (lgG2al 
C023 Tal (igG,1 
CD25 IL·2R(igG,1 
C032 IV.3 (l9G21» 
CD64 32.2 (igG,1 
HLA·DR L243 {lgG2al 
anti-macrophage Ag RFD9 (lgG,1 
isatype control (lgG,) 
isatype control (lgG2) 
COl' Leu-6 (lgG 2h) 
a. Becton Dickinson, Sunnyvale, CA. d. Vienna, Austria. 
source 
SO' 
SO 
SO 
Dr. N. Hoggb 
Dr. C.E. van der Schoote 
Dr. N. Hogg 
Dr. W. Knappd 
SO 
CLB, Amsterdam, The Netherlands 
Coulter Clone, Hialeah, Fl 
8iotest, Dreieick, Germany 
SO 
Medarex Inc., West lebanon, NH 
Medarex Inc. 
SO 
Or. L.W. Poulter~ 
SO 
SO 
SO 
b. london, UK. e. Royal Free Hospital School of Medicine, London, UK. 
c. CLB, Amsterdam, The Netherlands. f. Used as IgG2b isatyps control. 
RESULTS 
Long~term treatment with inhaled BDP in asthma is associated with differences in cell 
surface Ag expression by PBM compared with bronchodilator therapy or placebo 
The expression of various cell surface Ag by PBM from both non~smoking allergic 
asthmatics treated for 2.5 ye~us with either inhaled BOP or anticholinergic/placebo, and 
healthy volunteers is summarized in Table 3. PBM from patients who received 
anticholinergic/placebo did not show any significant alterations in the levels of cell 
surface Ag expression when compared with PBM from healthy controls. In contrast, 
PBM from patients treated with inhaled BDP differed significantly in the level of 
expression of CD11b (p<O.04), CD13 (p<O.05), CD14(p<O.02), and CD18 (p<O.04) 
Ag when compared with PBM from healthy controls (Figure 1). A reduced level of 
CD11b Ag expression was observed, whereas the expression of CD13, CD14, and 
CD18 Ag was higher. The only significant difference between both groups of patients 
concerned the level of CD14 Ag expression; PBM from patients who had received 
inhaled BDP expressed significantly higher levels of CD14 Ag than PBM from asthmatic 
patients who had received anticholinergic/placebo (Table 3, Figure 1). Both groups of 
patients and the control group, however, did not differ in the relative numbers of CD14 + 
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monocytes in peripheral blood (data not shown). Taken together, these results demon-
strate that long-term therapy with inhaled BOP alters the expression of some cell 
surface Ag on PBM. The most pronounced change is the enhanced expression of C014 
Ag. 
Table 3. Specific cell surface fluorescence by peripheral blood monocytes. 
PBMNC 
%CD15+ 
Monocytes 
CDllb 
CD13 
CD14 
CD16 
CDIB 
CD23 
CD25 
CD32 
CD64 
RFD9 
HLA-DR 
control group 
(n~7) 
0.7 (0.5-2.0)' 
19.2 (9.6-27.1 )'" 
5.3 (1.5-6.4) 
13.0 (9.4-18.7) 
1.1 (0.6-2.3) 
B.5 (5.7-11.0) 
1.0 (0.9-1.6) 
0.9 (0.7-1.3) 
11.7 (6.6-15.0) 
7.7 (4.3-10.4) 
1.3 (0.9-1.4) 
5.9 (3.8-6.6) 
a. Median values (range). 
anticholinergiclplacebo 
group (n=8) 
loB (0.4-5.5) 
12.6 (2.1-26.4) 
5.4 (3.6-12.9) 
11.9 (7.9-19.7) 
0.9 (0.6-1.6) 
13.B (6.3-33.4) 
1.1 (0.5-2.2) 
0.9 (0.5·1.3) 
13.4 (7.2-19.9) 
8.4 (4.2-12.4) 
1.4 (0.6-2.4) 
6.B (4.8-21.4) 
glucocorticoid group 
(n~4) 
1.6 (0.5-6.B) 
7.6 (4.1-13.0) clp<o.Q4! 
8.2 (6.1-1B.7) c!p<O,OS! 
20.4 (13.7-21.5) clp<o.o2! dlp<O,03! 
1.3 (0.7-1.6) 
12.5 (8.8-16.1) c1p<O.04! 
1.3 (0.7-1.B) 
1.1 (0.6-1.6) 
14.0 (11.5-17.6) 
7.0 (6.3-10.8) 
1.8 (1.7-2.0) clp<O.01) 
7.0 (5.7-9.3) 
b. MESF values, corrected for background fluorescence by isotype-matched control Ab. were calculated 
using a calibration line obtained with microspheres of known fluorescence intensities. Statistical 
analysis was performed using the two-tailed Mann-Whitney U test. 
c. Significantly different from control group. 
d. Significantly different from anticholinergic/placebo group. 
The expression of ROF9 by PBM of asthmatics treated with inhaled BOP was significant-
ly increased when compared with healthy controls (p<O.OH. However, this specific cell 
surface fluorescence fell within two-fold the fluorescence intensity of an isotype-
matched control mAb, suggesting that monocytes express negligible levels of RF09 Ag. 
No differences in the expression of C016 (FcyRIII), CD23 (FcERII), C025 (lL-2R), CD32 
(FeyRII) and CD64 (FeyRI) were observed between both groups of patients and healthy 
controls. The expression of CD16, C023, and C025 Ag fell within the two-fold the 
background fluorescence of isotype-matched control mAb, comparable with the 
expression of RF09 Ag. 
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Figure 1. Expression of CD11b, CD13, CD14 and COla cell surface Ag (expressed as MESF xl04) by 
PBM. Median values are represented as a horizontal dash (-). 
* Value of glucocorticoid group (3) differs significantly from control group (1). 
n Value of glucocorticoid group (3) differs significantly from anticholinergic/placebo group (2). 
Long-term inhaled therapy and differences in subsets of peripheral blood lymphocytes 
In addition to analyzing the cell surface Ag expression on PBM, we investigated 
whether long-term therapy with inhaled BOP is associated with differences in the 
percentage of T and B lymphocytes in peripheral blood (Table 4). No differences were 
observed in the percentages of either CD4+ or CD8+ T cells. However, both groups of 
patients had higher percentages of HLA-OR+ T cells in their peripheral blood than 
healthy controls. Treatment with inhaled BOP did not alter the percentage of these 
activated T cells. Interestingly, patients who received bronchodilator/placebo, but not 
the patients treated with inhaled BOP, had a significantly higher percentage of B 
lymphocytes (C020+ cells) in their peripheral blood compared with healthy controls 
(Table 4). 
236 
Inhaled therapy and monocytes in asthma 
Table 4. Lymphocyte subpopulations In peripheral blood. 
Lymphocytes 
% CD20+ 
% CD3+ 
% CD3+/CD4+ 
% CD3+/CD8+ 
% CD3+jHLA-DR+ 
ratio CD4/CD8 
control group 
(n=7) 
4.2 (3.1-g.1)a 
67.4 (57.1·82.2) 
34.5 (22.0·44.1) 
23.8 (16.3·30.2) 
1.0 (0.4·2.1) 
1.6 (0.7·2.1) 
a. Median values (range). 
b. Significantly different from control group, 
DISCUSSION 
anticholinergic/placebo 
group (n=8) 
7.2 (3.5-10,1) b (.,<0,04) 
68.3 (62.6·81.9) 
40.6 (29.1·53.9) 
21.2 (11.3·35.7) 
2.0 (1,2-9.3) b (p<0,03) 
1. 7 (0.8·3.6) 
glucocorticoid group 
(n=4) 
7.6 (3.9·16.4) 
73.5 (53.4·79.0) 
38.0 (32.1·40.9) 
33.0 (13.9·42.7) 
5.6 (2.0-8.8) b (p<0.02) 
1.2 (0.8·2.6) 
In this study, we show that the expression of cefl surface Ag on PBM from allergic 
asthmatics treated for 2.5 years with inhaled glucocorticoids (BOP, 800 ~g daily) differs 
from those treated with bronchodilator or placebo. Long-term treatment of asthmatic 
patients with inhaled glucocorticoids was associated with a significantly reduced 
expression of CD11b Ag on PBM, and a significantly increased expression of C013, 
CD14, and CD18 Ag compared with healthy control subjects. In addition, PBM of 
patients treated with inhaled glucocorticoids expressed an almost two-fold higher level 
of CO 14 Ag on their cell surface compared with PBM of patients who received anticho-
linergic/placebo. 
Glucocorticoids were introduced in 1949 as a new and promising drug in the 
treatment of inflammatory diseases (42), Shortly thereafter, local administration of 
glucocorticoids was commenced to by-pass the unwanted systemic side effects (43), 
Nowadays, inhaled glucocorticoids are widely accepted as the treatment of choice in 
chronic asthma (28), Several reports showed that inhaled glucocorticoids are safe and 
almost free of systemic effects. However, high doses of inhaled glucocorticoids may 
still influence the hypothalamus-pituitary-adrenal axis {28,44}. More evidence for 
systemic effects of inhaled glucocorticoids comes from studies on circulating 
eosinophils and T cells. Circulating hypodense eosinophils, which have been shown to 
exhibit a great inflammatory potential, were reduced in asthmatic subjects after short-
term treatment with inhaled glucocorticoids (45A6). Furthermore, a small but significant 
reduction in HLA-OR expression by peripheral blood T cells has been reported after 6 
weeks of therapy with inhaled glucocorticoids (27), To our knowledge, modulation of 
PBM by inhaled glucocorticoids has not been described up till now. 
Leukocyte adhesion molecules, among which the CDll/CD18 family of p, integrins, 
play an important role in the recruitment of cells from peripheral blood to the site of 
inflammation as well as in other immunological and inflammatory processes that require 
direct cellular interactions (35,47,48). 80th the expression and function of adhesion 
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molecules arB augmented in response to inflammatory mediators and cytokines (49). 
The reduction in CD 11 b Ag expression by PBM observed here in asthmatic subjects 
treated with inhaled glucocorticoids, may have indirectly resulted from the local 
glucocorticoid-mediated reduction in inflammatory mediators in the lung. Alternatively, 
systemically absorbed BDP may be directly responsible for the modulation of CD11 b Ag 
expression. In contrast to a reduced expression of CD11 b, a slightly but significantly 
elevated CD 18 Ag expression was seen on PBM of asthmatics treated with inhaled 
glucocorticoids when compared with PBM of healthy control subjects. The CD18 Ag is 
found on the cell surface in association with one of three different a chains, i.e. the 
CD11 a, CD11 b, or CD11 c Ag (47). Since the expression of CD11 a and CD11 c Ag were 
not analyzed in this study, we do not know whether the observed increase in CO 18 Ag 
expression coincides with an increased expression of C011 a and/or C011 c Ag. 
Long-term treatment of asthmatics with inhaled BOP was associated with an 
increased expression of CD 13 Ag by PBM compared with healthy controls. CD 13 Ag, a 
cell membrane-bound aminopeptidase-N, has been shown to play an important role in 
modulating the activity of regulatory oligopeptides (36). An increase in CD 13 Ag 
expression may therefore enhance the cell's capacity to inactivate harmful inflammatory 
peptides. In this context, it is noteworthy that CD13 Ag expression by purified PBM 
increases upon in vitro culture in the presence of Il-4, suggesting that this cytokine, like 
glucocorticoids, has potential anti-inflammatory effects (37,50). Future studies are 
needed to determine whether the increased expression of CD 13 Ag observed here is 
accompanied by an increased aminopeptidase-N activity. 
The CD 14 Ag expression by PBM of patients treated with inhaled glucocorticoids 
was significantly increased compared with both patients who received anticholiner-
gic/placebo and healthy control subjects. It has been shown that CD14 Ag can function 
as a receptor for lipopolysaccharide (LPS) (38). In addition, a role for CD14 Ag has been 
implicated in the adhesion of monocytes to cytokine-activated endothelial cells (51). 
CD 14 Ag expression decreases upon differentiation/maturation of monocytes into AM 
(38). This process can be inhibited by glucocorticoids (41,52). Therefore, it may be that 
in this study the interference <?f inhaled BOP with the maturation of PBM manifests itself 
in the increase of C014 Ag expression. 
In this study, we also show that all asthmatic patients, treated with either inhaled 
glucocorticoids or anticholinergic/placebo, had significantly increased percentages of 
HLA-DR+ T cells in their peripheral blood when compared with healthy control subjects. 
Long-term treatment with inhaled BDP did not reduce the percentage of circulating 
activated (HLA-DR+) T lymphocytes in both groups of patients. Recently, Wilson et al. 
(27) showed in an uncontrolled study that patients treated for 6 weeks with inhaled 
BOP showed a reduction in the percentage of activated T cells. Compared with our 
study, they used a higher dose of BDP and they did not compare their result with 
patients who did not receive inhaled glucocorticoids. In the present study, we also 
observed that patients treated with bronchodilator/placebo, but not the patients treated 
with inhaled BDP, had a higher percentage of B lymphocytes in peripheral blood 
compared with healthy controls. Therefore, treatment with inhaled glucocorticoids may 
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have influenced the proportion of circulating B lymphocytes in our group of patients. 
In summary, our data demonstrate that long·term therapy with inhaled 
glucocorticoids coincides with an altered expression of several cell surface Ag on PBM 
of allergic asthmatics. Future studies are needed to determine whether these changes in 
cell surface Ag expression are part of the antHnflammatory action of inhaled 
glucocorticoids, and whether they correlate with the glucocorticoid· induced improve· 
ment in FEV,t PC20 and clinical symptoms. 
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SUMMARY 
Both smoking and asthma are associated with inflammatory changes in the lung, which 
may be suppressed with the help of exogenous anti-inflammatory drugs or by the defence 
system of the body itself. Lipocortin-1 (Lc-1) is an anti-inflammatory protein in respiratory 
tract secretions. We report an inverse correlation between extracellular Lc-1 concentration 
and the bronchoconstrictor prostaglandin D, (PGD,) (r, =-0.597, p <0.05, n = 15) in 
bronchoalveolar lavage fluid (BALF) from allergic asthmatics, together with a positive 
relationship between BALF Lc-1 concentration and PC,o (r, = O. 720, n = 15, p < 0.01) in 
these subjects. We quantified Lc-1 concentration in BALF from asthmatic patients and 
found no significant difference between those receiving inhaled glucocorticoids (2x1 00 ~tg 
beclomethasone q.i.d. for 2.5 y; median 186 ng Lc-1/mg albumin, n = 6) and those who 
were not (median 126 ng Lc-1/mg albumin, n = 12), perhaps because inhaled drugs 
deposit predominantly in central airways which are poorly represented in BAL. Both 
asthmatic and healthy volunteers who smoked had higher levels of Lc-1 in their BALF than 
their non-smoking counterparts (e.g. asthmatic smokers, median 317 ng Lc-l/mg albumin, 
n = 10; asthmatic non-smokers, median 162 ng Lc-1/mg albumin, n = 18; P < 0.05). perhaps 
because smokers' lungs contain more alveolar macrophages, cells which release Lc-l. We 
observed a positive correlation between BALF Lc-l and BAL cell number (rs =0.821, n = 16, 
P < 0.001). Increased extracellular Lc-l may be part of a protective response of the lung 
to inflammatory insult. Control of PGD 2 levels may be one mechanism by which Lc-l 
suppresses inflammation. 
INTRODUCTION 
Inflammation is a key feature of many diseases of the respiratory tract and hence, 
there have been numerous studies to examine the effects of factors such as tobacco smoke 
(1-3) and inhaled allergens (4,5) which can initiate inflammatory processes in the lung. In 
addition, there have been many studies on the mechanisms of maintenance and resolution 
of these inflammatory processes, either spontaneously or drug-induced. 
In 1950, glucocorticoids were introduced in the treatment of asthma. Nowadays, we 
know that the suppression of chronic airway inflammation underlies the beneficial effects 
of exogenous glucocorticoids on bronchial hyperresponsiveness (BHR) in asthma (6). This 
chronic airway inflammation can be characterized by increased numbers and altered profiles 
of inflammatory cells and by elevated levels of inflammatory mediators in bronchoalveolar 
lavage fluid (BALF) and bronchial biopsies (4,5). More recently, it has been suggested that 
also physiological levels of endogenous glucocorticoids contribute to the control of immune 
function, because it was shown that treatment with the glucocorticoid antagonist RU 
38486 caused a reversible generalized exanthem in man (7). Glucocorticoids modulate the 
transcription of genes for both pro- and anti-inflammatory proteins (8), but their precise 
working mechanisms in the inhibition of inflammation are still incompletely understood. 
Since lipocortin-l (Lc-l) was identified and cloned, it has been reported by several research 
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groups to exhibit clear anti-inflammatory properties both in vitro and in vivo (9-11 i see 12 
for a recent review). The induction of this anti-inflammatory protein has been proposed to 
mediate, at least partially, some of the anti-inflammatory effects of glucocorticoids (12, 13). 
However, both the glucocorticoid-inducibility and the exact anti-inflammatory mechanisms 
of Lc-l are still under discussion (14,15). The anti-inflammatory actions of Lc-l are thought 
to include direct or indirect inhibition of the action of phospholipase A21 and thus the 
production of pro-inflammatory arachidonic acid metabolites (9) including those thought to 
playa role in the pathogenesis of asthma (16) and smoking-related lung diseases (3). 
Furthermore, Lc-1 may modulate cell functions by bind ing to specific cell surface receptors 
(17) and thus require secretion into the extracellular compartment for some or all of its 
biological activity. Recently, it was hypothesized that Lc-1, as a mediator of the anti-
inflammatory effects of glucocorticoids, may function as a "barrier" to inappropriate 
inflammatory and autoimmune responses (lS). It has been shown in rats that physiological 
levels of endogenous glucocorticoids both have a pharmacological effect on Lc-1 and 
regulate Lc-l in the absence of inflammation (19). 
Lc-1 is present in abundance in lung homogenates. It can be detected in human BALF 
(20,21) suggesting that it is released onto the epithelial lung surface. Treatment with oral 
glucocorticoids can increase Lc-l both extracellularly (20) and in SAL cells (22). 
Additionally, nonspecific inflammatory stimuli such as paraffin oil and LPS may also 
upregulate Lc-l levels (13,23). To date, there have been no studies on the effects of 
inhaled glucocorticoids on cellular or extracellular Lc-1 levels in the lung of any species, 
even though this route of administration provides effective control of asthma symptoms 
for many subjects. Therefore, the present study was undertaken to investigate the effects 
of a) inhaled glucocorticoid therapy and b) cigarette smoke, a nonspecific inflammatory 
stimulus known to increase eicosanoid levels in BALF, on extracellular Lc-1 and a number 
of inflammatory parameters in the epithelial lining fluid of patients with allergic asthma. 
BALF was chosen as starting-material, as BAL has been proven to be an excellent and safe 
tool with which to study inflammatory aspects of lung diseases. 
MATERIALS AND METHODS 
STUDY A: SUBJECTS WITH ALLERGIC ASTHMA 
Patient characteristics 
Twenty-eight allergic asthmatic patients (8 women and 20 men; median age 41, range 21-62 yr), both 
smokers (1 woman and 9 men; median age 42, range 21-62 yr) and nonsmokers (ll men and 7 women; 
median age 40, range 25-61 yr) were randomly sampled in two participating centers, Groningen and 
Rotterdam, of the Dutch CNSlD study group (24,25). Patients who had stopped smoking at least 6 months 
before the start of the study were included in the nonsmokers group. The diagnosis of asthma was based 
upon a history of attacks of breathlessness and wheezing without chronic (I.e. for more than 3 months per 
year) cough or sputum production, according to the criteria of the American Thoracic Society (26). Allergy 
was defined as a positive skin prick test to house-dust mite or to at least two out of twelve other common 
aeroallergens (mean wheal size;::: 70% of the histamine wheal size (24)J. At entry to the study, all patients 
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showed airway hyperresponsiveness defined as a 20% decrease in FEV 1 caused by inhalation of a histamine 
concentration (PC201 of =:; 8 mg/ml (24). Baseline reversibility of all patients was ~ 10% of predicted. Patients 
were treated double-blind with the inhaled /32-a90nI5t terbutaline {2 puffs of 250 ~lg q.i.d,j plus either the 
inhaled glucocorticoid beclomethasone dipropionate (2 puffs of 100 l-I9 q.i.d.; n = 12, 6 smokers), the 
anticholinergic bronchodilator ipratropium bromide (2 puffs of 20 ~tg q.i.d.; n = 8, 2 smokers) or. placebo q.i.d. 
(n =8, 2 smokers), At the end of the study, no significant differences with regard to FEV1• PC20 Of any of the 
biochemical parameters studied were found between the groups using either the 1l2-agonist plus 
anticholinergic bronchodilator or the 1l2-agonist plus placebo. Therefore, their data were eventually pooled 
for analysis as one single group (n:=: 16,4 smokers). Patient characteristics are shown in Table 1. The study 
protocol was approved by the Medical Ethics Committee of all participating centers, and all patients gave 
written informed consent. Further detaifs of the study methods have been described previously (24). 
Table 1. Patient characteristics. 
Patient Sex~ Age Smoking Inhaled After 2.5 year 
number status glucocorticolds 
FEV, PC20 
(% predicted) (mg/ml) 
F 44 45.4 0.04 
2 M 45 63.2 0.05 
3 M 25 59.6 0.58 
4 M 26 59.0 0.02 
5 F 37 47.2 0.06 
6 M 57 68.0 0.04 
7 M 31 71.9 0.02 
8 M 32 67.5 0.13 
9 M 30 96.4 0.42 
10 M 38 44.6 0.02 
11 M 42 65.9 0.87 
12 M 50 54.0 0.18 
13 F 32 + 53.4 0.10 
14 M 61 + 91.7 5.38 
15 M 37 + 60.3 1.46 
16 F 45 + 86.9 0.45 
17 F 61 + 93.2 0.96 
18 F 45 + 70.4 0.21 
19 M 21 + 72.1 0.96 
20 M 36 + 65.2 0.70 
21 M 58 + 55.6 2.00 
22 M 48 + n.d.b n.d. 
23 M 54 + + 61.4 2.56 
24 M 40 + + 77.4 0.96 
25 M 29 + + 64.4 1.16 
26 F 62 + + 56.1 0.05 
27 M 43 + + 82.1 0.40 
28 M 31 + + 92.4 1.79 
a. M: male F : female b. n.d. : not determined 
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Bronchoalveolar lavage 
At the end of the 2,5 year study, BAL was performed 2 to 7 days after the last follow-up visit at which 
FEV 1 and PC20 were determined_ SAL was performed at the end of the 2,5 year study in the same period of 
year (between August and December) in both centers, before breaking the code, SAL was done 30 min after 
premedication with atropine (0,5 mg i,m,l and 2 puffs of 250)..lg terbutaline, Local anesthesia was achieved 
using a lidocaine (2%, w/vl spray_ The bronchoscope was placed in wedge position in the right middle lobe, 
Four aliquots of 50 ml sterile and prewarmed {37°CI phosphate buffered saline were instilled, and aspirated 
immediately into a siliconized specimen trap placed on iced water, Immediately after collection, BALF was 
strained through a sterile gauze to trap large mucus particles, after which the cells were separated from the 
fluid by centrifugation at 4°C and 400g. Differential cell counts of the SAL cells were done after May-
Grunwald Giemsa staining. Supernatants were stored at -70°C or lower until biochemical analysis. 
Quantitation of eicosanoids 
The following eicosanoids were assayed in BALF using radioimmunoassays as described previously (3): 
prostaglandin (PG) O2 , PGF2a , 6-keto PGF1<t- (a metabolite of prostacyclin, PGI 2), thromboxane (Txl 8 2 {a 
metabolite of TxA2}, leukotriene (L Tl 8 4, and L TC4 • 
STUDY B: HEALTHY SUBJECTS 
Subject characteristics 
Twelve healthy women (5 smokers, median age 37, range 31-44 yr; 7 nonsmokers, median age 31, 
range 24-45 yr), who denied symptoms of pulmonary diseases, were hospitalized for laparoscopy, They did 
not use any steroidal or nonsteroidal anti-inflammatory drugs. SAL was performed during general anesthesia 
for laparoscopy. The bronchoscope was introduced via the endotracheal tube, and placed in wedge position 
in the right middle lobe. From this point, BAL was performed as described above for the asthma patients. All 
women gave informed consent, and the protocol was approved by the local Medical Ethics Committee. 
BOTH STUDIES 
Protein analyses 
Lc-1levels were assayed using a sensitive, specific ELISA for human Lc-1 as described previously (27). 
Albumin and total protein were determined by rocket immuno-electrophoresis using specific polyclonal 
antisera (28) and the Lowry method (29), respectively. All analyses were performed blind to the clinical and 
treatment status of the subject. 
Statistical analysis 
For data from asthmatic subjects, an Analysis of Variance {AN OVAl was used where multiple conditions 
were compared. Variables for which significant differences were found or significant trends observed were 
also analysed by simple comparisons between groups using unpaired Student's t-tests. Data from healthy 
subjects were analysed by unpaired Student's Hest only. Relationships between parameters were examined 
using the Spearman Rank Correlation Coefficient. Statistical significance was taken as p < 0.05. Differences 
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which were statistically significant with unpaired t-test8 were also significant at the p < 0.05 level in a 
Mann-Whitney U test. 
RESULTS 
STUDY A: ASTHMATIC PATIENTS 
Cell and fluid recovery 
More lavage fluid was recovered from the lungs of glucocorticoid-treated non-smokers 
than from those not inhaling gluGocorticoids (Table 2), There were no other significant 
differences in fluid recovery between groups. 
More cells were present in the BALF from smokers than non-smokers and a higher 
proportion of the cells were AM in smokers; these differences were statistically significant 
when the data from the subjects receiving and those not receiving inhaled glucocorticoids 
were pooled, whilst the difference in cell number was also significant when the subjects 
not treated with glucocorticoids were considered alone. No significant differences were 
observed in either SAL cell number or cell profile between the groups treated with 
glucocorticoids and those receiving other treatments (Table 2). 
Table 2. Fluid and cell recoveries of BALF from asthmatic subjects. 
Smoking Steroid n Fluid 8AL cells AM 
status status Imll (x 106) (%) 
12 73130-1351 3.5 10.4-10.01 90162·981 
+ 6 123 165-1441' 11.010.9-31.01 82 (70-1001 
+ 4 85 160-1601 21.112.4-30.71"" 95 194·971 
+ + 6 98 160-1271 27.4 (4.0-41.8)11 97190-981 
Data are shown as median values with the limits of the range in parentheses. 
a. > untreated non-smokers, p <0.05, Student's t-test. 
b. > pooled data from non-smokers, p<O.05, ANOVA. 
Protein and albumin 
Concentrations of total protein and albumin were lower in BALF collected from 
glucocorticoid~treated asthmatic subjects than from asthmatic subjects given no 
glucocorticoids; these differences were statistically significant in smokers even though 
there was no difference in fluid recovery between these groups (Table 3). There were no 
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differences in albumin/total protein ratios between any of the groups. 
Table 3. Total protein, albumin and Ifpocortin-1 concentrations in BALF from asthmatic subjects. 
Smoking Steroid n Total protein Albumin Albumin/protein lc-1 
status status (~lg/m1) (flg/mll (fl9!rlg) (ng/mll 
12 130 (25-180) 28 (12-32) 0.20 (0.11-0.50) 3 (1-16) 
+ 6 91 (53-155) 28 (15-42) 0.28 (0.24-0.53) 5 (2-9) 
+ 4 223 (53-810) 44 (22-65) 0.23 (0.08-0.41) 13 (4-33)' 
+ + 6 76 (48-163)' 22114-39)' 0.24 (0.20-0.44) 7 (3-26) 
Data are shown as median values with the limits of the range in parentheses_ 
a. < untreated smokers, p<0.05, Student's t-test. 
b. > non-smokers, p <0.05, Student's t-test. 
Eicosanoids 
There was considerable inter-subject variation in the concentrations of the eicosanoids 
measured, particularly in PGD" TxB, and LTB, (Table 4). 6-Keto PGF'a varied significantly 
between groups, smokers having more of this prostacyclin metabolite in their BALF than 
non-smokers (Table 4). Furthermore, glucocorticoid-treated subjects who did not smoke 
had lower levels of L TC4 in their BALF compared to non-smoking patients receiving other 
treatments (Table 4). 
Table 4. Eicosanoid concentrations in BALF from asthmatic subjects. 
Smoking Steroid PGD2 PGF2" TxB2 lTC4 lTB4 6kPGF ta 
status status pg/mi pg/ml pg/ml pg/ml pg/ml pg/ml 
77 19 76 16' 75 16 
(20-200) (11-25) (1-141) (6-53) 121-138) (10-28) 
+ 35 14 41 7 32 12 
117-138) (7-36) (3-194) (1-12) (23-279) (7-21) 
+ 48 21 10 11 48 31' 
(27-54) (8-53) (1-112) (3-12) (10-1711 (15-66) 
+ + 31 14 38 13 97 28' 
(17-172) (10-29) (7-67) (5-16) (23-171) (10-62) 
Data are shown as medians with the limits of the range in parentheses. 
a. > non-smokers using inhaled glucocorticoids. 
b. > non-smokers from equivalent treatment groups, > non-smokers when ± steroid data pooled, p < 0.05, 
Student's t-test, ANOVA. 
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Lipocortin-1 
In asthmatic subjects who did not use inhaled glucocorticoids, extracellular Lc-1 was 
significantly greater in BALF from smokers than from non-smokers whether the data were 
expressed per unit of fluid recovered (Table 3) or as ratios over albumin (Figure 1 A) or total 
protein (data not shown). When the data Were expressed per million SAL cells, there was 
no significant difference between smokers and non-smokers (Figure 1 B). Interestingly, no 
significant difference between smokers and non-smokers in extracellular Lc-' (expressed 
ng/ml) was observed in the glucocorticoid-treated asthmatics (Table 3). In contrast to 
smoking, glucocorticoid treatment had no significant effect on extracellular Lc-1 (Table 3, 
Figure 1 A, B). 
Relationships between Lc-1 and other parameters 
When the data from all asthmatic subjects were pooled irrespective of smoking and 
treatment status, there was a significant correlation between BAL cell number and both 
total Lc-l (n~27, r,~0.825, p<O.OOl) and 6-keto PGF," (n~26, r,~0.565, p<O.Ol). 
When the data from only those asthmatic patients not taking glucocorticoids were 
pooled, there was a positive relationship between total Lc-1 and both fluid recovery (n = 15, 
r,~0.796, p<O.01) and BAL cell number (n~ 16, r,~0.821, p<O.OOl). Similarly, in the 
absence of exogenous glucocorticoid, there was a positive correlation between Lc-1 
concentration and both total protein (n~15, r,~0.574, p<0.05) and albumine (n~15, 
rs = 0.942, P <0.001) concentrations. Interestingly, in the subjects not receiving 
glucocorticoids, Lc-1 (however expressed) was inversely related to the PGD2 concentration 
(e.g. Lc-l/ml vs PGD,/ml, n ~ 15, r, ~-0.597, p < 0.05; Lc-l/albumin vs PGD,/ml, r, ~ 
-0.783, p<O.Ol). but to no other eicosanoid (Figure 2). Furthermore, in the subjects not 
inhaling glucocorticoids, positive correlations were found between FEV 1 and Lc-1 expressed 
as a ratio either over albumin (n = 15, rs = 0.471, P < 0.05) or over total protein (n = 15,rs = 
0.586, p <0.05). PC,o was also significantly correlated to Lc-l/albumin (n ~ 15, r, ~0.645, 
p<O.Ol) and Lc-l concentration (n~15, r,~0.720, p<O.Ol; Figure 3). In asthmatic 
patients receiving glucocorticoid treatment, none of these relationships was significant, 
except that between Lc-l and cell number (n ~ 11, r, ~ 0.838, p < 0.01). 
STUDY B: SUBJECTS WITH HEALTHY LUNGS 
Cell and fluid recovery 
Although there were no significant differences in fluid recovery between smokers and 
non-smokers with healthy lungs, significantly more BAL cells were recovered from smokers 
than from non-smokers (Table 5). Irrespective of smoking status, more than 90 % of the 
cells were AM. 
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Figure 1. Comparison of extracellular Lc-l 
in asthmatic and healthy smokers and non-
smokers. When lc-l was expressed per 
unit albumin (Figures lA and le) smokers' 
BALF contained significantly more Le-
l/albumin than non-smokers. When lc-l 
was standardised to BAL cell number 
(Figures 1 Band 10J there was no 
significant difference between asthmatic 
smokers and non-smokers (Figure 18), 
whilst healthy smokers had significantly 
less Lc-1/106 BAL cells (Figure 10J. There 
was no difference in Lc-l between 
asthmatic subjects who had been treated 
with inhaled glucocorticoid and those who 
had not. 
a. > non-smokers, 
b. < non-smokers using Student's t-test. 
Column heights represent median values, 
whilst the error bars represent the inter-
quartile ranges. 
Neither total protein nor albumin concentrations, nor albumin/total protein ratios 
differed significantly between smokers and non-smokers with healthy lungs ITable 5), 
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PGD2 in BAlF from asthmatic subjects not treated 
with inhaled glucocorticoid. lc-l/ml BALF data are 
shown as logarithms for ease of illustration. Data 
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Figure 3. Relationship between extracellular Lc-l 
in BAlF and PC20 of asthmatic subjects not 
treated with inhaled glucocorticoid. PC20 values 
were determined at the end of the 2.5 y study 
period. lc-l/ml BALF data are shown as 
logarithms for ease of illustration. Data from both 
smokers and non-smokers are included (n= 15). 
Table 5. Fluid. cell and protein recoveries in BAlF from subjects with healthy lungs. 
Smoking n Fluid BAL cells Total Albumin Albuminl Lc-1 
status (mil (x 106) protein (pglml) total protein (ng/ml) 
(~lg/mIJ (~lghlgJ 
7 125 6.5 115 34.5 0.313 7 
(110-160) (4.7-16.8) (95-148) (20.7-70.11 (0.175-0.5531 (5-101 
+ 5 130 46.6" 130 43.3 0.365 16' 
(90-1501 (30.0-71.01 (78-2121 (20.9-47.51 10.158-0.5551 (8-211 
a.> non-smokers, p<O.05, Student's t-test. 
lipocortin-1 
As in asthmatic patients, there was more extracellular Lc-1 in BALF from healthy 
smokers than non-smokers whether the data were expressed per millilitre (Table 5) or as 
a ratio to albumin (Figure 1C) or total protein (data not shown). However, in contrast to the 
asthmatic patients, there was significantly less extracellular Lc-1/1 0' BAL cells in the BALF 
from healthy smokers than from non-smokers (Figure 1 D). 
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Relationships between Lc-1 and other parameters 
When data from smokers and non-smokers was pooled, there was a strong positive 
correlation between total extracellular Lc-1 recovery and BAL cell number (n = 12, 
r,~O.9091, p<O.001), but no significant relationship with any other parameter. 
DISCUSSION 
In this study, we have demonstrated that, in both control subjects without lung disease 
and patients with allergic asthma, there is a positive relationship between extracellular Lc-1 
in BALF and BAL cell numbers. This relationship may explain why tobacco smokers have 
more extracellular Lc-1 in their airspaces than non-smokers and may suggest that SAL cells 
are the principle source of the Lc-1 found in respiratory tract secretions, even though other 
lung cell types contain and may secrete this protein as well (30,31). In addition, we 
observed that in the lung lavage of asthmatic subjects who were not treated with inhaled 
glucocorticoids, there was an inverse correlation between extracellular Lc-1 and the 
bronchoconstrictor PGD2, and a positive correlation between Lc-1 and both FEV I and PC20, 
suggesting that there may be a link between these variables. 
Lc-1 has been shown to have anti-inflammatory effects in a variety of in vivo and in 
vitro models, including some involving the lung (9). It has been suggested that one of the 
anti-inflammatory mechanisms of Lc-1 may be to reduce the activity of phospholipase A2, 
either directly or indirectly (9,12) and hence, the synthesis of inflammatory mediators 
derived from arachidonic acid. The inverse correlation between Lc-1 and the eicosanoid 
PGD2 observed here, would support this hypothesis, but the fact that none of the other 5 
eicosanaids measured in this study was similarly related to Lc-1, might suggest a rather 
more selective mechanism of action for the protein. PGD2 is a mediator which may 
contribute to the early bronchoconstrictive reaction following allergen challenge in allergic 
asthma (16) and thus, could be a determinant of BHR. This would be supported by the 
observation that the higher the PGD2, the more responsive the airways to histamine as 
measured by the PC zo (manuscript in preparation). Thus, this study suggests that, in allergic 
asthmatic subjects not given exogenous glucocorticoids, Lc-1 may contribute to protection 
of the airways from histamine-induced bronchoconstriction; one possible mechanism for 
this could be via PGD2 regulation. 
Le-1 is made both by secretory cells in the lung (30,31) and by AM (22,32). Thus, the 
increase in extracellular Lc-1 in smokers' BALF could result from increased production of 
respiratory tract secretions, from the raised macrophage population, from activation of Lc-
1-producing cells, or a combination of these possibilities. However, Lc-1/protein tended to 
be higher in asthmatic smokers than non-smokers (p =0.065) and was significantly higher 
in control smokers than non-smokers (p <0.05), suggesting that the increased extracellular 
Lc-1 was not due simply to a non-specific increase in protein secretion. The strong positive 
correlation between Lc-1 and BAL cell number in both healthy subjects and those with 
asthma, would suggest the macrophage as the major source of Lc-1 in the respiratory tract 
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secretions, supporting the hypothesis of Ambrose and colleagues (32) to this effect. 
Furthermore, there was no significant difference in extracellular Lc-1 /1 0 6 SAL cells from 
asthmatic smokers and non-smokers, again indicating that the extracellular Lc-1 is a 
reflection of SAL cell number in these patients. Interestingly, this was not the case in the 
non-asthmatic volunteers, since in this group smokers had significantly less extracellular 
Lc-l/1 0' cells than non-smokers. Thus, it may be that in the healthy lung of smokers each 
cell secretes less Lc-l, or that Lc-l is released only by a subpopulation of AM, but that the 
greater cell number means that extracellular Lc-1 rises. 
The regulation of Lc-1 secretion into the epithelial lining fluid is not fully understood. 
Oral glucocorticoids have been shown to increase both extracellular Lc-1 in BALF (20,21) 
and intracellular levels in BAL cells (22). In addition, two studies in glucocorticoid-depleted 
(adrenalectomized) rats have shown that Lc-l in peritoneal leukocytes and lung 
homogenates can be increased by non-specific stimuli, namely paraffin oil (13) and 
lipopolysaccharide (23). Thus, it is possible that tobacco smoke also non-specifically 
induces an increase in Lc-1 production and/or secretion. Alternatively, the increase in 
extracellular Lc-1 observed in the current study could result from circulating cortisol. 
However, it is unknown whether circulating cortisol is increased in smokers. Furthermore, 
it is known that the promoter sequence of the gene for Lc-1 has regions which are similar 
to those found in acute phase proteins (33), so other factors could contribute to the control 
of Lc-1 expression either directly, or indirectly. 
In the present investigation, levels of extracellular Lc-1 in asthmatic patients who had 
been taking inhaled glucocorticoids were not different from those in asthmatics who had 
not taken inhaled glucocorticoids, even though both total protein and albumin were reduced 
in these subjects, and significantly so in smokers. This suggests that whilst inhaled 
glucocorticoids reduced the levels of other proteins, Lc-1 levels were maintained, but, in 
contrast to previous studies using oral or intravenous glucocorticoids (20-22), were not 
elevated above control values. The doses administered by inhalation may be insufficient to 
stimulate Lc-1 synthesis or secretion, or the glucocorticoid may be deposited and act in the 
upper and central airways which are poorly represented by conventional BAL (34). 
Alternatively, it is possible that Lc-1 synthesis andlor release is not glucocorticoid-inducible 
in patients with allergic asth.ma. This seems less likely, since De Caterina et al (22) 
observed an increase in cellular Lc-1 in BAL cells from asthmatic subjects following 
treatment with oral glucocorticoids. Interestingly, there were no significant correlations 
between Lc-1, PGD2 and lung function parameters in glucocorticoid-treated subjects, such 
as those seen in no-steroid treated patients, supporting the hypothesis that inhaled 
glucocorticoids suppress respiratory tract inflammation by multiple mechanisms. The data 
presented in this paper suggest that one relevant mechanism may be the suppression of 
L Te, release (Table 4). A future longitudinal study in which BAL is performed in the same 
subject both before and after treatment with inhaled glucocorticoid should enable us to 
address this problem more fully. 
The concentrations of Lc-1 observed in BALF from subjects with healthy lungs in this 
study are significantly higher than those from another study on volunteers by one of us 
(34). Differences in the number of BAL cells recovered do not account for the differences 
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in Lc-1 between the two studies. Sex may be one relevant factor, as all the volunteers in 
the current study were female, whereas those in the earlier study were male. In addition, 
the use of general anaesthesia may have stimulated Lc-1 release from cells, whilst the 
posture of the subject during lavage may also have affected the relative proportions of cells 
and extracellular material recovered in the lavage fluid. 
Interestingly, the PGI2 metabolite 6~keto PGF ,u was significantly increased in smokers. 
This may be due to an increase in the parent compound, leading to more PGI2 available for 
metabolism. Alternatively, an increase in metabolic activity or in prostanoid-carrier systems 
compared to non-smokers may explain this finding. Ninety-five percent of circulating PGI2 
normally passes the pulmonary circulation without being metabolized; this may not be the 
case in smokers. If prostanoid-carrier systems or metabolic pathways are upregulated by 
smoking, more PGI2 may be captured and metabolized by the lung. 
In summary, we have observed an increase in extracellular Lc-1 in smokers which we 
hypothesize to be part of a self-protecting mechanism to limit respiratory tract 
inflammation. We have confirmed that inhaled glucocorticoids down-regulate total protein 
and albumin in BALF. Finally, we present preliminary evidence suggesting that Lc-1 levels 
may be related to improved FEV1's and PC 20 's in allergic asthma, perhaps via PGD2 
regulation. The effect of inhaled glucocorticoid on Lc-1, and the role of Lc-1 and PGD2 in 
the aetiology of allergic asthma, may be worthy of a more detailed investigation using 
subjects as their own control in a prospective, double blind longitudinal study. 
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Probably no other cell type is having a more important part in so many different 
physiological and pathological processes than mononuclear phagocytes (1-3). In concert 
with many other cell types, mononuclear phagocytes are able to initiate, perpetuate, and 
suppress inflammation (4,5). Inflammation is a major component of many diseases, and 
sometimes a patient needs treatment to relieve symptoms of inflammation. Anti-
inflammatory treatment aims to influence the function of cells participating in the 
inflammatory response. Glucocorticoids are clinically being used in the treatment of 
inflammatory diseases since 1949 (6), but their precise cellular and subcellular working 
mechanisms are still not known (7). The very opposite concerns the field of cytokines: 
starting from a more or less clear understanding of their cellular working mechanisms, 
cytokines are now beginning to be used in the treatment of patients (8,9). The studies 
presented in this thesis were aimed at, on the one hand, delineating cellular and subcellular 
working mechanisms of glucocorticoids at the level of mononuclear phagocytes, in order 
to understand their well-known anti-inflammatory properties. On the other hand, we studied 
in vitro effects of IL-4 on mononuclear phagocytes with the intention of evaluating possible 
in vivo roles and therapeutical applications of IL-4. 
IL-4 was initially described to influence the differentiation of resting 8 cells. Nowadays 
we know that the function of many other cell types can be modulated by IL-4. Its influence 
on mononuclear phagocytes concerns various functional aspects. Some of these influences 
are transient, whereas others have a more prolonged or permanent effect. In the 
investigations presented in this thesis, IL-4 effects were studied in, as best as possible, 
homogenous cell populations which were cultured under serum-free conditions. Therefore, 
the IL-4 effects observed here under well-defined conditions could not be attributed to 
unidentified serum factors or products of other cell types. The effects of IL-4 on 
mononuclear phagocytes can be subdivided in 3 main groups. 
First, IL-4 affects the process of maturation in vitro. In the presence of IL-4, blood 
monocytes acquire morphological characteristics of the more mature macrophages: they 
increase greatly in cell size with a higher cytoplasm to nucleus ratio, and develop 
cytoplasmic protrusions. Furthermore, IL-4 induces a more mature immunophenotype: the 
expression of CD14 Ag is decreased, whilst the expression of RFD9 Ag is upregulated. 
Acid phosphatase, another marker of mononuclear phagocyte maturation, is also induced 
by IL-4. These maturation-associated changes appeared to be permanent. 
Second and concomitant with the induction of maturation, cell surface markers 
associated with activation of mononuclear phagocytes are affected by IL-4. The 
upregulation of MHC class II, CD13 and CD23 Ag may have important functional 
implications. The increased expression of class II Ag may explain the IL-4-induced increase 
in antigen-presenting capacity observed by others. An increased IgE-mediated cytotoxic 
activity may result from the IL-4-induced increase in FCERllb (CD23) expression. The IL-4-
mediated increase in CD13 Ag expression is accompanied with an enhanced aminopepti-
dase activity, through which cells may be turned into better processors of protein 
mediators. In line with this postulated function of aminopeptidase-N, this enzyme was 
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shown recently to degrade IL-8 and inactivate its chemotactic activity in vitro (10). All 
these effects of IL~4 on mononuclear phagocytes appeared transient and reversible, in 
contrast to the prolonged maturation-associated actions of IL-4. 
Third, IL-4 decreases the production of various mediators by mononuclear phagocytes, 
suggesting reduction of activation. In our studies, we showed a transient downregulation 
of the expression of the IL-l P gene in cultured human AM, whilst others observed an IL-4-
mediated inhibition of the secretion of IL-1P, IL-6, IL-8 and TNF-a, and an upregulation of 
IL-l RA. These findings can be interpreted as potential anti-inflammatory actions of IL-4. 
These three different aspects of IL-4 actions on mononuclear phagocytes stress the 
pleiotropy of cytokines, but they interfere with a clear idea of the in vivo effects of IL-4: 
how is an organism to cope with a cytokine that exhibits both activating and de-activating 
actions. In this matter, it is important to realize that the above-mentioned effects of IL-4 
were observed in a definitely inadequate model of the in vivo situation: effects of a single 
cytokine were studied on an isolated cell population, whereas in vivo, IL-4 will act in 
concert with a wide range of cytokines and other mediators. Additionally, influences 
mediated via either direct cell-cell or cell-matrix contact may be important in vivo. Future 
studies have to concentrate also on the latter aspects of cytokine effects, in order to really 
get to the bottom of the function of IL-4 in vivo. A glimpse of the in vivo complexity is 
exemplified by our finding that the IL-4 effects depend on the stage of maturation of 
mononuclear phagocytes (Table 1). 
Table 1. Differential effects of IL·4 on the expression of CD13 and CD23 Ag In human mononuclear 
phagocytes In different stages of maturation. 
Cell membrane 
Ag 
C013 
C023 
a. no effect on expression. 
b. increased expression. 
immature 
monocytic cell tines 
t 
peripheral 
blood monocytes 
t b 
t 
alveolar 
macrophages 
t 
Some effects of IL-4 may be therapeutically useful, whereas other actions may be 
considered as unwanted "side" effects. The anti-inflammatory effects of IL-4 are receiving 
a lot of attention from clinical immunologists (11-13). Recent studies showed that IL-4 
inhibited arthritis in bacterial cell wall-induced erosive polyarthritis in rats (1 2). Another 
study in rats showed protective effects of IL-4, and also IL-10, against experimental 
immune complex-induced lung injury (13). IL-13 has been suggested to be an anti-
inflammatory cytokine similar to IL-4 (14). Clinical application of IL-4, and anti-inflammatory 
cytokines in general, may depend on the selection of beneficial effects, which may be 
achieved by creating a particular context for IL-4. 
All the observed effects of IL-4 result from the modulation of gene expression. To 
achieve this, the binding of IL-4 to specific IL-4R on the cell membrane has to be linked to 
nuclear processes. As IL-4 itself is unable to pass the cell membrane, a cellular signalling 
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pathway is needed to transmit the extracellular presence of IL-4 to the nucleus. The first 
step in this signalling process is the binding of IL-4 to its cell membrane receptor. This IL-
4R falls into a large family of structurally related receptors for cytokines (15). The IL-4R is 
a heterodimer, and its yC chain is also utilized by other members of the receptor family (lL-
2R, IL-7R, and probably IL-9R and IL-13R). Upon binding of IL-4 to its receptor, the 
activation of (receptor-associated), intracellularly located, tyrosine kinases is induced. This 
may lead to the phosphorylation and activation of a cascade of other kinases, eventually 
resulting in the activation of transcription factors. Some transcription factors may be 
activated by kinases in the nucleus. Others may be activated in the cytoplasm, after which 
they are transported to the nucleus. In the nucleus, activated transcription factors may, 
either alone or in concert, modulate the transcription of target genes. 
Modulation of transcription is also the base of the cellular effects induced by 
glucocorticoids. Unlike cytokines, glucocorticoids are able to pass the cell membrane 
without the help of specific receptors on the cell surface. The binding of glucocorticoids 
to their intracellular receptors activates these receptors to interact as homodimers with 
specific DNA sequences. Eventually, this interaction results in modulated transcription of 
particular target genes. 
In the studies presented here, it was shown that glucocorticoids affect mononuclear 
phagocytes in vitro. Therefore, the clinical effects of glucocorticoids may be mediated, at 
least partially, via similar actions on this cell type. Characteristics of maturation (expression 
of acid phosphatase, RFD9 Ag and CD14 Ag) and activation !lL-1P gene expression} were 
found to be inhibited by glucocorticoids. Sometimes, a clear distinction between the 
influences of glucocorticoids on these two cellular processes is difficult. One explanation 
may be that, upon maturation, responsiveness to activation signals is acquired. Conse-
quently, glucocorticoid-mediated inhibition of maturation can also inhibit activation. This 
interrelation can be discussed in the light of two recent studies (16,17). Maturation of the 
monocytic cell line U937 can be induced by phorbol esters (PMA or TPA). In one study, 
TPA was shown to inhibit cell proliferation and to induce cell clustering and the release of 
lysozyme, reactive oxygen radicals, and prostanoids (16). Furthermore, TPA down-
regulated the expression of the proto-oncogens c-myc and c-myb, which is related to 
maturation of hematopoietic cell lines (16). Dexamethasone inhibited the effects of TPA on 
cell clustering, and the production of lysozyme, oxygen radicals, and prostanoids. However, 
the TPA-mediated effects on cell proliferation and the expression of c-myc and c-myb were 
unaffected by dexamethasone. It was concluded that glucocorticoids interfered with TPA-
induced functions of U937, which are typical for activated mononuclear phagocytes, whilst 
maturation and concomitant growth inhibition were not impaired. Another study showed 
that PMA inhibited proliferation of U937 cells, and induced morphological changes 
(cytoplasmic extensions) and adherence to plastic (17). Cortisol mainly inhibited the PMA-
induced morphological changes and reduced the proportion of cells that became adherent. 
Cell proliferation was only partially reduced. PMA-treated cells could be activated with LPS 
to express IL-1 p mRNA, whereas untreated cells could not. Cortisol inhibited this LPS-
induced expression. It was concluded that glucocorticoids inhibited some characteristics 
of maturation and activation of U937. 
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In spite of the different models used in these two studies and ours to investigate the 
influence of glucocorticoids (the effects of dexamethasone or cortisol on either TPA-, or 
PM A-treated U937 celis, or IL-4-treated PBM), it may be concluded that inhibition of 
maturation and activation of mononuclear phagocytes is one of the cellular working 
mechanisms of glucocorticoids. However, some glucocorticoid actions may be difficult to 
classify as either a maturational or an activational effect, which underlines our inadequate 
knowledge of these cellular processes. 
It is recognized nowadays that a whole range of transcription factors, including 
activated glucocorticoid receptors, may be involved in the regulation of gene transcription. 
Recent studies on the working mechanisms of glucocorticoids revealed that the 
glucocorticoid-mediated transrepression of the collagenase gene can be explained as a 
result of the interaction with AP-1 (18-20; for a recent review 21). This repression occurs 
without signs of glucocorticoid receptor binding to DNA, contrary to glucocorticoid-
mediated gene modulation through positive or negative glucocorticoid response elements 
(GRE). Moreover, this repression is a function of receptor monomers, whilst dimers of 
glucocorticoid receptors are required for binding to GRE. This was demonstrated in a recent 
study that described the use of point mutations in the D-Ioop region in the second zinc 
finger of the glucocorticoid receptor (Figure 1) (22). 
'" 
'" 
Figure 1. Schematic detail of the DNA-binding domain of the glucocorticoid receptor showing the two zinc 
fingers, and the amino acids relevant to the functions of this domain. Numbers refer to the sequence of the 
amino acids in this part (adapted from reference 19). 
C : cysteine 
N : amino-terminal part of the domain 
Zn : zinc 
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This region plays an important part in the dimerization of receptors and, consequently, in 
the binding to GRE. Dimerization was prevented as a result of the point mutations, but the 
ability to repress AP-1 activity was unaffected. Therefore, gene modulation via GRE binding 
and transrepression via AP-l interaction appear to be related to distinct regions of the 
glucocorticoid receptor. Furthermore, the choice of the ligand may also determine the kind 
of glucocorticoid effect: certain glucocorticoid analogues (e.g. RU 38486) that are able to 
bind to the glucocorticoid receptor, are unable to induce binding of the receptor to GRE. 
This explains the reduced or absent transactivation activity. However, these analogues still 
mediate the AP-1-associated transrepression, which demonstrates again that DNA binding 
is not required for this type of transrepression. These findings suggest that upon ligand 
binding, the changes in 3-dimensional structure of the receptor depend on the type of 
glucocorticoid analogue. The ultimate 3-dimensional structure determines whether the 
receptor is capable of interaction with either, as a dimer, GRE or, in monomeric form, 
certain transcription factors. This may enable us to develop synthetic glucocorticoids with 
more specific effects or without the most serious side effects, and thus may have an 
important impact on the clinical use of glucocorticoids. 
FUTURE STUDIES 
The concerted actions of a great variety of different cell types are essential in the 
initiation and perpetuation of the chronic airway inflammation of asthma. Today, the 
importance of cytokines in these cellular interactions is an accepted fact (23). Furthermore, 
there is increasing recognition that certain genes are important in the pathogenesis of 
asthma and the regulation of allergic responses. Recent studies suggest that several genes 
on chromosome 5q are central in the control of IgE production and inflammation in asthma 
(24). This part of chromosome 5 contains the genes encoding IL-3, IL-4, IL-5, IL-9, IL-13, 
GM-CSF and M-CSFR. Inhibition of the action of these cytokines may down-regulate the 
different aspects of the inflammatory processes in asthma. At the protein level, this 
inhibition may be realized with cytokine-antagonists or other (anti-inflammatory) cytokines, 
and may be important for a better treatment of asthma in the future (25). At the mRNA 
level, specific modulation of the expression of one (or a combination) of these genes on 
chromosome 5q is another promising therapeutic target. This may be realized by synthetic 
glucocorticoids more selective than the currently used glucocorticoids, or other transcrip-
tion factors. 
We showed that IL-4 is able to modulate phenotype and function of mononuclear 
phagocytes. Some effects of IL-4 result in an enhanced cellular capacity to process proteins 
(mediated by cell surface aminopeptidase-N) or a decreased IL-lp gene expression, and are 
therefore potentially anti-inflammatory. The physiological role of the IL-4-mediated increase 
in aminopeptidase-N expression is unknown, but it may be involved in the down-regulation 
of other cell membrane proteins, the degradation or activation of protein mediators (1 0), 
and the degradation of extracellular matrix (26). Aminopeptidase-N (26), together with 
other cell membrane proteases {27,28L has been suggested to playa role in the invasion 
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and metastasis of tumor cells. From the findings presented in this thesis it may be 
hypothesized that IL-4 in the micro-environment of tumor cells may lead to modulation of 
their metastatic properties. Recently it was found that aminopeptidase-N degraded IL-8 
(10). It would therefore be interesting to study whether IL-4-treated monocytes or 
macrophages are better in activators of IL-8 than untreated cells. 
It may be hypothesized that in vivo IL-4 modulates IL-B-mediated chemotaxis of 
neutrophilsvia the upregulation of aminopeptidase-N expression. Future studies should also 
focus on the clinical application of these aspects of IL-4, and antHnfiammatory cytokines 
in general. In the treatment of many diseases, new and more specific anti-inflammatory 
drugs are needed. Such drugs may be used in stead of, or in combination with, currently 
available drugs in order to reduce side-effects of the latter. More basic in vitro studies will 
be needed to get to the bottom of the complex in vivo phenomena, always fully 
understanding that interpretation of an isolated in vitro result demands an in vivo context. 
We also studied effects of glucocorticoids on mononuclear phagocytes. Future studies 
on the working mechanisms of these potent anti-inflammatory drugs should focus on their 
role in the regulation of gene expression. In the treatment of diseases, doctors daily 
encounter examples of abnormal cell function resulting from disrupted gene expression. 
They therefore need tools to modulate the relevant cell function. In the future, these tools 
will be increasingly based upon modulation of the genetic information and its expression 
in cells (29,30), although some physicians caution for too much enthusiasm (31). For a few 
diseases, such as cystic fibrosis, gene therapy has already become a reality in the 
experimental setting (32). Insight in the interaction mechanisms of the four major classes 
of transcription factors with DNA is growing and will help to develop new tools (33). 
Studies on the fUnctions of the heat shock proteins associated with the glucocorticoid 
receptor, studies on the process of receptor dimerization and on the interactions with other, 
known and unknown, transcription factors will eventually lead to new and better ways to 
modulate cell functions with glucocorticoids. The recent finding that certain glucocorticoid 
analogues prevented interaction of the glucocorticoid receptor with GRE, but did not 
influence the interaction with AP-1, may be a base for the development of more specific 
glucocorticoids (22). 
In some patients with asthma, glucocorticoids do not bring about the expected 
improvement in clinical symptoms (34). This clinical unresponsiveness may result from a 
defect in the cellular response to glucocorticoids (35-37). A recent study showed that a 
reduced number of glucocorticoid receptors available for GRE binding may underlie the 
phenomenon of glucocorticoid resistant asthma (38). The presence of an excess of AP-l 
or NF-KB interacting with glucocorticoid receptors was suggested to cause the reduced 
number of receptors available for binding to DNA (38). Therefore, modulation of the 
expression of additional transcription factors may indirectly lead to altered glucocorticoid 
responsiveness. These findings stress the importance of studies on the regulation of gene 
expression in lung diseases. 
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SUMMARY 
Since time immemorial, people are trying to influence the course of diseases. History 
tells us that insight into pathological processes usually resulted in better ways to cure 
patients. The reaction of our body against its own or foreign structures is nowadays better 
understood than some decades ago, thanks to many immunological, biochemical and 
molecular-biological achievements. At this moment, we believe that both the presentation 
of antigens and cellular interactions are important components of this reaction of our body. 
Under certain conditions, mononuclear phagocytes are able to initiate, to perpetuate or to 
inhibit this reaction. Therefore, mononuclear phagocytes are thought to play an essential 
role in the development of various diseases, including many lung diseases. The latter is 
easy to understand, as the lung is in close contact with the potentially hostile external 
world with numerous pathogenic micro-organisms and foreign substances, from which lung 
diseases may originate. As a consequence of this, processes are initiated continuously in 
which mononuclear phagocytes playa role. Great numbers of mononuclear phagocytes, 
represented by interstitial monocytes/macrophages, dendritic cells and alveolar 
monocytes/macrophages, are present in the lung. Manipulation of the function of these 
cells may enable us to influence the development of lung diseases and to cure lung 
patients. 
The base of this thesis is the inflammatory process in the airways of asthma patients. 
At present, we know that the airway inflammation in asthma is chronically presenC 
although the seriousness may vary in time. Furthermore, it is known that this chronic 
airway inflammation underlies the bronchial hyperresponsiveness which gives rise to the 
characteristic symptoms of asthmatic patients. We understand that a variety of different 
cell types (mononuclear phagocytes, T celis, neutrophils, eosinophils, mast cells and 
epithelial cells) is important in the initiation and perpetuation of this chronic airway 
inflammation. Mononuclear phagocytes are thought, however, to playa central role, 
because of their numerous different cell functions, e.g. their ability to modulate the 
function of many other cell types. At the beginning of this study, we intended to gain more 
insight in the functions of mononuclear phagocytes, in particular the functions that are 
important in the chronic airway inflammation in asthma. Furthermore, we wanted to study 
both established and new ways to influence these cell functions. On the one hand, we 
wanted to study the working mechanisms of glucocorticoids. They are being used in the 
treatment of asthma since 1950, but their working mechanism is still not known precisely. 
On the other hand, we aimed to study the effects of cytokines, which are known to play 
a role in the intercellular communication and the modulation of cellular functions. The 
ultimate goal of this thesis was to gain insight in the modulation of cell functions of 
mononuclear phagocytes, which may be useful in the treatment of asthma patients. 
Modulation of mononuclear phagocytes' functions which is theoretically beneficial in the 
treatment of inflammation, may indeed turn out to be important in the treatment of airway 
inflammation and the related symptoms in lung patients. 
Chapter 1 gives a summary of the present knowledge with regard to mononuclear 
phagocytes, cytokines and glucocorticoids. At the end of the last century, the 
phagocytosing capacity of macrophages was described. For a long time, it was thought 
that phagocytosis was the only function of macrophages. Nowadays we know that 
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mononuclear phagocytes have many important functions, e.g. their ability to modulate 
immunological reactions. Both the importance and the therapeutical modulation of 
mononuclear phagocytes' function in a variety of diseases are studied in many centers. The 
history of cytokines is shorter compared with macrophages, but their powerful influence 
on many physiological processes was recognized directly after their discovery. Cytokines 
are essential in the communication between cells and their concerted actions. As a result, 
cytokines may be used to influence pathological processes. The clinical use of cytokines 
is still in its infancy, but is promising. In contrast, gluGocarticoids are being used clinically 
since their first application in the treatment of rheumatoid arthritis in 1950. However, their 
working mechanism is still not known precisely, although it is thought that their function 
as modulators of the expression of a great variety of genes of known (e.g. cytokines) and 
probably also unknown proteins, is the most important. In chapter 2, the most important 
and presently known anti-inflammatory working mechanisms of glucocorticoids are 
described. 
Chapter 3 is a summary of the background of the experiments which are described in 
the chapters 4, 5 and 6. 
In chapter 4 it is shown that certain functions of mononuclear phagocytes can be 
modulated by cytoklnes. Alveolar macrophages are abundantly present in the lung, and the 
majority of these macrophages is derived from peripheral blood monocytes. These blood 
monocytes undergo many changes during their migration from the vasculature to the alveoli 
via the interstitial compartment. Part of these changes may be regarded as maturation. 
During this process of maturation, the expression of cell surface {glyco)proteins may be 
affected. The presence of these (glyco)proteins can be visualized with the use of specific 
monoclonal antibodies. The most important differences in the expression of cell membrane 
{glyco)proteins between blood monocytes and alveolar macrophages concern the CD14 and 
RFD9 antigens: the majority of blood monocytes exhibits a high and very low expression 
of the CD14 and RFD9 antigen, respectively, whereas the inverse is related to alveolar 
macrophages (chapter 4. 1). We conclude from these findings that the maturation of blood 
monocytes to alveolar macrophages is associated with the loss and appearance of CD14 
and RFD9 antigens, respectively. In chapter 5.1 it is described that these maturation-
associated changes in monocytes can also be observed during in vitro culture. IL-4 is 
shown to accelerate these changes in vitro. These findings support the hypothesis that 
maturation of mononuclear phagocytes in vivo is modulated by environmental factors. 
Possibly, IL-4 also plays a role in the in vivo maturation. Furthermore, these findings 
suggest that the use of IL-4 or anti-IL-4 may be therapeutically useful. Another interesting 
in vitro effect of IL-4 on mononuclear phagocytes is the upregulation of the expression of 
aminopeptidase-No Both blood monocytes and alveolar macrophages express this enzyme 
on the cell membrane. It can be detected with specific CD13 monoclonal antibodies, and 
its activity can be demonstrated with a specific enzyme assay. IL-4 increases the 
expression of this enzyme on the cell membrane of both blood monocytes and 
macrophages. This increased expression is associated with an increased functional activity 
of aminopeptidase-N (chapter 4.2). IL-4 also induces an increase in the mRNA encoding 
aminopeptidase-N in both blood monocytes and alveolar macrophages. As this peptidase 
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may be important in the inactivation of inflammatory mediators, IL~4 may indirectly enhance 
the anti-inflammatory properties of monocytes and macrophages via an increase in the 
activity of aminopeptidase-No In summary, we found that IL-4 on the one hand accelerates 
the maturation of mononuclear phagocytes, and on the other hand activates these cells 
resulting in the increased activity of aminopeptidase-No The latter IL-4-mediated activation 
could also be observed in endothelial cells (chapter4.2). However, this is not a generallL-4 
effect, as IL-4 did neither induce nor increase the expression of CD13 antigen in the 
precursor cells of blood monocytes. It was interesting to observe that these precursor cells 
were still responsive to IL-4, and therefore must possess functional IL-4 receptors {lL-4RL 
because FC6Rllb could be induced in these cells by IL-4. FC6Rllb could also be induced by 
IL-4 in blood monocytes, but not in alveolar macrophages. Therefore, also the maturation 
stage of a certain cell type, in addition to the presence of fUnctional cytokine receptors, 
seems to determine whether it will respond to a particular cytokine or not. 
In chapter 4. 4 another aspect of the maturation of mononuclear phagocytes is studied. 
Cell proliferation can be determined thanks to the presence of a nuclear antigen in 
proliferating celis, which can be detected with the monoclonal antibody Ki-67. A very smali 
subpopulation of blood monocytes exhibited proliferative activity. The percentage of 
proliferating alveolar macrophages was also small, but still larger than proliferating blood 
monocytes. These results were unexpected, as it is generally thought that cell maturation 
is associated with a reduction in proliferative activity. Therefore, lung tissue appears to 
create a micro-environment for mononuclear phagocytes which stimulates proliferation. 
This proliferation-inducing micro-environment seems to be determined by colony-stimulating 
factors, in particular GM-CSF. If the physiological pulmonary micro-environment really 
determines proliferation of mononuclear phagocytes, lung diseases may change it: in 
sarcoidosis, we found a higher percentage of proliferating alveolar macrophages, which 
may be hypothesized to result from an increase in the local levels of GM-CSF. 
In chapter 5 the effects of glucocorticoids on mononuclear phagocytes are described. 
As mentioned above, in chapter 5.1 it is shown that IL-4 is able to accelerate the 
maturation of blood monocytes. Maturation was studied by means of several parameters 
as will be mentioned later. Glucocorticoids are shown to inhibit maturation: morphologically 
they inhibited the stretching of monocytes, the increase in the cytoplasmic expression of 
acid phosphatase, and on the cell membrane the increase and decrease in expression of 
RFD9 and CD14 antigen, respectively. In addition, glucocorticoids inhibited the accelerating 
influence of IL-4 on the maturation. Therefore, the regulation of monocyte/macrophage 
functions appears to be the result of the interaction between immunological factors and 
hormones. In chapter 5.2 it is described that at least part of the anti-inflammatory effects 
of glucocorticoids may be mediated via a decrease of the gene expression of IL~1f3. This 
mechanism has been described previously with regard to blood monocytes. Our results 
support the idea that it is valid to apply glucocorticoids in the treatment of lung diseases 
in which inflammation is induced or perpetuated by IL-1 f3 produced by alveolar 
macrophages. In the same study it is shown that also IL-4 inhibited the IL-1P gene 
expression, possibly even better than glucocorticoids. Both this effect of IL~4 and the IL-4-
induced increase in aminopeptidase-N activity are indications that some IL-4 effects are 
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anti-inflammatory. The clinical application of these anti-inflammatory effects of IL-4 may 
be realized in the near future. It may concluded from the results described in the chapters 
5.1 and 5.2 that IL-4 and glucocorticoids may have either antagonizing or similar effects, 
but it depends on the cellular parameter studied which of the two effects will be observed. 
In cIJapter 5.3 another aspect of the anti-inflammatory working mechanisms of 
gluGocorticoids is studied. Here it is described that in alveolar macrophages the expression 
of lipocortin-1 mRNA is increased by glucocorticoids. Under the same experimental 
conditions, this effect of glucocorticoids was accompanied by a decrease in IL-1 p gene 
expression. In this chapter, it is also shown that the glucocorticoid effects on lipocortin-1 
and IL-1 p gene expression also differ with regard to their kinetics. Almost all the cellular 
effects of glucocorticoids described in the literature demand the presence of functional 
glucocorticoid receptors. This prerequisite has been discussed in chapter 2 in great detail. 
It has been unclear for a long time, because of technical problems, whether alveolar 
macrophages express specific and functional glucocorticoid receptors or noLln chapter 5.4 
it is described and shown conclusively that human alveolar macrophages actually express 
specific glucocorticoid receptors. 
It is studied in chapter 6 whether glucocorticoids used in the treatment of patients 
induce cellular effects similar to the effects observed in our in vitro experiments. In chapter 
6.1 it is shown that the expression of various cell membrane antigens of blood monocytes 
from allergic asthmatics, who were treated with inhaled glucocorticoids for 2.5 years, 
differs from healthy volunteers or patients treated with P2-agonists or placebo; the 
expression of CD13, CD14 and CD18 antigens was higher in the patients treated with 
glucocorticoids than in healthy volunteers. In contrast, CD11 b antigen expression was 
lower. Furthermore, CD14 antigen expression was significantly higher in the patients 
treated with inhaled glucocorticoids compared with the patients treated with P2-agonists 
or placebo. These findings seem to indicate that inhaled glucocorticoids have systemic 
effects, at least on blood monocytes, in addition to their local effects. Future studies are 
needed to find out whether these observed effects on blood monocytes are an important 
part of the clinical anti-inflammatory effects of inhaled glucocorticoids. In chapter 6.2 
various substances are studied in the bronchoalveolar lavage (BAL) fluid of the same 
patients described in chapter 6.1. The positive correlation between the levels of lipocortin-1 
and the numbers of cells in the BAL fluid appeared to be an important finding. Furthermore, 
the concentration of a arachidonic acid metabolite, the bronchoconstrictor PGD2 , was found 
to be inversely related to Iipocortin-1 levels. We have interpreted this as a possible sign for 
an anti-inflammatory role of Iipocortin-1 in the lung. We also found that smoking patients 
had more Iipocortin-1 in their BAL fluid than non-smoking patients, and this positive 
correlation between smoking and increased levels of Iipocortin-1 was also demonstrated 
in nonasthmatic, healthy volunteers. This may be explained by the fact that smokers have 
more cells in their BAL fluid. Lipocortin-1 may have anti-inflammatory properties, and its 
increased levels in smokers may therefore inhibit the pro-inflammatory effects of cigarette 
smoke on the airways. In this way, our body seems to cope locally with the noxious 
components of cigarette smoke. In this study, we could also demonstrate that treatment 
with inhaled glucocorticoids was associated with a lower concentration of total protein and 
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albumin in the BAL fluid, whereas levels of lipocortin-1 were unaffected. This may suggest 
that inhaled gluGocorticoids actively maintain the levels of Iipocortin-1 f whilst other protein 
components in SAL fluid are downregulated. 
In conclusion, the studies described in this thesis show some new insights in the 
working mechanisms of gluGocorticoids and IL-4 with regard to their influence on 
mononuclear phagocytes. Both cellular maturation and activation are modulated by 
gluGocorticoids and IL-4. The effects of gluGocarticoids and IL-4 on activation are 
comparable, but their effects are opposite with regard to maturation. Starting-point of the 
studies was the question whether the course of lung diseases could be influenced by 
interference in the cellular functions of mononuclear phagocytes. The clinical use of 
glucocorticoids in those lung diseases in which mononuclear phagocytes play a pro-
inflammatory role, is supported by our in vitro findings. More clinical and basic research is 
needed to investigate whether IL-4, alone or in combination with other agents, can be 
applied in a way similar to glucocorticoids. In the treatment of patients, including lung 
patients, clinicians are trying increasingly to modulate cell functions. These functions are 
largely determined by the genetic constitution of the cells. Future lung research should 
include studies on the regulation of the expression of the relevant genes, e.g. with drugs 
like glucocorticoids and cytokines. 
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Summary in Dutch 
Sinds mensenheugenis tracht men ziekteprocessen te be'invloeden. De geschiedenis 
leert ons dat meer inzlcht in een ziekteproces veelal ertoe leidde dat men beter in staat 
bleek een dergelijk proces ten goede te keren. De reactle van ons lichaam op 
lichaamsvreemde structuren, en ook die op lichaamseigen componenten, wordt 
tegenwoordig, dankzij talloze immunologische, biochemische en moleculair-biologische 
"wapenfeiten", beter begrepen dan enkele decennia geleden. Men veronderstelt 
tegenwoordig dat antigeen-presentatie en cellulaire interacties belangrijke onderdelen zijn 
van die reactie. Mononucleaire fagocyten zijn, onder bepaalde omstandigheden, in staat een 
dergelijke reactie te initieren, te onderhouden, of te remmen. Er wordt dan ook gemeend 
dat mononucleaire fagocyten een essentiele rol spelen in het ontstaan en het beloop van 
sommige ziekten. Onder die ziekten zijn vele longaandoeningen. Dit laatste is onder meer 
begrijpelijk, omdat onze longen organen zijn die in direct contact staan met de buitenwereld 
en derhalve continu bloot staan aan potentieel ziekmakende micro-organismen en 
lichaamsvreemde stoffen. Hierbij worden onophoudelijk reaeties opgeroepen waarbij 
mononueleaire fagoeyten een rol spelen. In de longen komen grote aantallen mononucleaire 
fagocyten voor in de vorm van interstitiele monocyten/maerofagen, dendritische cellen en 
alveolaire monocyten/maerofagen. Be'invloeding van deze cellen biedt de mogelijkheid om 
het beloop van longziekten te be'invloeden e,q. patienten met longaandoeningente genezen. 
In dit proefschrift is het onderliggende ontstekingsproces zoals dat aanwezig is in de 
luehtwegen van astmapatienten als uitgangspunt genomen. We weten dat dit 
ontstekingsproees eigenlijk ehroniseh aanwezig is bij deze patienten, hoewel in de tijd de 
ernst ervan kan fluctueren. Deze ehronisehe ontsteking wordt tevens verantwoordelijk 
geaeht voar de bronchiale hyperreaetiviteit welke zo kenmerkend is voor het 
klachtenpatroon van astmapatienten. We beseffen dat een breed scala van verschillende 
eeltypen (mononucleaire fagoeyten, T-Iymfocyten, neutrofiele en eoslnofiele granulocyten, 
mestcellen en epitheel) van belang is bij het ontstaan en in stand houden van deze 
ehronische luehtwegontsteking. Een centrale rol in dezen wordt toebedeeld aan 
mononucleaire fagocyten, gezien hun vele funeties, waaronder hun vermogen de functies 
van andere celtypen te be'invloeden. Aan het begin van deze studie stond ons voor ogen 
om eigenschappen van mononuclaire fagoeyten te bestuderen, Met name die 
eigenschappen die Van belang zouden kunnen zijn voor hun functioneren in het hierboven 
genoemde ontstekingsproces. Daarnaast werd grote waarde gehecht aan het verkrijgen van 
inzicht in de mogelijkheden tot be'invloeding van die eigensehappen, Enerzijds door 
glueoeortieo'iden die al sinds 1950 bij astma worden gebruikt, maar waarvan het 
werkingsmeehanisme nog deels onopgehelderd is. Anderzijds door cytokinen waarvan thans 
wordt gedaeht dat zij een grote rol spelen in de intercellulaire communicatie en be'invloeding 
van cellulaire funeties, Uiteindelijk doel van deze studie was om een beter inzieht te krijgen 
in de be'invloeding van de funeties van mononueleaire fagocyten, waarvan bij de 
behandeling van astmapatienten gebruik gemaakt zou kunnen worden, De be'invloeding van 
funeties van mononuelaire fagocyten die theoretiseh een gunstige uitwerking op ontsteking 
heeft, kan immers van belang zijn voor de behandeling van het ontstekingsproces in de 
luehtwegen en de daarmee samenhangende klaehten. 
In hoofdstuk 1 wordt een samenvatting gegeven van de huidige kennis over 
279 
SAMENVA TTING 
mononucleaire fagooyten, cytokinen en glucocartico'iden. Aan het einda van de verige eeuw 
werd het fagocyterende vermogen van macro fag en ontdekt. Lange tijd werd deze 
eigenschap beschouwd als de enige van belang zijnde. Thans kennan we meerdere 
belangrijke functies van mononucleaire fagooyten, waaronder hun vermogen om 
immunologische reacties te be'invlceden. Zowel het belang als de therapeutische 
be'invlceding van hun functies in diverse ziektebeelden zijn hedentendage onderwerp van 
vele onderzoeksprojecten. Cytokinen hebben aen veel kortere geschiedenis, maar hun 
krachtige invloed op tal van lichaamsprocessen werd eigenlijk direct onderkend. Vaor 
intercellulaire communicatie en samenwerking zijn cytokinen onmisbaar. Cytokinen varmen 
hiermee een waardevolle ingang om ontspoorde lichaamsprocessen te be·invlaeden. Hun 
klinische toepassingen staan pas in de kinderschoenen, maar zijn veelbelovend. De klinische 
toepassingen van glucocortico'iden daarentegen zijn al sinds hun eerste gebruik bij de 
behandeling van reumato"ide artritis in 1949 bekend. Toch zijn hun werkingsmechanismen 
nog niet volledig bekend, hoewel hun vermogen om de transcriptie te reguleren van 
bekende (en mogelijk nog te ontdekken) eiwitten, waaronder vele cytokinen, waarschijnlijk 
de belangrijkste is. In hoofdstuk 2 wordt uitgebreid ingegaan op de thans bekende 
werkingsmechanismen van glucocortico'iden. 
Hoofdstuk 3 is een korte omschrijving van de achtergrond van de experimenten zoals 
die worden beschreven in de hoofdstukken 4, 5 en 6. 
Hoofdstuk 4 beschrijft hoe enkele eigenschappen van mononucleaire fagocyten 
be'invloed kunnen worden door cytokinen. Alveolaire macrofagen, die in groten getale 
voorkomen in de longen, zijn voor het merendeel afkomstig van bloedmonocyten. Deze 
monocyten ondergaan een aantal veranderingen als zij vanuit het bloed, via het interstitium 
naar de alveolaire ruimten migreren. Die veranderingen kunnen worden gezien als onderdeel 
van een uitrijpingsproces. Tijdens dit uitrijpen verandert ondermeer de expressie van 
(glyco}prote'inen op de celmembraan. De aanwezigheid van dergelijke (glyco)prote'inen kan 
zichtbaar worden gemaakt met behulp van specifieke monoclonale antistoffen. De 
belangrijkste verschillen in expressie van eiwitten op de celmembraan tussen 
bloedmonocyten en alveolaire macrofagen betroffen het CD14 en RFD9 antigeen: 
bloedmonocyten brengen het CD14 antigeen hoog en het RFD9 antigeen laag tot expressie, 
terwijl dit bij alveolaire macro~agen juist omgekeerd is (hoofdstuk 4. 1). We concluderen 
hieruit dat het uitrijpen van bloedmonocyten tot alveo/aire macrofagen gepaard gaat met 
het verdwijnen van het CD 14 antigeen en het tot expressie komen van het RFD9 antigeen. 
In hoofdstuk 5. 1 wordt beschreven dat dit uitrijpingsproces in vitro is na te bootsen en dat 
het bovendien kan worden versneld door IL-4. Deze bevindingen zijn een belangrijke 
aanwijzing voor de hypothese dat uitrijping van mononucleaire fagocyten in vivo kan 
worden gestuurd door omgevingsfactoren: mogelijk speelt IL-4 ook in vivo een rol bij dit 
proces. Bovendien opent deze bevinding therapeutische mogelijkheden waarbij kan worden 
gedacht aan be'invloeding van dit proces met bijvoorbeeld IL-4 of anti-IL-4. Een tweede 
belangwekkende bevinding die werd gedaan bij de bestudering van effecten van IL -4 op 
mononucleaire fagocyten bleek het effect op de activiteit van het enzym aminopeptidase-N. 
Dit enzym komt tot expressie op de celmembraan van zowel bloedmonocyten als alveolaire 
macrofagen en kan op twee manieren worden aangetoond: enerzijds de aanwezigheid van 
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het enzym met specifieke monoclonale antistoffen (CD13) en anderzijds de enzymactiviteit 
met een specifieke enzymassay. IL-4 bleek in staat am de expressie van dit enzym op de 
celmembraan van bloedmonocyten en alveolaire macro fag en te verhogen. Deze verhoging 
ging bovendien gepaard met een verhoogde functionele activiteit van aminopeptidase-N 
(hoofdstuk 4. 2). Oak het mRNA dat codeert voor aminopeptidase·N bleek na incubatie met 
IL-4 in verhoogde mate voor te komen in bloedmonocyten en alveolaire macrofagen. Omdat 
dit enzym mogelijk van belang is bij onder andere de inactivatie van ontstekingsmediatoren, 
kan IL-4 mogelijk de ontstekingsremmende capaciteiten van mononucleaire fagocyten 
verhagen. Oerhalve lijkt IL-4 enerzijds de maturatle van rnononucleaire fagocyten te 
versnellen, terwijl het anderzijds deze cellen zodanig activeert dat een verhoogde activitelt 
van het enzym aminopeptidase-N kan worden waargenomen. 01t activerend vermogen van 
IL-4 blijkt oak waarneembaar op endotheelcellen (hoofdstuk 4.2). Tach is deze eigenschap 
van IL-4 niet van algemene aard, omdat IL-4 niet in staat bleek de expressie van het C013 
antigeen te induceren of te verhogen op voorlopers van bloedmonocyten (hoofdstuk 4.3). 
Oat deze voorlopers echter wei degelijk be'(nvloedbaar zijn door IL-4 en dus ook IL-4 
receptoren (lL-4R) moeten bezitten, bleek uit het feit dat de FCERllb op deze cellen wei 
induceerbaar was door IL-4. Ook bloedmonocyten waren gevoelig voor deze laatste 
eigenschap van IL-4. Op alveolaire macrofagen was de FCERllb echter niet te induceren met 
IL-4. Waarschijnlijk wordt de wijze waarop een celtype reageert op de aanwezigheid van 
een cytokine niet aileen bepaald door de aanwezigheid van functionele cytokine-receptoren, 
maar hangt deze mede af van andere factoren, waaronder het rijpingsstadium. 
In hoofdstuk 4.4 wordt een ander aspect van de rijping van mononucleaire fagocyten 
belicht. Proliferatie van cellen kan worden aangetoond middels de expressie van een 
bepaald antigeen in de kern van cellen. Hiervoor kan de monoclonale antistof Ki-67 worden 
gebruikt. Een zeer klein percentage van bloedmonocyten bleek in deling te zijn, Het 
percentage delende cellen onder alveolaire macrofagen bleek ook klein te zijn, maar lets 
hoger dan onder bloedmonocyten. Oeze bevindingen waren eigenlijk onverwacht omdat 
a/gemeen wordt aangenomen dat uitrijping van cellen gepaard gaat met een vermindering 
van de proliferatieve activiteit. Longweefsel lijkt derhalve een zodanig micromilieu voor 
mononucleaire fagocyten te creeren dat proliferatie wordt gestimuleerd. Een belangrijke 
factor in dezen lijkt de aanwezigheid van "colony stimulating factors", met name GM-CSF. 
Als het micromilieu van de longen inderdaad deze invloed heeft, lijkt dit tevens te kunnen 
worden be'jnvloed door ziekte: bij patienten met sarco'idose werd namelijk een verhoogd 
percentage proliferende alveolaire macrofagen aangetroffen, en dit kan mogelijk worden 
veroorzaakt door een verhoogde lokale concentratie van GM-CSF. 
Hoofdstuk 5 behandelt de effecten van glucocortico'iden op mononucleaire fagocyten. 
Zoals we hierboven reeds meldden, wordt in hoofdstuk 5. 1 beschreven dat IL-4 in staat is 
maturatie van bloedmonocyten te versnellen, waarbij maturatie werd vervolgd aan de hand 
van diverse, hieronder nader omschreven parameters. Glucocortico'(den bleken in vitro in 
staat die maturatie te remmen: ze remden morfologisch het strekken van monocyten, de 
toename van de expressie van zure fosfatase in het cytoplasma, en op de celmembraan de 
toename van de expressie van het RFD9 antigeen en de afname van de expressie van het 
CD14 antigeen. Bovendien bleken glucocortico'lden de versnellende invloed van IL-4 op de 
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maturatie tegen te gaan. Op grand van deze bevindingen lijkt er een wisselwerking te 
bestaan tussen enerzijds immunologische factoren en anderzijds hormonen met betrekking 
tot de regulatie van cellulaife activiteiten. In hoafdstuk 5. 2 wordt uiteengezet dat verlaging 
van de expressie van het gen dat codeert VQar IL-1 Jl een werkingsmechanisme kan zijn van 
de ontstekingsremmende eigenschappen van glucocortico,(den. Deze hypothese was reeds 
eerder geopperd ten aanzien Van bloedmonocyten. Onze bevindingen ondersteunen de 
gedachte dat het klinische gebruik van glucocortico'iden zinni9 is bij die longziekten waarbij 
alveolaire macrofagen via de produktie van IL-1 Jl een ontsteking induceren. IL-4 bleek in 
deze studie eveneens een verlaging van de expressie van IL-1 f3 mRNA te bewerkstelligen, 
en zo mogelijk nog krachtiger dan glucocortico'(den. Deze invloed van IL-4, tezamen met de 
verhoging van de aminopeptidase-N-activiteit door IL-4, lijkt de werking als potentiele 
ontstekingsremmer te bevestigen. Mogelijk zullen deze anti-inflammatoire aspecten van IL-4 
in de toekomst ook klinische toe passing vinden. Uit de resultaten beschreven in hoofdstuk 
5.1 en hoofdstuk 5.2lijkt bovendien geconcludeerd te moeten worden dat, afhankelijk van 
de cellulaire parameter die wordt bestudeerd, IL-4 en glucocortico"iden soms vergelijkbare 
en soms tegengestelde effecten hebben. 
In hoofdstuk 5.3 wordt ingegaan op een ander, en in de literatuur omstreden, 
mechanisme van de ontstekingsremmende effecten van glucocortico'iden. In onze studie 
werd een toename gezien van Iipocortine-1 mRNA in alveolaire macrofagen onder invloed 
van glucocortico'(den. Dit effect werd waargenomen onder experimentele condities waarbij 
de expressie van IL-l f3 mRNA jUist werd verlaagd door glucocortico·iden. Tevens wordt in 
dit hoofdstuk ingegaan op de bevinding dat de effecten van glucocortico'iden op de 
expressie van het IL-1 f3 en het Iipocortine-1 gen verschillen in kinetiek. Voor bijna aile 
beschreven effecten van glucocortico"iden op een eel dient deze in het bezit te zijn van 
functionele glucocortico'id receptoren. Aan deze voorwaarde is uitgebreid aandacht besteed 
in hoofdstuk 2. Door technische problemen die zijn gerelateerd aan eigenschappen van 
humane alveolaire macrofagen is het lang onduidelijk geweest of dit celtype in het bezit 
was van deze receptoren. Oat humane alveolaire macrofagen inderdaad specifieke 
glucocortico'(d-receptoren bezitten wordt beschreven en onomstotelijk aangetoond in 
hoofdstuk 5.4. 
In hoofdstuk 6 wordt onderzoek beschreven waarbij is geevalueerd of het therapeutisch 
gebruik van glucocortico'iden bij patienten cellulaire veranderingen induceert vergelijkbaar 
met die welke werden waargenomen in onze in vitro studies. In hoofdstuk 6.1 wordt 
beschreven dat de bloedmonocyten van allergische astmapatienten, die inhalatie-
glucocortico'(den gebruiken, een expressie vertonen van enkele eiwitten op hun 
celmembraan die verschilt van gezonde vrijwilligers of patienten die werden behandeld met 
een f32-sympathicomimeticum of placebo: de expressie van CD13, CD14 en CD18 
antigenen was hoger in de patientengroep die werd behandeld met glucocortico'{den dan 
bij gezonden, terwijl de expressie van CD11 b antigeen juist lager was. Verder bleek dat de 
expressie van CD14 antigeen significant hoger was in de graep die 2,5 jaar inhalatie-
glucocortico'iden had gebruikt dan bij de astmatici die anders werden behandeld. Deze 
bevindingen lijken in te houden dat inhalatie-glucocorticdiden niet aileen lokaal in de longen, 
maar ook systemisch effecten hebben, in ieder geval op bloedmonocyten. In hoeverre deze 
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veranderde expressie van membraaneiwitten door glucocortico,(den ook klinische betekenis 
heeft, vereist verder onderzoek. In hoofdstuk 6.2 zijn verschillende aspecten bestudeerd 
van de bronchoalveolaire lavage (BAL}-vloeistof van dezelfde patientengroep die ook in 
hoofdstuk 6.1 wordt beschreven. Een belangrijke bevinding bleek de positieve correlatie 
tussen de concentratie Iipocortine-1 en het aantal cellen in de BAL-vloeistof. Bovendien 
bleek de concentratie van een van de metabolieten van arachidonzuur, de 
bronchoconstrictor PGD2, negatief te zijn geeorreleerd aan de concentratie van lipocortine-
1. We hebben dit ge'(nterpreteerd als een mogelijke aanwijzing voor een anti-inflammatoire 
werking van lipoeortine-1 in de longen. Tevens werd waargenomen dat rokende patienten 
meer Iipocortine-1 in hun BAL-vloeistof hebben dan patienten die niet roken. De relatie 
tussen roken en verhoogde eoneentraties aan lipocortine-1 in de BAl-vloeistof kon ook 
worden aangetoond in gezonde, niet-astmatische proefpersonen. Waarschijnlijk kan deze 
bevinding worden verklaard doordat bij rokers hogere celaantallen in de BAL-vloeistof 
worden aangetroffen dan bij niet-rokers. Mogelijk hebben deze verhoogde concentraties aan 
lipoeortine, dat potentieel anti-inflammatoire eigensehappen bezit, een remmende invloed 
op de ontsteking in de luehtwegen die door roken wordt veroorzaakt. Aldus lijkt ons 
Iiehaam in staat spontaan lokaal voor een beschermende reactie te zorgen tegen de 
schadelijke componenten van sigaretterook. Daarnaast konden we aantonen dat 
behandeling van allergische astmapatienten met inhalatie-glucocortieo'lden geassocieerd is 
met lagere eoneentraties totaal eiwit en albumine in de BAL-vloeistof. Bij de coneentratie 
van lipoeortine-1 bleek dat niet het ·geval, hetgeen kan betekenen dat glucocortico'lden 
aetief de produktie van dit eiwit haog houden in tegenstelling tot verlaging van de vorming 
van andere eiwitcompanenten. 
Cancluderend kunnen we stellen dat het onderzoek dat is besehreven in dit proefschrift 
een aantal nieuwe inzichten in de werkingsmeehanismen van glucoeortico'(den en IL-4 he eft 
opgeleverd met betrekking tot hun lnvloed op mononucleaire fagocyten. Glucocortico"lden 
en IL-4 be'invloeden beide zowel de maturatie, met tegengesteld effect, als de activatie, met 
gelijkgericht resultaat. Uitgangspunt van het onderzoek was de vraag of het ziektebeloap 
van patienten met astma uiteindelijk gunstig zou kunnen worden bernvloed door ingrijpen 
in het functioneren van mononucleaire fagocyten. Het gebruik van glucocorticoIden bij 
longaandoeningen, waarbij mononucleaire fagocyten door hun pro-inflammatoire functies 
een rol spelen, lijkt te worden gesteund door onze in vitro bevindingen. Of ook voor IL-4, 
al dan niet in combinatie met andere middelen, vergelijkbare toepassingen zijn weggelegd, 
vereist verder klinisch en basaal onderzoek. In toenemende mate wordt in de kliniek, ook 
bij behandeling van longziekten, geprobeerd cellulaire functies te be'(nvloeden. Deze functies 
worden grotendeels bepaald door de genetische constitutie. Pulmonologisch onderzoek zal 
in de toekomst me de gericht moeten zijn op medicamenteuze regulatie van gen-expressie, 
bijvoorbeeld met behulp van medieamenten zoals glucocorticorden en cytokinen. 
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-----------ABBREVIATIONS -----------

ACTH 
ADCC 
Ag 
AM 
AP-l 
AMDGF 
ARDS 
BAL 
BALF 
BEAS 
BHR 
bp 
BSA 
cAMP 
'c 
CALLA 
CD 
CFU 
capo 
COUP-TF 
CREB 
DNA 
EAA 
EAR 
e.g. 
ELAM 
ERE 
ERR 
Flab) 
FACScan 
Fe 
FqR 
FCflR 
FCS 
FEV1 
ABBREVIATIONS 
adrenocorticotropic hormone 
antibody-dependent cell mediated 
cytotoxicity 
antigen 
alveolar mac(ophages 
activator protein-l 
alveolar macrophage-derived growth 
factor 
adult respiratory distress syndrome 
bronchoalveolar lavage 
bronchoalveolar lavage fluid 
a human bronchial epithelial cell line 
derived from normal human bronchial 
epithelial cells transformed by 
infection with adenovirus 12-SV40 
hybrid virus 
bronchial hyperresponsiveness 
basepair 
bovine serum albumin 
cyclic adenosine 3',5' 
monophosphate 
degree Celsius 
common acute lymphoblastic 
leukemia antigen 
cluster of designation/cluster of 
differentiation 
colony forming unit 
chronic obstructive pulmonary 
diseases 
chicken ovalbumin upstream 
promoter transcription factor 
cAMP response element binding 
protein 
deoxyribonucleic acid 
extrinsic allergic alveoli tis 
v-erb A-related (protein) 
exempli gratia (for example) 
endothelial-leukocyte adhesion 
molecule 
estrogen response element 
estrogen receptor related 
antigen binding fragment 
fluorescence-activated cell scanner 
crystallizable fragment 
Fc receptor for IgG 
Fc receptor for IgE 
fetal calf serum 
forced expiratory volume in 1 second 
FGF 
FlTC 
FMLP 
FRC 
9 
GAM 
G·CSF 
GM-CSF 
GR 
GRE 
h 
HeLa 
HIV 
HRE 
HRR 
hsp 
i.c. 
ICAM 
Le. 
IFN 
19 
IGF 
IL 
ISGF3 
kb 
LAF 
LAP 
LBP 
LPS 
mAb 
MCP 
M-CSF 
MESF 
MHC 
MIF 
MIP 
MMTV 
MNC 
mRNA 
n 
NAP 
fibroblast growth factor 
fluorescein isothiocyanate 
formyl-methiony[-feucyl-
phenylalanine 
functional residual capacity 
unit of gravity 
goat anti-mouse Ig antiserum 
granulocyte colony stimulating factor 
granulocyte macrophage stimulating 
factor 
glucocorticoid receptor 
glucocorticoid response element 
hour 
name of the cells of the first human 
continuously cultured carcinoma cell 
Hne; acronym of the name of the 
patient (Henriette Lacks) from whose 
carcinoma the parent cells were 
isolated in 1951 
human immunodeficiency virus 
hormone response element 
hormone response region 
heat shock protein 
in casu (in this case) 
intercellular adhesion molecule 
id est (that is) 
interferon 
immunoglobulin 
insulin-like growth factor 
interleukin 
IFN-stimulated gene factor-3 
kilobase 
lymphocyte-activating factor 
L-Ieucine-aminopeptidase 
LPS-binding protein 
lipopolysaccharide 
monoclonal antibody 
monocyte chemoattractant protein 
macrophage colony stimulating factor 
molecules equivalent to soluble File 
major histocompatibility complex 
migration inhibitory factor 
macrophage inflammatory protein 
mouse mammary tumor virus 
mononuclear cells 
messenger RNA 
number in study or group 
neutrophil activating protein 
2B7 
NEP 
NFl 
NF-KB 
NHIK 
NK cell 
NMS 
NO 
OTF-l 
PAF 
PBM 
PBS 
PCP 
PCR 
POGF 
PE 
PEEP 
PGE2 
PIE 
neutral endopeptidase 
nuclear factor I 
nuclear factor-KB 
cell line derived from a carcinoma of 
the human uterine cervix 
natural killer cell 
normal mouse serum 
nitric oxide 
octamer transcription factor-1 
platelet-activating factor 
peripheral blood monocytes 
phosphate-buffered saline 
provocative concentration (of a 
nonspecific agent, e,g, histamine) 
which causes a 20% decrease in 
FEV1 
Pneumocystis carinii pneumonia 
polymerase chain reaction 
platelet-derived growth factor 
phycoerythrin 
positive end-expiratory pressure 
prostaglandin E2 
pulmonary infiltration with blood 
eosinophilia 
PMA phorbol myristate acetate 
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PMN 
PRE 
q,Ld. 
r 
R 
RA 
RANTES 
RNA 
RNase 
SO 
SLE 
SSC 
TGF 
TNF 
TPA 
TSC 
U 
U937 
v, 
Yop 
polymorphonuclear cells 
progesterone response element 
quater in die (four times a day) 
recombinant {e.g. r1L-41 
receptor (e.g, IL-4RJ 
rheumatoid arthritis 
regulated upon activation, normal 
T expressed, and presumably 
secreted 
ribonucleic acid 
ribonuclease 
standard deviation 
systemic lupus erythematosus 
sodiumchloride sodiumcitrate 
transforming growth factor 
tumor necrosis factor 
12-0-tetradecanoylphorbol-13-
acetate 
total static compliance 
unit 
a human immature monocytic cell 
line 
tidal volume 
yersinial membrane protein 
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